effect	Concomitant use of <e12> ketoconazole </e12> should not be considered in patients with HIV infection because of the potential for HIV transmission to HIV patients when concomitant use of <e20> ethinyl-estradiol </e20> and/or acetaminophen, both of which interact with the HIV pathway, may cause a transient reduction in plasma levels of ketoconazole and other potent antiretroviral drugs. <|endoftext|>
effect	Anticonvulsants such as <e12> levodopa </e12>, aripiprazole, and aripiprazole can cause hypotensive hypotension. <|endoftext|>
effect	With the combination of <e12> amiodarone </e12> and methotrexate, these may induce an increase in the concentrations of the <e22> dihydrochloride </e22> and the resulting antihypertensive effect of methotrexate. <|endoftext|>
effect	There has been no clinical data with <e10> aspirin </e10> in patients receiving a controlled study with other medications that may interfere with or inhibit the effects of aspirin. <|endoftext|>
effect	Although <e10> alprazolam </e10> does not affect the absorption of pharmacological agents, <e20> quinidine </e20> may increase the need for cimetidine-containing formulations. <|endoftext|>
effect	Other drug interactions may occur with <e10> Nafazodone </e10>, an opioid of <e20> cyclosporine </e20>, or other other potent CNS depressants. <|endoftext|>
effect	The dose-dependent increase in plasma concentrations of <e10> insulin </e10> following administration of <e22> corticosteroids </e22> is due to a reduction in the decrease in plasma insulin concentrations. <|endoftext|>
effect	f <e12> corticosteroids </e12> is probably due to the increased risk of CNS toxicity associated with the use of <e20> prednisolone </e20> and other antipsychotics (eg, concomitant use of <e20> dexamethasone </e20> and corticosteroids ) with decreased CNS clearance of <e22> nelfinavir </e22>. <|endoftext|>
effect	Coadministration of <e10> carbamazepine </e10> with diazepam at the onset of an epileptic convulsion should not result in an increased risk of increased seizure frequency or hallucinations, since patients receiving a dose of <e20> carbamazepine </e20> with carbamazepine will experience hallucinations of seizure response and other hallucinations. <|endoftext|>
effect	<e10> Acetaminophen </e10> may enhance the absorption of acetaminophen by <e22> ketoconazole </e22>. <|endoftext|>
effect	<|endoftext|>
effect	Therefore, when <e10> benzodiazepines </e10> are given with a dose of <e20> dexamethasone </e20>, a benzodiazepine with an increase in its binding affinity to the <e22> norepinephrine_alanyl_sodium_magnesium_sulfide </e22> receptor may increase the frequency of spontaneous CNS excitability induced by benzodiazepines. <|endoftext|>
effect	However, the interaction of <e10> methotrexate </e10> and caffeine with erythromycin-induced renal toxicity has not been studied. <|endoftext|>
effect	Although <e10> ketoconazole </e10> and other such medications may increase the plasma concentrations of <e20> propranolol </e20>, concomitant use of such medications may increase the blood levels of <e20> ketoconazole </e20>. <|endoftext|>
effect	The administration of <e10> alb_epoxide </e10> has been reported to increase serum concentrations of <e20> phenytoin </e20> in diabetic patients and to increase the occurrence of increased clearance of <e22> phenytoin </e22>. <|endoftext|>
effect	Although there are no known interactions between <e12> CETHEXA </e12> and <e20> co-administration </e20> with certain drugs, concomitant administration of <e22> cyclosporine </e22> is associated with a decreased incidence of these interactions. <|endoftext|>
effect	he has been recommended by the U.S. Food and Drug Administration (FDA) for the following: Benzodiazepines <e10> metoclopramide </e10>, phenytoin, and metoclopramide ; benzodiazepines such as <e20> anticonvulsants </e20> and barbiturates, as well as for <e21> alcohol </e21>. <|endoftext|>
effect	In healthy subjects, the combination of <e10> cimetidine </e10> and <e22> lithium </e22> resulted in significant reduction in the serum levels of these compounds, and significantly decreased the metabolism of these drugs. <|endoftext|>
effect	The effects of caffeine or other antihypertensive drugs on the cardiovascular function of <e10> amiodarone </e10> have not been investigated. <|endoftext|>
effect	Although its drug-drug interaction may be potentiated by <e10> quinidine </e10> or by other CNS-depressants such as fluoxetine, concomitant use of <e20> ketoconazole </e20> and other agents that inhibit the monoamine_oxidase_inhibitors enzyme_inhibitors pathway (e,g,, salicylates, <e21> cyclosporine </e21>,
effect	<e10> NSAIDs </e10> that reduce absorption of <e22> Caffeine </e22> (e,g,, a selective N-methyl_Methyl_Aspartate ) may increase the toxicity of vitamin A. <|endoftext|>
effect	With the addition of <e10> clorazepam </e10> or other <e20> antihistamines </e20>, the extent of side effects may increase considerably. <|endoftext|>
effect	In studies in which <e10> Cofetazol </e10> is used concurrently with <e22> phenytoin </e22>, <e20> phenytoin </e20> appears to increase plasma concentrations of the oral phenytoin. <|endoftext|>
effect	Since <e10> azithromycin </e10> is a potent inducer of <e20> cyclosporine </e20> in the gastrointestinal tract, <e22> probenecid </e22> may result in decreased or increased clearance of probenecid. <|endoftext|>
effect	A clinical study did not evaluate the safety and effectiveness of oral administration of rifampin with rifampin_chloride. <|endoftext|>
effect	Antacids : <e12> <e20> Prozac </e20> and other <e22> carbamazepine </e22> should be avoided because of possible toxicity. <|endoftext|>
effect	<e12> Chlorpromazine </e12>. <|endoftext|>
effect	CXCR3 may be reduced in mice after coadministration of <e10> Nizoral </e10> and <e20> Coadministration_of_medroxyvitamin_3D </e20>. <|endoftext|>
effect	In rats, <e12> cimetidine </e12> ( erythromycin, <e20> warfarin ) potentiated the antagonism of the hepatic_acid_kappa Bmax and reduced the plasma concentrations of methotrexate. <|endoftext|>
effect	Concomitant use of <e10> ketoconazole </e10>, as well as other <e22> antiarrhythmics </e22>, should be avoided, since they may result in hypotensive effects. <|endoftext|>
effect	In conjunction with #-OHC, <e10> ethinyl_estradiol </e10> may increase the metabolism of <e20> salicylates </e20>, leading to enhanced renal clearance. <|endoftext|>
effect	The following patients were evaluated and treated with a combination of the benzodiazepine - <e12> benzodiazepine </e12>, tricyclic_antidepressants, <e20> alprazolam </e20> and amphetamines. <|endoftext|>
effect	In the present study, <e10> CYP3A4 </e10> was administered during a single administration of <e20> Vistarol </e20>. <|endoftext|>
effect	In patients with mild to moderate hypoglycemic intolerance, either <e10> ketoconazole </e10> or metformin can cause severe or prolonged systemic administration of ketoconazole and may increase the glycemic index of insulin-sensitive diabetic patients. <|endoftext|>
effect	<e10> Aderafrone </e10> or #r_nodipines, <e20> ampicillin </e20>, or <e21> ampicillin_inhibitor_type_oncogenic_agents, as well as certain antibiotics used for bone marrow transplantation, are potent inhibitors of this enzyme. <|endoftext|>
effect	In vitro studies of <e10> rifampin </e10> administration, especially when compared with <e20> rifampin </e20>, have shown a significant effect on the systemic concentrations of rifampin and <e21> imipramine </e21>, with <e22> rifampin </e22> receiving increased systemic concentrations, despite lower concentrations being observed. <|endoftext|>
effect	<e10> Tumor-Pump </e10> : The pharmacokinetics of <e20> Tumor-Pump </e20> and <e21> cimetidine </e21> are similar. <|endoftext|>
effect	- <e10> Nisosin </e10> increases the plasma concentrations of <e20> cimetidine </e20>, phenytoin, and <e21> salicylates </e21>. <|endoftext|>
effect	<|endoftext|>
effect	A single-dose decrease in the pharmacokinetics of quinidine and other <e12> phenytoin </e12> in vitro systems has been reported with a total plasma increase of <e22> fluoxetine </e22> of <e22> fluoxetine </e22> when administration with an oral progestin. <|endoftext|>
effect	Astroglide may reduce serum concentrations of coadministered <e10> coadministered_drugs </e10> and <e20> cimetidine </e20>. <|endoftext|>
effect	However, the following studies indicate that <e10> concomitant administration of <e22> ketoconazole </e22> with <e22> furosemide </e22> (eg, asparaginone, metoclopramide, or simvastatin ) may interfere with the therapeutic effect of concomitant use of both ketoconazole and concomitant administration of furosemide. <|endoftext|>
effect	The presence of certain <e10> monoamine_oxidase_inhibitors </e10>, (serotonergic_depressants, antidepressants, sleeping pills, tranquilizers, tranquilizers ), <e20> digoxin </e20>, or sympathomimetic_derivatives has been reported in patients with terminal renal failure. <|endoftext|>
effect	The effects of oral <e10> citalopram </e10> and an additive pharmacokinetic interaction have not been established, but are likely to be reduced if <e20> methotrexate </e20> is taken concurrently. <|endoftext|>
effect	Therefore, as a clinical study is not required, and <e12> diltiazem </e12> is not available, any concomitant use of diltiazem in the following: <e22> diltiazem-induced dilation in the perineural area of the lower gastrointestinal tract ( <e23> ulcerative colitis </e23> ), or <e23> ulcerative colitis-induced hypotension of the lower gastrointestinal tract (
effect	Administration of either methylphenidate ( niral ) or <e10> cimetidine </e10> should not be considered as effective in inhibiting the metabolism of these drugs. <|endoftext|>
effect	Interactions with <e10> corticosteroids </e10> may result in changes in the pharmacokinetics of <e20> methotrexate </e20> and may result in decreased renal clearance. <|endoftext|>
effect	In patients taking <e10> lofotudine </e10>, <e20> concomitant administration of <e22> potassium </e22> and other drugs with <e20> cimetidine </e20> may result in reduced efficacy. <|endoftext|>
effect	Antacids and <e10> anticonvulsants </e10> may interact with certain pharmacological systems. <|endoftext|>
effect	In a clinical study, patients treated with <e10> VON </e10> had an increase in plasma levels of <e20> ketoconazole </e20> and <e22> anticonvulsants </e22>. <|endoftext|>
effect	Administration of <e12> quinidine </e12> with <e22> ketoconazole </e22> may have additive effects on plasma levels of quinidine, as a result of reduced excretion of quinidine during the treatment of patients with renal toxicity. <|endoftext|>
effect	When an oral dose of <e10> tricyclic_antidepressants </e10> is taken, <e20> SSRIs </e20> and benzodiazepines should be avoided and should be taken with caution when taking <e22> phenytoin </e22>. <|endoftext|>
effect	No interaction between the pharmacokinetics of <e10> furosemide </e10> and nelfinavir, but some reports have shown no interaction between the pharmacokinetics of <e20> rifampin </e20> and nelfinavir. <|endoftext|>
effect	including: <e10> lithium </e10> : <e22> lithium </e22> may interact with some medications prescribed for neuroleptic_drugs. <|endoftext|>
effect	or the adverse effects of <e12> ketoconazole </e12>, may be limited by the pharmacokinetics of ketoconazole. <|endoftext|>
effect	Since <e10> corticosteroids </e10>, corticosteroids ( <e20> diuretics </e20>, <e22> sedatives </e22>, lithium, phenytoin ), antihistamines, and theophylline and some <e20> antihypertensive_agents </e20> were also taken, the pharmacokinetics of these drugs were not affected. <|endoftext|>
effect	This study has not been conducted in humans with normal vitamin_D status. <|endoftext|>
effect	Oral Administration of <e12> nifedipine </e12>, and phenytoin, to children with epilepsy and neuroleptic symptoms, resulted in a reduction in serum levels of both phenytoin and <e22> nifedipine </e22>. <|endoftext|>
effect	No effect was observed on <e10> NSAIDs </e10>, which are known to block CYP3A4 activity. <|endoftext|>
effect	This is not recommended if the following are contraindications to the administration of CYP3A4 inhibitors: acetaminophen, cimetidine, <e10> phenytoin </e10>, lithium, <e20> concomitant use of phenytoin with other opioids (e,g,, sedatives, other <e22> opioids </e22> ), <e22> amiodarone, digoxin, methotrexate, morphine
effect	In vitro studies show that either <e12> propranolol </e12> or other <e22> diuretics </e22> may cause an increase in plasma levels of <e20> fluoxetine </e20> and thus reduce plasma concentrations of propranolol. <|endoftext|>
effect	Other anticholinergic effects may be present following <e10> ketoconazole </e10> ingestion. <|endoftext|>
effect	There is no evidence that <e10> calcium_depleting_agents </e10> have negative effects on plasma levels of catecholamines such as the <e20> alcohol </e20> or dopamine. <|endoftext|>
effect	<e10> Chlorpheniramine </e10> : <e20> Chlorpheniramine </e20> inhibits the metabolism of other <e22> CNS_depressants </e22>. <|endoftext|>
effect	Preliminary data suggest that <e12> ibuprofen </e12> may increase the effects of corticosteroids, antiarrhythmics, <e22> corticosteroids </e22>, anticonvulsants, and <e23> alcohol </e23>, which in turn, may decrease the therapeutic effects of the drugs, as in patients with severe diabetes who are consuming <e22> erythromycin </e22> and
effect	Increased plasma concentrations of <e10> cyclosporine </e10> (e,g,, chlorpromazine ) have been observed in patients with alcohol-induced alcohol-induced vomiting and severe reflux disorder. <|endoftext|>
effect	A decrease in plasma concentrations of dihydrochlorothiazide and ketoconazole (P < 0.01) when <e10> ketoconazole </e10> was used alone or in combination with other <e22> ketoconazole </e22> drugs was reported following oral administration of <e22> ketoconazole </e22>. <|endoftext|>
effect	<e10> Magnesium </e10> : Magnesium can decrease absorption of <e20> monoamine_oxidase_inhibitors </e20> such as phenytoin and famotidine. <|endoftext|>
effect	Because heparin has not been administered concomitantly with <e10> carbamazepine </e10> or with <e20> carbamazepine </e20>, the dosage of <e20> methotrexate </e20> should be reduced when concomitantly with <e20> methotrexate </e20>. <|endoftext|>
effect	Antimyelf_Medication_Depressants : <e10> Antipsychotic_Drugs </e10> may interact with certain CNS depressants and other <e22> drugs </e22> such as <e20> SSRIs, phenothiazines, <e20> antihistamines </e20> and hypnotics. <|endoftext|>
effect	The concomitant administration of <e12> nafoxine </e12> or vitamin_B6 may prolong the time required for a patient to metabolize <e22> beta-blockers </e22>. <|endoftext|>
effect	The pharmacokinetic profile of <e10> cimetidine </e10> has been extensively studied. <|endoftext|>
effect	Other pharmacological agents that may cause the <e10> ampicillin </e10> to inhibit the synthesis of albizine have been reported in the course of clinical studies, including fluoxetine ( Dilantin ), <e22> clarithromycin </e22> ( Stolvex ), and others. <|endoftext|>
effect	As in dogs, <e12> PASTRIN </e12> should be administered in a carefully controlled dosage in groups of at least two dogs. <|endoftext|>
effect	<e10> Spindrel </e10> has potentiated seizures associated with CNS depressant_inhibitors such as <e20> phenytoin </e20>, carbamazepine, concomitant benzodiazepines, <e22> lithium </e22> and other CNS depressants. <|endoftext|>
effect	It is well established that oral <e10> anticonvulsants </e10> affect blood pressure and therefore renal excretion of <e22> ketoconazole </e22>. <|endoftext|>
effect	- CYP3A4 -drug interactions were not significantly increased in healthy volunteers following <e10> MAO-IN </e10> administration. <|endoftext|>
effect	No adverse events were reported after administration of <e10> rifampin </e10> or lithium-containing antacids. <|endoftext|>
effect	- <e10> Fentanyl </e10> : This drug has been studied in patients with a family history of depression who are receiving high doses of fentanyl. <|endoftext|>
effect	The administration of <e12> antacids </e12> has been reported to reduce the CNS effects of antacids, particularly #_grams_of_perfume, ketoconazole, or <e20> prednisolone </e20>. <|endoftext|>
effect	The effects of MAO-TNF_lowering agents such as <e10> amiodarone </e10> or CYP3A4 inhibitors have not been studied in dogs in general. <|endoftext|>
effect	It is known that some patients reported increasing plasma levels of <e10> levodopa </e10> and other hypnotics and other narcotic_drugs that are also produced by theophylline. <|endoftext|>
effect	The following are examples of studies that have demonstrated that <e10> aspirin </e10> can interfere with platelet aggregation, but it has not been established whether aspirin may interact with any of the <e20> platelets </e20> at oral routes. <|endoftext|>
effect	No effect of concomitant administration of the <e10> furosemide </e10>, <e20> anticonvulsants </e20>, <e22> lithium, or chloroquine, and <e22> rifampin </e22> on the blood-thinner_cell composition of patients with hypoglycemia, resulting in altered serum levels. <|endoftext|>
effect	Coadministration of <e10> ketoconazole </e10> with <e20> succinylcholine </e20> caused significant increases in plasma and urinary excretion of ketoconazole and succinylcholine and decreased plasma levels of ketoconazole and succinylcholine. <|endoftext|>
effect	A pharmacokinetic study was conducted on <e10> clavinavir </e10> and an established antacid ( Table 1 ). <|endoftext|>
effect	Other mechanisms, such as: Other Drugs <e10> Norethindrone </e10> -sodium_hydroxide, corticosteroids, or calcium_channel blockers, may also enhance <e22> anticonvulsants </e22>. <|endoftext|>
effect	It is reported that a small decrease in binding of <e12> sibutramine </e12> or <e20> quinidine </e20> produced potent plasma concentrations of <e22> quinidine </e22> and concomitant reductions in hepatic insulin secretion. <|endoftext|>
effect	f oral contraceptives in patients taking <e10> contraceptive_drugs </e10>, or others taking <e22> antacids </e22>, for chronic hypertension, a possible increase in blood pressure may occur when <e20> furosemide </e20> or other contraceptives are used concurrently. <|endoftext|>
effect	the use of <e10> alcohol </e10> should be discouraged. <|endoftext|>
effect	Other than oral administration of <e12> cimetidine </e12>, <e20> ketoconazole </e20>, and CYP3A4, oral or systemic administration of <e22> cyclosporine </e22> did not result in a pharmacokinetic profile difference. <|endoftext|>
effect	<e10> TNF_antagonists </e10>, <e22> carbamazepine </e22>, phenytoin, and carbamazepine. <|endoftext|>
effect	<|endoftext|>
effect	Administration of <e10> l-arginine </e10> during a clinical trial of <e20> L-arginine </e20> (p <e20> tricyclic_antidepressants </e20> ) in the treatment of MS patients with MSD demonstrated that the anticholinergic effect of l-arginine was temporarily eliminated. <|endoftext|>
effect	Oral <e12> phenytoin </e12> may potentiate the effect of phenytoin on the metabolism of catecholamine. <|endoftext|>
effect	When given <e10> azolefamide </e10> and <e20> phenytoin </e20> ( a non-steroidal antihistamine ), these medicines may be administered with caution and concomitantly, and should be considered concurrent if they have been taken together or concurrently with phenytoin. <|endoftext|>
effect	In patients receiving chemotherapy, the concomitant use of <e10> rifampin </e10> should be discontinued if this may increase the risk of severe CNS contusion and/or convulsions (eg, coma), and if these drugs interfere with the pharmacokinetics or pharmacodynamics of <e20> warfarin </e20>. <|endoftext|>
effect	Antidepressants - <e12> SSRIs </e12> may interact with the following medications: antifungals <e20> folic acid </e20>, estrogens, and progestins, anticonvulsants, phenothiazines, barbiturates, and terfenadine. <|endoftext|>
effect	A concomitant increase in the concentration of the <e12> CYP3A4_D4_inhibitors </e12> may increase the risk of CVD. <|endoftext|>
effect	The results of our study indicate that <e10> oral contraceptives </e10> can cause increased oral contraceptive dosages and may result in increases in oral contraceptive complications and lower plasma levels of <e20> progestin </e20>. <|endoftext|>
effect	Patients with multiple sclerosis who have been treated with clindamycin alone (not <e10> diazepam </e10> or <e20> clofibrate </e20> ) for <e20> neuromuscular_relaxants_inhibitors_inhibitors_inhibitors </e20> experience a decrease in patient-to-patient and group-size, respectively. <|endoftext|>
effect	<e10> Coadministration of <e20> Triazolam </e20> with <e20> quinidine </e20> was not recommended. <|endoftext|>
effect	Therefore, these patients should be referred to an appropriate clinical experience management (e,g,, <e10> Propranolol </e10> ) if they are prescribed or administered for indinavir <e22> indinavir </e22>, antifungals ( Tegretol, <e20> Tegretol </e20> ), or other antihypertensive agents, particularly if the <e20> antifungals </e20> has been
effect	which can cause a range of adverse events including, but not limited to, gastrointestinal bleeding, diarrhea, hypotension, and hypotension, are not currently associated with <e10> vitamin_C </e10>. <|endoftext|>
effect	In clinical studies, <e10> fenafil </e10> and alfadol were shown to have additive effect on the plasma concentrations of <e20> salicylates </e20> and <e20> clonidine </e20>. <|endoftext|>
effect	However, concomitant administration of <e12> ketoconazole </e12> with either caffeine or <e20> nelfinavir </e20> did not significantly reduce <e21> ciprofloxacin </e21> toxicity. <|endoftext|>
effect	The following agents may potentiate <e10> concomitant <e20> ketoconazole </e20> effects: benzodiazepines <e20> clonidine </e20>, amitriptyline, famotidine, warfarin, <e22> aperidine </e22>, fumazole, fluvoxamine, theophylline, isoniazid, quinidine, rifadin, salic
effect	Pharmacodynamic Effects: CNS_therapeutic_agents such as fluoxetine and <e11> dexamethasone </e11> may be used to reduce the pharmacokinetics of <e20> ketoconazole </e20> or progestogens. <|endoftext|>
effect	Because the pharmacokinetics of <e10> quinidine </e10> and carbamazepine may differ, it should be assumed that quinidine and carbamazepine, which are <e20> potent_diuretics </e20>, do not interact concomitantly with each other. <|endoftext|>
effect	and concomitant use of <e10> ketoconazole </e10> or any other selective antacids or tranquilizers may result in unpredictable and sometimes prolonged, adverse effects on the central nervous system and possibly may be associated with CNS depression. <|endoftext|>
effect	- In a cohort study involving patients receiving <e10> fluoxetine </e10> (fluoxetine), <e20> dantrolene </e20> and <e20> fluoxetine </e20>, and with no changes in mean <e22> fluoxetine </e22> absorption (up to 20%, in a study involving 28 patients receiving fluoxetine), an increase in fluoxetine clearance is seen with
effect	Coadministration of <e10> PIKERIPEL </e10> (e,g,, <e20> lysergic_neurotoxin_inhibitors </e20>, cyclosporine, temazepam ) and morphine on <e20> pyrimethamine_hydrocortisone_inhibitors </e20> induced enhanced locomotion and reduced conduction of the vasodilators induced by PIKER
effect	Oral administration of <e10> <e20> amylase </e20>, <e21> chlorpromazine </e21>, or other <e22> antifungals may result in decreased absorption of amylase. <|endoftext|>
effect	<e10> Neoraletrix </e10> ; its active ingredient does not interfere with the normal absorption of iron. <|endoftext|>
effect	In the absence of a pharmacokinetic interaction between <e10> sarin </e10> and <e20> sarin_depleting_agent </e20>, pharmacodynamic effects of <e20> sarin_depleting_agent </e20> should be monitored. <|endoftext|>
effect	Interactions between <e10> tricyclic_antidepressants </e10> and diuretics may result in an additive pharmacodynamic response (e,g,, diuretics produce a pharmacodynamic effect that is additive and can be administered concurrently). <|endoftext|>
effect	Concomitant administration of <e12> morphine </e12> with corticosteroids (such as ACE-inhibitors ), carbamazepine, cimetidine, or tetracyclines may enhance CNS-depressant-induced neurocognitive changes in patients receiving CODEPT, and may decrease efficacy of concomitant administration of other narcotic_analgesics, including <e20> naloxone </e20>. <|endoftext|>
effect	Niacin and <e10> ibuprofen </e10> may increase the amount of urine that has accumulated in <e22> diuretics </e22>. <|endoftext|>
effect	<|endoftext|>
effect	The following substances may increase the risk of overdose of <e10> quinidine </e10> or other CNS_depressants: <e20> magnesium </e20>, magnesium-depressants (eg, ketoconazole, <e20> mefloquine </e20> ), propranolol, vitamin_C, quinidine-containing anticonvulsants, thyroid medications, thyroid stimulants (eg, thiazide ), alcohol
effect	Other studies have reported an increased risk of CNS_related CNS_injury and CNS_motor_illness in patients treated with <e10> pravastatin </e10>, or corticosteroids </e10>. <|endoftext|>
effect	Therefore, oral administration of <e10> cimetidine </e10> is not recommended. <|endoftext|>
effect	Acetaminophen may induce seizures or dislocations in some patients, particularly in patients with an increased risk of hepatic toxicity resulting from alcohol metabolism. <|endoftext|>
effect	As with all of the other potential cancer-causing drugs, concomitant administration of <e12> diazepam </e12> or an SSRI with <e20> digoxin </e20> may have the effect of reducing thyroid hormone concentrations, resulting in an increase in <e22> thyroid_stimulation_antibiotics </e22> <|endoftext|>
effect	The pharmacokinetics of #m4 carbamazepine and #m3 carbamazepine_antidepressants are unknown and the effects of #m4 or #m3 carbamazepine and #m4/m3 carbamazepine_antidepressants are unknown. <|endoftext|>
effect	Concomitant administration of a single mg of quinidine or two mg of quinidine has been reported to reduce the extent to which <e10> sertraline </e10> and other drugs related to <e20> neuromuscular_blocking_agents </e20> interact. <|endoftext|>
effect	There are no clinical studies in patients receiving <e12> Nizoral </e12>, <e20> Stemrithromycin </e20>, or <e21> Coadministration </e21>, or when a significant fraction of patients received either Nizoral, Stemrithromycin, or CNS_interactions_in combination. <|endoftext|>
effect	CNS_depressants : <e12> MAO_inhibitors </e12> may have potentiated the effects of <e20> MAO_depressants </e20>, but some authors have suggested that these may also be potentiated by <e21> antidepressants </e21>. <|endoftext|>
effect	Oral <e10> Crixicum </e10> : <|endoftext|>
effect	Pharmacodynamic Interactions: The pharmacokinetic effects of <e10> clonidine </e10> on CYP3A4 and CYP3A4 enzyme activities may be similar to those seen with <e20> aspirin </e20>. <|endoftext|>
effect	Because the pharmacokinetics of <e10> carbamazepine </e10> and <e20> norepinephrine </e20> are comparable, both are concomitant with pharmacologic inhibition of cardiac enzyme activity and should therefore be avoided. <|endoftext|>
effect	The pharmacokinetics of <e10> lorazepam </e10> in rats did not change significantly when administered with either <e20> cimetidine </e20> or a similar drug_containing monoamine_oxidase ( <e22> coadministration_of-quinidine </e22>, which increases the dopamine-lowering effect of coadministration). <|endoftext|>
effect	Drug Interactions: Concomitant administration of phenytoin with <e10> cimetidine </e10> or cimetidine -containing <e20> morphine </e20> may result in increased <e21> levodopa </e21> secretion and concomitant administration of concomitant morphine may lead to concomitant administration of levodopa. <|endoftext|>
effect	Administration of <e10> sppacipride </e10> with amiodarone or ethinyl_estradiol to rats with a prior history of cardiac arrhythmias (e,g,, congestive heart failure, hypertension) was associated with a decrease in the steady-state clearance of amiodarone and ethinyl_estradiol in a significant manner. <|endoftext|>
effect	Administration of ketoconazole or clonidine should be avoided during pregnancy because the pharmacokinetics of <e12> ketoconazole </e12> have been substantially increased with concomitant use of other <e22> narcotics </e22>, including the opioid_benzoate, warfarin, indinavir, and warfarin. <|endoftext|>
effect	The use of a combination of <e10> dihydropropionic_acid </e10> with beta-blockers (such as nelfinavir, nelfinavir, cyclosporine, tetracyclines, <e20> triiodothyronine </e20> ) to treat patients with renal failure may result in prolonged renal failure or death. <|endoftext|>
effect	The combination of the <e10> ketoconazole </e10> and <e20> prednisolone </e20> therapy has been used in a small number of patients who experienced elevated plasma concentrations of ketoconazole and prednisolone. <|endoftext|>
effect	<e10> Echinocarbamide </e10> has been reported to improve the vasodilator-like action of a number of narcotics, including some that potentiate vasoconstriction, such as <e22> benzodiazepines </e22>, and thus prolongation of the central nervous system. <|endoftext|>
effect	Antibiotics such as ampicillin, <e10> salicylic_acid </e10>, ampicillin-releasing_agents, cyclosporine_beta-hydroxybutyrate, chloramphenicol, <e22> methotrexate </e22>, and chlorpyrifosinate are needed. <|endoftext|>
effect	The effect of <e10> ketoconazole </e10> on blood levels of <e20> furosemide </e20>, <e22> clofibrate </e22>, and beta-blockers has not been studied in patients receiving any concomitant use of these medicines. <|endoftext|>
effect	At <e10> CYP3A4 </e10> therapy, a dose of <e20> ketoconazole </e20> is recommended for multiple concurrent patients receiving either <e22> methadone </e22> or <e23> phenytoin. <|endoftext|>
effect	Coadministration of <e10> acetaminophen </e10> and <e20> quinidine </e20> produces a reduced plasma concentration of coadministration of erythromycin, a lower plasma concentration of salicylate, a lower plasma concentration of quinidine and a lower plasma concentration of salicylate. <|endoftext|>
effect	These effects are reversible when the metabolite_binding globulin in vitro is inhibited and excretion is increased by <e10> cyclosporine </e10>. <|endoftext|>
effect	Other psychotropic_agents that may be given concurrently: <e10> diclofenac </e10> and <e20> phenytoin </e20>, particularly in combination with <e22> prednisolone </e22>. <|endoftext|>
effect	The administration of alcohol (2 mg daily, as needed) with <e10> morphine </e10> is not recommended when <e22> ketoconazole </e22> is given concurrently with morphine. <|endoftext|>
effect	such as diuretics, <e10> magnesium </e10> and corticosteroids, should be avoided as they may interact with certain antihypertensive_agents (e,g,, <e20> magnesium </e20>, and/or potassium ). <|endoftext|>
effect	Concomitant administration of <e10> phenytoin </e10> with an alternate estrogenic diuretic, or <e22> metoprolol </e22> with a nonhydrochloric androgens, may reduce the clinical effect of <e20> concomitant <e20> estrogen </e20>. <|endoftext|>
effect	In another study, patients receiving <e12> TIRONET </e12> did not experience any clinically significant increases in plasma levels of dopamine, nor did they increase the plasma levels of salicylates and salicylates. <|endoftext|>
effect	<e10> Astromycin </e10>, <e22> morphine </e22>, and sedative_hypnotics such as <e20> phenytoin </e20> may interact with sedative_hypnotics, especially when concurrently given together with phenytoin. <|endoftext|>
effect	The interaction between <e10> rifampin </e10> and <e20> naproxen </e20>, or the combination of naproxen and naproxen, has been reported following pharmacokinetic studies with patients taking risperidone or cimetidine and following intravenous administration of antipsychotics (e,g,, amiodarone, amiodarone-type # ). <|endoftext|>
effect	However, as in studies with the <e12> <e20> morphine </e20>, no statistically significant difference was observed in the change in plasma concentrations of the two classes of <e20> morphine </e20> when compared to the <e20> morphine_oxidase_inhibitor </e20>. <|endoftext|>
effect	<e10> Carbamazepine </e10> may interfere with metabolism of <e20> morphine </e20> and certain carbamazepine metabolites. <|endoftext|>
effect	such as antacids, antidepressants, <e10> cyclosporine </e10> and <e20> phenytoin </e20>. <|endoftext|>
effect	<e10> Benzodiazepines </e10> : In clinical studies with patients receiving <e20> ketoconazole </e20>, <e22> phenytoin </e22>, and <e22> methotrexate </e22>, pharmacologic or pharmacodynamic interactions should be considered when an interaction occurs. <|endoftext|>
effect	<e10> Aroacid </e10> may induce an increase in the serum iron levels in the CNS and other parts of the brain resulting in increased CNS activation. <|endoftext|>
effect	Both <e10> Phenobarbital </e10> and <e20> aldaparin </e20> have significant inhibitory effects on the central nervous system. <|endoftext|>
effect	Drugs containing <e12> ketoconazole </e12> : theophylline, quinidine, <e20> temazepam </e20>, cyclosporine, cyclosporine_sodium, butorphanol, quinidine_sodium, warfarin, temazepam_diuretics, phenytoin, succinylcholine, triazole, <e22> warfarin </e22>
effect	<e10> NSAIDs </e10> : <e20> beta-blockers </e20>, cimetidine, diuretics, diazolam, naltrexone, and quinidine may reduce the absorption of <e22> beta-blockers </e22>. <|endoftext|>
effect	Based on a single dose of <e10> CIM-100 </e10>, <e20> clozapine </e20> was given to men taking <e20> fenofibrate </e20> and women taking cimetidine. <|endoftext|>
effect	Patients with an elevated level of vitamin_D_D should be carefully monitored closely for the possible involvement of certain substances in their serum levels. <|endoftext|>
effect	<e10> Phenobarbital </e10> ( erythromycin ) and <e20> ampicillin </e20> should be avoided during the development of the CNS hypersensitivity reaction. <|endoftext|>
effect	Therefore, we used <e10> dizoxazole </e10> in patients receiving chemotherapy for cancer, and at least twice for patients receiving other treatment (eg, proton-blockers, <e20> alanine </e20> ). <|endoftext|>
effect	- Interactions with other antacids : <e10> acetaminophen </e10> ( Tylenol ) and <e22> lithium </e22> ( Magnesium Magnesium ) may reduce the ability of <e22> thyroid_contraceptives </e22> to treat thyroid function and diminish the pharmacokinetics of <e22> thyroid_contraceptives </e22>. <|endoftext|>
effect	Erythromycin is often used with caution when using <e10> methyldopa </e10>, an inhibitory effect of concomitant use of <e20> rifampin </e20>, concomitant use of <e22> haloperidol </e22>, or oral administration of phenytoin. <|endoftext|>
effect	Drug-induced increases in serum levels of AÎ² and C1 may result in changes in serum levels of certain antacids that may result in adverse effects on plasma metabolism. <|endoftext|>
effect	While not clinically significant, <e10> morphine </e10> may enhance <e20> anticonvulsants </e20> toxicity when administered orally in patients with <e22> alcohol </e22> intoxication. <|endoftext|>
effect	Based on evidence from patients treated with <e10> triazolam </e10>, no increase in the bioavailability of <e20> fenofibrate </e20> or fluoxetine is observed. <|endoftext|>
effect	The efficacy of <e10> pravastatin </e10> may depend on the extent to which this vitamin, a potent inhibitor of CYP3A4 activity, is coadministered with phenytoin or <e20> phenytoin </e20>. <|endoftext|>
effect	The effect of <e10> amylase </e10> on catecholamines metabolism in rats (i.e., <e20> amylase_inhibitors </e20> ) is known to be mediated by the concomitant reduction in serum CYP3A4 concentrations, as well as by the clearance of amylase_inhibitors. <|endoftext|>
effect	This is a safe and potent antihistamines that should not be taken concurrently with concomitant administration of <e10> salicylates </e10>. <|endoftext|>
effect	Pharmacokinetic effects of <e10> anticoagulants </e10>, <e22> monoamine_oxidase_inhibitors </e22>, cholestyramine and <e20> rifampin </e20> have been studied in combination with other <e22> anticholinergic_agents </e22>. <|endoftext|>
effect	In patients receiving propranolol, <e10> benzodiazepines </e10>, corticosteroids, antihypertensive medications (e,g,, sodium hypokalemia ), hypoglycemia medications (e,g,, concomitant administration of <e22> Phenobarbital </e22>, or lithium lithium salts ), benzodiazepines, and alcohol, CNS depressants (e,g,, diazepam ), the effects of <
effect	However, there is a marked increase in catecholamine and <e10> fluoxetine </e10> in the serum of <e22> ritonavir </e22> and other antacids - and in the metabolism of the drugs used to aid with the reduction of plasma Cmax. <|endoftext|>
effect	Therefore, pharmacokinetic interactions are possible with other <e10> beta-adrenergic_blocking_agents </e10> and with other CNS_blocking_agents, such as propofol, methotrexate, <e20> phenytoin </e20>, aripiprazole, lithium, <e22> benzodiazepines </e22>, and ketoconazole. <|endoftext|>
effect	<e10> Inviriquet (Trexox), a beta-blocker, may interfere with the metabolism of <e22> proton-blocking agents </e22> (e,g,, ampicillin, clofibrate, diclofenac, clarithromycin, clarithromycin-e-propionate, clarithromycin-e-butane, clofibrate, warfarin, theophylline,
effect	Acute Administration of the Erythromycin or Magnesium_Sodium_Clinidine with any of the following: ACEP3_inhibitors : Erythromycin, <e10> ACEP3_inhibitors </e10>, and amiodarone, isocarboxylate, protease-inhibitors, methotrexate, <e20> magnesium_sodium_clinidine </e20>, <
effect	<e10> Lipitor </e10> is not recommended if <e20> carbamazepine </e20> is <e20> clonidine </e20> administered concurrently. <|endoftext|>
effect	Concomitant administration of <e10> carbamazepine </e10> with <e20> carbamazepine </e20> increases the chance of increased blood levels of <e22> methyldopa </e22> and decrease the bioavailability of this inhibitor, but does not significantly alter the pharmacokinetics of this clinically significant dose. <|endoftext|>
effect	but not concomitant, isoenzolam : The concomitant administration of <e10> co-administration of coadministration of <e22> indinavir </e22> with or without cimetidine or indinavir can increase the clearance of these drugs in combination with coadministration of co-administration of indinavir with or without co-administration of co-administration of co-administration of co-administration of indinav
effect	Since <e10> Phenobarbital </e10> is metabolized by CYP3A4 enzymes, it should be noted that phenobarbital may interfere with the clearance of endogenous <e22> CYP3A4 </e22> and interfere with CYP3A4 enzyme activation. <|endoftext|>
effect	Increased urinary excretion of <e10> salicylate </e10> has been observed following administration of <e20> phenytoin </e20>, but not following administration of salicylate. <|endoftext|>
effect	Since a concurrent administration of an ethinylestradiol_conjugated with <e10> <e22> <e20> furosemide </e22> resulted in significant decreases in anticonvulsants, d-tetrahydrocannabinol (DHT) concentrations have been noted. <|endoftext|>
effect	<e10> Benzodiazepines </e10> ( Etridex, Phenobarbital, Felbatol, Fortovac, Kaletra, Kiperine, MAOIs, Phenobarbital, Triazolam, Kaletra, Norfloxacin, <e20> Valium </e20>, and St, Johns wort should not be administered alone or concurrently with a <e22> sedative_drug_containing
effect	It is highly unlikely that <e10> morphine </e10> will impair normal CNS_dopamine_receptor_activities. <|endoftext|>
effect	The potential for increased intestinal permeability to <e10> PEGIDEX </e10> and <e22> phenylbutazone </e22> is well known. <|endoftext|>
effect	Phenothiazines may affect blood levels of several of the <e10> phenobarbital </e10> ( phenobarbital, phenobarbital_sodium, <e20> metformin </e20> ) and CYP3A4 receptors, as well as increases the risk of blood clots in patients taking concomitant <e20> nelfinavir </e20>. <|endoftext|>
effect	<e10> Phenobarbital </e10> and <e20> norethindrone </e20> may increase <e21> dopamine </e21> levels in the nucleus accumbens and nucleus accumbens. <|endoftext|>
effect	Concomitant administration of <e10> methyldopa </e10> with <e22> anticonvulsants </e22> may result in an increase in plasma concentrations of <e22> potassium </e22> and aluminum. <|endoftext|>
effect	Phenothiazines : Triazine, <e10> phenothiazines </e10>, phenobarbital, and indomethacin are potent antipsychotic agents. <|endoftext|>
effect	<e10> Potassium </e10> or the salts conjugated with magnesium or potassium would prevent absorption of <e20> potassium </e20>. <|endoftext|>
effect	If <e10> cimetidine </e10> is administered chronically with <e20> rifampin </e20> or <e22> ampicillin </e22>, it should be indicated that concomitant administration of <e22> digoxin </e22> with antibiotics or other similar drugs containing digoxin or digoxin should be avoided. <|endoftext|>
effect	There have been reports that caffeine ingestion may increase blood concentrations of caffeine following exposure to <e10> caffeine_spices </e10>. <|endoftext|>
effect	Coadministration of <e12> ketoconazole </e12> with <e22> ethytoin </e22> may result in increased acetylcholine levels. <|endoftext|>
effect	While the initial results are promising, there are other potential clinical, clinical, and animal data to support the potential for the interaction of <e10> amoxicillin </e10> with other <e20> selective <e21> amoxicillin </e21> agents. <|endoftext|>
effect	In clinical studies of <e10> quinidine </e10> and cyclosporine, the dose of quinidine decreased by 18%, while the increase in plasma levels was not significant (r = 0.38). <|endoftext|>
effect	Drugs that affect the adrenergic system: -propranolol, sympathomimetics (e,g,, <e10> adrenergic_inhibitors </e10> ), <e20> naproxen </e20>, <e21> <e22> phenothiazines </e22>, barbiturates, phenytoin, and thiazides are all likely to enhance the effects of <e23> phenytoin </e
effect	Acetaminophen may cause severe side effects in an animal model that has a history of toxicity to monoamine_oxidase_inhibitors such as benzodiazepines, <e10> phenytoin </e10>, phenytoin_depressants, or methotrexate. <|endoftext|>
effect	The presence of <e10> levodopa </e10> and <e22> valproicillin in the oral cavity caused by <e22> tetracycline </e22> is clinically demonstrated to interfere with metabolism of levodopa. <|endoftext|>
effect	<e10> Coadministration of <e22> N-acetylsalicylic_acid </e22> with erythromycin, <e20> NIRACEPTEX </e20>, or cefofibrate resulted in significantly higher plasma levels of <e20> imidazole </e20>, while total plasma levels of <e20> metoprolol </e20> were approximately half that of diflu
effect	There is no relationship between ketoconazole and increased plasma levels of antidiabetic_acid_drugs. <|endoftext|>
effect	This study examined the pharmacokinetics of either <e10> dapyridine </e10> or <e22> phenytoin </e22> in treated patients receiving <e20> azathioprine </e20>. <|endoftext|>
effect	-Chenanib ( <e10> DILONIC </e10> ), <e20> phenobarbital </e20>, fluoxetine, theophylline, dronabinol, <e22> tricyclic_antidepressants </e22>, prednisolone, ampicillin, diclofenac, and temazepam. <|endoftext|>
effect	In vitro studies indicate that an intravenous_depressant_acid <e12> niacinamide </e12> (injection in healthy volunteers) increases the pharmacokinetics of <e20> phenytoin </e20> and other drugs. <|endoftext|>
effect	In the present study, we did not evaluate any interaction between dietary magnesium and diuretics, <e10> calcium </e10> and <e22> <e20> magnesium </e20>, or other noncaffeinated erythromycin ( erythromycin ) concomitantly with <e20> <e22> thiazide </e22>. <|endoftext|>
effect	It has been reported that when <e10> ketoconazole </e10> is administered in combination with # mg of <e20> naproxen </e20> and # mg of # mg of # mg of # mg of # mg of # mg of # mg of # mg of # mg of # mg of # mg of # mg of # mg of # mg of # mg of # mg of # mg of # mg of # mg of # mg of
effect	Drugs which may increase the activity of <e12> adrenergic_reuptake_inhibitors </e12> (including <e22> metformin </e22> ) may have a similar effect. <|endoftext|>
effect	Antacids and <e12> Niacin </e12> are potentiated by <e20> fluvoxamine </e20>. <|endoftext|>
effect	It is possible that additional exposures may result from higher doses of <e12> benzodiazepines </e12> and/or others that have been used for years and have been associated with hypertension, hypertension-related changes, or other side effects. <|endoftext|>
effect	Increased pharmacokinetics in normal volunteers have been reported following increases in the fraction of <e12> dibutamic_glucose </e12> and <e20> insulin </e20>. <|endoftext|>
effect	Other drugs that decrease the affinity of <e10> anticonvulsants </e10> or enhance the concomitant administration of <e22> furosemide </e22> should be avoided. <|endoftext|>
effect	A similar, but concomitant, approach was used with intravenous <e12> norepinephrine </e12> and <e20> norepinephrine_NEX </e20>, which both have high plasma levels. <|endoftext|>
effect	Although concomitant administration of <e10> azathioprine </e10> and caffeine is associated with a slight reduction in the clearance of <e20> nitrous oxide </e20> and a modest increase in the bioavailability of acetaminophen, concomitant use of these drugs should be avoided when concurrently using opioid analgesics or <e22> alcohol </e22>. <|endoftext|>
effect	In some patients, <e10> oral <e20> ketoconazole </e20>, especially with <e22> diuretics </e22>, are capable of inducing a dose-dependent decrease in <e22> alopecine </e22> plasma concentrations. <|endoftext|>
effect	It should be noted that <e12> CYP3A4 </e12> (such as CYP3A4 inhibitors), such as co-administered and metabolized methyldopa, may increase the potentiation of the <e22> cyclosporine </e22> class (conjugated) inducers. <|endoftext|>
effect	No clinically significant interaction was found between <e10> vitamin_C </e10> and <e20> vitamin_C </e20> in patients receiving the concomitant therapy of <e22> vitamin_C </e22> or a local blood thinner. <|endoftext|>
effect	In humans, <e10> antihypertensive_agents </e10> ( erythromycin, corticosteroids, <e22> lidocaine </e22>, ciprofloxacin, lidocaine-containing narcotics ), butyrozole, furosemide ( furosemide ), furosemide_depletion ( furosemide ), and/or <e20> benzodiazepines </e
effect	an antidepressant or antipsychotic, antianxiety-like effects may occur if <e10> furosemide </e10> is taken with <e20> ketoconazole </e20>. <|endoftext|>
effect	Although most patients experience no statistically significant clinical adverse effect, there is no established, established pharmacodynamic effect on <e12> <e20> carbamazepine </e20>, concomitant administration of <e22> ketoconazole </e22> or similar drugs. <|endoftext|>
effect	The concomitant administration of <e10> rifampin </e10> with <e20> cimetidine </e20> should not occur. <|endoftext|>
effect	The pharmacokinetics of <e10> concomitant administration of <e22> acetaminophen </e22> and <e20> tetracycline </e20> with <e22> alprazolam </e22> have not been studied. <|endoftext|>
effect	Although <e10> N-methyl-D-aspartate </e10> and <e20> triazolam </e20> may decrease plasma concentration of <e22> morphine </e22>, they are not the main antagonists of the CYP3A4 enzyme. <|endoftext|>
effect	Interactions: Interactions may occur when <e10> benzodiazepines </e10> are administered concurrently, and the oral contraceptive effect may be delayed or suppressed (e,g,, <e20> cimetidine </e20>, <e22> levonorgestrel ). <|endoftext|>
effect	Astrogenital_acid_depressant effects may be transient when taken at a dose lower than a dose that does not increase apomorphine or other <e10> thyroid_depressants </e10>. <|endoftext|>
effect	The present study demonstrated that an intraperitoneal administration of <e10> benzodiazepines </e10> and <e20> fibrillators </e20> potentiated the effect of <e22> benzodiazepines </e22> on CNS depressant conduction and increased the maximum excitation time of the ventral ventricle. <|endoftext|>
effect	Nervous system effects and gastrointestinal disturbances with lithium and other <e10> lithium_hypoglycemic_agents </e10> have been reported. <|endoftext|>
effect	The elimination of propranolol resulted in a decrease in plasma levels of ketoconazole, indomethacin, estrogens, <e10> ketoconazole </e10>, <e20> salicylates </e20>, indomethacin, lidocaine, temazepam, haloperidol, <e22> valproic_acid </e22>, and cimetidine. <|endoftext|>
effect	There is no known association between <e10> antihistamines </e10> and <e20> anticholinergic </e20> side effects. <|endoftext|>
effect	Concomitant use of <e12> cimetidine </e12> with <e20> ketoconazole </e20> should be stopped if the dose is reduced below 25%. <|endoftext|>
effect	- CYP3A4 : <|endoftext|>
effect	<e10> Ethanol </e10> : At this dose, ethanol is approximately 15% higher than nifedipine, and ethanol alone produces 30% to 45% lower caffeine and higher <e20> barbiturates </e20> absorption. <|endoftext|>
effect	The interaction between <e12> caffeine </e12> and <e20> norepinephrine </e20> was not examined. <|endoftext|>
effect	Therefore, a low-dose regimen of <e10> carbamazepine </e10> with carbamazepine_inhibitors or erythromycin and <e20> azathioprine </e20> with carbamazepine may decrease the elimination of <e22> ketoconazole </e22> and potentially prolong the plasma half-life of ketoconazole. <|endoftext|>
effect	Therefore, the effect of <e10> aspirin </e10> on the inhibition of certain CYP3A4 enzymes has been studied in a clinical setting. <|endoftext|>
effect	The primary pharmacological interaction of <e10> nifedipine </e10> with <e20> tetracycline </e20> is by its elimination from plasma levels, leading to an increase in hepatic clearance of the drug. <|endoftext|>
effect	such as sedative_medications, anticonvulsants, <e12> antacids </e12>, or other potent <e20> anticonvulsants </e20> that may enhance its absorption. <|endoftext|>
effect	<e10> Prolonged oral administration of <e20> naltrexone </e20>, a potent inducer of the serotonin-neuronal_antagonists (e,g,, <e21> aspirin </e21> ), may impair the efficacy of <e22> antihypertensive_agents </e22>, clarithromycin, <e23> valproic_antibiotics </e23>, azithromycin, or
effect	Although CYP3A4, butyrate and vitamin_C should not be used concurrently, vitamin_C may be a potent antioxidant. <|endoftext|>
effect	<e12> MAO-inhibitors </e12> may increase the clearance of erythromycin (e,g,, phenytoin, or </e12> ketoconazole ) in individuals who are taking <e22> diuretics </e22>, including <e22> carbamazepine </e22>, <e22> diuretics </e22>, and carbamazepine. <|endoftext|>
effect	<e10> Agonist : Anticoagulants </e10> and <e20> azathioprine </e20> may have an additive effect on the pharmacokinetics of oxcarbazole, as well as interfere with other CYP3A4 substrates. <|endoftext|>
effect	In humans, there is no significant effect of <e10> NSAIDs </e10> on the extent of hyperprolactinemia or hyperparathyroidism. <|endoftext|>
effect	A combination of <e12> ketoconazole </e12> and <e20> coadministration of <e22> ketoconazole </e22> with a chewable powder may result in a small increase in plasma levels of <e20> ketoconazole </e20> in certain patients. <|endoftext|>
effect	Other drug interactions have been reported in patients receiving nifedipine_acetol. <|endoftext|>
effect	The potential interactions of <e10> ketoconazole </e10> with other opioids and benzodiazepines, <e20> opiates </e20>, narcotic-like substances, non-steroidal_depressants, <e21> methotrexate </e21>, and tranquilizers have not been established. <|endoftext|>
effect	A pharmacokinetic profile for phenytoin was assessed using 4-hydroxy_phenytoin (EXP), phenytoin alone or in combination with <e12> phenytoin </e12>, at 4 weeks after administration of # mg of # mg of erythromycin. <|endoftext|>
effect	Therefore, it has been recommended that the use of <e10> quinidine </e10> with the following active components of <e20> rifampin </e20> and <e22> norepinephrine </e22> is recommended: norepinephrine, progestin, quinidine, and <e22> diphenhydramine </e22>. <|endoftext|>
effect	There have been reports of concomitant pharmacologic interactions between CYP3A4, CYP3A4_serotonin_adrenergic_blocking_agents, <e12> corticosteroids </e12>, <e20> metformin </e20>, and a CYP3A4_serotonin_blocking_agent. <|endoftext|>
effect	<e12> Agonistin </e12> and other antibiotics may increase the risk of <e20> HIV </e20> toxicity. <|endoftext|>
effect	<e10> Nuxor </e10> is a potent antihistamines, and may decrease blood pressure when used as a concomitant with <e20> prednisolone </e20>. <|endoftext|>
effect	Antimicrobial Agents, as well as <e10> concomitant use of <e20> phenytoin </e20> with narcotics such as narcotics containing <e20> salicylates </e20>, or benzodiazepines, should be avoided. <|endoftext|>
effect	In patients taking <e10> metformin </e10>, it may be useful to avoid <e20> metformin </e20> concomitantly with other drugs that may potentiate the effects of metformin. <|endoftext|>
effect	<|endoftext|>
effect	The clinical presentation of <e10> CRIARACTIVE </e10> may suggest increased use of <e20> CYP3A4 </e20> in patients taking CYP3A4. <|endoftext|>
effect	Drugs which inhibit the CYP3A4 pathway and the phosphorylation of a protein necessary for metabolism of <e10> ketoconazole </e10> may also have a negative effect on the hepatic metabolism of ketoconazole. <|endoftext|>
effect	Coadministration of <e12> nelfinavir </e12> with anticonvulsants, such as <e20> clofibrate </e20>, has been shown to have no clinically significant effect. <|endoftext|>
effect	In healthy volunteers, <e10> Teflon </e10> was shown to increase plasma levels of ampicillin by 40% when a dose of # mg was given <e20> haloperidol </e20> plus <e22> ampicillin </e22> or with either a beta-blocker or a <e22> beta-blocker_channel_inhibitor_inhibitor </e22>. <|endoftext|>
effect	Interactions with <e10> corticosteroids </e10> may be more pronounced if <e20> corticosteroids </e20> are given concurrently and <e22> concomitant therapy with either <e23> antipsychotics </e23> or <e24> anticonvulsants </e24>. <|endoftext|>
effect	When <e10> Phenobarbital </e10> is given concomitantly with rifampin, <e20> diazepam </e20>, benzodiazepines, <e22> prednisolone </e22>, prednisolone, coumarin, warfarin, warfarin, erythromycin, and oral antibiotics, the action of <e20> phenobarbital </e20> is diminished
effect	Although there is no known interaction between <e10> tetracyclines </e10> and CCR6, the effects of tetracyclines on the CYP2D6 and CYP2C9_inhibitors involved may be similar. <|endoftext|>
effect	The influence of <e10> amylase </e10> is limited by the effect of amylase on the <e20> Coadministration of <e22> VANEX </e22>. <|endoftext|>
effect	Cimetidine -induced reduction in serum MAO -induced levels in subjects receiving <e10> cimetidine </e10> -controlled doses (12 mg/kg/day) and <e22> cimetidine </e22> (12 mg/kg/day) in vivo were not observed. <|endoftext|>
effect	<e10> Niacin </e10> : <e20> diuretics </e20> and <e22> antihypertensive_agents <|endoftext|>
effect	When <e12> ketoconazole </e12> is administered concurrently with phenobarbital ( <e20> VNAP </e20> ), the vasoconstriction may result. <|endoftext|>
effect	The use of <e10> phenytoin </e10> may decrease the plasma levels of <e20> dihydrochlorothiazide </e20> and aromatic_antagonists, increase the plasma excretion of <e22> acetaminophen </e22> and may alter renal renal clearance in some patients. <|endoftext|>
effect	<e10> Ketoconazole </e10> -induced anxiolytic effects may occur if a patient with CYP3A4-mediated CNS depressant interactions is receiving <e20> nelfinavir </e20>, or concomitant administration of CNS depressant to CNS depressants (e,g,, <e21> sertraline </e21> and fluoxetine ) with <e22> tricyclic_antidepress
effect	Although <e12> Aderafrime </e12> should not be used on patients who have received other NSAIDs, should not be used with acetaminophen with concomitant use of antacid_drugs such as acetaminophen, albendazole, cyclosporine, <e20> ampicillin </e20>, ergotoxan, clofibrate, verapamil, or temazepam. <|endoftext|>
effect	-C-glucuronide -coumarin -corticosteroids Oral contraceptives: <e10> diclofenac </e10>, <e20> progestin </e20>, <e22> oral contraceptives </e22>, <e23> antifungals </e23>, and oral contraceptives containing <e23> quinidine </e23>, may reduce the plasma concentrations of these drugs and increase the
effect	The CYP3A4 enzyme_depletingant, CYP3A4, is known to be activated by <e10> thyroid_depletingants </e10> and thyroid_irritants, causing increased thyroid clearance and clearance of <e20> thyroid_serum </e20>. <|endoftext|>
effect	<e10> Coadministration of <e20> erythromycin </e20> with a <e22> thyroid_stimulator </e22> may result in significant decreases in the thyroidal effects of lithium. <|endoftext|>
effect	The therapeutic effect of <e10> benzodiazepines </e10> on the central nervous system (CNS) has been examined in patients treated with hypoglycemia with <e20> sertraline </e20>, and in patients treated with a combination of benzodiazepines and sedatives. <|endoftext|>
effect	Drugs that inhibit the CYP3A4 enzyme Cys_Akt, e,g,, quinidine, doxycycline, diazepam, warfarin, <e10> warfarin </e10>, cimetidine, morphine, barbiturates, phenytoin, barbiturates-_bromide, warfarin_hydrochloride, warfarin_lactate, warfarin_methion
effect	Although pharmacokinetics of ampicillin and its metabolite, <e10> lovastatin </e10>, may be unaffected by alcohol, if <e22> verapamil </e22> is used on a lower dose than usual, it is possible that other drug interactions may occur. <|endoftext|>
effect	Therefore, <e10> carbamazepine </e10> and #_TNF_antagonists were administered concurrently, <|endoftext|>
effect	<|endoftext|>
effect	In the current study, we observed a decrease in serum levels of ketoconazole and <e11> ketoconazole </e11> within weeks after initial administration of <e20> ketoconazole </e20> and ketoconazole, and an increase in serum levels of ketoconazole. <|endoftext|>
effect	<e10> amiodarone </e10> : In a crossover trial of patients receiving either <e20> anacine </e20> or amiodarone, there was a statistically significant reduction in the clearance of the amiodarone diuretic by #% in # hours after oral administration. <|endoftext|>
effect	Concurrent administration of <e10> naltrexone </e10>, or a combination of them, with <e20> cimetidine </e20>, resulted in no significant changes in the pharmacokinetics or plasma levels of alprazolam. <|endoftext|>
effect	because these effects occur during prolonged <e10> antihistamines </e10>, have been reported. <|endoftext|>
effect	Co-administration of caffeine with any non-medicated drug (e,g,, <e12> lithium </e12> ) should be considered in combination with the following: <e20> anticonvulsants </e20>, or an oral solution containing both the catecholamines ( lithium and <e22> lithium_anticonvulsants </e22> ) and <e23> aripiprazole </e23>. <|endoftext|>
effect	Atopic dermatitis and <e10> eneressin </e10>, some patients may experience a small but persistent increase in anorexia nervosa, and <e20> dithiostatin </e20> may result in a reduced clearance of <e22> eneressin </e22>. <|endoftext|>
effect	While <e10> Antidepressants </e10> may enhance neuroendocrine effects, concomitant use of the above medications with cimetidine and <e20> corticosteroids </e20> may increase the toxicity of <e20> corticosteroids </e20>. <|endoftext|>
effect	However, in rats, <e10> digoxin </e10> resulted in a substantially increased plasma_glucose concentration compared to those following <e20> digoxin </e20>. <|endoftext|>
effect	Natalizumab may decrease the pharmacokinetics of <e12> ibuprofen </e12> in dogs who do not have a <e22> ketoconazole </e22> diet. <|endoftext|>
effect	Drug-related adverse events include: gastrointestinal disturbances (e,g,, indigestion ); muscle and neuromuscular problems (e,g,, neuromuscular paralysis ); headache; blurred vision; renal dysfunction (e,g,, renal failure ); weakness (e,g,, hypertension ); and seizures. <|endoftext|>
effect	At the initiation of therapy with CYP3A4 inhibitors (e,g,, MAOIs or phenothiazines ), the combination of <e10> tetracycline </e10> and <e22> methotrexate </e22> must be discontinued and concomitantly <e20> concomitant_use_inhibitors </e20> must be initiated. <|endoftext|>
effect	The pharmacokinetics of <e10> fluoxetine </e10> and other <e20> <e22> ketoconazole </e22> are comparable. <|endoftext|>
effect	<e10> Proton-CoA </e10> - and <e20> Coadministration </e20> may be administered concurrently or concurrently with proton-coA. <|endoftext|>
effect	<e10> PEG-1 </e10> may inhibit its binding to renal tubular receptors. <|endoftext|>
effect	but because there is no known association between <e10> ibuprofen </e10> and blood pressure and concomitant use of <e22> antihypertensive_antibiotics </e22>, there may be increased risk of death. <|endoftext|>
effect	<e10> Phenobarbital </e10> may decrease plasma concentrations of <e20> furosemide </e20> and cimetidine. <|endoftext|>
effect	Combination of <e10> citalopram </e10> with other <e20> antidepressants </e20> may reduce the benefits of CYP3A4 (eg, <e22> barbiturates </e22> ), clozapine, warfarin, and zolpidem. <|endoftext|>
effect	"Furthermore, when AIM is administered with <e10> amiodarone </e10>, <e20> beta-blockers </e20>, or other beta-blockers, there is increased plasma concentrations of amiodarone and other beta-blockers, which may have a potent <e20> anticoagulant effect."" <|endoftext|>"
effect	<e10> Choline </e10> may enhance the metabolic effect of <e22> phenothiazines </e22> and enhance their clearance of dopamine. <|endoftext|>
effect	The effects of this opioid agonist on the binding of <e10> fentanyl </e10> to opioid receptors may be increased when <e20> morphine </e20> is administered to the same volume of the oral brain. <|endoftext|>
effect	The effectiveness of <e12> ketoconazole </e12> in healthy volunteers is therefore augmented by the additive effects of <e20> amitriptyline </e20> and <e22> verapamil </e22>. <|endoftext|>
effect	In a study of rats treated with s/n â¥10 mg/kg_dose of <e10> siponam</e10>, there was no significant difference in plasma concentrations of <e20> phenytoin </e20> and <e22> fluconazole </e22>. <|endoftext|>
effect	Thus, at least in rats given <e10> tranylcypromine </e10> or <e20> phenytoin </e20>, these antipsychotics should not occur in highly elevated concentrations because of the possible interaction between the effects of these two drugs on catecholamine_inhibitors. <|endoftext|>
effect	Antacids : <e10> Antifungals </e10> can interfere with the anticoagulants that induce hypertension. <|endoftext|>
effect	In clinical trials, <e10> VARALONE </e10> is contraindicated and should not be given in conjunction with other <e20> antihypertensive_agents </e20> or at <e22> other time periods. <|endoftext|>
effect	Also, in patients who received d-amphetamine_benzodiazepines such as <e11> erythromycin </e11> or other <e20> tranquilizers </e20>, erythromycin may interfere with the pharmacokinetics of <e22> d-amphetamine </e22>. <|endoftext|>
effect	Therefore, prolonged exposure to <e12> corticosteroids </e12> and # # mcg/kg doses of <e22> lithium </e22> with <e20> aluminum </e20> may reduce the clearance of lithium and aluminum, respectively, resulting in an increase in the plasma levels of # mcg of aluminum and # mcg of lithium. <|endoftext|>
effect	Coadministration of <e10> N-acetylcholine </e10> with <e20> quinidine </e20> may increase its toxicity, and concomitantly, the clinical effects of these medications may be diminished. <|endoftext|>
effect	HCl and <e10> phenytoin </e10> : inducers of cimetidine receptor antagonism (decrease in concentration and concomitant release of potent opioids ) occur with high-dose, <e20> acetaminophen </e20>, and/or <e22> nifedipine </e22>, respectively. <|endoftext|>
effect	A combination of <e10> caffeine </e10> and alcohol </e10> may enhance the effects of other opioids. <|endoftext|>
effect	Patients receiving a pharmacokinetic profile similar to that used in dogs with schizophrenia may require coadministration of <e10> amiodarone </e10> with a <e20> potentiation_agent </e20>. <|endoftext|>
effect	- Diuretics : - Concomitant use of <e10> morphine </e10> with <e20> rifampin </e20> should be avoided, because of the potentially deleterious effect on diuretics and sedative-hypnotics. <|endoftext|>
effect	However, the results indicate that when <e12> carbamazepine </e12> is given concurrently with <e22> nelfinavir </e22>, plasma levels of carbamazepine and <e20> carbamazepine </e20> will be significantly increased. <|endoftext|>
effect	In the general population, <e10> carbamazepine </e10> ( Zymazepine ) and ketoconazole ( <e20> Kalgoril </e20> ) are frequently used concurrently. <|endoftext|>
effect	Coadministration of <e12> lithium </e12> with <e20> clozapine </e20> may be effective in inhibiting tumor necrosis factor-Î±, blocking chemotherapy-induced apoptosis, or initiating other therapeutic antiseptic-related anticonvulsants. <|endoftext|>
effect	Drugs other than <e10> ketoconazole </e10> may increase the CNS effects of <e22> ketoconazole </e22>. <|endoftext|>
effect	such as concomitant use of the <e12> norepinephrine </e12> system, for <e20> fluoxetine </e20> and <e21> valproic acid </e21> may cause severe side effects. <|endoftext|>
effect	Pharmacokinetic and pharmacodynamic effects of <e10> carbamazepine </e10> and <e22> rifampin </e22> on patients receiving carbamazepine, <e20> lidocaine </e20>, quinidine, <e20> cyclosporine </e20>, and warfarin may occur. <|endoftext|>
effect	A decrease in plasma levels of H2C9 (e,g,, <e10> H2C9 </e10> ) may be important when CYP3A4 inhibitors such as <e20> estrogens </e20> or progestogens (e,g,, methotrexate ) are used concurrently. <|endoftext|>
effect	While an increased <e10> antacids </e10> plasma concentrations may be needed to slow down the clearance of a given <e22> HIV_antibiotics </e22>, this therapy is not recommended to patients receiving <e20> methyldopa </e20>. <|endoftext|>
effect	<e10> Concomitant use of any drugs containing phenytoin, indomethacin, ketoconazole, terfenadine, or other prednisolone (see WARNINGS) that do not enhance <e20> dopamine_blocking_agents </e20> metabolism, such as chlorpromazine, ketoconazole, and <e22> cyclosporine </e22>, may result in a significant decrease in central potassium and potassium
effect	<e10> Prothrombin_Agents </e10> : <e22> Cimetidine </e22> may potentiate some of the effects of coadministration of prednisolone, progestogens, or other tranquilizers. <|endoftext|>
effect	<e10> Ketoconazole </e10> should not be used with opioids (e,g,, quinidine, cimetidine, <e20> methotrexate </e20>, phenytoin, tranquilizers, quinidine, or any other potentiating_drugs such as barbiturates, barbiturates, <e20> warfarin </e20>, and <e20> cimetidine </e20
effect	The pharmacokinetics of <e12> antacid_sodium_depleting_agents </e12> and acetaminophen in pediatric patients receiving pharmacodynamic adjustment should be considered when using these agents in combination with the <e20> drug_drug_inhibitors </e20>. <|endoftext|>
effect	The effect of a single oral solution of <e10> VICTOR </e10> is significantly lower in healthy volunteers who are receiving <e20> rifampin </e20>. <|endoftext|>
effect	In clinical studies, erythromycin, <e10> ketoconazole </e10>, and <e20> aspirin </e20> are safe and effective in preventing anorexia nervosa. <|endoftext|>
effect	Combination of <e12> quinidine </e12> with other antacids, such as <e22> diphenhydramine </e22>, anticonvulsants, and sympathomimetics, may be required to achieve steady-state elimination of <e20> quinidine </e20>. <|endoftext|>
effect	in conjunction with other drugs such as <e10> ampicillin </e10> and prednisolone, it has been suggested that the use of concomitant use of <e22> anticonvulsants </e22> in combination with anticonvulsants may result in a greater incidence of <e22> sedative_inhibitors </e22>. <|endoftext|>
effect	Anticholinergic Agents : Combination with <e10> clonidine </e10> may increase the plasma concentrations of anticholinergic agents and decrease their bioavailability. <|endoftext|>
effect	The coadministration of <e10> quinidine </e10> with <e20> morphine </e20> or ketoconazole has been associated with impaired ketoconazole metabolism and decreased renal clearance in rats. <|endoftext|>
effect	concomitant with lithium_oxidase_drug_interactions, <e10> lithium </e10> may interfere with <e22> lithium_oxidase_drug_interactions </e22> in the concomitant administration of other <e22> lithium_oxidase_drugs </e22>. <|endoftext|>
effect	It has been reported that <e10> fenfluramine </e10> in plasma plasma during the administration of clonidine -induced hyperkalemia and diazepam-induced vomiting is not related to fenfluramine toxicity. <|endoftext|>
effect	or even a reduced <e10> potassium </e10> may also be needed. <|endoftext|>
effect	Oral <e10> diclofenac </e10>, concomitantly with <e20> morphine </e20>, may cause hepatic and renal failure. <|endoftext|>
effect	<e10> Oral </e10> : The ingestion of oral oral <e22> oral_depressants </e22> is not recommended, since the clinical effects are much less pronounced when these drugs are administered concurrently. <|endoftext|>
effect	Concurrent use of a <e10> cimetidine </e10> with any of the following medicines: oral contraceptives, birth control pills, and <e20> anticoagulants </e20> : lithium and thyroid hormones, anticonvulsants, cyclosporine, phenytoin, anticonvulsants, aspirin, <e22> lithium </e22> (preventive-antacid), warfarin (preventive-
effect	The following medications may increase the pharmacokinetics of <e12> tetracyclines </e12>, such as cimetidine, aripiprazole, tricyclic_antidepressants ( <e20> clonidine </e20> ), <e22> sedative_drugs </e22>, and phenytoin. <|endoftext|>
effect	Antihypertensive-antibiotics may be administered to patients receiving <e10> alapramide </e10>. <|endoftext|>
effect	The elimination of <e10> propranolol </e10> may be associated with decreased plasma levels of propranolol, an an inhibitor of <e22> insulin </e22> metabolism. <|endoftext|>
effect	Prolonged use of <e12> ketoconazole </e12> and <e22> diclofenac </e22> is a less effective method of reducing the antihypertensive effects of erythromycin. <|endoftext|>
effect	<e12> Anticonvulsants </e12> have potent antipsychotic effects. <|endoftext|>
effect	Probenecid may be safely used alone or in combination with other <e10> antibiotics </e10>, other <e20> benzodiazepines </e20>, antihistamines, and other general-purpose antibiotics. <|endoftext|>
effect	There is no pharmacokinetic interaction with other <e12> opioids </e12>. <|endoftext|>
effect	Patients with chronic renal failure may experience increased blood pressure and tachycardia. <|endoftext|>
effect	Protease-blocking drugs may reduce the incidence of patients who undergo therapy-resistant depression. <|endoftext|>
effect	Therefore, if <e10> NSAIDs </e10> should be used with caution, they should be taken with caution when they occur on <e20> nelfinavir </e20> as they may increase the chance of diarrhea. <|endoftext|>
effect	Pharmacokinetics of <e10> Phenytoin </e10> may also be increased in patients receiving ketoconazole or <e20> ketoconazole </e20>. <|endoftext|>
effect	Other drugs with an additive action have been reported to enhance or decrease the antidepressant effects of SSRIs. <|endoftext|>
effect	A number of studies have shown that <e10> amiodarone </e10> is potentiated by amiodarone, and similar results have been reported with the administration of concomitant <e22> antihypertensive_agents </e22>. <|endoftext|>
effect	Therefore, caution should be exercised when <e10> citalopram </e10> is administered with any pharmacological action that is reported following concomitant administration of citalopram with narcotics such as morphine, morphine derivatives, or nitrous_oxide, or drugs containing benzodiazepines such as <e20> clonidine </e20>. <|endoftext|>
effect	The concomitant administration of <e12> albuterol </e12> (40 mg/day for a total of 72 hours) with lithium, ethinyl_estradiol, barbiturates, # mg/day of <e20> cimetidine </e20> or another lithium drug ( # mg/day for a total of 51 hours) has been reported to reduce calcium levels and decrease renal excretion in rats. <|endoftext|>
effect	<e10> Antacids </e10> or other antacid-like effects on the blood-pressure_lowering_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_
effect	It is not known whether this is the effect of oral <e10> diazepam </e10> on a general anesthetic-induced analgesia or an <e22> potentiation </e22> to a general anesthetic-induced analgesia. <|endoftext|>
effect	The results of such studies were found to be inconclusive, because plasma concentrations of <e10> nelfinavir </e10> were not elevated. <|endoftext|>
effect	With all four doses of vitamin_D, # mg oral vitamin_D_enriched <e10> aspirin </e10> containing <e22> tetracyclines </e22> was administered concurrently. <|endoftext|>
effect	There is no data available regarding the additive effect of <e12> diclofenac </e12>, <e22> ketoconazole </e22>, or diclofenac. <|endoftext|>
effect	<e10> Cholestyramine </e10> may interact with the following medicines: ACE_inhibitors <e20> barbiturates </e20>, benzodiazepines, tranquilizers, and sedatives. <|endoftext|>
effect	Therefore, when the <e10> ketoconazole </e10> is administered with potassium clonidine and <e22> diuretics </e22>, oral calcium concentrations should be increased. <|endoftext|>
effect	<e10> Propranolol </e10>, <e20> phenytoin </e20>, vitamin_D2, potassium, and some antacids, may increase the CNS antihypertensive effect of CYP3A4 inhibitors. <|endoftext|>
effect	Because caffeine is metabolized in <e10> phenytoin </e10>, it is possible that other potentially toxic <e22> antidepressants </e22> may increase or decrease its metabolizing activity. <|endoftext|>
effect	<e10> L-myroxyphenicol </e10> should not be administered to patients who are on either of the following medications: <e22> phenytoin </e22> or valproic acid. <|endoftext|>
effect	<e10> Carbamazepine </e10> may interact with the interaction of <e20> temazepine </e20> and <e21> amitriptyline </e21>. <|endoftext|>
effect	<e10> Coadministration of <e20> aspirin </e20> with <e21> ampicillin </e21> resulted in a significant increase in the plasma concentrations of the pharmacologically active <e22> cyclosporine </e22> and <e23> temazepam </e23>. <|endoftext|>
effect	<e10> Phenobarbital </e10> : In patients receiving <e20> phenobarbital </e20>, concomitant administration of <e21> phenobarbital </e21> with an IV <e22> phenobarbital </e22> should be expected. <|endoftext|>
effect	This study also evaluated the effect of furosemide on the metabolism of <e10> metoprolol </e10>, but with less potent results. <|endoftext|>
effect	Although the pharmacokinetics of <e10> cimetidine </e10> are similar to those of concomitant antibiotics, dosing or maintenance of <e20> oral contraceptives </e20> is recommended for patients who need <e22> propranolol </e22> therapy for the following: <e22> hypertension </e22> and diabetic or cardiac disease. <|endoftext|>
effect	There is no known effect of <e10> antiarrhythmics </e10> on the serum and/or plasma levels of either NSAIDs </e10> or any of the following: - NSAIDs - Antacid_Drugs <e20> cimetidine </e20> - Antacid_Drugs <e20> cyclosporine </e20> - Antiarrhythmics <|endoftext|>
effect	Because <e10> Coadministration_of-hydrocortisone </e10> and oral <e20> cyclosporine </e20> inhibited myocardial infarction in healthy volunteers, it should be noted that both oral and oral administration of <e20> cyclosporine </e20> (e,g,, amiodarone, temazepam, fluoxetine, and fluvoxamine ) should not be used
effect	It has been shown that phenytoin and <e10> tricyclic_antidepressants </e10> may produce potent psychotropic effects when administered concomitantly with <e20> concomitant psychotropic_drugs </e20>. <|endoftext|>
effect	Contraceptives : Although the amount of the drug given may vary slightly from one patient to the next, it is recommended that patients taking <e10> carbamazepine </e10> should be administered with the following drugs: acetaminophen, cimetidine, <e20> amiodarone </e20>, and cimetidine. <|endoftext|>
effect	A second example of such studies is the Aromoadministration of erythromycin with nelfinavir in patients receiving concomitant administration of <e10> quinidine </e10> with antacid <e20> sildenafil </e20> and its associated salts (e,g,, halothane ). <|endoftext|>
effect	This interaction has been shown to be important for: (i) maintenance of <e10> diltiazem </e10> in patients receiving <e22> theophylline </e22>, corticosteroids, and cholestyramine. <|endoftext|>
effect	There has been a steady increase in the incidence of <e10> methyldopa </e10> and <e20> azithromycin </e20> in the pharmacokinetics of the latter. <|endoftext|>
effect	f <e10> Coadministration of <e20> nelfinavir </e20> with <e22> phenytoin </e22> resulted in a 15% decrease in the blood levels of <e20> ketoconazole </e20> (approximately USPUC) and significantly lower plasma concentrations of <e22> coadministration of <e20> phenytoin </e20> with phenytoin and concomitant
effect	- <e10> Carbamazepine </e10> has been shown to decrease the clearance of insulin-like growth factor-B (IGF-B), a metabolite of FASP, in some subjects and increases in aflatoxin levels. <|endoftext|>
effect	Since cefuroxime (an NSAID) and <e10> norethindrone </e10> have similar concentrations and are administered with <e22> ketoconazole </e22> and <e22> norethindrone_conjugate </e22>, the effect of ketoconazole and norethindrone should be considered when caution should be exercised when concomitantly administering the same regimen. <|endoftext|>
effect	<e10> AstraZeneca </e10> and other corticosteroids may interact with <e20> phenytoin </e20>. <|endoftext|>
effect	<e12> NSAIDs </e12> can be administered <e20> ibuprofen </e20> or <e22> ampicillin </e22> in combination with <e22> temazepam </e22> to increase the risk of serious adverse reactions. <|endoftext|>
effect	Astralfacial effects may occur when concomitant administration of <e10> alfalfa </e10>, an alcohol-containing metabolite, with phenytoin ( erythromycin ) may result in phenytoin toxicity. <|endoftext|>
effect	Interactions: Niacin may interact with certain antacid_reuptake_agents, which may result in <e12> concomitant administration of <e20> cimetidine </e20> and other <e22> phenytoin </e22>. <|endoftext|>
effect	The clinical pharmacokinetics of <e10> lysergic_blocking_agents </e10> are unknown. <|endoftext|>
effect	In addition, when administered concomitantly with other <e10> diuretics </e10>, <e20> temazepam </e20>, aspirin, estrogens, acetaminophen, levodopa, thyroid_depressants, and <e22> sedatives </e22>, <e22> thyroid_depressants may interact with the beta-adrenergic system, leading to elevated levels of the same beta-adrenergic
effect	Concomitant use of <e10> warfarin </e10> in combination with <e20> phenytoin </e20> or warfarin alone should not be tolerated. <|endoftext|>
effect	In patients receiving <e10> methadone </e10>, renal function can be impaired and blood levels decrease when the concomitant administration of <e22> coadministration_to_IVHAC </e22> is concomitantly given. <|endoftext|>
effect	Asteroid interactions with the thyroid_compound_drug_drug_drugs_containing_drugs_inhibitors have been reported in the context of <e10> methotrexate </e10>. <|endoftext|>
effect	Thus, <e10> rifampin </e10> may interfere with the clearance of <e22> oral </e22> preparations by cations or by oral-acidic_acid_acid_acid_acid. <|endoftext|>
effect	It is suggested that pharmacokinetic (dose) of <e10> ketoconazole </e10> in combination with <e20> tricyclic_antidepressants </e20> may enhance the pharmacokinetics of these drugs. <|endoftext|>
effect	<e10> erythromycin </e10> and other drugs that increase the clearance of <e20> sympathomimetic_agents </e20> from the CNS and thereby may impair the metabolism of these agents. <|endoftext|>
effect	In a study, <e12> oral <e20> oral contraceptives </e20> were given to 18 healthy volunteers concurrently with <e20> ketoconazole </e20> given concurrently with a daily dose of # mg to decrease <e22> creatinine </e22> by 87%. <|endoftext|>
effect	Preliminary studies indicate that niacin may be administered in conjunction with <e10> amiodarone </e10> or other selective antipsychotic_agents, which may be associated with elevated plasma levels of niacin. <|endoftext|>
effect	Antihypertensive Agents : <e10> Antibiotics </e10> : Cholestyramine, <e20> ampicillin </e20>, antibiotics_inhibitors, phenytoin, <e21> probenecid </e21>, salicylic_acid_antibiotics, verapamil, tetracyclines, diclofenac, <e22> phenytoin </e
effect	Although the interaction between these agents has not been established, the results of the <e10> naltrexone </e10> plasma concentrations are comparable to those of <e20> potentifolium </e20>, with or without any additive effect. <|endoftext|>
effect	Administration of <e10> antihypertensive_agents </e10> (eg, <e20> digoxin, <e20> thiazide </e20>, phenytoin, corticosteroids, phenothiazide, and theophylline ), a substrate to which both protease_inhibitors and protease_inhibitors have been added (e,g,, tricyclic_antidepressants ), has been shown to alter
effect	It is not recommended that other CNS_blocking agents be used with the CNS_blocking_agents_inducers_inducers package (e,g,, azithromycin, halothane, <e10> diltiazem </e10>, omeprazole, prednisolone, triamterene, <e22> clofibrate </e22>, <e22> phenobarbital </e22>, rifadin,
effect	Based on the data collected from three patients in whom serum concentrations of <e12> furosemide </e12> or <e20> divalvox </e20> had been obtained in addition to those in whom serum concentrations of ketoconazole and ketoconazole were obtained, results of a single study showed that the serum concentrations of both ketoconazole and furosemide in patients receiving the second-generation (1,6 mg/day) ant
effect	The following pharmacokinetic studies showed a reduction in plasma <e12> beta-blockers </e12> and progestogens and decreased plasma levels of propranolol. <|endoftext|>
effect	It has been reported that concomitant administration of <e12> azathioprine </e12>, cimetidine, clofibrate, and <e20> ampicillin </e20> can increase the clearance of <e22> <e23> azathioprine </e23> by 50%. <|endoftext|>
effect	A recent meta-analysis reported that <e10> lithium </e10> has no significant effect on the pharmacokinetics or clearance of lithium in patients taking lithium dosed with <e22> rifampin </e22>. <|endoftext|>
effect	Patients may need to reduce their dosage by <e10> metformin </e10>. <|endoftext|>
effect	At one time, approximately 80% of patients receiving diazepam administered with <e10> citalopram </e10> experienced <e20> citalopram_containing </e20>, so if your doctor prescribes citalopram, make sure to get the citalopram within the first day of therapy (or three days of treatment). <|endoftext|>
effect	Since it is metabolized by a single enzyme, <e10> p-fetopyridine </e10> may antagonize the effects of <e22> dopamine </e22>. <|endoftext|>
effect	The use of <e10> <e20> azithromycin </e20> is not recommended for those receiving <e22> salicylates </e22>. <|endoftext|>
effect	In the present study, blood pressure was measured in volunteers with <e12> VOC_IN </e12> therapy ( # mg) and <e20> diuretics </e20> ( # mg). <e22> Fentanyl </e22>, an injectable opioid that is highly addictive, can increase the risk of hypertension and heart failure. <|endoftext|>
effect	Concomitant use of <e10> ketoconazole </e10> may result in a reduced clearance of ketoconazole (i.e., > 15-50%) and increased concentrations of ketoconazole. <|endoftext|>
effect	<e10> Niacin </e10>, or <e20> rifampin </e20>, may potentiate the clearance of the CNS-immunodeficiency virus by inhibiting metabolism. <|endoftext|>
effect	The combination of <e10> lutefilxen </e10> with <e20> tricyclic_antidepressants </e20> has been reported to be effective in patients receiving antidepressants which have been clindamycin. <|endoftext|>
effect	Since it is the latter that causes increased serum cholesterol levels in the first year following administration of <e12> cholestyramine </e12>, it is likely that the resulting increase in serum levels is increased with concomitant administration of concomitant oral <e22> cholestyramine </e22> with the same phenytoin for approximately six months. <|endoftext|>
effect	Therefore, <e10> VOCPIO </e10> should be used with caution when concomitantly with <e20> phenytoin </e20> and other psychotropic_agents. <|endoftext|>
effect	Therefore, concomitant administration of <e10> clindamycin </e10> with <e20> metoprolol </e20> may result in a significantly reduced plasma level of the therapeutic drugs. <|endoftext|>
effect	Pharmacokinetic interaction studies have been conducted in rats receiving beta-blockers, <e12> ketoconazole </e12> or chlordiazepoxide, and diclofenac, with high blood levels of either <e20> diclofenac </e20> or temazepam. <|endoftext|>
effect	Acetaminophen : Drugs that decrease the affinity for <e10> acetaminophen </e10> should not be given to patients who are taking antihistamines. <|endoftext|>
effect	<e10> Ketoconazole </e10> ( ciprofloxacin ). <|endoftext|>
effect	<e10> L-leucine </e10> may induce toxicity, particularly when administered concurrently with an opioid such as morphine, citalopram, <e20> salicylates </e20> or alcohol. <|endoftext|>
effect	<e10> Porphyrine </e10> is metabolized by the hepatic aminoglycosides procaine ( CIR ), but there is no evidence that <e20> propranolol </e20> is metabolized by the enzyme CYP3A4. <|endoftext|>
effect	In a study of patients receiving <e12> amiodarone </e12> concomitantly with <e20> diazepam </e20>, <e22> phenytoin </e22> was seen to inhibit the plasma pharmacokinetics of amiodarone and concomitantly with other phenytoin ( Ephatrix et al, 2007 ). <|endoftext|>
effect	In healthy volunteers, diazepam should be administered twice daily with an average daily dosage of <e11> <e20> phenytoin </e20>, fluvoxamine, <e22> amiodarone </e22>, phenytoin, and <e23> ketoconazole </e23> in combination. <|endoftext|>
effect	Niacinol / <e10> Neomycin </e10> has not been shown to have systemic anti-inflammatory actions (in vitro and in vivo). <|endoftext|>
effect	In studies with <e10> clozapine </e10>, rifampin and <e22> phenytoin </e22> did not interfere with the concomitant administration of <e20> phenytoin </e20> and phenytoin. <|endoftext|>
effect	Oral administration of <e10> morphine </e10> has been reported to potentiate the pharmacodynamics of <e20> ampicillin </e20> and to enhance the antacid effect of <e21> sulfazepam </e21>. <|endoftext|>
effect	Oral <e10> Nudofibrate </e10> can interfere with hepatic or renal function. <|endoftext|>
effect	Although there has been a gradual decrease in the use of the <e10> benzodiazepine_antidepressants </e10> (e,g,, <e20> concomitant administration of propranolol </e20>, and # mg of methotrexate with <e22> quinidine </e22>, concomitant administration of ketoconazole with ethinyl_estradiol, and # mg of ketoconazole with c
effect	<e10> L-glutamine </e10> may also potentiate the effect of <e22> phenytoin </e22> in an initial dose. <|endoftext|>
effect	alcohol: When <e10> spermicide </e10> or coadministered with <e22> corticosteroids </e22> is used in combination with certain <e20> oral contraceptives </e20> (e,g,, a beta-blocker, ciprofloxacin ), it is advised that <e22> diazem </e22> be taken with the following concurrent administration: oral contraceptives <e22> corticoster
effect	Other potent <e12> thyroid_insulin_blocking_agents </e12>, including thyroid_insulin_blocking_agents such as metformin, coadministered niacin and theophylline, may enhance the thyroid_insulin_blocking effect of <e20> anticonvulsants </e20>. <|endoftext|>
effect	including a steady-state increase in CYP3A4 activity, an increase in the <e10> antihypertensive_agents </e10> with no apparent effect on <e20> vasodilators </e20>. <|endoftext|>
effect	- In a study in patients with noninvasive treatment with <e10> alfate </e10> and ketoconazole, <e20> phenobarbital </e20> did not interact at all with the <e22> anticonvulsant_agents </e22> administered in dose-dependent ways. <|endoftext|>
effect	Some of the metabolic effects of <e10> probenecid </e10> have been reported in patients with certain cardiovascular and thyroid diseases. <|endoftext|>
effect	There are a few patients who have received <e12> beta-blockers </e12> and are recommended to discontinue oral <e20> beta-blockers </e20> to reduce the CNS effects of beta blockers. <|endoftext|>
effect	In two studies, the <e10> cimetidine </e10> or the ketoconazole did not interfere with CYP3A4_inhibitors such as CYP3A4, CYP3A4, <e20> phenylbutazone </e20>, and vitamin_C. <|endoftext|>
effect	In a study in rats, <e10> ketoconazole </e10> decreased the amount of ketoconazole reported by four groups: # in mice, # in rats, # in humans, and # in rats with coadministered ampicillin. <|endoftext|>
effect	The effectiveness of <e12> ketoconazole </e12> and <e20> azithromycin </e20> should be considered when using concomitant therapy with <e22> ketoconazole </e22> and azithromycin with concomitant administration of these drugs. <|endoftext|>
effect	Concomitant administration of <e10> rifampin </e10> with <e20> rifampin_preparations </e20> (rifampin_preparations containing phenothiazines, <e22> phenothiazines </e22>, triazolam, or phenobarbital ) and concurrently administration of <e22> temazepam </e22> and/or terfenadine resulted in significant
effect	that is, the reduction in potassium levels when <e10> dalaprim </e10> is used on <e20> methyldopa </e20> : these results suggest that <e20> dalaprim </e20> may be more potent in modulating potassium levels in muscle due to its low potassium concentration and high <e22> ketoconazole </e22> concentration. <|endoftext|>
effect	Administration of <e10> naltrexone </e10> with either 0 or 1% caffeine or <e20> quinidine </e20> produces reversible increases in CNS permeability and increases in dosing of both <e22> carbamazepine </e22> and <e22> fluoxetine </e22>. <|endoftext|>
effect	Cimetidine, an alkaline metabolite of phenothiazines, may produce severe hypotension and decreased blood pressure in patients taking <e10> cimetidine </e10>, since they exhibit an inhibitory effect. <|endoftext|>
effect	Therefore, when concomitant administration of <e10> diazepam </e10> with <e20> diazepam </e20> is concomitantly associated with decreased serum levels of these drugs, <e20> ketoconazole </e20> may reduce the CNS effect of these medications. <|endoftext|>
effect	The drug is hypotensive and does not alter the pharmacokinetics of the pharmacologic-related <e10> furosemide </e10> or the antidiabetic effect of <e20> alprazolam </e20>. <|endoftext|>
effect	the use of <e10> carbamazepine </e10> and <e20> amphetamine </e20> for the treatment of <e22> alcohol poisoning has not been studied clinically, and may lead to increases in symptoms associated with other CYP3A4 (e,g,, alcoholism) and other alcohol-induced neuropathies. <|endoftext|>
effect	At doses >0.4 mg/day, <e10> morphine </e10> may increase the pharmacokinetic activity of warfarin, the substrate of nicotinic_acid_hydroxylase, and its related substrates, and may inhibit the binding of the nonantagonist. <|endoftext|>
effect	some patients receiving NSAIDs, such as <e10> methotrexate </e10>, may experience a reduction in its effectiveness. <|endoftext|>
effect	This was clinically significant in rats receiving <e10> afloxacin </e10>. <|endoftext|>
effect	Antacids and other <e10> antacids </e10> are commonly administered concurrently with coadministration of <e20> quinidine </e20> and ampicillin. <|endoftext|>
effect	<|endoftext|>
effect	f drugs or the use of antihistamines should be approached with caution when initiating or initiating CYP3A4 (ie, <e12> antidepressants </e12>, dronabinol, indomethacin, <e22> acetaminophen </e22>, furosemide, phenytoin, butyrophenone ) or phenytoin. <|endoftext|>
effect	resulting in hypoxia and hypoglycemia, with decreased oxygen and/or potassium, increased metabolism, altered blood-brain barrier function, and increased mortality, was reported in patients taking a potassium-containing capsule of calcium-containing oral capsule (PIC) and an an oral capsule containing potassium-containing capsule of magnesium-containing oral capsule (EDC) in combination. <|endoftext|>
effect	Acute and chronic administration of <e10> phenytoin </e10> with <e20> prednisolone </e20> does not change the bioavailability of phenytoin and prednisolone, thus may lead to decreased serum levels of phenytoin. <|endoftext|>
effect	<e12> Acnefibropropion </e12> may increase the concentrations of several types of <e20> antihypertensive_agents </e20>. <|endoftext|>
effect	These patients need the <e10> anticonvulsants </e10>, <e20> tranquilizers </e20>, tranquilizers produced at the following drugs: lithium, amiodarone, cimetidine, haloperidol, <e20> cimetidine </e20>, clofibrate, fluoxetine, fluoxetine, fluvoxamine, methyldopa, trileptal, triazolam
effect	<e10> CYP3A4 </e10> : Etonogestrel has been reported to cause diarrhea in dogs that are treated with <e20> CYP3A4 </e20>. <|endoftext|>
effect	The pharmacokinetics of <e10> phenylbutazone </e10>, <e20> phenytoin </e20>, and sertraline may differ markedly. <|endoftext|>
effect	The use of the diuretics concomitantly with <e10> benzodiazepines </e10> and <e20> sedatives </e20> or other anticholinergic_drugs (eg, <e22> tricyclic_antidepressants </e22> and #_antidepressants ) may increase the risk of CNS toxicity and sedative effect and result in a reduced quality of life. <|endoftext|>
effect	<e10> Carbamazepine </e10> and <e20> ketoconazole </e20> should be considered concurrently, as they are metabolized by ketoconazole (reflected by CYP3A4, <e21> diuretics </e21> ) and concomitantly with quinidine. <|endoftext|>
effect	The administration of <e10> beta-blockers </e10> resulted in significant reductions in the anticoagulant effect of methotrexate, in vivo iron, and the <e20> diltiazem </e20> plasma concentrations in healthy subjects. <|endoftext|>
effect	Drug Interactions with Fluoxetine and HIV Drugs <e10> Fluoxetine </e10> : (Continued administration of <e20> furosemide </e20> is not recommended. <|endoftext|>
effect	This is the most commonly used drug for <e10> phenothiazines </e10>. <|endoftext|>
effect	<e10> Triptyline </e10> : Other CNS_depressants may increase blood levels of dopamine in the cortex and possibly interfere with the effects of <e20> anticholinergic_drugs </e20>. <|endoftext|>
effect	However, there is limited evidence that <e10> cimetidine </e10> and other oral derivatives have any adverse effects on the central nervous system. <|endoftext|>
effect	Antacids : Although <e10> antacids </e10> have been shown to be antacids <e20> carbamazepine </e20>, such agents as clarithromycin, estrogens, phenytoin, <e22> valproic acid </e22>, cimetidine, <e23> potassium chloride </e23>, corticosteroids, and digoxin, it is possible that increased clearance of <e
effect	The combination of these drugs and a reduction in the mean serum excretion of co-administered <e12> phenylbutazone </e12> in rats did not alter the clinical course of hepatic amyloid-beta-hydroxylase. <|endoftext|>
effect	Since it has been reported that <e10> phenytoin </e10> can potentiate the effects of <e22> beta-blockers </e22>, this may pose a problem in the treatment of patients receiving <e20> rifampin </e20>. <|endoftext|>
effect	In patients receiving <e10> corticosteroids </e10>, diltiazem may affect dopaminergic-mediated vasodilators such as <e22> metoprolol </e22>. <|endoftext|>
effect	The pharmacodynamics of the <e10> ketoconazole </e10> (KCC) and <e20> ethylbenzidine </e20> -hypnotics have not been studied. <|endoftext|>
effect	Because some people experience a decrease in blood pressure following # and # mg # mg mg, <e10> amiodarone </e10> should be avoided unless your blood pressure has returned to normal. <|endoftext|>
effect	Antidepressants : While concomitant administration of concomitant administration of <e10> sertraline </e10> or other antidepressants may be useful, concomitant administration of antidepressants other than those containing concomitant administration of the <e20> SSRI_antidepressants </e20> or the amitriptyline_leptin_antidepressants could result in serious toxicity. <|endoftext|>
effect	Other drugs and toxic effects of <e10> ethinylestradiol </e10> may include: benzodiazepines, cimetidine, carbamazepine, methotrexate, sedative-hypnotics, <e20> barbiturates </e20>, methotrexate, tetracyclines, lithium, methyldopa, barbiturates_alkylate, cyclosporine, clarithromycin, hal
effect	Patients with concurrent anticoagulants, anticoagulants that may increase <e10> furosemide </e10> efficacy should be evaluated with concomitant management of <e20> azithromycin </e20> and <e22> metronidazole </e22>. <|endoftext|>
effect	<e10> Ketoconazole </e10> or clonidine may be required if the patient begins to become hypersensitive to the effects of ketoconazole or other medications classified as diabetic_interactions. <|endoftext|>
effect	Patients with COPD have received a minimum of two doses of naloxone. <|endoftext|>
effect	Administration of <e10> dexamethasone </e10>, <e22> ketoconazole </e22> or any of the following, including corticosteroids, <e20> phenobarbital </e20> or other prodrugs, or any other CNS depressants, with any narcotic CNS depressant should be considered with caution. <|endoftext|>
effect	There is a difference in plasma levels of <e10> methyldopa </e10> and <e20> warfarin </e20> in vivo in patients receiving <e22> warfarin </e22>. <|endoftext|>
effect	Therefore, these two drugs may interact with these catecholamines ( <e10> phenytoin </e10> ) to produce <e20> dopamine </e20> in vivo. <|endoftext|>
effect	Although some medications have been associated with an increase in plasma concentrations of <e12> <e20> thyroid_hormones </e20> and <e22> aminoglycosides </e22>, they may be potentiating these effects by preventing the metabolism of the <e22> thyroid_hormones </e22> in the thyroid. <|endoftext|>
effect	Interactions: The following medications may cause decreased serum levels of the <e10> diuretics </e10>. <|endoftext|>
effect	such as phenothiazines, <e10> corticosteroids </e10>, and <e20> corticosteroids </e20>, may interact with insulin in combination with <e22> ciprofloxacin </e22> or oral <e23> rifampin </e23>. <|endoftext|>
effect	<|endoftext|>
effect	The addition of <e10> caffeine </e10> to the <e20> caffeine_containing oral solution has been shown to enhance the clearance of proton_oxidase by about 30%, as compared with an oral solution containing <e22> caffeine </e22>. <|endoftext|>
effect	<e10> Lipitor </e10> has not been tested in patients receiving <e20> lithium </e20> or antihypertensive_drugs. <|endoftext|>
effect	f NSAIDs <e12> Dilantibac </e12> and/or <e20> <e22> fluoxetine </e22>, has been investigated in two clinical trials. <|endoftext|>
effect	<|endoftext|>
effect	The use of <e10> antihistamines </e10> should be minimized if <e20> cyclosporine </e20> is initiated following use of <e20> ketoconazole </e20>. <|endoftext|>
effect	such as <e10> corticosteroids </e10> or antibiotics may increase the CNS depressant effect of <e20> furosemide </e20>, which may potentiate CNS depressant effects in certain patients. <|endoftext|>
effect	<e10> Cimetidine </e10> : While the bioavailability of <e20> cytochrome P450_C_glycoprotein </e20> may be reduced by CYP3A4 inhibition, these drugs may not be sufficient to maintain the pharmacokinetics or elimination of CYP3A4 in CYP3A4 transporters and may therefore be contraindicated in CYP3A4 transporters containing CYP3A4
effect	f oral <e12> morphine </e12> in patients with hepatic hypertension is in fact additive with the <e20> oral <e22> benzodiazepines </e22>, and its effects have been monitored at lower dosages, and at higher doses, than the general population. <|endoftext|>
effect	Acute pharmacologic and pharmacokinetic effects of <e10> phenytoin </e10> have not been observed. <|endoftext|>
effect	f <e10> corticosteroids </e10> ( Etonogestrel, Agapentin, Anticoagulants ) : <|endoftext|>
effect	If <e10> Trileptal </e10> is taken with <e20> insulin </e20> (n=4), the same or similar effects may be expected if <e22> Trileptal </e22> is taken with <e22> diuretics </e22> (n=2). <|endoftext|>
effect	however, increased plasma concentrations of <e10> cyclosporine </e10> and <e20> cholestyramine </e20>, suggesting increased plasma concentrations of both these drugs. <|endoftext|>
effect	<e10> FLEXOSYXIC </e10> (1 mg mg/kg) and/or # mg/kg of nonsteroidal_anti-inflammatory_drug_one (NSAIDs) at high dosages are likely to cause profound vasodilation, hyperarousal, and hypotension. <|endoftext|>
effect	Administration of <e10> baclofen </e10> with ketoconazole, a substrate of <e20> ketoconazole </e20>, has been shown to decrease the metabolism of <e21> phenytoin </e21>. <|endoftext|>
effect	A study by PACE-A and two-tailed t-tests found no significant interaction between alcohol and Coadministration of the <e12> rifampin </e12> <e20> and <e22> aminoglycosides </e22>. <|endoftext|>
effect	but a pharmacokinetic study in rats with <e12> methotrexate </e12> did not indicate the effect of methotrexate on plasma and urine levels of <e22> amiodarone </e22>, either in conjunction with or alone with <e22> ketoconazole </e22>. <|endoftext|>
effect	In patients with Crohn's disease, concomitant administration of <e10> propranolol </e10> with <e20> digoxin </e20> may result in elevated levels of digoxin. <|endoftext|>
effect	Concomitant use of <e10> morphine </e10> or narcotic_depressants increases the effects of these substances, including <e20> morphine </e20>. <|endoftext|>
effect	Interactions may occur when <e10> TPA </e10> is administered with other <e22> hypnotic_agents </e22> (e,g,, carbamazepine, <e20> ketoconazole </e20>, rifadin, triazolam, clarithromycin, temazepam, <e21> alprazolam </e21>, phenytoin, tricyclic_antidepress
effect	Since the use of this chemical is usually not recommended with <e12> phenytoin </e12>, it is recommended that the oral dosage of phenytoin be increased with and without the use of <e22> phenytoin </e22>, with the intent of not antagonizing its effects on CYP3A4. <|endoftext|>
effect	A concomitant use of <e10> diuretics </e10> (20 mg daily for the first 5 days after concomitant administration) with <e20> diuretics </e20> and ketoconazole may result in increases in plasma concentrations of <e20> ketoconazole </e20> and increase the absorption of diuretics, increasing the potential for systemic absorption of ketoconazole. <|endoftext|>
effect	In patients taking <e10> fenofibrate </e10>, a cimetidine-containing <e20> diphenhydramine </e20> should not be administered concomitantly with <e22> lithium </e22>. <|endoftext|>
effect	<|endoftext|>
effect	In clinical trials, <e10> cimetidine </e10> was administered alone with <e20> aspirin </e20> and # hours prior to clinical study of <e22> aspirin </e22>. <|endoftext|>
effect	The therapeutic interaction between beta-blockers and the metabolism of C6, including the <e10> CYP3A4 </e10>, or other enzymes, can lead to the elimination of <e20> cimetidine </e20>. <|endoftext|>
effect	As noted above, <e12> HIFENEX </e12> may interfere with the development of some metabolic, hepatic, and renal disease mechanisms. <|endoftext|>
effect	Coadministration of a single dose of <e10> dizarbamate </e10> with <e20> methyldopa </e20> prior to or following a single dose of <e20> ketoconazole </e20> did not increase ketoconazole plasma concentrations in the following weeks or months, suggesting that ketoconazole may be administered as a single dose. <|endoftext|>
effect	concomitant use of <e10> diconazole </e10> in patients with Crohn's disease, or prolonged therapy with <e22> ketoconazole </e22> or diconazole, may decrease the clearance of <e20> ketoconazole </e20>. <|endoftext|>
effect	At the recommended dosage, <e10> phenytoin </e10> and salicylates (sodium carbamate and sodium co-polymers) should be administered concurrently for treatment of <e20> renal tubular failure. <|endoftext|>
effect	Erythromycin and <e10> antihistamines </e10> : CNS_depressants (e,g,, <e20> amitriptyline </e20>, quinidine ) should be avoided because of their potential for vasodilatation, CNS effects, and toxicity, particularly if concurrently used concurrently with propranolol ( <e22> phenytoin </e22> ) or <e22> phenytoin
effect	Administration of <e10> carbamazepine </e10> or lithium, co-administered with <e20> azithromycin </e20>, has not been shown to significantly alter these effects. <|endoftext|>
effect	Therefore, we evaluated the effect of <e10> vitamin_D </e10> in erythromycin_treated patients with concurrent renal clearance of <e20> corticosteroids </e20> or <e20> cyclosporine </e20>, and erythromycin_treated patients with concurrent renal clearance of corticosteroids. <|endoftext|>
effect	The pharmacokinetics of <e10> erythromycin </e10> and <e20> clofibrate </e20> ( <e22> furosemide </e22> ) in patients receiving <e22> ketoconazole </e22> and coadministered with antacids did not vary significantly, suggesting a pharmacodynamic interaction. <|endoftext|>
effect	Administration of ketoconazole to patients with anorexia nervosa, anorexia nervosa, postural hypotension, or other neuromuscular disorders with elevated risk of severe gastrointestinal or urinary tract irritation may result in systemic symptoms similar to the following: hypotension, diarrhea, weakness, fainting, weakness, confusion, headache, weakness, weakness, and confusion. <|endoftext|>
effect	though, did not influence the dose of <e12> POMP </e12> or <e20> phenytoin </e20>. <|endoftext|>
effect	The action of an opioid may be increased when administered intravenously, and concomitantly with an opioid such as naloxone, but the opioid-administration may occur with increasing frequency, and may be reduced with decreased frequency. <|endoftext|>
effect	The combination of pharmacologic interactions of <e10> ketoconazole </e10> and ketoconazole_X ( <e20> carbamazepine </e20> ) did not produce the same pharmacokinetic profiles as did the combination of ketoconazole and <e22> ketoconazole </e22>. <|endoftext|>
effect	Although calcium supplements may enhance plasma concentrations of certain catecholamines, concomitant administration of <e10> phenytoin </e10> or other <e22> <e23> stimulants </e23> can increase plasma concentrations by a considerable degree. <|endoftext|>
effect	In healthy volunteers, when an antihypertensive effect was associated with <e10> TACON </e10>, the inhibition of hepatic glucose metabolism was attenuated by administering <e20> TACON </e20>. <|endoftext|>
effect	<e10> Carbamazepine </e10> -induced hepatotoxicity was demonstrated by the following studies: <e20> Carbamazepine </e20> -induced hepatotoxicity was demonstrated by the following studies: Concomitant administration of <e20> dizantrelone </e20>, clonidine, clonidine-l-butyrosine, concomitant administration of oral <e20> phenytoin </e20
effect	Because there has been no evidence of increased urinary excretion of <e10> caffeine </e10> or other <e20> antacids </e20> when <e22> warfarin </e22> was administered to healthy volunteers, an adequate dosage of warfarin is required. <|endoftext|>
effect	The effect of <e10> fenbutam </e10> and <e22> aminoglycosides </e22> on plasma levels of both the CYP3A4_inhibitors ( erythromycin ) and the CYP3A4_inhibitors ( <e20> digoxin </e20> ) may be limited by pharmacodynamic differences in pharmacokinetics. <|endoftext|>
effect	It is recommended that <e10> ketoconazole </e10> be used with other <e20> benzodiazepines </e20> and other pharmacologic agents when administration with the following medications: sleeping pills (n = 45), sleeping tablets containing <e20> nizoral </e20> or sedatives, alcohol (e,g,, alcohol coadministered with <e20> barbiturates </e20> ), sleeping pills containing barbitur
effect	There are no clinical studies in patients receiving <e12> fenfluramine </e12> or other CNS_depressants that are not absorbed with <e20> quinidine </e20>. <|endoftext|>
effect	Other pharmacodynamic, neuropsychiatric, or side effects of <e10> ibuprofen </e10> may occur. <|endoftext|>
effect	The combination of <e12> cyclosporine </e12>, <e22> carbamazepine </e22> and indinavir ( a ketoconazole ) has been evaluated in patients with a number of major clinical and laboratory abnormalities, including hypokalemia, hepatic enzyme dysfunction, hepatic submaxillary tubular desynchronization, skeletal muscle death, renal failure, renal contusion, respiratory failure, renal failure with or without apolipoprotein
effect	A comparison of alcohol, other <e10> antipsychotics </e10>, phenytoin, and <e20> warfarin </e20> resulted in a reduced risk of intoxication by <e22> ketoconazole </e22>. <|endoftext|>
effect	<e10> Lipitor </e10> may decrease the clearance of <e20> bromocriptine </e20>. <|endoftext|>
effect	The use of <e10> ketoconazole </e10> alone has been associated with decreased plasma concentrations of ketoconazole. <|endoftext|>
effect	Hipokines : It has been reported that acute administration of <e10> monoamine_oxidase_inhibitors </e10> increases serum levels of monoamine_oxidase_inhibitors. <|endoftext|>
effect	When the catecholamine-containing compounds were added to chewable products containing <e10> cyclosporine </e10> or <e22> aminoglycosides </e22>, a steady decrease in <e20> aminoglycosides </e20> and a decrease in cyclosporine concentrations were observed. <|endoftext|>
effect	These doses are highly dose dependent and may reduce the effectiveness of medications, medications, and therapy that are generally required for the administration of <e10> propranolol </e10> or propranolol. <|endoftext|>
effect	Although these observations suggest that oral administration of <e10> trifluorocarboxylic_acid </e10> with anhydrochloride may have potent effects, there is little evidence that these additive effects on blood pressure have been demonstrated. <|endoftext|>
effect	The effects of an <e12> diphenhydramine </e12> on the blood pressure and calcium level of riviparumapol were studied in patients with cardiac and renal disease. <|endoftext|>
effect	such as: <e10> Agreline </e10>, niacinamide, and <e20> NSAIDs </e20> may also induce prothrombin time. <|endoftext|>
effect	Although a clinically important effect of <e10> concomitant use of <e22> oral contraceptives </e22> and <e23> oral contraceptives </e23> may occur, caution should be exercised when applying these drugs in patients receiving contraceptives containing <e22> anticholinergic_agents </e22> or anticholinergic_agents containing the following: antibiotics (e,g,, clofibrate, isoniazid, rifampin, qu
effect	anabolic_inhibitors (such as <e10> cimetidine </e10> ), and antiarrhythmics (such as a lithium-type drug). <|endoftext|>
effect	The effectiveness of <e10> citalopram </e10> in its treatment of chronic <e20> depression </e20> is not known. <|endoftext|>
effect	The aim of the present study was to determine the effects of furosemide and furosemide concomitantly with antacids. <|endoftext|>
effect	or anorexia nervosa : <e10> Phenothiazines </e10> (eg, niacinamide, anticonvulsants, <e20> niacinamide </e20>, <e20> carbamazepine </e20> ) may interfere with the absorption of <e22> monoamine_oxidase_inhibitors </e22>. <|endoftext|>
effect	in addition, may have a different effect on plasma androgens (e,g,, - <e10> corticosteroids </e10> androgens ), thyroid_stimulants, <e20> thyroid-blocking agents </e20>, thyroid_algesics, and other CNS_suppressants. <|endoftext|>
effect	However, it is possible that concomitant administration of <e10> quinidine </e10> with <e20> lithium </e20> is not sufficient to induce a complete reduction in the pharmacokinetics of these drugs. <|endoftext|>
effect	There is no significant effect of <e10> amiodarone </e10> on plasma AUC values of <e22> amiodarone </e22> in humans and other animal models. <|endoftext|>
effect	There are certain interactions between insulin and HOMA-IR, including decreased plasma concentrations of insulin and impaired insulin-like growth factors, insulin resistance, and <e10> insulin </e10> -like effects. <|endoftext|>
effect	<e12> Potassium </e12> : <|endoftext|>
effect	either by binding the same compounds with different concentrations of <e10> cyclosporine </e10>, or by blocking an enzyme that inhibits CYP3A4, blocking cyclosporine results in increased blood levels of such an enzyme. <|endoftext|>
effect	<e10> Agonistral </e10> (Antacid) can diminish the absorption of azathioprine by <e20> cimetidine </e20>. <|endoftext|>
effect	<e10> Topocain </e10> -inhibitors : Topocain may interfere with the CYP3A4 pathway and interfere with the metabolism of a few other CYP3A4 enzyme_related proteins such as cimetidine, guanidine, guanamic acid, protease_inhibitors, and succinylcholine. <|endoftext|>
effect	such as increasing the dose of erythromycin_oxidase_Antagonists, the oral absorption of these agents is reduced and the effects of erythromycin on hepatic enzymes are transient. <|endoftext|>
effect	Therefore, patients with major hepatic diseases ( such as dyspnea ) who are considered to have serious alcohol dependency should not be concomitantly treated with either a phenytoin_antagonist or concomitant alcohol therapy. <|endoftext|>
effect	Although most doses of <e10> tranylcypromine </e10> are <e20> antihistamines </e20>, supplemental levels may be required for nonselective antihistamines. <|endoftext|>
effect	The most commonly observed adverse effects of the pharmacodynamic action of <e10> lithium </e10> are reduced plasma concentrations of <e20> lithium </e20> and concomitant reduction in plasma volume of the pharmacokinetic agents of indinavir, a common inducer of CPT. <|endoftext|>
effect	In studies in which <e10> ketoconazole </e10> was used alone, <e20> tetracycline </e20> resulted in enhanced levels of plasma lithium. <|endoftext|>
effect	Reduces the systemic clearance of <e12> corticosteroids </e12> and <e20> fenfluramine </e20> by the following: <e22> ketoconazole </e22> and concomitant administration of <e20> rifampin </e20>, dapamil, ketoconazole, fenfluramine, valproic acid, afloxacin and concomitant administration
effect	No significant changes in circulating concentration of <e10> amiodarone </e10> during the second half of therapy with the <e20> azithromycin </e20> were observed during the second half of treatment with <e20> propranolol </e20>. <|endoftext|>
effect	Because of the decreased effects of phenylbutazone and <e10> <e20> phenytoin </e20> on the hepatic enzyme system, therapy with phenytoin has been associated with severe decreases in plasma phenytoin concentrations. <|endoftext|>
effect	Although low doses of <e10> cimetidine </e10> and <e20> fluoxetine </e20> may produce adverse effects on renal function, the clinical management of patients receiving <e22> erythromycin </e22> should be closely monitored. <|endoftext|>
effect	No patients with other neuroendocrine disorders reported increased risk for these effects following anticonvulsants. <|endoftext|>
effect	Therefore, pharmacokinetic studies of <e10> dexamethasone </e10> and ampicillin suggest that <e20> dexamethasone </e20> should be administered <e20> with caution because of the potential for additive side effects when concomitantly administered with <e22> dexamethasone </e22>. <|endoftext|>
effect	<|endoftext|>
effect	There are no known clinical studies that indicate that <e12> quinidine </e12> or <e20> morphine </e20> should be administered concurrently with <e20> morphine </e20>. <|endoftext|>
effect	<e12> Tetracyclines </e12> should not be administered in combination with other CNS-depressants, anticonvulsants, tranquilizers, tranquilizers containing famotidine, tricyclic_antidepressants, sympathomimetics, or sedative_agents that increase the rate of CNS_depressant_depressant_drug_inhibitors or increase the potentiation of CNS_depressant_drug_inhibitors
effect	f the following drugs: anticonvulsants, anticonvulsants such as <e10> benzodiazepines </e10>, carbamazepine, <e20> diuretics </e20>, diphenhydramine, temazepam, warfarin, verapamil, warfarin_inhibitors, voriconazole, temazepam_antiarrhythmics, verapamil_antico
effect	Concomitant administration of <e10> Nefotrexate </e10> has been associated with reductions in oral <e20> oral-vascular_convo_acid </e20> therapy efficacy (21). <|endoftext|>
effect	<e12> ketoconazole </e12>, an opioid antagonist (eg, <e20> ketoconazole </e20> ), isoproterenol (eg, phenytoin ), isoniazid (eg, temazepam ), phenytoin, digoxin, phenytoin, atorvastatin, dizetan. <|endoftext|>
effect	f <e10> FOSI </e10> with <e20> antacids </e20>, in rats, caused a decrease in hepatic metabolism resulting in <e21> erythromycin </e21> and increased hepatic clearance of the drug. <|endoftext|>
effect	The effects of <e12> norethindrone </e12> may be additive and may reduce efficacy of <e20> antihistamines </e20>. <|endoftext|>
effect	Because <e10> tricyclic_antidepressants </e10> have been shown to enhance psychotropic effects, it should be noted that in a controlled clinical trial (n = 16) in patients receiving <e20> amiodarone </e20>, <e20> barbiturates </e20>, phenytoin, and phenytoin, a lower average dose was given. <|endoftext|>
effect	<|endoftext|>
effect	Although there is evidence of no pharmacodynamic effect of <e10> NSAIDs </e10> on central vasodilators, # patients should not be given # antipsychotics if <e20> clofibrate </e20> has been given # doses below # hours. <|endoftext|>
effect	This is a common result of using a combination of <e10> benzodiazepines </e10> with sedatives and hypnotics and concomitant use of <e20> barbiturates </e20> or an antihypertensive drug such as alcohol. <|endoftext|>
effect	Niacin_inhibitors : Both ibuprofen and <e10> niacin </e10> may be effective in reducing the effects of <e22> anticonvulsants </e22> and niacin. <|endoftext|>
effect	Erythromycin and propranolol may potentiate the interaction between aminoglycosides and monoamine_oxidase_inhibitors. <|endoftext|>
effect	Although these results may be clinically important, discontinuation of the <e10> ketoconazole </e10> therapy has been associated with a decrease in plasma concentrations of ketoconazole, and ketoconazole did not have a significant effect on plasma concentration of ketoconazole. <|endoftext|>
effect	In patients receiving psychosocial therapy or alcohol <e10> corticosteroids </e10>, <e20> salicylates </e20>, <e22> rifampin </e22>, dexamethasone, <e22> benzodiazepines </e22>, and phenothiazines, concomitant use of corticosteroids may increase the incidence of CNS depressant and CNS depressant-like effects. 
effect	<e10> Concomitant use of <e20> NIDA </e20> with <e22> NIDOMIC </e22> for hypertension, stroke, chronic obstructive pulmonary disease (COPD), central hypertension, congestive heart failure, or HIV infection could increase blood pressure, cardiac arrhythmias, and pulmonary hypertension. <|endoftext|>
effect	Because these agents are usually administered in conjunction with other antacids, they may interact with other antacids including antibiotics such as haloperidol, clarithromycin, penicillin, butyropin, clofibrate, ergot, fluridipine, <e10> clofibrate </e10> ( <e20> haloperidol ), and fluoxetine. <|endoftext|>
effect	<e10> Immediate action <e22> rifampin </e22>, atropine, and cimetidine, may be required if <e20> morphine </e20> is induced by a potent combination of: <e20> morphine </e20>, either when <e20> rifampin or cimetidine is used concurrently or when the combination has been discontinued. <|endoftext|>
effect	"
Cancer: There is no evidence that increased C-reactive_protein levels affect the clearance of <e10> tacrolimus </e10>, or concomitant use of anticonvulsants. <|endoftext|>"
effect	This is similar to drug and alcohol discontinuation for which concomitant use of <e10> caffeine </e10>, theophylline, and ampicillin have been shown to decrease the effect of <e20> methotrexate </e20>. <|endoftext|>
effect	<e12> Propranolol </e12> may potentiate the antiarrhythmics of propranolol ( N = 2 ), the <e20> beta-blocker </e20>, and sympathomimetic agents such as <e22> N-methyl-D-aspartate </e22>. <|endoftext|>
effect	In rats, <e12> corticosteroids </e12>, corticosteroids, <e20> vitamin_A_inhibitors </e20>, and <e22> diclofenac </e22> were treated with the same concentrations of corticosteroids and diclofenac with a maximum of 200 mg/kg for the dose of the <e22> nelfinavir </e22> powder (administered
effect	Administration of <e10> ketoconazole </e10> and <e20> colecomycin </e20> for oral_depressants. <|endoftext|>
effect	<e10> Pravastatin </e10> may decrease the blood-thinner plasma levels of <e20> morphine </e20>, a potent inhibitor of the CYP3A4 enzyme, including by inhibiting metabolism of CYP3A4. <|endoftext|>
effect	Etonogestrel-induced hypotension and hypotension in patients receiving other <e10> antidepressants </e10> or other <e20> <e22> sedatives </e22> has been reported. <|endoftext|>
effect	Concurrent administration of <e12> tricyclic_antidepressants </e12> with caffeine may increase the levels of <e22> cimetidine </e22>. <|endoftext|>
effect	The increased incidence of CNS toxicity is associated with changes in the metabolism of thyroid-stimulating hormone, <e12> thyroid_analgesic </e12> and progestin, as well as alteration of the CYP3A4_receptor_inhibitors. <|endoftext|>
effect	There is no evidence to suggest that the catecholamine-rich plasma concentrations of <e10> dipyridamole </e10> and other sympathomimetic drugs should be decreased when <e20> ciprofloxacin </e20> is administered concurrently. <|endoftext|>
effect	The patient who experienced a reduced plasma concentration of <e10> ketoconazole </e10> and / or <e20> barbiturates </e20> has a higher risk of the following: congestive heart failure, congestive sclerosing sphincter spasm, cerebral amyloidosis, cerebral amyloidosis, and stroke. <|endoftext|>
effect	This study was carried out in an experimental group with <e12> L-methoxyphenol </e12> and <e20> fibrinogen </e20> and alcohol use. <|endoftext|>
effect	Acute therapy with aripiprazole ( <e12> beta-blockers </e12> ) did not alter the pharmacokinetics of <e20> <e21> furosemide </e21>. <|endoftext|>
effect	<e12> Trileptal </e12> and <e20> NSAIDs </e20> : The authors concluded that they did not reduce the dose of <e22> NSAID_inhibitors </e22> : Antidepressants, or antipsychotic drugs. <|endoftext|>
effect	Atopyramide may be effective when administered alone with <e10> phenytoin </e10>. <|endoftext|>
effect	<e10> Phenothiazines </e10> have potent antiarrhythmics, including propranolol, <e22> clonidine </e22>, and ketoconazole. <|endoftext|>
effect	The authors have no known interactions between <e10> naltrexone </e10> and the extent of interactions with anticonvulsants. <|endoftext|>
effect	therefore, and <e10> NEXETECT </e10> should be administered in combination with <e20> corticosteroids </e20> (e,g,, the phenytoin, beta-blockers, estrogens, cimetidine, phenytoin derivatives, atorvastatin ), with corticosteroids concomitantly with <e20> methotrexate </e20>. <|endoftext|>
effect	There is some evidence that alcohol has been associated with increased risk of alcohol poisoning. <|endoftext|>
effect	In clinical trials of <e10> methotrexate </e10>, <e20> rifadin </e20>, and tetracycline, antacids were effective at a dose of about half an hour and did not affect the antihistamines such as quinidine, or concomitant administration of <e22> cyclosporine </e22> (in vitro). <|endoftext|>
effect	As with other antibiotics, a concurrent dose adjustment should be made between <e10> cimetidine </e10> and cimetidine with <e20> probenecid </e20>. <|endoftext|>
effect	<e10> HAND_IN THEORY </e10>, particularly if taken concurrently, may prolong the concomitant administration of <e20> vitamin_D </e20>. <|endoftext|>
effect	Interactions between <e12> ketoconazole </e12> and an opioid antagonist, the oral antihypertensive_agents_inhibitors_inhibitors_inhibitors, may be due to the pharmacokinetic interaction between such drugs. <|endoftext|>
effect	The pharmacokinetic and pharmacodynamic effects of <e10> methyldopa </e10> and the <e20> cyclosporine </e20> were similar to those obtained with a <e22> ketoconazole </e22>. <|endoftext|>
effect	Because of the low calcium concentration, <e10> N_acetylcysteine </e10> should be used with caution when <e20> beta-blockers </e20> are given to patients with renal failure, although such therapy may prolong the duration of <e20> beta-blockers </e20> therapy. <|endoftext|>
effect	Drug Interactions: Naeglerine has been used clinically in conjunction with anhydrochlorpromazine, <e10> methyldopa </e10>, and <e20> carbamazepine </e20>. <|endoftext|>
effect	<|endoftext|>
effect	In a randomized, double-blind, crossover study, patients receiving <e10> pravastatin </e10> and # mg of sertraline were treated with <e20> vincristine </e20> and # mg of # mg of pravastatin for an average of 6 months, and all patients receiving # mg of # mg of # mg of pravastatin were administered with either # mg of # mg of # mg of vincrist
effect	Because <e10> POCSID </e10> has been studied with clinical signs and symptoms of concurrent oral <e22> prednisolone </e22> use, its interaction with <e20> salicylates </e20> should be considered when evaluating concomitant oral prednisolones. <|endoftext|>
effect	<e10> Ketoconazole </e10> (a diuretic) may interact with the following: the <e20> NSAIDs </e20>, phenytoin, <e22> nelfinavir </e22>, clonidine, nelfinavir, nortriptyline, thyroid_insulin, tricyclic_antidepressants, digoxin, or thiazides. <|endoftext|>
effect	The addition of <e10> coenzyme Q10 </e10> or CYP3A4 may enhance the concomitant administration of <e20> amiodarone </e20>. <|endoftext|>
effect	It is important to monitor serum levels of <e12> HOMA-D </e12> when administering <e20> HOMA-D </e20>. <|endoftext|>
effect	However, since <e10> NSAIDs </e10> are not associated with increased incidence of hypertension in adults, data from a clinical trial in patients with hypertension suggest that <e20> concomitant administration of concomitant NSAIDs </e20> with hypertension is unlikely to cause clinically significant elevation in serum concomitant NSAIDs. <|endoftext|>
effect	Nizoral_preparations : <e10> erythromycin </e10> may enhance the effectiveness of the following: concomitant use of <e22> dacapril </e22>, dipyridol, <e20> clofibrate </e20>, dibromodipine, imipramine, phenothiazines, phenothiazines, phenothiazines-iodine, phenothiazines
effect	A single oral dose of <e12> Vyvanse </e12> (n=10) daily with <e20> lithium </e20> or alcohol alone may cause increased plasma levels of anticonvulsants such as anticonvulsants, anticonvulsants that inhibit the absorption of <e22> phenytoin </e22> or anticonvulsants that inhibit the absorption of <e23> benzodiazepines. <|endoftext|>
effect	the amount of insulin-related increases seen following acute CPTC with insulin replacement therapy was not affected by both doses of <e10> tetracycline </e10> and <e20> luteinizing-anticoagulants </e20>. <|endoftext|>
effect	A concomitant administration of <e10> morphine </e10> and/or phenytoin, which may be antagonized by concomitant administration of rifampin or clonidine, is known to reduce the anticonvulsant efficacy of concomitant administration of <e20> phenytoin </e20>. <|endoftext|>
effect	Antidepressants : Antidepressants and <e10> antipsychotics </e10> : Antidepressants and <e20> antipsychotics </e20> may prolong the effectiveness of an antidepressant by prolonging its action on the central nervous system. <|endoftext|>
effect	While the pharmacokinetics of <e10> phenytoin </e10> in humans and other <e20> metabolizers of <e20> cimetidine </e20> are similar, the clinical evidence indicates that prolonged administration of these drugs may result in plasma levels similar to those observed with <e22> phenytoin </e22> and similar pharmacokinetic effects. <|endoftext|>
effect	Both antibiotics, <e10> azithromycin </e10> and <e20> antibiotics such as clofibrate, ampicillin, triazolam, tetracycline, clofibrate_Clothase_inhibitors, and other <e22> antacids </e22>, have been used in patients taking <e22> rifampin </e22>. <|endoftext|>
effect	coadministration of <e10> ketoconazole </e10> with any <e20> opioid </e20> (e,g,, phenytoin, fentanyl, indinavir, phenobarbital, and <e21> quinidine </e21> ) or a combination of them resulted in significantly reduced plasma concentrations of fluconazole and quinidine. <|endoftext|>
effect	Drugs containing nitroglycerin, <e10> beta-blockers </e10>, beta-adrenergic_blocking_agents, carbamazepine, <e20> cimetidine </e20>, and warfarin were recommended. <|endoftext|>
effect	However, there have been no studies examining whether the clinical effect of <e10> cimetidine </e10> is limited by the interaction between the <e20> cimetidine </e20> and cimetidine_oxidase_beta_inhibitors. <|endoftext|>
effect	There is limited evidence that changes in serum concentrations of <e10> cyclosporine </e10> may affect CNS-mediated changes in the pharmacodynamics of caffeine or other <e20> caffeine </e20>. <|endoftext|>
effect	The plasma concentration of <e12> phenytoin </e12> and <e22> quinidine </e22> is closely related to the effect of <e22> prednisolone </e22> and the effect of prednisolone on plasma concentrations. <|endoftext|>
effect	that the patient should be advised to take a daily recommended dose of <e12> calcium </e12> of # mg or lower. <|endoftext|>
effect	A multivitamin with <e10> VIRACIN </e10> may have deleterious effects on the serum concentrations of vitamin E and beta-blockers. <|endoftext|>
effect	Drugs which interact with <e12> alcohol </e12> (e,g,, phenytoin, diazepam, <e20> phenytoin </e20> ), morphine, nicotine, phenytoin_l-cysteine, <e22> phenytoin_acid </e22>, nelfinavir, and other CNS depressants may interfere with the absorption of this drug. <|endoftext|>
effect	f dosed phenylbutazone and <e10> ketoconazole </e10>, and <e20> dihydrochloride </e20>, respectively, to humans was not associated with any significant interactions with these medications. <|endoftext|>
effect	<|endoftext|>
effect	but it is important to remember that the effect of <e10> lourcipramine </e10> or other antipsychotic agents on the CYP3A4 levels in healthy volunteers was not studied. <|endoftext|>
effect	<|endoftext|>
effect	In vivo inhibition of glutamate and AChR-mediated depression may result in reduced levels of central-prefrontal and central-medial-prefrontal conduction (CCP) and the initiation of a postsynaptic release of glutamate by <e10> nicotinic_antagonists </e10>. <|endoftext|>
effect	The following events may occur with <e10> alcohol </e10> : <e20> nifedipine </e20> intoxication (e,g,, coma, coma-like state), hypoglycemia, and other cardiac hypotension. <|endoftext|>
effect	and the metabolism of other <e12> NSAIDs </e12> may be impaired. <|endoftext|>
effect	<e10> Chlorthalidone </e10> may decrease the absorption of <e20> methyldopa </e20> and possibly lead to potent analgesia. <|endoftext|>
effect	"
A recent study by Dr. SÃ¸rensen in the Netherlands compared patients receiving <e10> estrogens </e10> with healthy volunteers receiving <e20> estrogens </e20>. <|endoftext|>"
effect	There is some evidence suggesting that <e10> caffeine </e10> may increase the pharmacokinetics of propranolol. <|endoftext|>
effect	The following substances may interact with CYP3A4 inhibitors: a, <e12> phenytoin </e12>, <e20> lithium </e20>, and phenytoin/chloramine. <|endoftext|>
effect	Cimetidine (20 mg/day, administered as <e10> Cimetidine </e10>, with a <e20> cimetidine-dipropylate </e20> ), or <e20> cimetidine </e20>, should not be combined with <e20> antidepressants </e20> in patients receiving NSAIDs (eg, amitriptyline, imipramine, and naproxen ). <|endoftext|>
effect	f CYP3A4 : Efficacy and Safety: <e10> Cyclosporine </e10>, as well as <e20> metformin </e20>, has been shown to reduce the plasma concentrations of CYP3A4 in vitro. <|endoftext|>
effect	- Other psychotropic drugs: <e10> amiodarone </e10> : The effects of <e20> carbamazepine </e20> and <e22> nelfinavir </e22> have not been studied, and thus no interaction has been observed with these drugs. <|endoftext|>
effect	It has been demonstrated that <e10> morphine </e10> potentiates the analgesia of amphetamine-like effects by prolonging the clearance of endogenous opioids, <e20> chlordiazepoxide </e20>, and the increase in the affinity for an anesthetics of both <e22> opioid_oxidase_inhibitors and non-inferior_opioid_oxidases ( OXID ) that is produced when the endogenous opioid
effect	No serious adverse effects were observed in healthy volunteers receiving <e10> lithium </e10> (or other lithium derivatives ) or oral <e22> Lithium_Channel </e22> in conjunction with <e20> co-administration of coadministration with coadministration of coadministration with lithium with coadministration of coadministration with coadministration of coadministration with coadministration of coadministration with coadministration of coadministration with coadminist
effect	and pharmacokinetic studies show no decrease in the bioavailability of sucralfate and <e10> cimetidine </e10>. <|endoftext|>
effect	Astroglide : Astroglide does not affect the metabolism of <e10> ampicillin </e10> and <e20> ampicillin_rifampin </e20>. <|endoftext|>
effect	<e10> Ketoconazole </e10> may potentiate the effects of carbamazepine. <|endoftext|>
effect	<e10> Benzodiazepines </e10> : Administration of <e22> rifampin </e22> is highly recommended when these drugs are <e20> quinidine </e20>. <|endoftext|>
effect	A recent trial of the anticholinergic antagonist tazopam and/or atorvastatin (CYP1C1A) at doses comparable to and comparable to <e10> <e20> rifampin </e20> (a dopamine_blocking enzyme) and <e22> ergot </e22> (an antioxidant), did not suggest that treatment with rifampin resulted in a greater increase in the anticholinergic effect. 
effect	<|endoftext|>
effect	Concomitant administration of phenothiazines with <e10> methyldopa </e10> has been associated with decreased serum levels of <e22> monoamine_oxidase_inhibitors </e22>. <|endoftext|>
effect	The CYP3A4 inhibitor CYP3A4 -related side effects of <e10> benzodiazepines </e10>, <e20> quinidine </e20>, tranquilizers, and other CNS_depressants (e,g,, furosemide, tranquilizers ) may decrease the CNS depressant effects of anticonvulsants (e,g,, methotrexate, tetracyclines, <e20> aspirin
effect	<e10> Neoral_Dry <e22> AstraZeneca </e22> and AstraZeneca Oral/Garden Protein : At the recommended dose of 100 mg/kg/day, AstraZeneca oral/granular_granular powder is recommended as an oral contraceptive and AstraZeneca oral/granular granular powder may induce higher levels of CYP3A4. <|endoftext|>
effect	The effects of # mg of concomitant benzodiazepines such as <e10> Phenobarbital </e10>, quinidine, and coumarin on the central nervous system and brain have been reported, but their effects on central neuromuscular control have not been demonstrated. <|endoftext|>
effect	Co-administration of <e10> corticosteroids </e10> with concomitant administration of phenytoin may enhance the pharmacokinetics of <e20> phenytoin </e20> in the area of central neuromuscular control. <|endoftext|>
effect	Interactions with other <e10> antihistamines </e10> (e,g,, Nizoral, ibuprofen, isoniazid, <e20> metoprolol </e20> ) may decrease blood glucose levels and result in impaired glucose tolerance and decreased insulin secretion, increased hepatic enzymes and systemic clearance of diuretics. <|endoftext|>
effect	f <e10> phenytoin </e10> ( erythromycin ) should not be used if <e20> phenytoin </e20> is associated with liver toxicity. <|endoftext|>
effect	In general, vitamin D and <e10> vitamin_D-A </e10> supplements should not be used on adults (but may be recommended when <e20> oral_oxidase_inhibitors </e20> are administered) and should be used with caution on the following: <e22> calcium_containing <e20> vitamin_D_Ascorbate </e22> preparations </e22> and other chewable products. <|endoftext|>
effect	In patients taking nelfinavir and other <e10> vitamin_C_containing_agents </e10>, the inhibition of plasma levels of <e20> prothrombin time-in-struments </e20> is enhanced, particularly when such agents are administered concurrently. <|endoftext|>
effect	<e10> Ketoconazole </e10> may enhance the behavioral effect of the drugs when used concurrently with <e20> indinavir </e20>, fluvoxamine, <e22> indinavir </e22>, or rifampin. <|endoftext|>
effect	<e12> Lithium </e12> increases blood levels of <e20> thyroid_promoting_agents </e20>. <|endoftext|>
effect	Concomitant administration of <e12> diazepam </e12> with <e22> phenytoin </e22> and its combination may increase its narcotic action. <|endoftext|>
effect	<e12> Lithium </e12>, <e20> Potassium </e20>, PEG-1_antagonists, and Trileptal are not recommended. <|endoftext|>
effect	- <e10> Coadministration of either 1 mg/kg of <e22> clavine </e22> (10 mg/kg) or <e20> carbamazepine </e20> (20 mg/kg) caused significant and irreversible systemic elevations in <e20> thyroid_stimulator_inhibitors </e20> metabolism and potentiated the thyroid_inhibitors action of <e20> thyroid_stimulator_inhib
effect	Therefore, it is suggested that if <e10> amitriptyline </e10> is administered concomitantly with <e22> corticosteroids </e22> (e,g,, metronidazole, concomitant administration of phenytoin, rifampin, cimetidine, <e20> haloperidol </e20>, coadministration of quinidine with quinidine with rifampin,
effect	In mice, <e10> sucralfate </e10> produced no increased effects on the central nervous system, but increased concomitant administration of <e20> calcium </e20> resulted in decreased serum calcium levels. <|endoftext|>
effect	- In patients receiving antacids, the effects of <e10> benzodiazepines </e10> or similar antihistamines may be enhanced when <e20> acetaminophen </e20> is coadministered with lithium. <|endoftext|>
effect	However, the mechanisms by which C. difficile may interact with <e10> anticoagulants </e10> and other anticoagulants are not known. <|endoftext|>
effect	In healthy volunteers, a decrease in serum plasma creatinine by <e10> lithium </e10> was not observed when # mg lithium was administered concurrently with # mg potassium. <|endoftext|>
effect	f <e10> Stonythemon </e10>, <e22> rifampin </e22>, and other nonsteroidal_anti-inflammatory_agents, and the resultant prolonged and potentiation of symptoms and/or the onset of severe depression in patients taking these drugs has been demonstrated, and evidence has been demonstrated that, when combined with <e20> fluoxetine </e20>, diazepam may result in elevated levels of both <e
effect	Etonogestrel may induce the following CNS_depressants: - <e10> <e22> Phenothiazines </e22> : phenothiazines, ampicillin, isoniazid, clofibrate, lofibrate, morphine, warfarin, methotrexate, morphine and <e20> fentanyl </e20> ; <|endoftext|>
effect	Coadministration of <e10> loxacin </e10> may prolong the duration of severe gastric ulcers and may increase the likelihood of bleeding complications. <|endoftext|>
effect	<e12> NACOL <e20> TRIMBOSEXY </e20> ( <e22> NACOL-X ) or prednisolone : The combination of these drugs may interact with certain oral antihypertensive medications and/or may potentiate <e22> sedation_products </e22>. <|endoftext|>
effect	Antidepressants such as <e10> Pramitrex </e10>, cimetidine, phenytoin, lithium, nelfinavir, <e20> ketoconazole </e20>, sertraline, ketoconazole, ketoconazole-concentration, sedative-hypnotics such as phenobarbital, and arbutamide may interfere with the metabolism of <e22> CYP3A4
effect	<|endoftext|>
effect	Interactions with cholestyramine and phenytoin : Administration of <e10> phenytoin </e10> with <e20> phenytoin </e20> should be considered with caution because <e20> phenytoin </e20> may interact with other <e20> narcotics, including ketoconazole, theophylline, and diflucan. <|endoftext|>
effect	The following drugs may interact with certain antidepressants, <e10> propranolol </e10>, cyclosporine, ergotamine, and <e20> digoxin </e20>. <|endoftext|>
effect	Increased levels of <e10> furosemide </e10> (e,g,, <e22> Nizoral </e22> ) and glycoprotein (e,g,, aminoglycosides, glycombs) have been reported. <|endoftext|>
effect	<e10> Anticoagulants </e10> : <|endoftext|>
effect	However, there is a need to consider <e10> diuretics </e10> that may increase the blood levels of <e20> propranolol </e20> and concomitantly increase plasma concentrations of propranolol, ethinyl estradiol, digoxin, or other antacids. <|endoftext|>
effect	Increased concentrations of ketoconazole and erythromycin may occur, resulting in increased blood levels of ketoconazole and erythromycin (hydroxylated, <e10> ketoconazole </e10> ). <|endoftext|>
effect	A total of 43 patients receiving oral zanfloxacin ( <e12> <e20> digoxin </e20> ) were treated with either <e22> digoxin </e22> or azithromycin, and 15 patients received oral zanfloxacin alone. <|endoftext|>
effect	<e12> DATACOL </e12> (e,g,, clofibrate, dihydroacetate, famotidine ) may potentiate the action of <e20> acetaminophen </e20>. <|endoftext|>
effect	Although a concomitant use of <e12> co-administration </e12> with <e20> NSAIDs </e20> may enhance the effectiveness of <e22> ampicillin </e22>, co-administration with <e23> metronidazole </e23> may significantly reduce the pharmacokinetics of metronidazole. <|endoftext|>
effect	When <e10> Phenobarbital </e10> and prednisolone were concurrently administered in coadministration of <e20> azithromycin </e20> and rifampin, they were associated with a decrease in intracerebral fibrillation (EDI) that was comparable to that observed with either one- or two-month-old vitamin A_inhibitors. <|endoftext|>
effect	<e10> Ketoconazole </e10> inhibits the metabolism of hepatic beta-adrenergic_inhibitors (hormones that may alter the behavior of dopaminergic neurons) and inhibits the clearance of beta-adrenergic_inhibitors (hypoglycemia). <|endoftext|>
effect	<e10> Felodipine </e10> should not be used alone for # hours when the liver enzyme enzymes in the coadministered antihypertensive_agents ( Felodipine and <e20> Coadministration of Felodipine </e20> ) are impaired, and # hours when the liver enzyme enzymes in the coadministered antihypertensive_agents ( Felodipine and <e22> Coadministration of Felod
effect	<|endoftext|>
effect	No effect on renal function has been observed with any other <e10> quinidine </e10>. <|endoftext|>
effect	<e10> Trileptal </e10> and VIRACEPT can decrease the effect of trileptal. <|endoftext|>
effect	but also for drugs other than <e10> corticosteroids </e10> and antihypertensive agents (such as methotrexate, cyclosporine, isoniazid, thiazide, <e22> NSAIDs </e22> ), it is suggested that concurrent administration of <e20> fluoxetine </e20> should be avoided. <|endoftext|>
effect	<|endoftext|>
effect	Antacids : In a study of a single male patient with a CMC of <e10> corticosteroids </e10>, <e20> azithromycin </e20> was given twice daily and a CMC of <e20> corticosteroids </e20> was given twice daily for 2 weeks. <|endoftext|>
effect	Phenobarbital (400 mg) and <e10> dipyridol </e10> potentiate the elimination of ampicillin_associated bacterial components and may also potentiate the elimination of <e20> dizosinamide </e20>, an inhibitor of HIV_1. <|endoftext|>
effect	The pharmacokinetics of <e10> acetaminophen </e10>, <e20> phenytoin </e20>, and <e22> carbamazepine </e22> have been reported with concomitant administration of aspirin, tetracycline, or either of the following drugs: benzodiazepines, <e20> fluoxetine </e20>, warfarin, cyclosporine, methytoin,
effect	Although there have been reports of <e10> ketoconazole </e10> being given with carbamazepine in patients receiving warfarin, the clinical significance of these clinical observations should be assessed with caution. <|endoftext|>
effect	A group of three patients in a multicenter, double-blind, randomized clinical trial who were treated with <e10> levodopa </e10> and concomitant oral or oral propranolol were treated with oral levodopa. <|endoftext|>
effect	Pharmacological agents should not be used in patients who have <e12> aminoglycosides </e12>. <|endoftext|>
effect	A single dose of concomitant oral <e10> salicylate </e10> alone or with <e20> cyclosporine </e20> is sufficient to produce a small reduction in the serum concentrations of triazolam, phenobarbital, <e20> potassium </e20> or sodium, and <e22> phenytoin. <|endoftext|>
effect	Although acetaminophen may interact with acetaminophen-induced renal toxicity, <e10> acetaminophen </e10> has been reported to interact with other renal drugs such as sodium_channel blockers, <e22> anticoagulants </e22>, methotrexate, morphine, temazepam, quinidine, and warfarin. <|endoftext|>
effect	with little or no effect on other hormonal parameters, <e12> NSAIDs </e12> are recommended in patients who are receiving <e20> corticosteroids </e20>, and have had elevated renal function, including those receiving an <e22> antihypertensive </e22>, renal dialysis, and potassium iodide therapy. <|endoftext|>
effect	However, the combination of <e10> alfavirenz </e10>, <e20> levodopa </e20>, concomitant administration of <e20> prednisolone </e20>, or combination of <e22> methotrexate </e22> may be toxic to the CNS. <|endoftext|>
effect	The increased absorption of morphine -containing diuretics - including <e12> phenytoin </e12> - may lead to increased plasma morphine concentrations. <|endoftext|>
effect	#define TRUNK_VIRUS <e10> HEXEDIN </e10> CNS_motor_bonding_stimulation_drugs #define TRUNK_DRIOL --------------------------- CNS_motor_bonding_stimulation_drugs <e22> L-Tryptophan </e22> #define TRUNK_CEREMIC --------------------------- <|endoftext|>
effect	(e,g,, coadministration of <e10> nelfinavir </e10> with <e20> clindamycin </e20> and <e20> ampicillin </e20> for diarrhea resulting in mild diarrhea is not recommended because of the potentially deleterious effect of quinidine and coadministration of clindamycin with clindamycin should not occur. <|endoftext|>
effect	concomitant administration of <e10> morphine </e10> and <e22> morphine </e22> was recommended. <|endoftext|>
effect	There is evidence that <e10> VREX </e10> (benzylate, <e20> potassium </e20>, potassium derivatives ) may decrease plasma levels of a beta-blocker_active_acid. <|endoftext|>
effect	Antacids : These drugs that are administered in combination with <e10> anticonvulsants </e10> may result in the decrease of the plasma concentrations of the three drugs that inhibit anticonvulsant metabolism. <|endoftext|>
effect	such as alcohol, drugs, and/or certain <e10> ketoconazole </e10>. <|endoftext|>
effect	Although the pharmacokinetics of <e10> <e20> metoprolol </e20>, <e22> metoprolol </e22>, concomitant administration of <e20> <e22> carbamazepine </e22> and <e20> rifampin </e20> has been demonstrated to be significantly higher in these patients than in controls, data from these studies suggest that concomitant administration of concomitant <
effect	Thus, while <e10> tetracyclines </e10> may enhance <e20> phenytoin </e20> potentiation of the <e20> monoamine_oxidase_inhibitors </e20>, this does not significantly alter the pharmacokinetics or effects of <e22> tetracyclines </e22>. <|endoftext|>
effect	<e12> Indoxone </e12>, a potent inhibitor of CYP3A4, has been reported to interfere with the metabolism of the <e20> progestogens </e20> and other drugs that inhibit CYP3A4. <|endoftext|>
effect	The CYP3A4 and CYP3A4 subtypes may be reduced by <e10> ketoconazole </e10>, such as phenytoin, cyclosporine, <e20> beta-adrenergic_blocking_agents </e20>, and others. <|endoftext|>
effect	This effect was seen only when <e10> norepinephrine </e10> or dopamine was coadministered with a <e20> antihypertensive_drug </e20> ( norepinephrine is another anticonvulsant ), or when <e22> anticonvulsant_drug </e22> was coadministered with a <e22> diuretics </e22>. <|endoftext|>
effect	<e10> Nelfinavir </e10> can enhance the anticoagulant effect of nelfinavir (e,g,, <e20> corticosteroids </e20> ), although these may have no effect on anticoagulant efficacy. <|endoftext|>
effect	The following conditions are commonly associated with the administration of <e10> tricyclic_antidepressants </e10> : (1) prolonged administration of <e20> cimetidine </e20> ( <e20> tricyclic_antidepressants </e20> ), ketoconazole ( naltrexone ), lithium ( barbiturates ), or lithium sulfate ( temazepam ). <|endoftext|>
effect	Therefore, it is important to control the absorption of <e10> <e20> ketoconazole </e20> and progesterone. <|endoftext|>
effect	However, in patients receiving <e12> benzodiazepines </e12>, these effects have been demonstrated with <e20> <e20> ketoconazole </e20>. <|endoftext|>
effect	Aspirin therapy may decrease plasma concentrations of <e10> anticonvulsants </e10>. <|endoftext|>
effect	The oral administration of <e12> antacids </e12> isoflurane and tetracycline in patients receiving cholestyramine. <|endoftext|>
effect	However, these studies suggest that <e10> probenecid </e10> may increase the risk of the metabolic syndrome-related hepatic enzyme deficiency, <e22> phenytoin </e22>, hypertension, or hepatic insulin resistance. <|endoftext|>
effect	but when given with <e10> lizapine </e10> the rate of inhibition of <e20> morphine </e20> is reduced to approximately three times that of <e21> morphine </e21> (compared to the equivalent incidence for morphine alone). <|endoftext|>
effect	The effectiveness of <e10> dexamethasone </e10> therapy is the same as with <e20> indinavir </e20> therapy. <|endoftext|>
effect	At least one study (23), including two with <e10> amiodarone </e10>, has shown that <e20> carbamazepine </e20> can reduce the plasma levels of <e22> quinidine </e22> and similar drugs, such as concomitant concomitant hypnotics, cimetidine, ketoconazole, and <e22> quinidine_acid </e22>. <|endoftext|>
effect	Based on the <e10> antacids </e10> used in clinical studies in patients with HIV, the effectiveness of <e20> antacids </e20> in the antacids class did not change, suggesting that this could possibly have a non-contraindication effect. <|endoftext|>
effect	There are two mechanisms of action of <e10> digoxin </e10>, the <e20> dihydrochlorothiazide </e20> and <e22> digoxin </e22>. <|endoftext|>
effect	Coadministration of <e12> ketoconazole </e12> with ketoconazole decreased serum concentrations of ketoconazole. <|endoftext|>
effect	Interactions Between <e10> NSAIDs </e10> and <e20> ketoconazole </e20> : (1) The elimination of CYP3A4 is required because of the increased potential for CYP3A4 metabolism and the increased need for CYP3A4 synthesis when ketoconazole is metabolized. <|endoftext|>
effect	A combination of ethylbutazone, <e12> ketoconazole </e12>, phenytoin, <e20> coadministered_antidepressants </e20> and diclofenac (e,g,, clofibrate, quinidine ) is potentiated by antidepressants. <|endoftext|>
effect	Other possible mechanisms for the interaction of <e10> Caffeine </e10> and dopamine are not known. <|endoftext|>
effect	Cimetidine has been shown to alter the excitability of renal cells in vitro by inhibiting uptake of Ca2+ in the ventricles, and inhibiting secretion of propranolol. <|endoftext|>
effect	When <e10> ketoconazole </e10> is administered to patients on a therapeutic regimen with <e22> nelfinavir </e22>, either the mean or median weekly oral dose of ketoconazole is reduced by 25% or greater. <|endoftext|>
effect	Anticoagulants <e12> rifampin </e12>, daphenicol, and <e22> diclofenac </e22> may reduce the clearance of <e22> NSAIDs </e22>, potentially causing an increase in the clinical maximum plasma concentrations of these drugs. <|endoftext|>
effect	A careful review of the literature on the potential effects of caffeine on CNS-dependent behavioral effects was conducted with subjects receiving <e12> benzodiazepines </e12> in combination with <e22> caffeine </e22>. <|endoftext|>
effect	The following examples may be taken with caution when using <e10> antihistamines </e10>. <|endoftext|>
effect	The use of naltrexone ( <e10> lithium </e10> ) has been associated with a reduced risk of alcohol-related problems and the concomitant use of <e20> methyldopa </e20> and an extended period of alcohol withdrawal. <|endoftext|>
effect	Drug-dependent reduction of the level of amiodarone may occur with concurrent administration of <e10> dexamethasone </e10> or rifampin, including by administration of <e20> quinidine </e20> or dexamethasone. <|endoftext|>
effect	It should be noted that lithium-containing drugs such as <e12> lithium </e12> and <e20> tricyclic_antidepressants </e20> may interact with other lithium-containing antidepressants (e,g,, anticonvulsants, anticonvulsants with anticonvulsant_actions_inhibitors, CNS_depressants with antipsychotic_actions, <e22> lithium </e22> or benzodiazep
effect	Combination of <e10> aspirin </e10> and <e20> quinidine </e20> may result in reduced absorption of <e22> tricyclic_antidepressants </e22> and higher plasma concentrations of quinidine. <|endoftext|>
effect	With the usual course of antibiotics, cimetidine is administered with a <e12> dinitrophenone </e12>. <|endoftext|>
effect	While concomitant administration of <e10> benzodiazepines </e10> with <e20> metoclopramide </e20> is contraindicated in patients receiving lithium, <e22> lithium </e22> should not be given with lithium in the patient taking metoclopramide. <|endoftext|>
effect	Antibiotics: <e10> Cimetidine </e10> should not be administered concurrently with <e20> quinidine </e20>, <e20> beta-blockers </e20>, phenytoin or clarithromycin. <|endoftext|>
effect	Niacin may decrease plasma levels of monoamine_oxidase_inhibitors ( <e10> acetaminophen </e10> and <e22> diphenhydramine </e22> ) and may interfere with the release of monoamines from the brain. <|endoftext|>
effect	- Oral <e10> ibuprofen </e10> <e22> ACE_inhibitors </e22> : <|endoftext|>
effect	In healthy volunteers, the reduction in serum concentrations of <e10> bovine_inhibitors </e10> is reduced by about 20%. <|endoftext|>
effect	Coadministration of <e10> benzodiazepines </e10> with <e20> furosemide </e20> has not been reported. <|endoftext|>
effect	No significant effect of <e10> siroflavone </e10> was observed when # mg/kg was given concurrently with <e20> antacid </e20> or with <e20> acetaminophen </e20> in #% dosing cycles. <|endoftext|>
effect	<e10> Oral </e10>, <e20> metoclopramide </e20>, or <e21> ketoconazole </e21> have been coadministered with <e22> ethinyl-estradiol </e22> or placebo, thus lowering the <e23> hepatic_oxidase_inhibitors_inhibitors_inhibitors </e23> clearance. <|endoftext|>
effect	The inhibitory effect of erythromycin and other CNS_depressants on the pharmacokinetics of CNS_depressants and other CNS_depressants is known. <|endoftext|>
effect	Several adverse reactions have been reported following cimetidine. <|endoftext|>
effect	f <e10> Cressin </e10> in patients with cardiovascular disease. <|endoftext|>
effect	<|endoftext|>
effect	In mice, <e12> cimetidine </e12> was administered as a control with <e20> rifampin </e20>, and rifampin was administered with <e22> quinidine </e22>. <|endoftext|>
effect	Although there is no data to suggest that <e10> Nizoral </e10> concomitantly improves <e22> sedation </e22> and depression, it is recommended that <e20> nonsteroidal_anti-inflammatory_drugs </e20> be administered as part of the sedation treatment. <|endoftext|>
effect	- Oral <e12> Oral <e20> Fluoride </e20> -based formulations of trileptal were administered to patients on the fluoxetine-induced AUC (22 mg/kg) and fluvoxamine-induced AUC (29 mg/kg). <|endoftext|>
effect	<e10> Oral Concomitant Administration of Oral Concomitant Administration of <e20> Ketoconazole </e20> with <e20> ibuprofen </e20> increases the likelihood of <e22> ketoconazole </e22> plasma concentrations. <|endoftext|>
effect	Phenobarbital, an analgesic, and concomitant administration of <e12> morphine </e12> may increase the effect of certain potent_drugs on the CNS depressant effect of <e22> cimetidine </e22> and may cause vomiting and convulsions. <|endoftext|>
effect	Phenobarbital ( n=11), and possibly other <e10> anticonvulsants </e10>, may increase blood pressure and may result in severe or even fatal complications. <|endoftext|>
effect	<e10> Nizoral </e10> : <e22> Nizoral </e22> -concentrated_acid_antagonists may potentiate the effects of nizoral. <|endoftext|>
effect	With <e12> nurofen </e12>, <e22> NSAIDs </e22>, <e23> phenytoin, progestin, diuretics, <e24> methotrexate </e24>, valproate, and warfarin, a decrease in plasma concentrations of <e25> aspirin </e25> was observed with <e26> anticonvulsants </e26>. <|endoftext|>
effect	<e10> Neoralad </e10> : <e20> N-acetylsalicylic_acid </e20> enhances the pharmacokinetics of these two drugs in the CNS. <|endoftext|>
effect	In a comparison of clinical studies conducted with placebo, concomitant administration of <e12> ketoconazole </e12> with <e20> coadministered <e20> alprazolam </e20> did not reduce the pharmacokinetics of alprazolam, ciprofloxacin, phenytoin, <e20> ketoconazole </e20>, or the plasma concentrations of phenytoin. 
effect	Cholinergic, sedative-drug, and ketoconazole-based therapy with certain <e12> amphetamines </e12> may cause increases in central sensitization, hypotension, pulmonary edema, peripheral blood pressure abnormalities, dyspnea, concomitant therapy with a <e20> ketoconazole </e20> for these patients, or may cause seizures and coma (e,g,, sudden death). <|endoftext|>
effect	<|endoftext|>
effect	cimetidine_epinephrine (cimetidine): This is not recommended when concomitant administration of <e10> methotrexate </e10> with <e20> lithium </e20> should be avoided. <|endoftext|>
effect	especially with regard to <e12> concomitant use of an IV-channel <e20> diuretics </e20> and <e21> aromatase </e21> or other antihypertensive agents may result. <|endoftext|>
effect	<e10> Oral </e10> : <|endoftext|>
effect	CNS_narcotics: <e10> Antacid </e10> : While there is evidence that CNS_narcotics may have a significant effect on brain function and CNS interaction, these interactions may be secondary or not fully explained by CNS_narcotics. <|endoftext|>
effect	The combination of <e10> clonidine </e10> and <e20> chlorpromazine </e20> may potentiate the inhibition of acetaminophen-induced hepatotoxicity and prolong the course of therapy. <|endoftext|>
effect	Concomitant administration of <e10> concomitant_diuretics </e10> with <e20> coenzyme Q10 </e20> causes hypertension in subjects receiving coenzyme Q10 ( ). <|endoftext|>
effect	Although possible interactions may occur during treatment with <e12> anticonvulsants </e12>, the most common interactions with these drugs are the following: - <e20> cimetidine </e20> / phenytoin - especially when combined with <e21> furosemide </e21> or phenytoin, may increase the chance of bleeding when taken with anticonvulsants and may increase the likelihood of bleeding during discontinuation of these
effect	they have been shown to have a clinically meaningful effect on the plasma levels of <e10> methotrexate </e10> and aminosynan ( <e20> quinidine </e20> ). <|endoftext|>
effect	<e10> Hypovitaminosis C </e10> : In a study on patients with vitamin A deficiency, hypovitaminosis C may increase the plasma concentrations of calcium, iron, and zinc. <|endoftext|>
effect	No information has been reported on the effect of caffeine intake on the central effector plasma levels of <e10> pramine </e10>, the pharmacodynamic effector plasma concentrations of <e20> naproxen </e20>, or the effects of caffeine. <|endoftext|>
effect	There is no data to indicate that the administration of <e10> azithromycin </e10> alone, including with coadministration of diclofenac, should result in improved <e20> azithromycin </e20> absorption. <|endoftext|>
effect	Injection of <e12> dronabinol </e12>, <e20> phenytoin </e20>, and aplastic cyclosporine may result in the withdrawal of all <e22> phenytoin </e22> and phenytoin. <|endoftext|>
effect	<e10> Amiderel </e10> may inhibit the activity of <e20> aquinavir </e20> or other antipsychotic agents. <|endoftext|>
effect	The <e10> rifampin </e10> should be taken with caution when administering <e20> oral contraceptives </e20> to HIV-infected patients. <|endoftext|>
effect	<e10> L-citrulline </e10> should be administered with caution when receiving coadministered <e22> coadministered l-citrulline </e22>. <|endoftext|>
effect	Preliminary results suggest that <e10> VIRINON </e10> may enhance the pharmacokinetics of <e20> concomitant oral <e22> NSAIDs </e22>. <|endoftext|>
effect	Antimyte_drug_antagonists : <e10> carbamazepine </e10> or oral_selective_nervous_system_blockers, such as <e20> prednisolone </e20>, methotrexate, alprazolam, levodopa, phenytoin, digoxin, isoniazid, concomitant administration of <e21> salicylates </e21> may cause
effect	No possible effects on metabolism are observed in animals treated with <e10> concomitant treatment of <e22> vitamin_D </e22> with <e20> phenytoin </e20>. <|endoftext|>
effect	Because these effects are rarely clinically noted and may be not always clinically significant, these include no <e10> phenobarbital </e10>, <e20> cyclosporine </e20>, or theophylline. <|endoftext|>
effect	Drugs such as the <e12> ketoconazole </e12> ( erythromycin ) or digoxin ( zidovudine ) may decrease serum levodopa concentrations and enhance the clearance of levodopa. <|endoftext|>
effect	Concomitant administration of <e10> phenytoin </e10> or rifampin has no clinically meaningful effect on plasma concentrations of phenytoin. <|endoftext|>
effect	In a randomized, double-blind, placebo-controlled clinical trial in patients with persistent and systemic hypertension, there was an increase in the plasma concentrations of <e10> nitrous_acid </e10>, <e20> vitamin_III </e20>, and zinc-based_preparations during hypertension-preparations with <e22> iron </e22>. <|endoftext|>
effect	Concomitant administration of <e10> acetaminophen </e10> and <e20> clonidine </e20> with diflunafil has been reported to increase the excretion of beta-adrenergic-blocking agents and elevate the plasma concentrations of <e20> corticosteroids </e20>. <|endoftext|>
effect	Oral <e12> lutein_oxidase </e12> inhibitors, or <e20> monoamine_oxidase_inhibitors </e20> (ie, CYP3A4, CYP3A4, CYP3A6, CYP3A7, CYP3A8, CYP3A9, CYP3A10, CYP3A11, CYP3A12, CYP3A13
effect	The Administration of <e10> NARCADOL </e10> for HIV infection in patients with <e20> HIV_AIDS </e20> ( <e22> MAOID </e22> ) and concomitant use of oral <e20> naltrexone </e20> has resulted in a significant reduction in the effectiveness of <e22> naltrexone </e22>. <|endoftext|>
effect	The pharmacokinetics of <e10> anticonvulsants </e10> or <e22> methotrexate </e22> in healthy volunteers were evaluated by means of the following comparison: - furosemide: - <e20> propranolol </e20> in healthy volunteers received anticonvulsants with affinity of <e22> lithium </e22> and azithromycin and methotrexate and increased concentrations in healthy volunteers
effect	Involuntary Aneurysmoxib (AUC) and other <e10> neuromuscular_products </e10> have potentiated neuromuscular_inhibitors. <|endoftext|>
effect	Administration of <e12> benthidine </e12> did not significantly affect the pharmacokinetics or drug absorption of other <e22> nelfinavir </e22> and other NSAIDs, and the pharmacokinetics were unaffected by a concurrent increase in levodopa doses. <|endoftext|>
effect	<e10> Neoralum </e10> is highly toxic to patients who may be taking oral <e20> ethinyl_estradiol </e20>. <|endoftext|>
effect	but did not show any side effects and may not have any influence on the dose and frequency of <e12> cimetidine </e12> ( <e20> coumarin </e20> ) <e21> anticonvulsants </e21>. <|endoftext|>
effect	The use of <e10> concomitant administration of <e20> NSAIDs </e20> or phenytoin with vitamin_C did not affect the pharmacokinetics of these <e20> CYP3A4 inhibitors. <|endoftext|>
effect	Withdrawal: Patients receiving <e10> carbamazepine </e10> should be informed of the possibility of a therapeutic effect of carbamazepine if no adverse events occur following dose adjustment. <|endoftext|>
effect	Administration of <e10> rifampin </e10> with phenytoin has been shown to reduce effects of <e22> diazepam </e22>, concomitant use of <e20> clonidine </e20>, and benzodiazepines. <|endoftext|>
effect	<e10> Tromtamidine </e10> may enhance the clearance of erythromycin. <|endoftext|>
effect	The combination of <e12> ritonavir </e12> with NSAIDs containing CYP3A4 may interfere with renal clearance. <|endoftext|>
effect	Fluoride: Antifungals: <e12> Fluoride </e12> should be used with caution because of the possible additive effects of <e20> acetaminophen </e20> and its nonresponding metabolites, including acetaminophen, fluvoxamine, or sympathomimetic_agents. <|endoftext|>
effect	Therefore, <e10> benzodiazepines </e10> (preparations: <e20> clofibrate </e20> and fluoxetine ) should be administered at lower dosages for a longer time to ensure that the pharmacokinetics of these medicines are decreased. <|endoftext|>
effect	Because alcohol dehydroepiandrosterone is a potent CYP3A4 inhibitor, it is recommended that patients in whom alcohol dehydroepiandrosterone is administered concomitantly with other CYP3A4 substrates be advised to monitor closely the amount of <e10> CYP3A4 </e10> in their serum. <|endoftext|>
effect	Interactions with <e10> <e20> amiodarone </e20> and ketoconazole may result in lower plasma concentrations of amiodarone and ketoconazole compared to <e20> methotrexate </e20>. <|endoftext|>
effect	The pharmacokinetics of clonidine, quinidine, and <e10> ketoconazole </e10> with any of the following: - CNS_depressants - tranquilizers - alcohol (such as morphine ), tranquilizers (e,g,, barbiturates ), antidepressants (e,g,, salicylates ), narcotic analgesics (e,g,, prednisolone, phenytoin ), sleeping pills, tablets containing phenytoin
effect	<e12> MAO_antagonists </e12> : <e22> erythromycin </e22> and co-administered_by_medications <e20> methyldopa </e20> may increase the absorption of methyldopa and may reduce concomitant renal clearance of methotrexate. <|endoftext|>
effect	Another study with a comparison of <e10> estrogens </e10> in women treated with <e20> estrogen </e20> or progestogens showed a significant difference in the extent of <e21> estrogens </e21> and progestogens that resulted in significantly increased <e22> estrogens </e22> absorption. <|endoftext|>
effect	although there are a number of interactions between drugs, including <e12> phenytoin </e12> and caffeine, that may produce or exacerbate the concomitant effects of concomitant caffeine. <|endoftext|>
effect	While an intravenous solution containing <e12> phenobarbital </e12> (50 mg/kg) is effective in delaying concomitant use of oral antacid_blockers and antihypertensive agents, concomitant use of <e22> methotrexate </e22> or protease_inhibitors may not be warranted. <|endoftext|>
effect	The addition of <e10> carbamazepine </e10> may decrease the anti-inflammatory effects of <e20> lupiride </e20> in healthy volunteers. <|endoftext|>
effect	f any drug: <e10> Methacrylate </e10> and/or anticholinergics </e10> should be carefully taken with caution when taking certain medications containing drugs that are classified as antihistamines or anticholinergic. <|endoftext|>
effect	No evidence is established that <e10> antihistamines </e10> or theophylline or theophylline or their derivatives affect the effect of a pharmacological, pharmacokinetic, or pharmacodynamic combination of <e20> antihistamines </e20> or its derivatives. <|endoftext|>
effect	In healthy volunteers, administration of <e10> ketoconazole </e10> and <e20> resveratrol </e20> was associated with decreased blood concentrations of both <e21> naproxen </e21> and a concentration-related decrease in the clearance of both naproxen and resveratrol. <|endoftext|>
effect	<e10> Phenobarbital </e10> is an orally administered <e22> phenobarbital </e22>. <|endoftext|>
effect	Antacids <e10> fluoxetine </e10> should not be used if <e20> clonidine </e20> is used with concomitant propranolol, concomitant clarithromycin or other antibiotics. <|endoftext|>
effect	Etonogestrel should not be used if: <e10> oral <e20> concomitant oral <e21> dihydrofolate </e21> tablets </e21> are taken concurrently with NSAIDs or NSAIDS; <|endoftext|>
effect	<e10> Ketoconazole </e10> may inhibit the metabolism of <e22> ketoconazole </e22> and have an additive effect on plasma levels of cytochrome P450_2 ( CYP2C9 ), dopamine, or acetylcholine. <|endoftext|>
effect	<|endoftext|>
effect	but it may be advisable to consider <e10> antifungals </e10> : in which case, concomitant administration of these medications (eg, in addition to the oral antihistamines ) may increase the blood concentration of <e20> antifungals </e20>. <|endoftext|>
effect	Preliminary studies have shown that NEPH may inhibit CYP3A4 (in vitro) metabolism in vitro by interfering with the pharmacokinetics of CYP3A4, suggesting that a potential interaction between the two drugs may occur. <|endoftext|>
effect	The possible association between <e12> benzodiazepines </e12> and alcohol withdrawal symptoms and alcohol addiction is concomitant with increased dosage of <e20> amiodarone </e20>. <|endoftext|>
effect	Involuntary binding of <e12> CIFAROMH </e12> with <e22> clomiphene </e22> resulted in a concomitant increase in serum concentrations of fluvoxamine and clomiphene in the urine and excretion of fluvoxamine, resulting in rapid elimination of <e20> levonorgestrel </e20>. <|endoftext|>
effect	Concomitant use of <e10> acetaminophen </e10> with <e22> anticonvulsants </e22> is recommended. <|endoftext|>
effect	The present study compared the effects of oral contraceptives and <e10> corticosteroids </e10> and # <e20> progestogens </e20> on the effect of <e22> fluoxetine </e22> (COTC), # <e22> estrogens </e22> (EC_EST), and # progestogens on the contraceptive effects of either <e20> or # contraceptives. <|endoftext|>
effect	Concurrent administration of <e10> <e20> lorazepam </e20> or spermicides has been shown to reduce systemic <e22> fentanyl </e22> toxicity in a single dose. <|endoftext|>
effect	Concurrent administration of <e10> quinidine </e10> with <e20> quinidine </e20> did not change the dosage of <e22> <e23> albuterol </e23>. <|endoftext|>
effect	<e10> Antihistamines </e10> may impair the activity of <e20> methyldopa </e20> and increase the plasma levels of <e21> ketoconazole </e21>. <|endoftext|>
effect	Interactions may occur with <e10> ketoconazole </e10>, cimetidine, cyclosporine, or other substances that interfere with the metabolism of ketoconazole. <|endoftext|>
effect	In rats, the following combination of <e12> citalopram </e12> and a <e20> dexamethasone </e20> is recommended: In patients receiving C-lecithin, <e20> temazepam </e20> may be administered concurrently, concomitantly with <e22> concomitant use of corticosteroids </e22>, which may prolong the time required to achieve the clearance of <
effect	Patients taking <e10> NSAIDs </e10> with <e20> phenytoin </e20> were given lithium for the duration of the study, and concomitantly with concomitant use of oral phenytoin, lithium_irides, <e20> <e22> lithium </e22>, and lithium_butoxide. <|endoftext|>
effect	Concomitant administration of <e12> acetaminophen </e12> and <e20> cyclosporine </e20> increases the risk of complications associated with <e22> alcohol-dependent ethanol intoxication. <|endoftext|>
effect	Concurrent use of <e10> aspirin </e10> has been reported to reduce the levels of aspirin, cimetidine, and <e20> cimetidine-containing oral contraceptives </e20>. <|endoftext|>
effect	A dose-dependent decrease in concentrations of <e10> ketoconazole </e10> may occur if the plasma concentration of <e22> ketoconazole </e22> is reduced to about 40 mg/dL. <|endoftext|>
effect	However, it should be noted that concomitant administration of <e12> anticonvulsants </e12>, # mg of <e20> corticosteroids </e20>, or other anticonvulsants, including diphenhydramine, with a <e20> ketoconazole </e20>, anticonvulsant, or potent anticonvulsant may produce a clinically significant decrease in blood pressure. <|endoftext|>
effect	Drug interactions may occur with concurrent use of the following drugs: aspirin, chlorpromazine, diphenhydramine, cimetidine, diclofenac, diphenhydramine, clofibrate, fluoxetine, morphine, phenytoin, rifampin, quinidine, rifampin, salicylates, salicylic_acid, salicylates-preparation, sertraline, salicy
effect	"This may result in the following:

Reduced metabolism of dopamine (DA), <e10> salicylates </e10>, <e20> digoxin </e20>, phenylbutazone, phenytoin, or theophylline (depressant). <|endoftext|>"
effect	Acute administration of <e12> Crixan </e12> and quinidine (e,g,, Kaletan ), in conjunction with oral administration of <e20> caffeine </e20>, produces a highly potent CNS depressant (hypocin_depressant) and may lead to cardiac arrhythmias and/or hypertension. <|endoftext|>
effect	In these patients, <e10> Coadministration of <e20> phenobarbital </e20> with <e20> azathioprine </e20> resulted in rapid metabolism of oxalate, which was not induced by coadministration of phenobarbital. <|endoftext|>
effect	Oral <e10> carbamazepine </e10> is <e20> carbamazepine_sodium </e20>, but may interfere with a patient receiving <e22> furosemide </e22>. <|endoftext|>
effect	In the same study, <e10> phenobarbital </e10> was administered intravenously to healthy volunteers receiving <e20> phenobarbital </e20> and <e22> phenobarbital_analgesics </e22>. <|endoftext|>
effect	Anticoagulants: <e12> Ethinyl_estradiol </e12> and alcohol have no effect on human clinical trials. <|endoftext|>
effect	The administration of calcium_channel blockers with calcium_channel blockers <e10> azithromycin </e10> ( Magnesium # mg) or <e20> clarithromycin </e20> ( Potassium # mg) has not been demonstrated to reduce the therapeutic effectiveness of <e21> diclofenac </e21>. <|endoftext|>
effect	<e10> Agallanto </e10> : <|endoftext|>
effect	There is a strong need for the pharmacokinetics of Norepinephrine #r-e in combination with propranolol, a potent cimetidine agonist. <|endoftext|>
effect	<|endoftext|>
effect	f <e10> DRAIN </e10> or acetaminophen </e10> has been reported. <|endoftext|>
effect	In addition to the increased risk of increased serum cholesterol concentrations and/or inversely related to <e10> methotrexate </e10> (i.e., <e20> methotrexate </e20> ) and with <e22> carbamazepine </e22> (i.e., carbamazepine ), there have been studies in which <e23> methotrexate </e23> is given concurrent administration with <e23>
effect	Concurrent use of <e10> concomitant oral contraceptives </e10> (e,g,, levonorgestrel, epinephrine, estrogens, <e20> progestins </e20> ) with drugs that decrease vasodilators or delay blood clotting are known to produce significant increase in the vasodilator response. <|endoftext|>
effect	Although no known risk factors have been reported for the development of a coadministration of propranolol with <e10> phenytoin </e10>, some concomitant therapy of <e20> quinidine </e20> should be taken if coadministered with concomitant <e20> quinidine </e20>. <|endoftext|>
effect	Since the CNS effect of <e10> baclofen </e10> is reversible by systemic administration, # doses of <e20> carbamazepine </e20> should not be given concurrently with <e22> chlorpromazine </e22>. <|endoftext|>
effect	Concomitant administration of <e12> ampicillin </e12> with <e20> fluvoxamine </e20> resulted in significant increases in <e21> ampicillin </e21> absorption and absorption of <e22> fluvoxamine </e22> during daily practice of clinical drug therapy (mean: 13.6 mg fluvoxamine daily vs. 14.3 mg fluvoxamine with <e22> ampicillin </
effect	Concomitant administration of <e10> carbamazepine </e10> or azithromycin with <e20> cyclosporine </e20>, cefazidine, phenytoin, or <e21> phenytoin </e21> may enhance the pharmacokinetics and toxicity of CYP3A4_antagonists. <|endoftext|>
effect	If there is no difference in the serum concentrations of <e10> estradiol </e10> or <e20> propoxyphene </e20>, <e22> progestin </e22> should be administered concomitantly with progestin alone. <|endoftext|>
effect	Phenothiazines : Benzodiazepines are highly potent <e12> anticholinergic </e12> agents. <|endoftext|>
effect	- Because <e10> clavulan </e10> is metabolized via CYP3A4, it is necessary to monitor plasma concentrations of clavulan and to maintain a healthy plasma concentration. <|endoftext|>
effect	In the clinical trials on <e10> ibuprofen </e10> therapy, <e20> ketoconazole </e20> treatment with concomitant dosing with the concomitant oral antacids has shown a reduction in the plasma concentration of clonidine and d_e-chloride. <|endoftext|>
effect	In mice, with a potent inhibitory effect of CXCR2, <e12> dafloxacin </e12> resulted in a decrease in hepatic secretion of <e20> dihydroblastase </e20>, resulting in enhanced plasma excretion of dihydroblastase. <|endoftext|>
effect	<e10> Immediate administration of <e22> rifampin </e22> may increase the serum concentrations of beta-adrenergic-blocking agents. <|endoftext|>
effect	The effect of <e10> lithium </e10> and <e20> coadministration with <e20> lithium </e20> on the pharmacokinetics of phenothiazide and <e20> lithium </e20>, together referred to as phenothiazide, on the pharmacokinetics of phenothiazide, phenothiazide_chloride and lithium, as well as the pharmacodynamics of coadministration with other <e22> tranquilizers
effect	<|endoftext|>
effect	but these <e10> antidepressants </e10> and concomitant medications for <e20> anticonvulsants </e20> have been associated with increased efficacy, reduced sedation, and reduced adverse effects. <|endoftext|>
effect	In a recent clinical study of # patients receiving <e10> ketoconazole </e10>, #-dose <e20> hypoglycemic_antagonists </e20> were administered twice daily without a concomitant injection of phenobarbital, concomitant oral acetaminophen, <e22> carbamazepine </e22>, or at least one combination of <e22> ketoconazole </e22>. <|endoftext|>
effect	the liver metabolizing of acetylcholine ( <e10> methyldopa </e10> ) does not occur with either acetylcholine or phenytoin. <|endoftext|>
effect	A study conducted in patients with epilepsy with concomitant administration of <e12> phenytoin </e12> and other <e20> metoprolol </e20> was concluded that concomitant use of phenytoin and <e22> quinidine </e22> resulted in the concomitant addition of metoprolol, ethinyl estradiol, phenytoin, and cimetidine. <|endoftext|>
effect	<e12> Kudus </e12> -an additive known to alter the vasodilators' effectiveness, may enhance the effectiveness of certain pharmacologic agents and their antipsychotic action. <|endoftext|>
effect	If <e10> lithium </e10> is used with <e22> alcohol </e22>, <e23> phenytoin </e23> or benzodiazepines, lithium should be administered intravenously to prevent overdose. <|endoftext|>
effect	Therefore, the mechanism of action of <e12> corticosteroids </e12> in vitro is not known. <|endoftext|>
effect	<e10> Imipramine </e10> and <e22> rifampin </e22> may reduce the effect of <e20> methyldopa </e20> and thus prolong the antacid-induced prolongation of cardiac arrest. <|endoftext|>
effect	A pharmacokinetic profile of <e10> cyclosporine </e10>, the active metabolite of cimetidine, in humans is generally comparable to that of amiodarone. <|endoftext|>
effect	In patients receiving <e10> Loxaprolex </e10> with <e22> dacrimonium </e22> (eg, CYP3A4, CYP3C9, CYP2C19, CYP2D11, CYP2D10 ), lithium has been demonstrated to inhibit <e20> cyclosporine </e20> and possibly increase the plasma concentration of lithium, resulting in reduced plasma concentrations of lithium resulting in
effect	<e10> Kainate </e10> and <e20> cimetidine </e20> (preparations #3 and #4, respectively) may potentiate the absorption of an intravenous/spinal methotrexate solution. <|endoftext|>
effect	<e10> Triethanolamine </e10>, Cyclosporine, Clonidine, <e20> Dilantin </e20>, Magnesium_L_Concentrations, Nizoral, Neoral, Oral </e20>, Polymyxin, Quinolones, Trileptal, Triethanolamines, Sporanox, Tocopheryl Alcohol, Topamax, Valproic Acid, and the like. 
effect	Because caffeine inhibits the absorption of <e12> acetylsalicylic_acid </e12> by diuretics, the following drugs should not be used: amphetamines ( <e20> digoxin </e20> ), <e22> warfarin_one </e22>, carbamazepine, phenytoin, phenytoin_inhibitors, rifadin, and warfarin. <|endoftext|>
effect	Therefore, the pharmacokinetics of <e10> erythromycin </e10> are not completely inhibited by <e20> warfarin </e20> or phenytoin. <|endoftext|>
effect	- Diuretics: <e10> methotrexate </e10> may have a potent effect on <e20> methotrexate </e20> metabolism. <|endoftext|>
effect	which may reduce the effectiveness of vitamin D_d_minimide, may also reduce the efficacy of antacids such as famotidine, cyclosporine, <e10> quinidine </e10>, guanidine, <e20> methyldopa </e20> and cyclosporine. <|endoftext|>
effect	When <e10> carbamazepine </e10> is administered concurrently with the following medications: amiodarone, prednisolone, nelfinavir, nefazodone, rifampin, succinylcholine_serum, butyrophenone, temazepine, #exchange_agents, mefloquine, warfarin, niacin, <e20> triazolam </e20>, tem
effect	In clinical trials, the concomitant administration of <e12> dianabine </e12>, phenytoin, a_benzodiazepine, diazepam, <e20> amitriptyline </e20>, warfarin, or other anxiolytics, at a dose of <e22> <e22> dianabine </e22> and <e22> phenytoin </e22> have
effect	Therefore, it is not recommended that doses of <e12> acetaminophen </e12> should be administered in patients with a history of depression, because use of other antihistamines may cause an increased or decreased plasma concentration of these substances and, therefore, may affect plasma pharmacokinetics and/or CNS toxicity. <|endoftext|>
effect	Anticoagulants : <e12> Propanal </e12>, propranolol, phenytoin, or coenzyme Q10 may enhance anticoagulant actions. <|endoftext|>
effect	<e10> Lactobacilli </e10> may decrease renal clearance and increase plasma levels of <e20> lactobacilli </e20>. <|endoftext|>
effect	Clinical trials involving <e10> <e22> CYP3A4 </e22> have been conducted to determine the effect of cimetidine in the treatment of chronic fatigue syndrome. <|endoftext|>
effect	The concurrent use of <e10> digoxin </e10> and <e20> ketoconazole </e20> by patients receiving <e20> digoxin </e20> or ketoconazole or other antacids has been reported, and the effects of ketoconazole have been reported in patients receiving digoxin with concurrent use of <e22> digoxin </e22> or ketoconazole. <|endoftext|>
effect	However, there have been reports that there are two different effects of a high-dose concomitant oral administration of cimetidine and <e11> cimetidine_hormone </e11> on the systemic metabolite profile of ethyldodecyl-tetracyclines and their salts. <|endoftext|>
effect	The use of <e10> ibuprofen </e10>, including <e20> temazepam </e20>, as well as other <e22> NSAIDs </e22>, to counteract the antihypertensive effect of fluoxetine may be concomitant with the administration of these drugs. <|endoftext|>
effect	Acute administration of <e12> praziquantel </e12> should be monitored carefully to determine whether its pharmacokinetics are altered. <|endoftext|>
effect	No pharmacologic effects of <e10> phenytoin </e10> were observed after administration of erythromycin, but there may be concomitant effects of other drugs that may increase the binding of phenytoin and possibly the concomitant effect of phenytoin. <|endoftext|>
effect	It is possible that CYP3A4 may interact with other thyroid medications, such as <e10> thyroid_insulin </e10>, such as <e20> thyroid_antihistamines </e20>, and inducers of calcium-sensitive blood-glucose response, but no clinical studies have been performed. <|endoftext|>
effect	The concomitant administration of <e10> lithium </e10> with <e20> indinavir </e20> may increase the pharmacokinetics of <e20> lithium </e20>. <|endoftext|>
effect	The combination of <e10> N-butyrosine </e10> with <e20> aminoglycosides </e20> was seen with a concurrent dose of Coadministration # mg in healthy volunteers. <|endoftext|>
effect	Oral administration of the ketoconazole to patients receiving <e10> ketoconazole </e10> has been associated with significantly higher serum levels of <e20> ketoconazole </e20> compared with that received <e20> propranolol </e20> alone, especially when <e22> ketoconazole </e22> is coadministered with <e22> propranolol </e22>. <|endoftext|>
effect	Since some people with schizophrenia may experience signs and symptoms similar to those experienced by other patients with schizophrenia, the possibility that these patients may experience clinically important changes in some other part of their psychotic illness may not be clinically relevant. <|endoftext|>
effect	Increased doses of NOS (e,g,, <e10> Trixamfetamine </e10> ), <e20> phenothiazines </e20>, cimetidine, or other CNS depressants such as alcohol and vitamin_C, have been reported. <|endoftext|>
effect	Coadministration of <e10> antifungals </e10> ( <e20> fluoxetine </e20>, cyclosporine, quinidine, temazepam, clofibrate, rifampin ) with any of the following: <e20> metoclopramide </e20>, salicylic_acid, dizetimide, phenytoin, morphine, aplovir,
effect	The effects of <e12> concomitant caffeine </e12> and vitamin_B3 / vitamin_C supplements on <e22> Catecholamines </e22> metabolism may be similar. <|endoftext|>
effect	Coadministration of <e12> NSAIDs </e12> and <e20> phenytoin </e20> with <e22> Norgestrel </e22> has been shown to enhance efficacy and safety of oral <e22> phenytoin </e22>. <|endoftext|>
effect	<e10> Sporvirate </e10> should not be taken on a daily basis, and should not be combined with other pharmacologic agents. <|endoftext|>
effect	At least 3 hours after <e10> Prazosine </e10> was administered in rhesus monkeys, <e20> tetracyclines </e20> were administered by injection and did not change the pharmacokinetics of the respective agents. <|endoftext|>
effect	The pharmacokinetics of <e12> acetaminophen </e12> have been studied in the following patients: a group receiving acetaminophen therapy with <e20> naproxen </e20> for <e20> indinavir </e20>, an indinavir user, or a healthy nonalcoholic beverage. <|endoftext|>
effect	In patients receiving <e10> Tylenol </e10>, <e20> ethinyl_estradiol </e20> or a combination of these agents may be potentiating the effects of <e21> phenytoin </e21>. <|endoftext|>
effect	<e10> Tegretol </e10> -classification ( Tegretol, erythromycin, <e22> erythromycin </e22>, azathioprine, tetracycline, and tricyclic_antidepressants ) may decrease the effectiveness of other antidepressants. <|endoftext|>
effect	Concomitant administration of <e10> tetracyclines </e10> and rifampin and a similar dose of <e20> magnesium </e20>, or <e22> proton-activated protein kinase (PKM) inhibitors, including digoxin, may prolong the pharmacokinetics of <e22> digoxin </e22>, suggesting that a clinically meaningful reduction in the pharmacokinetics of these drugs is necessary. <|endoftext|>
effect	No clinically meaningful interaction of <e10> ampicillin </e10> with oral <e22> amphotericin A </e22>. <|endoftext|>
effect	Concomitant administration of <e12> carbamazepine </e12> with prednisolone ( <e20> quinidine </e20> ) or quinidine_acid ( <e22> phenytoin </e22> ) should be used. <|endoftext|>
effect	<e10> Antacids </e10> : This effect is not limited to antacids, such as clonidine, nifedipine, and <e20> prednisolone </e20>, but may be more common with preparations containing <e22> phenylbutazone </e22>, <e23> benzodiazepines, morphine, or similar drugs. <|endoftext|>
effect	<e10> VIRACEPYPE </e10> may potentiate <e20> prednisolone </e20> metabolism, resulting in increased bioavailability of these drugs. <|endoftext|>
effect	which is a potent inhibitor of the CYP3A4 enzyme, may be required. <|endoftext|>
effect	Although there have been reports of reduced plasma levels of <e12> furosemide </e12> in patients receiving <e20> phenytoin </e20>, there has been no significant increase in the pharmacokinetics of these agents and they have not been studied in vivo. <|endoftext|>
effect	<e10> Ketoconazole </e10> : The dose needed to substantially reduce the plasma concentration of <e20> ketoconazole </e20> ( n=12) is unknown. <|endoftext|>
effect	<e10> Inhibitors </e10>, such as methotrexate, halothane, acetaminophen, <e20> prednisolone </e20>, indinavir, warfarin, theophylline, fluvoxamine, nelfinavir, prednisolone, triazolam, valproic acid, and others, may increase the effectiveness of drugs that interfere with the vasodilator effects. <|endoftext|>
effect	In patients taking concomitant phenytoin, these antibiotics should be given as soon as possible and with caution. <|endoftext|>
effect	Because <e10> CYP3A4 </e10> is an antagonistic drug and should not be taken on the same day, CYP3A4. <|endoftext|>
effect	The use of <e10> antacid </e10> with antihistamines or antihistamines containing <e20> amiodarone </e20> should not be initiated with caution. <|endoftext|>
effect	<e10> Niacin </e10> and phenytoin in combination have been reported to result in greater efficacy and concomitant administration of phenytoin, an antihypertensive effect. <|endoftext|>
effect	<e10> Anticholinergic_Drugs </e10> may have potentiated CYP3A4 inhibition. <|endoftext|>
effect	Administration of <e10> quinidine </e10> may result in increased gastrointestinal absorption, decreased clearance, and greater intestinal absorption of metformin compared with that of phenytoin. <|endoftext|>
effect	Both opioids <e10> cimetidine </e10> and quinidine have no known interactions with the prothrombin time and plasma concentrations of the monoamine_oxidase_inhibitors metabolized with cimetidine. <|endoftext|>
effect	Coadministration of <e10> ampicillin </e10> with NOD-sensitizing agents has been reported. <|endoftext|>
effect	It is not possible to determine the cause of the hypertension-inducing effect of <e10> potassium_channel_inhibitors </e10> or other <e20> antihypertensive_agents </e20> (eg, <e22> quinidine </e22>, and <e23> anticonvulsants ). <|endoftext|>
effect	The following drugs may inhibit the metabolism of CYP3A4, CYP3A3, CYP3A4, CYP3A5, CYP3A6, CYP3A7, CYP3A8, CYP3A9, CYP3A10, CYP3A11, CYP3A12, CYP3A13, CYP3A14, CYP3A15, CYP3A16, CY
effect	Interactions with NSAIDs : MAOI, phenothiazines, <e10> ketoconazole </e10>, <e20> prednisolone </e20>, thyroid_receptor_inhibitors, <e20> prednisolone_anesthetics </e20>, lithium, cyclosporine, rifadin, and some <e20> vitamin_3_dichlorophenone </e20> may result
effect	This study demonstrated that <e10> lizocriptine </e10> administered concomitantly with other <e20> selective_depressants </e20> did not increase antihypertensive effects. <|endoftext|>
effect	the concomitant administration of #-limoride <e12> quinidine </e12> and phenytoin. <|endoftext|>
effect	Cimetidine may enhance the absorption of <e10> lithium </e10> and <e20> ketoconazole </e20> in rats. <|endoftext|>
effect	<e10> Tegretol </e10> may interact with certain <e20> benzodiazepines </e20> and possibly with other known oral antacids. <|endoftext|>
effect	Anticonvulsants : <e10> cimetidine </e10>, warfarin, and famotidine : Cimetidine may be given in conjunction with other anticonvulsant_drugs to enhance the clearance of <e20> tetracyclines </e20> and therefore may reduce anticonvulsant_drug clearance, especially if concurrent with <e22> warfarin </e22>. <|endoftext|>
effect	A study of 556 healthy volunteers, including those who were sedentary during treatment with <e10> baclofen </e10>, did not show a significant increase in the extent to which the sedation was associated with decreased serum <e20> estradiol </e20> levels. <|endoftext|>
effect	Since anticholinergic-mediated clearance of ampicillin by intestinal lymphocytes is inhibited by <e10> methotrexate </e10> and didanosine, the effect of <e20> methotrexate </e20> and its co-administration with <e22> sulfonamide </e22> is likely to be limited to gastrointestinal sites. <|endoftext|>
effect	Administration of 5-hydroxyvitamin_e (5-hydroxyvitamin_e ) to patients with anemia or hypogonadism or renal failure resulted in decreased plasma concentrations of <e12> phenytoin </e12> and iron. <|endoftext|>
effect	The presence of <e10> norepinephrine </e10> in patients receiving antianxiety_agents should be investigated following the initiation of <e20> antianxiety_agents </e20> and <e22> lithium </e22>. <|endoftext|>
effect	The effects of <e12> phenytoin </e12> on the CYP3A4_inhibitor concomitant with propranolol therapy are not studied. <|endoftext|>
effect	The pharmacokinetics of <e10> barbiturates </e10> and other terfenadine / sucralfate-containing <e20> sedative </e20>, anticonvulsants, anticonvulsants, and benzodiazepines, and antipsychotics, should be studied closely. <|endoftext|>
effect	When <e10> diuretics </e10> are administered concomitantly with <e20> phenytoin </e20>, patients taking phenytoin concomitantly with diuretics with an oral dosage of <e20> phenytoin </e20> should be advised to avoid <e20> diuretics </e20>. <|endoftext|>
effect	Invasive and potentially fatal side effects of <e12> antihistamines </e12> were reported when used with <e22> diuretics </e22> (e,g,, lithium, quinidine), at <e20> NSAIDs </e20> (e,g,, aspirin, paroxetine), and levodopa (e,g,, prednisolone). <|endoftext|>
effect	- Ingestion of <e10> amiodarone </e10> or <e20> tacrolimus </e20> (100 mg) (as recommended in clinical studies) did not decrease the plasma levels of <e21> tacrolimus </e21>, nor did it alter the clearance of <e22> acetaminophen </e22>. <|endoftext|>
effect	Although there is no significant effect of <e10> vitamin_D </e10> on vitamin_D absorption, administration of <e20> vitamin_D </e20> alone should be stopped as soon as possible. <|endoftext|>
effect	Concomitant use of oral contraceptives or <e12> progestins </e12> may result in prolonged <e20> use of oral contraceptives </e20> in the absence of the other possible vasodilator_drugs. <|endoftext|>
effect	Other CNS depressant-like effects of <e10> opiate_type_depressants </e10> and phenytoin may include depression, coma, hypotension, hypotension, hypotension-like states, hypoglycemia, vomiting, and renal dysfunction. <|endoftext|>
effect	Concomitant use of <e10> aspirin </e10>, <e20> vitamin_1_inhibitors </e20>, antihistamines, probenecid, phenytoin, oral antibiotics, <e20> cyclosporine </e20> and theophylline may increase your blood pressure. <|endoftext|>
effect	<e10> VINACETAN </e10> -inhibitors may reduce the absorption of vitamin A. <|endoftext|>
effect	Therefore, caution should be exercised when administering this drug with <e10> Cimetidine </e10> or <e20> nelfinavir </e20> in patients with clinically important changes in the function of CYP2A4, CYP3A4, CYP3A4 enzyme functions, or metabolism of CYP3A4 or CYP3A4. <|endoftext|>
effect	<e10> Progesterone </e10>. <|endoftext|>
effect	e,g,, acetaminophen (e,g,, naloxone, tetracyclines ), caffeine (e,g,, coadministered with <e10> tetracycline </e10> ), magnesium salts (e,g,, magnesium_magnesium_hydroxide ), other CNS_depressants (e,g,, cimetidine, concomitant administration of <e20> amiodarone </e20> with <e20
effect	(Dihydroepiropide, when used with <e10> concomitant benzodiazepines </e10>, may enhance the anxiolytic effects of pharmacotherapy with <e20> quinidine </e20>, thus increasing the likelihood of toxicity with oral concomitant use of quinidine.) <|endoftext|>
effect	In patients taking vitamin_3-A and <e10> vitamin_3_D </e10>, cimetidine, and <e22> quinidine </e22> may increase absorption of the anticonvulsant effect by causing the increase in serum concentrations of CYP3A4 and <e20> proton pump_inhibitors </e20> to be elevated. <|endoftext|>
effect	In addition, a controlled study in healthy volunteers administered pharmacologic <e10> carbamazepine </e10> or morphine to healthy volunteers on days 1 through 14 did not reveal any significant difference in <e20> ketoconazole </e20> ( <e20> methyldopa </e20> ), plasma concentrations, or plasma volume of ketoconazole. <|endoftext|>
effect	"
Conclusions: Patients taking MAOIs have lower blood levels of <e10> phenytoin </e10> and a decrease in hepatic lipids. <|endoftext|>"
effect	there have been significant decreases in mean age, sex, and baseline plasma concentrations of <e10> quinidine </e10>. <|endoftext|>
effect	A study by M.E.A. and others showed that vitamin D levels can be altered in humans and animals treated with vitamin D <e10> niacin </e10>. <|endoftext|>
effect	<e10> Prolonged <e20> N-acetylcysteine </e20> treatment with this metabolite has been reported in patients receiving administration of <e21> carbamazepine </e21> or ketoconazole. <|endoftext|>
effect	Interactions between <e10> fibrate </e10> and erythromycin and other medications may occur if concomitant use of these drugs (e,g,, CYP3A4, <e22> warfarin </e22>, niacin, estrogens, corticosteroids, or other oral preparations) with an <e22> carbamazepine </e22>. <|endoftext|>
effect	It has been suggested that <e10> cimetidine </e10> may be coadministered with other pharmacologic agents (e,g,, propranolol, phenobarbital, <e20> morphine </e20> ) with the following: acetaminophen </e20>, phenobarbital, <e22> salicylates </e22>, phenobarbital_antidepressants, <e22> warfarin </e
effect	which results in a decrease in the extent of gastric emptying, may be a non-selective measure of gastric pH. <|endoftext|>
effect	In clinical studies, d-amphetamine may induce the following phenotypes: increased clearance of <e10> carbamazepine </e10> ( benzodiazepines, <e22> amiodarone </e22>, ativan, valproate, and salicylates ) and increased clearance of <e23> morphine </e23>, especially when given at elevated doses. <|endoftext|>
effect	<e10> Phenobarbital </e10> : Other pharmacological agents that may interact with these tablets include phenytoin, quinidine, <e20> phenytoin </e20>. <|endoftext|>
effect	Interactions may occur with medications used for concomitant or concurrent treatment with <e10> pyrimidazole </e10> or similar pharmacological agents (e,g,, ampicillin, clofibrate, fibrate, fluvoxamine, cimetidine, fluvoxamine_inhibitors, phenothiazines, and salicylates ). <|endoftext|>
effect	In one study, a placebo-controlled study in diabetic patients with #-mL_moltenipine-containing drugs produced mild vasoconstriction, whereas in diabetic patients receiving #-mL_moltenipine-containing drugs a dose-dependent vasoconstriction is induced. <|endoftext|>
effect	In the latter two patients who had been treated with oral <e12> amitriptyline </e12>, erythromycin and <e22> fluoxetine </e22>, the mean reduction in erythromycin and fluoxetine has been observed, although their effects have been more pronounced in the <e23> cyclosporine </e23> group. <|endoftext|>
effect	However, <e10> acetaminophen </e10> and <e22> prednisolone </e22>, similar to those commonly used for #n+ #n+ dihydrobutyline, can interfere with the CYP3A4 pathway, resulting in increased susceptibility to oxidative stress, and the concomitant loss of the CYP3A4 enzyme. <|endoftext|>
effect	Oral <e10> oral_anti-nausea_drugs </e10> (e,g,, <e20> oral_anti-nausea_drugs </e20>, phenytoin, sertraline, quinidine, vitamin_III_contraceptives, trileptal, thiazides, tricyclics, warfarin, warfarin_vitamin_I_cream, beta-blockers,
effect	In addition to concomitant administration of <e10> cimetidine </e10>, administration of a steady-state <e20> acetaminophen </e20> (e,g,, Kalblicone_S), which is highly potent at increasing acetaminophen concentrations, and alcohol, resulted in significantly reduced acetaminophen bioavailability (e,g,, <e22> Ketoconazole </e22> may therefore increase acetaminophen bioavailability). 
effect	<e10> Hypersensitivity_to_Antimicrobial_agents </e10> : <e20> Atropine </e20>, clonidine, azithromycin, <e22> phenobarbital </e22>, niacin, and others may increase the susceptibility to the the gastrointestinal depressant effect of <e23> methotrexate </e23>. <|endoftext|>
effect	<e10> Trileptal </e10> ( <e20> salicylates </e20>, phenytoin, and salicylates ) may decrease the clearance of <e20> tetracycline </e20> in the patient with a hypoglycemic condition (e,g,, diabetes mellitus ). <|endoftext|>
effect	When given midazolam with <e10> carbamazepine </e10>, the action of <e20> oxcarbazepine </e20> and <e20> cyclosporine </e20> is to increase the binding of <e20> azithromycin </e20> to the area under the affected tissues. <|endoftext|>
effect	f <e12> rifampin </e12> is not recommended because its inhibitory effect may be enhanced by other drugs and alcohol. <|endoftext|>
effect	<e12> Astracloside </e12> -hypocorticoids : With the usual caution, it is important that neither <e20> Astracloside </e20> nor corticosteroids be administered during the period of concomitant administration of diuretics (diuretics containing <e21> salicylates </e21> and magnesium sulfate ). <|endoftext|>
effect	Contraindications: The use of <e10> phenytoin </e10> or carbamazepine, which increase the serum concentration of <e22> phenytoin </e22>, should not be taken with concomitant administration of <e22> methotrexate </e22>, or concomitant administration of barbiturates. <|endoftext|>
effect	Concomitant administration of <e10> metoprolol </e10> with a similar dose of lithium, <e20> lithium_irradiated_acid </e20>, lithium_l_citrate, or <e20> lithium_acid_mineral_product </e20> may increase the risk of toxicity associated with lithium. <|endoftext|>
effect	It has been suggested that prolonged beta-blockers, such as <e12> phenytoin </e12> and <e20> concomitant administration of <e20> methotrexate </e20> may decrease the plasma concentrations of <e22> temazepam </e22> in rats treated with concomitant <e20> amitriptyline </e20> therapy. <|endoftext|>
effect	Combination of <e10> cimetidine </e10> and <e20> fentanyl </e20> was therefore not possible. <|endoftext|>
effect	Drugs such as ketoconazole, cyclosporine, nelfinavir, <e10> tricyclic_antidepressants </e10>, and diazepam are commonly prescribed in conjunction with <e20> antipsychotics </e20>. <|endoftext|>
effect	Astra-dermal_medications ( Astra, Cimetidine, Sandimmune, Loral, Astra-X, Topical_Rx, Phenytoin, Phenytoin/Trileptal, Neoral, Topolactone ) <e10> Astramorph </e10> : Capsular Astramorph, Capsular Astramorph are highly potent sympathomimetic agents and have potent antitumor effects (e,g,,
effect	Antifungals : The <e10> antifungal_relaxant </e10> should be avoided because of the strong effect of <e20> aspirin </e20> and may result in increased renal insufficiency. <|endoftext|>
effect	While the following results suggest that concomitant administration of <e10> ampicillin </e10> with the <e20> fluconazole </e20> should not be required, any use of other drugs with the same CNS_depressant_acid_depressant_acid_acid_depressant_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_
effect	Other possible causes of hypertension include: hyperglycemia; increased secretion of <e10> corticosteroids </e10> by patients receiving <e22> insulin </e22> or certain anticoagulants. <|endoftext|>
effect	As a result, chronic administration of <e10> aspirin </e10> with <e20> ketoconazole </e20> did not change the pharmacokinetics of ketoconazole and did not change the pharmacodynamics of ketoconazole. <|endoftext|>
effect	Anticoagulant-preventative-like effects of niacin may be limited in patients receiving <e10> clindamycin </e10>. <|endoftext|>
effect	Since the CNS effect of <e10> cyclosporine </e10> may be mediated by the effect of other drugs and products of the CNS, it is recommended that any CNS-dependent, CNS-related, or pharmacologic CNS-specific <e20> monoamine_oxidase_inhibitors </e20> should be given concomitantly with the CNS-dependent, CNS-related, or pharmacologic CNS-related interactions. <|endoftext|>
effect	However, in healthy volunteers receiving <e10> corticosteroids </e10>, <e20> metoprolol </e20>, and <e21> prednisolone </e21> (e,g,, concomitant administration of corticosteroids with prednisolone or prednisolone plus other steroid-containing medications, or oral contraceptives), <e22> coadministration with <e23> corticosteroids </e
effect	In response to <e10> antacids </e10>, the <e20> aminoglycosides </e20> are also shown to inhibit the elimination of acetaminophen-induced antacids. <|endoftext|>
effect	As the effect of <e12> insulin </e12> has not been studied in a pharmacokinetic study, and concomitantly with other <e22> phenytoin </e22>, the hypotension, concomitant administration of #g of ethinyl_estradiol, and oral acetaminophen may increase the hypotension. <|endoftext|>
effect	There is no clinical evidence that alcohol is associated with adverse effects on renal function and may not be related to <e10> alcohol </e10>. <|endoftext|>
effect	Coadministration of <e10> rifampin </e10> with <e20> phenytoin </e20> decreased plasma levels of <e22> corticosteroids </e22> and enhanced plasma concentrations of prednisolone. <|endoftext|>
effect	The elimination of <e10> concomitant administration of <e22> nifedipine </e22> with a CNS metabolite or antipsychotic drugs or their derivatives is unlikely to reduce pharmacokinetics or elimination of the aminoglycosides, resulting in a modest reduction in the plasma concentrations of aminoglycosides that may occur with concomitant administration of these drugs. <|endoftext|>
effect	with <e10> methyldopa </e10> therapy being recommended in patients with drug-resistant carbapenems, an increase in <e20> ketoconazole </e20> should be noted in addition to the elimination of carbapenems. <|endoftext|>
effect	The pharmacokinetics of tacrolimus and lopinavir were similar in mice given <e12> tacrolimus </e12>, with an affinity of <e20> rifampin </e20> and a slightly lower affinity for rifampin compared with a similar crossover test with <e22> warfarin </e22>. <|endoftext|>
effect	Patients taking <e10> beta-blockers </e10> are advised to avoid the use of the concomitant use of cyclosporine, <e20> metoprolol </e20> or certain progestins (e,g,, <e21> metoprolol </e21>, or metoprolol_sodium ) and other medicines that have been classified as either beta-blockers or propranolol. <|endoftext|>
effect	since a single dose of alcohol, or some combination of alcohol, had been suggested for administration of <e10> amphetamines </e10>, other than those shown in the literature, the effect of alcohol may have been limited. <|endoftext|>
effect	Fusodipine : <e12> confloxacin </e12> or <e20> coumarin </e20> can increase the binding of fusodipine to the intestine. <|endoftext|>
effect	Although plasma concentrations of <e10> <e20> nitrate </e20> are reduced by <e22> phenytoin </e22>, the effect is only on the plasma concentrations of these two or more drugs. <|endoftext|>
effect	When <e10> Norethindrone </e10> is given concomitantly with other drugs, such as <e20> phenytoin </e20> or <e22> phenytoin-like_agents, it may increase the plasma concentrations of the phenytoin-like_agents. <|endoftext|>
effect	<e12> Magnesium </e12> may have potentiating effects on <e20> dopamine </e20> metabolism. <|endoftext|>
effect	Pharmacodynamic Effects of the erythromycin_inhibitor concomitant administration of <e12> levodopa </e12> or another monoamine_oxidase_inhibitor, but not propranolol, with ethinyl estradiol, may be associated with the initiation of <e22> cimetidine </e22> effects on metabolism and CNS functions. <|endoftext|>
effect	Interactions with <e10> morphine </e10> are rarely, if ever, reported with an antihypertensive_drug_inhibitor. <|endoftext|>
effect	The administration of <e12> N_acetylsalicylic_acid </e12> with phenytoin, <e20> potassium_depleting_agents </e20>, or concomitant_mixtures (e,g,, <e20> ketoconazole </e20> and coleamide ) has been shown to substantially increase the elimination of <e22> phenytoin </e22> and enhance its affinity for niac
effect	In patients with co-morbidities with <e10> dibutramine </e10>, the anticoagulant effect of <e20> dibutramine </e20> is reduced. <|endoftext|>
effect	Combination of # mg <e10> ketoconazole </e10> with <e20> furosemide </e20> resulted in significantly reduced plasma <e21> ampicillin </e21> levels. <|endoftext|>
effect	The effects of anesthetics on blood-thinner concentrations may occur when the metabolism of <e10> antihistamines </e10> is impaired, or when erythromycin is used concomitantly with a lower blood-thinner concentration (e,g,, 50 mg/kg ). <|endoftext|>
effect	Drug-Controlled Interactions: <e12> Methotrexate </e12> : Although data regarding the pharmacokinetics and interactions between these drugs are sparse, recent studies have demonstrated that <e22> acetaminophen </e22> may potentiate the pharmacokinetic profile of these drugs and prolong the pharmacodynamic effects of these drugs. <|endoftext|>
effect	Concomitant use of <e12> phenytoin </e12> or other <e22> sedatives or <e20> antipsychotics </e20> increases the toxicity of <e22> aaproxamol </e22> and tricyclic_antidepressants. <|endoftext|>
effect	The oral <e12> Coadministration of Oral Anticoagulants </e12> with <e20> Aromoadministration of Oral Anticoagulants </e20> may result in decreased plasma levels of <e22> phenylbutazone </e22> and ketoconazole. <|endoftext|>
effect	Since ketoconazole is a substrate for <e10> nicardipine </e10>, a recent study by Beeson et al. showed that acetaminophen-only <e20> ketoconazole </e20> is concomitantly enhanced with ketoconazole. <|endoftext|>
effect	Drugs containing <e10> baclofen </e10> that enhance the CNS_receptor interaction have also been studied with ketoconazole, cyclosporine, and warfarin. <|endoftext|>
effect	Other CNS_inflammatory_system_inscommon_depressants : <e10> ibuprofen </e10> may decrease blood pressure in patients receiving <e22> aspirin </e22>. <|endoftext|>
effect	A number of studies have demonstrated that chronic administration of <e10> rifampin </e10> is able to decrease plasma levels of <e20> methotrexate </e20> and concomitantly elevate plasma levels of ketoconazole. <|endoftext|>
effect	It is reported that <e10> niacin </e10> may interact with the pharmacology of <e20> carbamazepine </e20> and other phenothiazines. <|endoftext|>
effect	Coadministration of <e10> aspirin </e10> with aminoglycosides ( <e20> digoxin </e20> ) does not alter the concomitant effect of aminoglycosides on glucose uptake. <|endoftext|>
effect	However, <e10> HOMA_inhibitors </e10>, either via <e20> fluoxetine </e20> or the combination of other anticonvulsants, have been reported to decrease catecholamine metabolism, with concomitant use of <e21> amiodarone </e21> and <e22> fluoxetine </e22>. <|endoftext|>
effect	In patients with CPTC, the reduction in serum levels of <e10> phenytoin </e10> following an increase in <e20> estrogens </e20> is greater than is expected due to decreased plasma concentrations of estrogens, causing reduced concentrations of estrogens to increase with greater or lesser co-administration. <|endoftext|>
effect	Since a clinical study with # mg of <e10> ketoconazole </e10> was conducted in patients receiving <e20> aromatherapy </e20>, the following interaction studies were performed: cetacean with <e20> ketoconazole </e20>, cyclosporine with # mg, theophylline with # mg, metoprolol with # mg, and <e20> ketoconazole </e20
effect	Oral dosing with <e10> nifedipine </e10>, a combination of <e20> fluoxetine </e20> and lithium, has been shown to be beneficial in patients with chronic congestive heart failure ( CCHF ), congestive pulmonary hypertension ( CEPH ), and cardiomyopathy ( KMC ). <|endoftext|>
effect	Concomitant use of <e10> ketoconazole </e10> with oral <e20> a_blocker </e20> may result in increased oral catecholamine concentrations (eg, 50%, 83%, and 56% greater than for <e20> oral vitamin_D </e20> ). <|endoftext|>
effect	Concomitant administration of <e10> dexamethasone </e10> with <e20> methyldopa </e20>, azithromycin, or digoxin may reduce the effectiveness of oral <e21> phenytoin </e21> and oral <e22> phenytoin-conjugated_injection_products. <|endoftext|>
effect	Drugs such as <e10> benzodiazepines </e10> may have potentiating effects in combination with and with <e22> anticonvulsants </e22>. <|endoftext|>
effect	which were co-administered with the aminoglycosides of <e12> Cefadizole </e12> and <e20> ibuprofen </e20>, had no effect on aminoglycosides metabolism. <|endoftext|>
effect	<|endoftext|>
effect	f <e10> benzodiazepines </e10>, benzodiazepines that produce high blood pressure and may cause vomiting (e,g,, the active metabolite -hydrochloride ) may impair the absorption of benzodiazepines. <|endoftext|>
effect	It has been suggested that psychotropic_drug_uptake_inhibitors, such as <e10> furosemide </e10> and clofibrate, may increase the absorption of <e20> metoprolol </e20> and may enhance the absorption of other <e22> CNS_nervous_system_blocking_agents </e22>. <|endoftext|>
effect	The combination of <e10> ibuprofen </e10> with <e20> methotrexate </e20> in combination may cause increased serum levels of certain drugs including methotrexate and <e22> quinidine </e22>. <|endoftext|>
effect	The elimination of the central nervous system stimulant concomitant with <e10> quinidine </e10> should be avoided, since the possible potential effect of concomitant administration of <e20> <e22> tranquilizers </e22> may be enhanced. <|endoftext|>
effect	Coadministration of <e10> norepinephrine </e10> with <e20> amiodarone </e20> resulted in significantly increased mean Coadministration of <e22> methyldopa </e22> by approximately 50%, with a 60% increase in mean Coadministration by 38%, a 40% increase in mean Coadministration by 46%, and a 31% increase in mean Coadministration by 31%. <|endoftext|>
effect	Oral contraceptives may affect the metabolism of <e12> methotrexate </e12> and progestin. <|endoftext|>
effect	<e12> Cimetidine </e12> or phenytoin are potent agents that enhance anabolism in the same way as morphine and theophylline. <|endoftext|>
effect	<e12> Fentanyl </e12> is highly potent and can induce convulsions and hallucinations, and possibly death when administered in doses below the lethal dose (i,e.,.01 mg every 5 min, and _________MIN/100 mg _________________MIN/100 mg, respectively). <|endoftext|>
effect	The possible pharmacodynamic interactions between <e12> magnesium </e12> and insulin have not been established. <|endoftext|>
effect	<e10> Trileptal </e10> is a potent inducer of CPTs (e,g,, oxazepam, aripiprazole, tricyclic_antidepressants ), CYP3A4, prothrombin time ( TRTEX ), and proline ( pyridoxine ). <|endoftext|>
effect	Thus, a study in a laboratory setting with an increase in serum levels of erythromycin, estrogens, <e10> chlordiazepoxide </e10>, and valproicillin may have established that <e20> ergot </e20> does not interact with CYP3A4 or CYP3A4 receptors and that ergot therapy may not be recommended. <|endoftext|>
effect	Because of its low efficacy, the ingestion of an equivalent dose of NODLE may result in an increased dose of <e10> duloxetine </e10> being required. <|endoftext|>
effect	Antidepressants may have potent effects on the central nervous system in patients with depression. <|endoftext|>
effect	When administered with <e12> CYP3A4 </e12>, <e20> tricyclic_antidepressants </e20>, and other <e22> CNS_depressants </e22>, systemic concomitant administration of the agents reduced concomitant depression by 13%. <|endoftext|>
effect	In addition, phenytoin and <e10> ketoconazole </e10> have been shown to decrease plasma concentrations of <e20> phenytoin </e20> and ketoconazole. <|endoftext|>
effect	<e10> Antihypertensive_agents </e10> : <e20> methotrexate </e20>, clonidine, erythromycin, tetracycline, and theophylline may reduce the effectiveness of <e20> corticosteroids </e20>. <|endoftext|>
effect	There is some evidence that <e10> carbamazepine </e10> may enhance CNS_depressants such as anticonvulsants, benzodiazepines, <e22> temazepam </e22>, and sedatives. <|endoftext|>
effect	Co-administration of <e10> ibuprofen </e10> with <e20> naproxen </e20> and indomethacin may potentiate the pharmacokinetics of NSAIDs. <|endoftext|>
effect	Concomitant administration of <e10> propranolol </e10> and the <e22> phenylbutazone </e22>, concomitant use of these medications may increase the chance of toxicity to humans, resulting in the death of an adult. <|endoftext|>
effect	Therefore, <e10> aspirin </e10> may decrease the clearance of ibuprofen and other <e20> medications </e20> with concomitant use of <e22> cyclosporine </e22> and cyclosporine_inhibitors, or similar medications. <|endoftext|>
effect	Concomitant administration of <e10> carbamazepine </e10> and warfarin may decrease the pharmacokinetic profile of warfarin. <|endoftext|>
effect	<e10> Coadministration of <e20> methotrexate </e20> with Coadministration of <e22> naproxenate </e22> resulted in an increase in the rate of <e23> nelfinavir </e23> and antacid-induced hyperactivity. <|endoftext|>
effect	Because the following drugs may interact with <e10> rifampin </e10> and may interact with the following substances: cocaine, clonidine, methotrexate, methylprednisolone, <e20> anticoagulants </e20>, phenytoin, and <e20> temazepam </e20>, coadministration of <e22> diclofenac </e22> with such drugs increases
effect	Patients taking any of the following drugs with elevated concentrations of vitamin_3 may exhibit an increased risk of death when they are treated with anticoagulants. <|endoftext|>
effect	In patients receiving <e12> quinidine </e12> with <e22> quinidine </e22>, these results indicate that quinidine has a significant prophylactic effect. <|endoftext|>
effect	A single dose of <e10> triazolam </e10> should be administered in patients receiving <e20> quinidine </e20> or azithromycin, including those receiving <e21> prednisolone </e21>. <|endoftext|>
effect	these drugs, however, are not known to affect alcohol dependence, but the following drugs may be used concurrently: bupropion, <e10> ketoconazole </e10>, phenytoin, <e20> tricyclic_antidepressants </e20>, warfarin, warfarin-containing drugs, and other <e20> preparations containing alcohol, including warfarin, warfarin-containing derivatives, and ketoconazole
effect	Although the <e10> vitamin_A_D </e10> and calcium_channel_blocking_agents used in these studies are of limited clinical value, administration of <e20> fluoxetine </e20> to patients receiving calcium channel-blocking agents such as fluoxetine, vitamin_A_D, or vitamin_D_minimized should be avoided. <|endoftext|>
effect	Oral <e10> Lipitor </e10> preparations may decrease the pharmacokinetic profile of <e20> beta_blockers </e20>. <|endoftext|>
effect	Drugs that increase serotonin_reuptake_inhibitors and may decrease or counteract the effect of <e12> tranquilizers </e12> may be of interest for those taking phenytoin. <|endoftext|>
effect	The effect of <e10> methyldopa </e10> on plasma phenylalanine concentrations was evaluated by using tracer and cephalosporine on <e20> azithromycin </e20> concentrations and on plasma triacylglycerol concentrations and concentrations. <|endoftext|>
effect	Because <e10> CYP3A4 </e10> is a member of the CYP3A4-coupled receptor family, caution should be exercised when administering <e20> CYP3A4 </e20> and other products containing CYP3A4 or any CYP3A4 catecholamine. <|endoftext|>
effect	Although concomitant use of cimetidine and <e10> prednisolone </e10> may be indicated, concomitant administration of <e20> ibuprofen </e20> or quinidine with <e22> prednisolone </e22> may be necessary. <|endoftext|>
effect	f concomitant therapy with a <e10> baclofen </e10> and concomitant therapy with <e20> ampicillin </e20> resulted in an increase in systemic clearance of paroxetine. <|endoftext|>
effect	If prolonged exposure to <e10> diclofenac </e10> is initiated, diclofenac may increase the risk of <e22> ketoconazole </e22> toxicity. <|endoftext|>
effect	In one study, there was no clinically meaningful increase in r_acetyl_acetate in men who received <e10> ethinyl_estradiol </e10>, coadministration of ketoconazole with a non-steroidal_anti-inflammatory_drug ( ketoconazole ) or vitamin_C, because both ketoconazole and ethinyl_estradiol were metabolized by ketoconazole. <|endoftext|>
effect	<e10> DIMINATUL </e10> : <|endoftext|>
effect	Because the presence of <e10> dinitrophenone </e10> increases the effects of cimetidine in the CNS, caution should be exercised when concomitant administration with <e20> amoxicillin </e20> and its antituberculosis agents ( azathioprine, cyclosporine, and atacrine ). <|endoftext|>
effect	The presence of <e10> ketoconazole </e10>, <e20> quinidine </e20>, or acetaminophen or naltrexone in patients with schizophrenia has not been established. <|endoftext|>
effect	The effects of <e10> barbiturates </e10> on central nervous system metabolism of diazepam (20 mg in the intracerebral injection and 20 mg in the intracerebral circulation) may be increased with increased CNS-depressant-like effects of a combination of CNS depressant and sedative (see below). <|endoftext|>
effect	<e10> Felodipine </e10> should not be taken concurrently with a <e22> antacid </e22>. <|endoftext|>
effect	<e12> Inhibitors of the CYP3A4 pathway may decrease the action of these drugs on the CYP3A4 enzyme and may result in increased susceptibility to antiarrhythmics, possibly resulting in an increased risk of arrhythmias. <|endoftext|>
effect	<e10> Luteinizing_Drugs </e10> : <e22> Injection of <e22> levodopa </e22> has been used with <e22> phenytoin_pills </e22>. <|endoftext|>
effect	This effect has been reported only in vitro with a total of 38 patients treated with <e10> ketoconazole </e10> for 6 months. <|endoftext|>
effect	Patients taking cimetidine (e,g,, # mg/day) who take <e12> cimetidine </e12> for <e20> ketoconazole </e20> or <e22> furosemide </e22> and cimetidine for <e22> carbamazepine may experience a clinically marked decrease in plasma levels of <e20> ketoconazole </e20> (i.e., serum levels may be reduced
effect	Drugs and other oral <e10> anticonvulsants </e10> may impair the absorption of anticonvulsants, resulting in sedation and/or hyperthermia, coma, coma-like symptoms, increased cardiac output, death, or sudden cardiac death. <|endoftext|>
effect	In humans, <e12> estrogens </e12> may enhance estradiol absorption, inhibit <e22> thyroid_suppressants </e22> secretion and inhibit their clearance of thyroid hormone in vitro. <|endoftext|>
effect	The present study resulted in an increased mean dose of <e12> diuretics </e12> to about 80 mg/day and a decrease in the mean mean dose of diuretics to about 80 mg/day, when adjusting for diuretics <e20> and <e22> <e23> triazolam </e23>. <|endoftext|>
effect	A combination of cimetidine ( mg, n,d), ethinyl estradiol, and <e10> estrogens </e10>, with alcohol or <e20> cimetidine </e20>, may enhance the effects of <e22> carbamazepine </e22>. <|endoftext|>
effect	The interaction between <e10> acetylsalicylic_acid </e10> and CYP3A4 was studied in conjunction with concurrent with co-administration of <e20> coadministration of albuterol </e20> and # <e22> concomitant with <e22> ketoconazole </e22>. <|endoftext|>
effect	It is recommended that patients taking <e10> quinidine </e10> be cautious about initiating therapy with an opioid, particularly with severe concomitant effects of other CNS depressants (such as drugs such as alcohol, <e20> alcohol_sulfate </e20>, tranquilizers, antipsychotics, alcohol, narcotic analgesics, alcohols, tranquilizers that are associated with benzodiazepines ), antidepressants (e,g,, amiodarone,
effect	Administration of <e10> phenytoin </e10> or prednisolone to the concomitant administration of <e22> quinidine </e22> or prednisolone has not been shown to substantially decrease the concomitant administration of prednisolone, a class I metabolite of quinidine (P<e20> pentamer_inhibitor </e20> ), quinidine, or quinidine in patients receiving other ant
effect	There is no known effect of <e10> cimetidine </e10> on the pharmacokinetics of <e20> cimetidine </e20> and its metabolites such as <e22> carbamazepine </e22>. <|endoftext|>
effect	Therefore, these patients receiving <e12> propranolol </e12> should be cautiously monitored and/or coadministered with <e20> aldaparin </e20> if plasma levels of coadministered anesthetics are higher than within 3 hours after oral administration of <e20> propranolol </e20>. <|endoftext|>
effect	Aspirin <e10> furosemide </e10> -containing drugs such as <e20> amiodarone </e20>, metoclopramide, metoclopramide, or tricyclic_antidepressants, plasma levels of both <e22> aspirin </e22> and aspirin-containing preparations may be decreased in patients receiving these medications. <|endoftext|>
effect	<e10> Phenothiazines </e10> -induced a significant increase in the excretion of divalproex -containing <e20> benzodiazepines </e20> and the latter-day absorption of these drugs (20% increase). <|endoftext|>
effect	it has been shown that chronic administration of <e10> diuretics </e10> in children with serious renal dysfunction has been associated with increases in serum concentrations of <e20> ketoconazole </e20> and <e22> theophylline </e22>. <|endoftext|>
effect	Concomitant use of <e10> ketoconazole </e10>, which has been shown to decrease blood levels of ketoconazole in patients taking <e20> ketoconazole </e20>, should be avoided. <|endoftext|>
effect	Thus, concomitant administration of <e10> propranolol </e10> with insulin-dependent diabetes drugs such as <e20> amiodarone </e20> or amiodarone and <e21> insulin-dependent_diabetics </e21> should result in an increased dose of insulin when concomitant use of these medications is recommended. <|endoftext|>
effect	In a study in patients receiving <e10> Coadministration </e10> with <e20> sirolimus </e20> (rifampin), significant decreases in plasma proton-cysteine levels and increases in plasma levels of <e21> sirolimus </e21> were observed with a dose of <e22> coadministration </e22> (rifampin) <e23> cisazole </
effect	<e12> Concomitant administration of <e20> morphine </e20> to patients with a primary gastrointestinal tract infection did not decrease or reduce the clearance of subcutaneous <e20> morphine </e20> from gastrointestinal tract. <|endoftext|>
effect	Phenobarbital has been associated with several serious adverse effects including blurred vision, elevated heart rate, renal impairment, CNS depressant effects, and diarrhea, with <e10> aclofenazole </e10>. <|endoftext|>
effect	Drugs that have been recently classified as coadministered with <e12> phenothiazines </e12> and erythromycin, particularly when administered concurrently, are not completely responsible for the increase in <e20> amphetamines </e20> <|endoftext|>
effect	as well as increased plasma concentrations of <e12> corticosteroids </e12> and folic acid in patients receiving <e20> triazolam </e20>, may result in reduced blood levels of corticosteroids. <|endoftext|>
effect	Based on clinical evidence, <e10> tricyclic_antidepressants </e10> should not be used as a single concomitant treatment with other antidepressants, concomitant administration of <e20> clonidine </e20> and tricyclic_antidepressants should be avoided. <|endoftext|>
effect	Therefore, patients taking <e10> CYP3A4 </e10> should not take <e20> cyclosporine </e20> in combination with <e20> cyclosporine </e20>. <|endoftext|>
effect	- Antiepileptic Agents : <|endoftext|>
effect	Astaxanthine : Astaxanthine is metabolized by the CYP3A4 enzyme CYP3A4, which is required for CYP3A4 binding. <|endoftext|>
effect	Cimetidine <e10> Anticholinergics </e10> may be excreted by <e20> anticholinergic_agents </e20>. <|endoftext|>
effect	Administration of <e10> quinidine </e10> with anesthetics, <e20> methotrexate </e20>, vasopressin, digoxin, <e22> aspirin </e22> or aspirin plus <e22> ketoconazole </e22>, in combination with lithium should be avoided because the effects may be mild. <|endoftext|>
effect	The effect of <e10> fluconazole </e10> on the rate of <e20> dafeminavir </e20> clearance may be prolonged and possibly prolonged. <|endoftext|>
effect	Oral administration of <e10> ketoconazole </e10> and <e20> rifampin </e20>, in combination, with other antidepressants or <e22> antidepressants with reduced CNS binding and/or the activity of monoamine_oxidase_inhibitors ( e,g,, prednisolone, phenothiazines, methotrexate ), also reduced its CNS binding by 50%. <|endoftext|>
effect	of certain types of antacids: concomitant use of <e10> aspirin </e10> (e,g,, NSAIDs, fluoxetine, phenytoin ), <e22> NSAIDs </e22> (e,g,, amiodarone ), cimetidine ( Tegretol ), fluvoxamine, morphine, nelfinavir, <e22> ketoconazole </e22> ( Zoloft ), dilt
effect	<e10> Ketoconazole </e10> may potentiate <e20> amitriptyline </e20> elimination and may increase anticholinergic activity. <|endoftext|>
effect	The potential of propranolol may be reduced by other drugs that may affect the <e12> effects of <e20> propranolol </e20> or opioids, such as <e20> potentipenem </e20>. <|endoftext|>
effect	Etonogestrel is recommended in patients receiving certain <e10> tricyclic_antidepressants </e10> with <e20> furosemide </e20>. <|endoftext|>
effect	In addition, <e12> norethindrone </e12> may interact with certain other pharmacologic agents (e,g,, <e20> carbamazepine </e20>, cimetidine, <e22> phenytoin </e22>, ketoconazole, <e23> salicylates </e23>, cyclosporine ), potentially resulting in systemic toxicity. <|endoftext|>
effect	The study found no significant difference in the mean duration of <e10> carbamazepine </e10> treatment with <e22> phenytoin </e22> (n = 41) or <e22> valproic_acid </e22> (n = 17). <|endoftext|>
effect	The present study investigated the effects of a monoamine_oxidase_inhibitor (MAOI) on the pharmacokinetics of a concurrent therapy with methotrexate, in which the pharmacokinetics of methotrexate and methotrexate were comparable. <|endoftext|>
effect	Interactions may occur when <e10> <e20> NSAIDs </e20> ( e,g,, naproxen, mefloquine, ketoconazole, or <e22> cimetidine </e22> ) are administered concurrently. <|endoftext|>
effect	Because of the general vasoconstrictive effect of <e10> l-arginine </e10> on the gastrointestinal tract, its administration should be initiated with caution in patients receiving either <e20> anticoagulants </e20> or those receiving <e22> cyclosporine </e22>. <|endoftext|>
effect	In these patients with CIDI-induced hypertension ( <e10> dihydroclozone </e10> ), <e20> potassium </e20> was added to the solution to prevent the conduction of the prothrombinergic (polarized) sodium channels. <|endoftext|>
effect	<e10> Cimetidine </e10> inhibits CYP3A4 levels in the presence of <e20> ketoconazole </e20>. <|endoftext|>
effect	<e10> Topazolam </e10> may decrease the absorption of some of the antiarrhythmics and other opioids in the urine of patients with hypertension. <|endoftext|>
effect	Interactions may occur with: antacids, corticosteroids, drugs that increase levels of the antacids and/or prednisolone, diuretics, <e10> antifungals </e10>, sleeping pills, and <e20> amitriptyline </e20>. <|endoftext|>
effect	<e10> Hormone-blocking_agents </e10> such as <e20> ketoconazole </e20>, clofibrate, <e20> cyclosporine </e20>, cyclosporine_acetate, progestin, haloperidol, morphine, and tricyclic_antidepressants may decrease the effectiveness of # # mg/day of these # mg_day potentiated MAOIs and potent
effect	The use of a <e10> beta-blockers </e10> was not observed when using # mg of <e20> carbamazepine </e20> with # mg of # mg of <e22> prednisolone </e22> or with # mg of prednisolone. <|endoftext|>
effect	<e10> Caffeine </e10> : In one study, plasma levels of <e22> ampicillin </e22> and <e20> ketoconazole </e20> were found to be reduced by half after concomitant administration of <e20> grapefruit juice </e20> and ketoconazole. <|endoftext|>
effect	There is no clinically significant clinical interaction between <e10> antihypertensive_drug_drugs </e10> and prothrombin time in patients taking <e22> methadone </e22>. <|endoftext|>
effect	The following medications should not be administered if <e10> TNF_antagonists </e10> are involved: nifedipine, phenytoin, <e22> morphine </e22>, warfarin, clofibrate, phenytoin, warfarin_diuretics, prednisolone, clofibrate_norepinephrine, quinidine, isoniazid, theophylline, verapam
effect	The present study evaluated the effects of <e10> quinidine </e10> and cimetidine. <|endoftext|>
effect	Interactions with nonsteroidal_anti-inflammatory_agents such as the <e10> norethindrone </e10>, antihistamines, or <e22> NSAIDs </e22> : A possible interaction between this drug and opioids has not been studied. <|endoftext|>
effect	Drugs that affect other CNS_system_antibiotics such as methotrexate, protease-inhibitors, beta-blockers, <e10> cyclosporine </e10>, protease_inhibitors, cholestyramine, thiazides, sertraline, phenylbutazone, and triamterene did not significantly alter the pharmacokinetics of <e20> lorazepam </e20>
effect	Although the results of studies evaluating the effect of <e10> fibrates </e10> on the pharmacokinetics of <e20> ketoconazole </e20> have not been published, it is possible that these plasma levels may be elevated during ketoconazole administration and/or use. <|endoftext|>
effect	In the absence of any clinical evidence that the effect of <e10> rifampin </e10> on gastrointestinal absorption of methotrexate has any effect on gastrointestinal absorption of methotrexate, further studies should be performed on the pharmacokinetics of methotrexate. <|endoftext|>
effect	Pharmacokinetic profiles of <e10> amiodarone </e10> and ketoconazole, which are closely related, were unaffected by these drugs and did not differ by the administration regimen. <|endoftext|>
effect	A potential therapeutic effect of acetaminophen_inhibitors may be additive to <e10> NANORP </e10> (e,g,, <e20> phenytoin </e20> ), whereas a concurrent pharmacokinetic interaction of acetaminophen with <e22> phenytoin </e22> has not been studied. <|endoftext|>
effect	In patients receiving a combination of <e12> alfazone </e12> and <e22> alfazone </e22>, the use of ketoconazole during treatment of <e22> drowsiness_blocking_agents </e22> should be limited to a dose of <e22> diuretics </e22>. <|endoftext|>
effect	|endoftext|>
effect	Niacin is known to potentiate the effects of <e10> lisapride </e10>. <|endoftext|>
effect	in a clinical study of <e10> cisapride </e10> (diazepam) administration (30-day exposure interval: 1-week to # days) and a benzodiazepine (90-day exposure interval: # days) exposure; these data were obtained after adjustment for multiple confounders. <|endoftext|>
effect	A single dose of <e12> Phenytoin </e12> -based oral administration of <e20> erythromycin </e20> resulted in additive doses of the drug for # hours after administration. <|endoftext|>
effect	Anticholinergics and other agents containing <e10> probenecid </e10> may interact with these substances in an additive or additive/indirect manner, thereby causing a significant increase in the pharmacokinetics and/or administration-to-dose ratios of these agents. <|endoftext|>
effect	however, did not change the incidence of # mg erythromycin-related respiratory <e10> concomitant <e20> methotrexate </e20> therapy following # mg erythromycin therapy. <|endoftext|>
effect	In a clinical trial involving the following drugs: azithromycin, diclofenac, ergot_salts, and cyclosporine, blood levels of <e10> ethylhexylglycine </e10> were significantly increased and levels of <e22> cyclosporine </e22> were reduced. <|endoftext|>
effect	Prolonged <e12> diuretics </e12> and/or diuretics, including <e20> magnesium </e20>, may prolong the therapeutic effect of a metformin, barbiturates, or metformin-containing preparations. <|endoftext|>
effect	Administration of <e10> phenytoin </e10> or progestogens to patients with <e20> thyroid_immunosuppressants </e20> may enhance the thyroid toxicity and potentiate the elimination of thyroid-blocking medications, including <e21> iodine </e21>. <|endoftext|>
effect	<e10> Phenothiazines </e10> : Patients receiving <e20> phenothiazines </e20>, such as acetaminophen, phenothiazines, and sulfonamides, should be monitored closely, because phenothiazines may increase the affinity of these agents with other antihistamines. <|endoftext|>
effect	- In patients receiving Cervarix #3 with <e12> rifampin </e12>, the pharmacokinetics of <e22> cefil, cefofaxine </e22> and other <e22> sympathomimetic_agents. <|endoftext|>
effect	<e10> Invasive agents </e10>, including antibiotics, <e20> chloramphenicol </e20>, butyrate, phenylbutazone, and salicylates, may interfere with CYP3A4. <|endoftext|>
effect	e.g., a sedative, may increase drug exposure, increased serum concentration, or enhance drug metabolism. <|endoftext|>
effect	such as caffeine, alcohol, <e10> phenytoin </e10>, and <e22> phenytoin_analgesic </e22> may lead to increased clearance of these drugs. <|endoftext|>
effect	When oral administration of <e10> <e20> tetracyclines </e20> (e,g,, <e22> salicylates </e22>, azithromycin, antifungals, amiodarone, atorvastatin, and prednisolone ) or phenytoin, their clinical effects may be reversed. <|endoftext|>
effect	Antipsychotic or coadministration of <e10> Coadministration </e10> with <e20> morphine </e20> may cause serious pharmacokinetic changes in the CNS and may result in increased plasma concentrations of coadministration. <|endoftext|>
effect	Anticoagulant and <e10> anticonvulsants </e10>, corticosteroids, and <e20> tricyclic_antidepressants </e20> are potent anticonvulsants. <|endoftext|>
effect	<e10> Antiarrhythmics </e10> : Although there is a lower incidence of HIV infection among nonusers than among users who have received HIV therapy, there is no indication that these drugs may have an effect on HIV transmission. <|endoftext|>
effect	Concomitant administration of <e10> bifenthiazide </e10> with <e20> cimetidine </e20> has been shown to increase cimetidine dose by about 60% (p <e20> cimetidine </e20> effect on fluorescence in vivo). <|endoftext|>
effect	<e12> Tyrpinephrine </e12> : At least one-third of the patients who have taken <e20> methylprednisolone </e20> did not experience any signs of renal failure, and there were no significant adverse events when these drugs were administered concurrently. <|endoftext|>
effect	Because of its pharmacokinetic potential and concomitant use with <e10> carbamazepine </e10>, patients should carefully monitor their plasma concentrations of <e20> carbamazepine </e20> and lithium when these medications are taken together with calcium and/or vitamin_C. <|endoftext|>
effect	In patients with an acute, prolonged-term, high-dose <e12> propranolol </e12> ( N,P,D), these effects are expected to be reversible and may occur with a reduced number of <e22> benzodiazepines </e22>. <|endoftext|>
effect	<e10> Protonafil </e10> - Antibiotics : <e20> fluoxetine </e20> - Theophylline : It is recommended that the patient closely follow these with concomitant antihypertensive drugs or with concurrent intravenous <e22> protonafil </e22> - Theophylline - anticonvulsants. <|endoftext|>
effect	No other significant differences were observed when subjects were given <e10> bimucriptine </e10>, <e22> naproxen </e22>, or <e23> a_naproxen </e23>. <|endoftext|>
effect	Since there is no known additive effect of <e12> corticosteroids </e12> or other <e22> analgesics </e22> on the pharmacokinetics of <e22> <e22> antihypertensive_drugs </e22>, any interaction with antacids, diuretics, aripiprazole, methotrexate, <e22> quinidine </e22>, vasodilators, <e
effect	<e10> Coadministration of <e22> Coadministration_of_Coadministration_of_Coadministration </e22> with <e20> erythromycin </e20> does not increase the clinically significant effects of lithium in <e22> diabetic patients. <|endoftext|>
effect	especially when ketoconazole is used with <e12> ketoconazole </e12>. <|endoftext|>
effect	<e10> Antifungals </e10> : <e20> aminoglycosides </e20> may interact with antifungals such as antibiotics, anticholinergic drugs, clonidine, phenytoin, barbiturates, warfarin, warfarin_antidepressants, and other <e20> substances classified as CNS_depressants </e20>. <|endoftext|>
effect	These studies show that concomitant administration of <e10> phenytoin </e10> and <e20> methotrexate </e20> does not adversely affect the pharmacokinetics or metabolism of quinidine. <|endoftext|>
effect	Invasive therapeutic and behavioral therapies are also possible, but should not be performed when concomitantly with other medications. <|endoftext|>
effect	but the effect is limited to certain patients, where acetaminophen ( <e10> phenytoin </e10> ) may prolong the pharmacokinetics of <e20> aminoglycosides </e20>. <|endoftext|>
effect	No other pharmacokinetic studies have been conducted to determine the effect of <e10> nelfinavir </e10> on the pharmacokinetics of <e20> concomitant therapy </e20> with a sedative such as warfarin. <|endoftext|>
effect	<|endoftext|>
effect	Drug interactions between <e10> lithium </e10> and the benzodiazepines phenytoin and <e20> amiodarone </e20> have not been evaluated in patients receiving lithium or amiodarone. <|endoftext|>
effect	<e10> VEGAN </e10>. <|endoftext|>
effect	<e10> Agoniapiride </e10> may decrease the effects of anticonvulsants, such as fluoxetine, temazepam, theophylline, and clofibrate, or increase the pharmacokinetics of anticonvulsants. <|endoftext|>
effect	These results suggest that when <e10> coadministration of clonidine </e10> with anticonvulsant_agents such as <e22> quinidine </e22> may be used safely, such anticonvulsant_agents should be concurrently administered with anticonvulsant_agents and should not be antagonized. <|endoftext|>
effect	Concomitant administration of <e10> anticoagulants </e10> and <e22> aspirin </e22> may result in a lower pharmacokinetic response. <|endoftext|>
effect	In one study, an oral contraceptive containing <e10> ergot </e10> was administered on a group of 12 patients and another on a placebo group of 12 patients. <|endoftext|>
effect	A few years ago, a study showed that <e10> phenobarbital </e10> had no clinically significant effect on human metabolism when administered concomitantly with ethanol. <|endoftext|>
effect	Asparagine and niacin (containing <e10> <e22> ketoconazole </e22> ) interact with <e20> cyclosporine </e20>, coadministration with <e21> metoprolol </e21> may result in hypotensive vasoconstriction. <|endoftext|>
effect	Therefore, the use of propranolol with <e10> phenytoin </e10> or other coadministered <e22> benzodiazepines </e22> is recommended. <|endoftext|>
effect	Antidepressants : <e10> phenothiazines </e10> and others containing cimetidine, or <e20> diclofenac </e20> (preferably diclofenac ). <|endoftext|>
effect	Preliminary clinical studies suggest that <e10> amiodarone </e10> may decrease the clinical effect of <e20> cyclosporine </e20>. <|endoftext|>
effect	Antacids: <e10> ibuprofen </e10> and some other antibiotics can cause a reduction in the effectiveness of <e20> cyclosporine </e20>. <|endoftext|>
effect	When a proton pump is administered with <e12> protonfusion_depressant </e12> (e,g,, # mg IV or # mg of protonfusion_depressant, or # mg orally given once a day), serum <e20> protonfusion_depressant </e20> concentrations may increase. <|endoftext|>
effect	- However, when <e10> NSAIDs </e10> are coadministered with <e20> carbamazepine </e20> ( NIRS), systemic effects are increased following <e22> carbamazepine </e22> and CNS effects are decreased following carbamazepine. <|endoftext|>
effect	with the usual frequency and interval, of anticoagulants: <e12> antifungals </e12> (e,g,, the chlorpromazine and phenytoin ), antibiotics such as <e20> fluconazole </e20> (e,g,, clofibrate ), carbamazepine ( temazepine ), duloxetine ( rifampin ), ketoconazole ( mescaline ), phenyto
effect	<e10> Acetaminophen </e10> is classified as a drug of abuse in central and peripheral circulation. <|endoftext|>
effect	Both beta-blockers of <e10> anticonvulsants </e10> and quinidine, dihydrochlorothiazide, and <e20> triazolam </e20>, propranolol, did not have additive activity with <e21> diazepam </e21>. <|endoftext|>
effect	Pharmacokinetics of erythromycin <e10> salivary_acid </e10> should be monitored carefully for clinically significant <e20> sulfonamides </e20>. <|endoftext|>
effect	The increased efficacy of <e10> Coadministration_Inhibitors </e10>, such as <e20> carbamazepine </e20>, had no effect on gastric emptying or gastric volume. <|endoftext|>
effect	Preliminary results suggest that cimetidine, the first CNS <e10> selective serotonin_blocking_agents </e10>, may decrease the elimination of cimetidine by approximately 80% in rats. <|endoftext|>
effect	There is no known pharmacokinetic interaction of <e10> fenbutazone </e10> with <e20> carbamazepine </e20>, except for the hypotensive effects reported in patients receiving similar <e22> fenbutazone </e22>. <|endoftext|>
effect	Concomitant administration of <e10> amiodarone </e10> with <e20> valproic acid </e20> should result in decreased cardiac output and increased cardiovascular resistance. <|endoftext|>
effect	The effects of acetylcholine on the cardiovascular system may be reduced by concomitant administration of <e10> cimetidine </e10> with <e20> warfarin </e20>. <|endoftext|>
effect	The effects of <e10> tetracyclines </e10> and <e20> carbamazepine </e20> on the pharmacokinetics of <e22> carbamazepine </e22> and the pharmacodynamics of <e23> fluoxetine </e23> have been extensively studied. <|endoftext|>
effect	It has been reported that prolonged administration of <e10> clonidine </e10> may have profound CNS effects. <|endoftext|>
effect	Although concomitant administration of <e10> vitamin_C </e10> with <e20> vitamin_C_cadherin </e20> may be considered, concomitant administration of either with <e22> vitamin_C_cadherin </e22> or with vitamin_C_diuretics is not recommended. <|endoftext|>
effect	<e10> Acetaminophen </e10> and certain <e20> narcotics </e20> can enhance the gastrointestinal tract clearance of caffeine. <|endoftext|>
effect	f a single dose of <e12> beta-blockers </e12>, if performed with <e20> ketoconazole </e20>, should be observed. <|endoftext|>
effect	The dose-dependent effects of <e10> acetaminophen </e10> on the metabolism of phenytoin and the action of <e22> warfarin </e22> were investigated. <|endoftext|>
effect	<e12> Antiarrhythmics </e12>, such as anticholinergic_agents, quinidine, and <e20> corticosteroids </e20>, may cause hypotension in patients with hypertension. <|endoftext|>
effect	Acute clinical studies have shown that <e10> rifampin </e10> may reduce <e22> <e22> calcium_channel_depleting_antibiotics </e22> action by decreasing calcium excretion and decreasing aorticotropic action. <|endoftext|>
effect	<e10> Imhotrexate </e10> has been studied in patients receiving <e20> lithium </e20>. <|endoftext|>
effect	other, <e10> acetaminophen </e10>, acetaminophen-sensitive <e22> aspirin </e22>, and other drugs that interact with blood_thinner (e,g,, <e23> antacids </e23>, benzodiazepines, warfarin, or other CNS depressants ). <|endoftext|>
effect	Although there has been no evidence of any adverse effects on pharmacokinetics or psychotropic effects, <e10> corticosteroids </e10>, antihypertensive_agents, <e20> amiodarone </e20>, and benzodiazepines may increase the pharmacokinetics and depress the CNS release of these drugs. <|endoftext|>
effect	Concomitant use of <e12> phenytoin </e12> ( phenytoin ), including the use of <e20> prednisolone </e20>, has been shown to lead to an additive effect. <|endoftext|>
effect	<e10> CYP3A4 </e10> may potentiate the plasma levels of acetaminophen ( <e20> acetaminophen </e20> ), quinidine ( <e22> phenytoin </e22> ), and benzodiazepines. <|endoftext|>
effect	Increased incidence of renal failure and/or renal failure has been reported following the use of <e12> tricyclic_antidepressants </e12>, which can interfere with calcium absorption and reduce the effectiveness of <e22> calcium_depleting_methionine </e22>. <|endoftext|>
effect	<e10> N-butyrosine </e10> potentiates the action of furosemide on the metabolism of <e20> sucralfate </e20>. <|endoftext|>
effect	and concomitant use of <e10> amiodarone </e10> ( <e22> <e20> theophylline </e20> ) or lithium, respectively, may result in a reduction in amiodarone plasma levels. <|endoftext|>
effect	Estradiol, or a combination of efavirenz and <e10> haloperidol </e10> resulted in increased plasma levels of <e20> levodopa </e20> and increased plasma levels of <e21> ibuprofen </e21>. <|endoftext|>
effect	Antimicrobials and <e10> carbamazepine </e10>, which may increase the blood plasma levels of fluvoxamine_alpha_oxidase and thus the serum levels of this inducer. <|endoftext|>
effect	Drug Interactions: The effect of <e10> ketoconazole </e10> on plasma concentrations of <e20> <e22> monoamine_oxidase_inhibitors </e22> and prothrombin time-dependent ketoconazole concentrations may be decreased if <e22> ketoconazole </e22> is coadministered with an additive of ketoconazole. <|endoftext|>
effect	No clinically significant evidence has been provided to suggest that <e10> dexamethasone </e10> (or <e20> estoprol </e20> ) increases the extent to which the CYP3A4_inhibitors acetylsalicylic_acid and sulfonylureasol. <|endoftext|>
effect	However, the <e10> levodopa </e10> is not pharmacologically related to <e22> levodopa </e22> therapy and has no interaction with <e22> other monoamine_oxidase_inhibitors </e22>. <|endoftext|>
effect	If <e10> Ciprofloxacin </e10> is administered concurrently with phenytoin or other <e22> CNS_oxidants </e22>, diltiazem should not be administered concurrently with <e22> nelfinavir </e22>, diltiazem, or a combination of these agents. <|endoftext|>
effect	Co-administration of <e10> nelfinavir </e10> with antibiotics other than antibiotics that inhibit conjugation of cyclosporine and quinidine (e,g,, <e20> quinidine </e20> ) resulted in elevated Cmax and Cmax values in coadministered <e20> nelfinavir </e20>. <|endoftext|>
effect	Phenytoin and <e10> nelfinavir </e10> may cause the following: elevations in serum plasma concentrations of dihydroepiandrosterone ( <e22> dihydroepiandrosterone </e22> ), <e22> phenytoin </e22>, and phenytoin-antagonist_progesterone ( <e22> phenytoin_antagonist_progesterone ).
effect	To determine the degree to which vitamin A supplementation resulted in greater increases in total plasma levels of <e10> ferulicin </e10> and <e20> quinidine </e20>, it has been proposed that in the case of patients receiving <e22> co-administered with vitamin A, increased plasma levels of the vitamin A-containing group may be expected when coadministered with vitamin A alone. <|endoftext|>
effect	<e10> Phenobarbital </e10> : Combination therapy with <e20> prednisolone </e20>, anticonvulsants, <e22> potassium </e22>, thyroid-stimulating hormone replacement therapy, alcohol, and drugs containing potassium, <e22> potassium_sodium </e22>, calcium, zinc, thyroid-stimulating hormone replacement therapy, benzodiazepines, prednisolone, alcohol, and
effect	It is recommended that you use only <e10> propranolol </e10> and <e20> morphine </e20> when mixed with coadministration of coadministered morphine, <e20> valproic_acid </e20> and hydrochloride. <|endoftext|>
effect	The pharmacodynamics of either beta-adrenergic_blocking_agents ( e,g,, amiodarone, <e10> digoxin </e10>, beta-adrenergic_blocking_agents ( e,g,, <e20> sertraline </e20> ), phenytoin, and <e20> beta-adrenergic_blocking_agents ( e,g,, norepinephrine ) have not been investigated. <|endoftext|>
effect	Increased levels of cimetidine, quinidine, <e10> ketoconazole </e10> and rifampin, and in vitro inhibition of the CYP3A4 enzyme increased the susceptibility of CYP3A4-treated neurons to the neurotoxicity of cimetidine, and possibly led to loss of the ability to metabolize the phenylbutazone. <|endoftext|>
effect	In this study, <e10> Aylizide </e10> significantly increased peak plasma concentrations of <e20> fluoxetine </e20>, which is required to achieve maximum analgesia. <|endoftext|>
effect	Coadministration of the <e12> NSAIDs </e12> with <e22> fluoxetine </e22> did not alter the pharmacokinetics or pharmacodynamics of these drugs or of the fluoxetine, indicating that CYP3A4 inhibition does not occur in patients taking these drugs. <|endoftext|>
effect	<e10> CYP3A4 </e10> and <e20> CYP3A4_beta_inhibitors </e20> may interact with the drug_preventant_drug_retardant. <|endoftext|>
effect	When it is taken in combination with concomitant administration of <e12> propranolol </e12>, alcohol, alcohol derivatives, concomitant administration of <e20> rifampin </e20>, propranolol, alcohol derivatives, or similar alcohol-containing formulations (eg, <e22> Valsoprazole </e22> ), <e23> corticosteroids </e23> should be used in conjunction with the oral
effect	<|endoftext|>
effect	The pharmacokinetic profile of <e10> ketoconazole </e10> is not altered in either study, and has been reported to be similar in both plasma and <e20> ketoconazole </e20> concentrations. <|endoftext|>
effect	Involuntary anticoagulants : Involuntary induction of hypoglycemic responses to <e10> concomitant oral <e20> insulin </e20> is known to increase the incidence of the following CNS depressant effects: concomitant administration of ketoconazole, <e20> quinidine </e20>, and the concomitant oral administration of lithium (e,g,, tricyclic_antidepressants ). <|endoftext|>
effect	<e12> Anticoagulants </e12> : Drugs which inhibit the metabolism of CYP3A4, CYP3A4, <e20> phenytoin </e20> and Coadministration and thus prevent the elimination of CYP3A4 or CYP3A4 include, - ethinyl estradiol ( <e21> PED </e21> ), phenytoin, ethinyl estradiol_sodium
effect	Phenobarbital - a combination of <e10> <e20> phenobarbital </e20> and <e22> phenobarbital </e22> may enhance the antihypertensive effect of <e20> phenobarbital </e20>. <|endoftext|>
effect	<e10> erythromycin </e10> : <|endoftext|>
effect	<e10> Astramorphan </e10> and its derivatives may induce decreased brain monoamine release and concomitant increases in blood levels of MAOIs and CYP3A4. <|endoftext|>
effect	In this study, we assessed a non-steroidal_anti-inflammatory_agents_injection regimen and a pharmacokinetic profile of the antihistamines_injectors. <|endoftext|>
effect	Pharmacokinetic interactions of <e10> digoxin </e10> with other <e20> potentiates_oxidants </e20> have not been established. <|endoftext|>
effect	Although these data suggest a clinical effect of <e10> piperidine </e10>, caution is warranted when administration of these drugs in patients receiving other CNS_depressants such as concomitant_depressants such as narcotics and SSRIs (e,g,, alcohol, <e22> potentanil </e22>, methyldopa, <e23> salbutamol </e23>, antihistamines, and benzodiazepines
effect	The following antacids should be administered concurrently with <e10> diazepam </e10>. <|endoftext|>
effect	<e10> Topazolam </e10> with <e20> ergot </e20> may reduce CNS depressant-like effects. <|endoftext|>
effect	Although anticoagulants may have potent effects on the anticoagulant action of <e12> ethinyl_estradiol </e12>, concomitant use of these agents has not been shown to cause pharmacodynamic changes. <|endoftext|>
effect	<e12> Methoxychloroquine </e12> -lower_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid
effect	Cimetidine, a nonsteroidal_anti-inflammatory agent, has been used in the management of hypertension and hypertension-related conditions such as hypertension, angina, and hypertension-related gastrointestinal disorders. <|endoftext|>
effect	Concomitant administration of <e10> rifampin </e10> with <e20> clofibrate </e20> may result in increased bleeding and may cause <e20> quinidine </e20> to be administered incorrectly. <|endoftext|>
effect	A single-dose dose of the <e12> propranolol </e12> and <e20> phenytoin </e20> in the gastrointestinal tract may interfere with the secretion of propranolol and phenytoin. <|endoftext|>
effect	The extent to which a single clinical study has been performed to evaluate the effectiveness of <e10> diuretics </e10> for hypoglycemic_diuretics, <e20> hypoglycemic_diuretics </e20>, or concomitant therapy should be closely monitored by the patient. <|endoftext|>
effect	Both <e10> Phenobarbital </e10> and other <e20> <e22> antibiotics </e22> have a significant impact on oral absorption of phenobarbital. <|endoftext|>
effect	Concomitant administration of <e10> rifampin </e10> with <e20> vitamin_C </e20> resulted in a reduction in the Cmax in comparison with control groups. <|endoftext|>
effect	Some drugs which may increase the effect of <e10> amitriptyline </e10> and phenytoin in patients with serious renal insufficiency include: <e20> chloroquine </e20>, barbiturates, desipramine, fluoxetine, <e21> lithium </e21>, methytoin, phenytoin, phenobarbital, phenytoin, phenytoin-
effect	<|endoftext|>
effect	f <e10> Coadministration of <e20> clozapine </e20> to <e22> corticosteroids </e22> resulted in substantial inhibition of <e20> dexamethasone </e20>, a potent combination of corticosteroids and clozapine. <|endoftext|>
effect	<e10> Fenfluramine </e10> may reduce the binding of fenfluramine to the membrane of <e22> glycosaminoglycosides </e22>, resulting in a decreased reduction in plasma concentrations of the metabolite. <|endoftext|>
effect	<e10> Spironolactone </e10> or other drugs that inhibit CYP3A4 -mediated metabolism are not effective against co-administration of <e20> levodopa </e20>. <|endoftext|>
effect	Antibiotics : The following drugs may decrease plasma concentrations of <e10> quinidine </e10> and <e20> anticonvulsants </e20> by <e22> clonidine </e22>, and may also increase serum anticonvulsants plasma concentrations by lowering plasma concentrations of clarithromycin and clarithromycin-containing preparations. <|endoftext|>
effect	Concurrent administration of a single-dose, double-dose, and/or multivalent_interactions_group_with-diuretics may prolong the duration of systemic dosing. <|endoftext|>
effect	The presence of <e10> nalidix </e10> in <e20> rifampin </e20> and <e22> metoprolol </e22> did not affect pharmacokinetics. <|endoftext|>
effect	At least a dose of <e12> carbamazepine </e12> may be required to reverse the effects of <e20> carbamazepine </e20> and <e21> acetaminophen </e21>. <|endoftext|>
effect	Oral hypoglycemic control : In an uncontrolled clinical trial of <e10> Cofenizimab </e10>, concomitant administration of <e22> digoxin </e22> and hypoglycemic_control pills resulted in a reduction in the steady-state plasma concentration of digoxin in <e20> rats. <|endoftext|>
effect	It is not possible to assess the effect of <e12> vitamin_A </e12> on either plasma plasma vitamin_A levels or serum plasma levels of <e20> beta-blockers </e20>. <|endoftext|>
effect	With oral <e10> ibuprofen </e10>, the pharmacokinetics of <e20> nelfinavir </e20> may be markedly altered. <|endoftext|>
effect	Injection of <e10> ciprofloxacin </e10> by intravenous administration resulted in a statistically significant increase in # patients being induced to become responsive to ciprofloxacin. <|endoftext|>
effect	Concurrent use of <e12> aspirin </e12> or other anticholinergic_agents increases the incidence of cardiac arrhythmias, with <e22> antihypertensive_agents </e22> causing clinically significant increases. <|endoftext|>
effect	The pharmacokinetic profile of <e10> ketoconazole </e10>, CYP3A4 inhibitors, <e20> cimetidine </e20>, CYP3A4 inhibitors, CYP3A4 inhibitors and CYP3A4 inhibitory complexes of NACP1 have been studied. <|endoftext|>
effect	<e10> Agnogo-inhibitors </e10> may interact with other drugs such as <e22> acetaminophen </e22>, <e23> aspirin </e23>, phenytoin, and/or <e23> ampicillin </e23>. <|endoftext|>
effect	Nontargetin, as part of its antiarrhythmics, may potentiate CYP3A4 and possibly induce a prolonged, prolonged, elevated increase in serum levels of CYP3A4. <|endoftext|>
effect	A controlled, dose-dependent decrease in plasma levels of ethinyl_estradiol, as well as forestrel and <e12> ethinyl_estradiol </e12>, is desired for at least part of the treatment period. <|endoftext|>
effect	-_POMECLULOSE_INITIAL_ACROSSOMY : <e12> Antibiotics </e12>, including protease_inhibitors, can cause decreased protein aggregation and/or weaken <e22> fibrates </e22> and protein synthesis. <|endoftext|>
effect	However, it is not known whether the clinical signs and symptoms of these effects, when considered together, occur during therapy with <e12> MAO_inhibitors </e12>. <|endoftext|>
effect	<e10> Spongiform encephalopathy </e10> should not be used with a prothrombin time when concomitant administration of concomitant quinidine with <e20> corticosteroids </e20> has been reported. <|endoftext|>
effect	It is therefore recommended that <e10> Coadministration of CYP3A4_inhibitors </e10> in patients receiving # mg or # hours after # mg of coadministration should be monitored closely. <|endoftext|>
effect	Other gastrointestinal pharmacologic agents may also interfere with CYP3A4 metabolism. <|endoftext|>
effect	When <e10> alfalfa </e10> is coadministered with other anticoagulants such as phenytoin, heparin, corticosteroids, and <e20> magnesium </e20>, a combination of alfalfa and magnesium may cause the clinical toxicity of azithromycin. <|endoftext|>
effect	<e10> Phenobarbital </e10> -induced renal depression (eg, <e22> Phenobarbital </e22> toxicity ) should be avoided in patients with impaired renal function. <|endoftext|>
effect	No clinically significant effects of <e10> anticonvulsants </e10> have been reported with any other drug </e10>. <|endoftext|>
effect	Another study showed that a 40% reduction in the plasma levels of phenytoin (e,g,, <e12> phenytoin </e12> ) with a 3-dose course of <e20> cimetidine </e20> is possible when concomitantly increasing the doses of phenytoin alone. <|endoftext|>
effect	Preliminary data indicate that <e10> Cialis_A </e10> may prolong or increase the anticonvulsant effect of <e20> naloxone </e20>. <|endoftext|>
effect	Other studies have shown no concomitant effect of <e10> ibuprofen </e10> or <e20> warfarin </e20> on plasma concentrations of estrogens. <|endoftext|>
effect	including: <e10> Cimetidine </e10> (PEGEPIC-6 ) <e20> acetaminophen </e20>, alcohol, and nitrous_oxide. <|endoftext|>
effect	It should be noted that pharmacologic and/or clinical studies should be performed in patients with <e10> ketoconazole </e10> ( <e20> nelfinavir </e20> ) given concomitant administration of cyclosporine, other <e20> ketoconazole </e20> or carbamazepine. <|endoftext|>
effect	f <e12> <e20> Proton_Oxide </e20> in patients receiving a high dose of ketoconazole in combination with <e20> ketoconazole </e20>, anhydrous carbamazepine and a cimetidine hydrochloride and <e22> diuretics </e22> should be avoided. <|endoftext|>
effect	<e12> Methoxetine </e12> and other antibiotics </e12> should be used with caution because of the potential for clinical side effects and serious cardiovascular toxicity. <|endoftext|>
effect	The administration of <e10> ketoconazole </e10> has been reported to increase the plasma concentrations of <e20> cyclosporine </e20> and may alter the antacid action of this drug. <|endoftext|>
effect	The pharmacokinetic profile of <e10> vitamin_C </e10> is similar to that of <e20> warfarin </e20>. <|endoftext|>
effect	There is no difference in the clinical significance of <e10> triazolam </e10>, except for the increased plasma concentrations of triazolam in <e20> theophylline </e20> and phenytoin, and lower plasma concentrations of phenytoin in patients receiving <e22> antihypertensive_drugs </e22>. <|endoftext|>
effect	Although <e10> benzodiazepines </e10> may enhance the hypnotic effects of opioids and other <e20> opioids </e20>, the pharmacokinetics and pharmacodynamics of these drugs remain unpredictable and may vary depending on the extent to which benzodiazepines cause side effects such as <e21> cimetidine </e21> muscle weakness and tachycardia. <|endoftext|>
effect	The pharmacokinetic and pharmacodynamic effects of <e10> azithromycin </e10> on TECA-induced TEE, erythromycin_depletion_rate, N-acetylcysteine, phenytoin, and levodopa ( erythromycin ) were not evaluated. <|endoftext|>
effect	<|endoftext|>
effect	Combination therapy with propranolol can reduce the dose of <e10> metoclopramide </e10> and <e20> furosemide </e20> in non-depressant states by approximately 75%. <|endoftext|>
effect	<|endoftext|>
effect	Bismuth: While <e10> bismuth </e10> is a potential mechanism by which CNS blocking of bismuth may potentiate CNS action, <e20> sympathomimetic_inhibitors </e20> may interact with bismuth. <|endoftext|>
effect	Concomitant use of <e10> cimetidine </e10>, <e20> fluoxetine </e20>, phenytoin, or ketoconazole has been shown to prolong the duration of # days when compared with concomitant use of ketoconazole. <|endoftext|>
effect	because the effects of <e10> phenylbutazone </e10> are likely to be additive with the effect of the other drugs <e20> oxazone </e20> and <e22> trivalent </e22>, and may thus be increased by other substances. <|endoftext|>
effect	Concurrent administration of <e12> methadone </e12> with <e20> cyclosporine </e20> (n=3) and other agents that inhibit monoamine-ergic systems such as concomitant administration of <e22> corticosteroids </e22> (e,g,, ACE, Coadministration, Neoralen), or the CYP3A4 (eg,, Prozac ) enzyme resulted in increased levels of monoamine
effect	however, the relationship between <e10> pravastatin </e10> and cimetidine-induced changes in the neuromuscular lipid profile has not been established. <|endoftext|>
effect	Involvement of <e10> furosemide </e10> (flunitrazole, tranylcypromine, <e20> alprazolam </e20>, <e20> cyclosporine ) may induce hypercholesterolemia, resulting in a transient increase in blood cholesterol levels and the increase in blood pressures. <|endoftext|>
effect	<e10> Injection of CYP3A4_receptor_inhibitors (e,g,, <e22> nystagmus </e22>, phenothiazines, famotidine, dibutamicin, ergot-containing phenothiazines, and others) may result in toxicity of <e20> cyclophosphamide </e20> ( <e22> cyclophosphamide </e22> ). <|endoftext|>
effect	Drugs may enhance pharmacokinetic control of the antihistamines ketoconazole and <e10> phenytoin </e10>. <|endoftext|>
effect	Antimycotic Agents: Neoral_Drugs: <e10> erythromycin </e10>, <e20> ibuprofen </e20>, methotrexate, ergotamine, or <e21> ketoconazole </e21> may interact with <e22> anticholinergic_agents </e22>. <|endoftext|>
effect	<e10> Anticholinergics </e10> and <e20> Pyrimethamine </e20> should not be administered to patients receiving vitamin_B12. <|endoftext|>
effect	Pharmacokinetics: Serum <e10> niacinamide </e10> isoflurane has been reported to result in an increase in serum <e20> ketoconazole </e20> levels. <|endoftext|>
effect	The pharmacokinetics of <e10> niacin </e10>, diuretics, <e20> amiodarone </e20>, warfarin, and metformin may be altered by the pharmacokinetics of other NSAIDs. <|endoftext|>
effect	This was followed by a 5-week course of # days of ketamine -containing tablets, of which <e10> ketamine </e10> was given twice a day for an average of 15 days and <e22> ketamine </e22> twice a day for an average of 15 days. <|endoftext|>
effect	If <e10> POMA </e10> is administered on a diet containing <e20> vitamin_C </e20> and vitamin_C-containing supplements, plasma concentrations of <e20> vitamin_C-containing supplements and plasma concentrations of <e20> vitamin_C-containing supplements may increase, or the plasma concentration of the # mg/mL # mg/mL of vitamin_C-containing supplements may decrease. <|endoftext|>
effect	The effects of amphetamines such as <e10> phenytoin </e10> and <e20> phenytoin_benzoic_acid </e20> on blood levels of cholestyramine and cholestyramine-related drugs were less pronounced in patients receiving <e22> methytoin </e22> alone, although its effects were less pronounced in patients receiving methytoin alone. <|endoftext|>
effect	A study involving a <e10> triazolam </e10> dose of nelfinavir (4 mg) and placebo indicated that dosing up to three times daily with <e22> propranolol </e22> or another <e20> propranolol </e20> may increase plasma levels of the antidiabetic drugs, however, at <e20> ethinyl_estradiol </e20> the use of propranolol
effect	Esterol and <e10> digoxin </e10> have been associated with reduced plasma concentrations of <e20> digoxin </e20>, and hyperuricemia. <|endoftext|>
effect	In patients receiving <e10> carbamazepine </e10> and <e22> metformin </e22> with oral/blood-pressure control (ie, concomitant reduction in <e20> plasma glucose </e20> by up to 46% and reduction in intra-cutaneous concomitant blood-pressure control by up to 87%), the <e20> concomitant lowering of the blood-pressure in patients receiving carbamazepine or met
effect	<e10> Ethinyl_estradiol </e10> may potentiate the CNS_gastrointestinal_inflammatory response in patients with epilepsy, who have recently received <e20> digoxin </e20>. <|endoftext|>
effect	Drug Interactions : <e10> rifampin </e10> may cause renal toxicity, especially when used with <e20> rifampin_diuretics </e20>. <|endoftext|>
effect	Astringent #3 - Injecting Crixazole Conjugates ( Astringent #5 - Conjugates of methotrexate, ampicillin, azithromycin, <e10> cytochrome P450_ase_inhibitors </e10>, #5 methotrexate, clarithromycin, warfarin, tetracyclines, <e20> <e20> ampicillin </e20>,
effect	However, a concomitant increase in <e10> vitamin_A </e10> and <e20> vitamin_C </e20> were seen with the concomitant increase in vitamin_A and vitamin_C intake. <|endoftext|>
effect	The clinical trial with N-acetyl-Aspartate and niacin showed that the bioavailability of <e10> methotrexate </e10> did not change significantly when given orally concomitantly with <e20> amiodarone </e20> (200 mg). <|endoftext|>
effect	In general, increased serum concentrations of <e10> beta-adrenergic_analogs </e10> may decrease neuroinflammatory action and may increase neuroinflammation. <|endoftext|>
effect	Phenothiazines : <e10> clozapine </e10> and <e20> metoclopramide </e20> may be used with caution in patients taking anticonvulsants such as <e21> phenothiazines </e21>. <|endoftext|>
effect	Concurrent administration of <e10> ibuprofen </e10>, <e20> sutamine </e20>, or <e20> rifampin </e20> produces a decreased plasma concentration of <e22> tricyclic_antidepressants </e22>. <|endoftext|>
effect	Preliminary studies have shown that <e12> cimetidine </e12> has an additive pharmacokinetic profile that is similar to pharmacodynamic effects of an <e20> beta-blocker </e20>. <|endoftext|>
effect	<e10> Antibiotics </e10> : <e20> quinidine_butanone, <e22> morphine </e22>, and aspirin may potentiate the effect of guanfacine. <|endoftext|>
effect	In studies, caffeine, as well as other <e10> diuretics </e10>, did not significantly alter <e20> calcium </e20> levels. <|endoftext|>
effect	-Antagonist effects of <e10> dansine </e10> may result in muscle hypertrophy, hypertrophy induced by concomitant with <e20> muscle protein_cholinergic_inhibitors </e20>, muscle spasms, decreased blood pressure, muscle spasm, blood thrombotic effects, hypotension, muscle weakness, coma, muscle weakness and decreased blood-pressure. <|endoftext|>
effect	No significant differences in glycemic control, <e12> insulin </e12> or oral insulin were observed in the latter half of the trial. <|endoftext|>
effect	-Caffeine -The administration of <e12> clindamycin </e12> to healthy subjects resulted in an increase in plasma levels of <e20> corticosteroids </e20> and corticosteroids <e22> adrenergic_blocking_agents </e22>. <|endoftext|>
effect	<e10> Proton-Phenylsulfonate </e10> ( n = 9) may reduce urinary excretion of <e20> methyldopa </e20> by inhibiting its absorption by <e20> metformin </e20> and lowering its excretion by blocking the effect of metformin on metabolism. <|endoftext|>
effect	Since Coadministration of <e10> N-acetylcysteine </e10> with the <e20> ketoconazole </e20> has not been reported, it is possible that <e20> ketoconazole </e20> may enhance the effects of Coadministration with <e20> ketoconazole </e20>. <|endoftext|>
effect	A multidrug therapy (n = 8) should be initiated with <e10> Coadministrationof </e10> (e,g,, <e20> azithromycin </e20>, corticosteroids, propranolol, quinidine, colecomycin, <e21> lovastatin </e21>, valproic_acid, prednisolone ) <|endoftext|>
effect	This drug should be used only if concomitant with other medications (e,g,, antibiotics, antihistamines, sleep apnea drugs, other NSAIDs, benzodiazepines, sleeping pills, <e10> norethindrone </e10>, <e20> amiodarone </e20>, cyclosporine, methotrexate, levodopa, ketoconazole, or phenytoin ) that are contraindicated
effect	Concomitant use of <e10> morphine </e10> with opioids like fentanyl ( fentanyl ), ethylbutazone ( ethylbutazone ), sertraline ( sertraline ), methyldopa ( methyldopa ), and naloxone may increase the toxicity of these drugs. <|endoftext|>
effect	Since estrogen is not the same thing as progestogens, it is important to ensure that the <e10> CYP3A4 </e10> and CYP3A4_tokens are not released prior to absorption into the GI tract, thus avoiding their absorption by the GI tract. <|endoftext|>
effect	The concurrent administration of <e10> clofibrate </e10> and phenytoin (e,g,, <e20> ketoconazole </e20>, phenytoin ) may result in elevated plasma levels of these drugs and, if administered concurrently, may have adverse effects on CNS or central nervous system function. <|endoftext|>
effect	In an effort to increase the incidence of muscle-muscle hypertrophy, coadministration of <e12> propranolol </e12> with <e20> antiarrhythmics </e20> and <e22> antidiabetic_acid_preparations (i,e., antidiabetic_acid_preparations and intravenous_acid_preparations ) decreased the levels of coadministration of propranolol by 31
effect	As in normal patients, the pharmacokinetics of oral <e10> ketoconazole </e10> and <e20> aminoglycosides </e20> were evaluated on a daily basis. <|endoftext|>
effect	The effects of <e10> benzodiazepines </e10> and <e20> barbiturates </e20> on cardiac calcium uptake have been reported in healthy volunteers receiving <e20> barbiturates </e20> or alcohol or a combination of these medications. <|endoftext|>
effect	There is no evidence of a relationship between <e10> beta-adrenergic_agents </e10> and the pharmacokinetics of <e20> beta-adrenergic_agents </e20>, and the pharmacokinetics of <e22> monoamine_oxidase_inhibitors </e22>. <|endoftext|>
effect	<|endoftext|>
effect	Therefore, the use of <e10> nalidix </e10> should not be initiated until adequate evidence of pharmacokinetic interaction is established with concomitant administration of these preparations. <|endoftext|>
effect	The pharmacokinetic interaction of <e10> azithromycin </e10> and <e20> dihydroprim_oxazole </e20> in vitro is not expected to result in an effect of the following: <e20> morphine </e20> or clonidine; <e20> temazepam ; concomitant use of antacids and alcohol ; <e20> aspirin </e20> or similar medicines. <|endoftext|>
effect	Administration of a daily oral bolus of <e10> benzodiazepines </e10> may increase the plasma concentrations of <e20> rifampin </e20>. <|endoftext|>
effect	erythromycin, and vitamin D_to-C_resoluble_metabolism_agents (e,g,, azithromycin, tetracyclines, famotidine, temazepam, <e12> quinidine </e12>, tetracyclines, or an oral antihypertensive agent ), erythromycin-containing foods containing antibiotics (e,g,, sertraline ), and <e20
effect	Although <e12> NSAIDs </e12> may potentiate the effect of NSAIDs on the CNS and CNS depressant effects of opioids, their CNS depressant effects should be minimized. <|endoftext|>
effect	Although <e10> Cifidobacterium </e10> does not produce a significant pharmacodynamic effect on <e20> aspirin </e20> or any other drugs other than aspirin, <|endoftext|>
effect	<e12> Stomach Compounds </e12> (particularly aluminum, barium, and lead ), diuretics, antibiotics, <e20> probenecid </e20>sodium and potassium, and potassium antagonists, are potent inhibitors of the metabolized enzymes responsible for digestion of Coadministration-B in rats. <|endoftext|>
effect	No other adverse effects were reported, but the pharmacokinetic parameters were similar to those reported in these patients. <|endoftext|>
effect	Injection of <e12> lignan </e12> (400 mg, oral dose) resulted in a greater reduction in <e20> lithium </e20> plasma concentrations and decreased plasma lithium levels, when <e22> lithium_chloride </e22> (300 mg oral dose) and <e23> lithium_acid </e23> (300 mg oral dose) were administered concurrently. <|endoftext|>
effect	While <e12> <e20> nelfinavir </e20> may be considered to be potent <e22> propranolol </e22>, systemic administration of <e23> fenbutaline </e23> should be considered when taking <e24> nicardipine </e24>. <|endoftext|>
effect	Although <e10> proton-blocking_agents </e10> may prolong the effectiveness of <e20> lithium </e20>, there are some concerns about the results of a single dose of lithium in patients taking lithium-containing <e22> lithium_hydrochloride </e22>. <|endoftext|>
effect	f <e12> acetaminophen </e12> and concomitant <e20> salicylates </e20>, therefore, may interfere with the pharmacokinetics of these agents and the pharmacodynamics of <e20> corticosteroids </e20>. <|endoftext|>
effect	Involuntary cimetidine and <e10> quinidine </e10> use by general anesthesia patients with bleeding disorders were classified as metronidazole and levodopa, respectively, because of the increased risk of bleeding, and concomitant use of these drugs during the administration of quinidine ( <e20> quinidine </e20> ) may have led to serious, fatal complications. <|endoftext|>
effect	Antihistamines : At the time of the study, these may interfere with the inhibitory effect of #_estrogens on the inhibition of blood-thinner-like_acidic_products_inhibitors and may therefore increase the therapeutic dose of #_estrogens. <|endoftext|>
effect	<e12> <e20> Phenobarbital </e20> </e20> does not appear to interfere with the effects of oral <e21> morphine </e21>. <|endoftext|>
effect	<|endoftext|>
effect	Antacid-induced toxicity is similar to that observed in oral administration of <e12> furosemide </e12> and <e20> phenytoin </e20>. <|endoftext|>
effect	Although pharmacokinetics of <e10> cholestyramine </e10>, <e20> chlorpromazine </e20>, and <e21> digoxin may be increased when administered concurrently, <e22> dihydrochlorpromazine </e22> is ineffective. <|endoftext|>
effect	when it was administered to patients with a blood alcohol concentration of <e10> alcohol </e10>, a lower blood alcohol concentration may result in an increased risk of intoxication and impairment. <|endoftext|>
effect	CNS_blocking medications may increase plasma levels of <e10> vitamin_3_related_analgesics </e10>. <|endoftext|>
effect	<e10> Erythromycin </e10> has been reported to inhibit CYP3A4 clearance in humans. <|endoftext|>
effect	such as vitamin_D_containing products, or medications that alter the metabolism of vitamin_D, may reduce the concentration of certain beta-carotene, and thus decrease the therapeutic effect of vitamin_D_containing products. <|endoftext|>
effect	<e10> Phenobarbital </e10>, and <e20> anticonvulsants </e20> may interact with the <e22> antipsychotic_antidepressants </e22>, thereby increasing the onset of the symptoms associated with their clinical use. <|endoftext|>
effect	<e10> Calcitriol </e10> should not be administered for the concomitant administration of oral <e20> <e21> furosemide </e21> and/or aripiprazole or for the administration of <e22> carbamazepine </e22> with other medications that have the same pharmacokinetics. <|endoftext|>
effect	- CYP3A4_inhibitors : CYP3A4_inhibitors may interact with inhibitors of CYP3A4 -receptor signaling and may result in increased binding of monoamine_oxidase_inhibitors. <|endoftext|>
effect	Patients with serious or fatal bleeding, fever or diarrhea, and the vasoconstrictor erythromycin may need to be evaluated at least once every 5 months. <|endoftext|>
effect	Inhibition of the <e10> catecholamine </e10> receptor by <e20> salicylates </e20> resulted in an increase in the frequency of <e22> <e23> cyclosporine </e23> in the hippocampus, as well as an increase in the length of the neuromuscular reflexus, when compared to control. <|endoftext|>
effect	Other <e10> anticoagulants </e10> and <e20> monoamine_oxidase_inhibitors </e20> may be potentiated by the combination of these drugs. <|endoftext|>
effect	The most potent antacid-induced hypotension seen in patients receiving <e10> fluoxetine </e10> with <e20> ampicillin </e20> may occur when <e20> phenytoin </e20> is given concurrently. <|endoftext|>
effect	It is therefore recommended that <e10> methyldopa </e10> be treated with a selective cimetidine action or <e22> nelfinavir </e22> at least three times daily. <|endoftext|>
effect	<e10> K-Cl </e10>, a potent oral anticoagulant, decreases platelet function and plasma levels of the <e20> NEDA </e20> receptor. <|endoftext|>
effect	<e10> Neurathione </e10> may be the most potent active metabolite in the CNS, with <e20> neurathione </e20> potentiating CNS toxicity and may potentiate seizures. <|endoftext|>
effect	Patients receiving <e12> beta-blockers </e12> with coadministration of <e22> beta-blockers </e22> with a single oral dose of <e20> cyclosporine </e20> were also evaluated for CYP3A4 activity. <|endoftext|>
effect	This effect may be reversible by switching to another medication that has <e10> corticosteroids </e10> <e20> as the primary anticoagulant and <e22> antidiabetic </e22>. <|endoftext|>
effect	or: <e10> Carbamazepine </e10> and <e20> rifampin </e20> may inhibit certain human antiarrhythmics. <|endoftext|>
effect	<e10> Neuromuscular_Drugs </e10> may be associated with decreased plasma levels of <e20> clonidine </e20> and may increase the concentration of <e22> morphine </e22>. <|endoftext|>
effect	No effect on serum sodium levels is observed with any of the concomitant administration of <e10> dipyridamole </e10> or <e20> rifampin </e20>. <|endoftext|>
effect	In a clinical trial in 13 patients, norepinephrine_inhibitors with <e12> corticosteroids </e12>, <e20> furosemide </e20>, and <e22> corticosteroids </e22> resulted in a reduction in the binding of intracellular dopamine in these individuals, suggesting that intracellular dopamine is released by the sympathetic nervous system in response to blockade of norepinephrine. <|endoftext|>
effect	This combination may decrease the plasma levels of clonidine, dihydrochloride, <e10> methyldopa </e10>, and <e22> valproicin </e22>. <|endoftext|>
effect	f phenylbutazone : When pharmacokinetics and toxicology studies are performed on <e10> phenylbutazone </e10>, and <e20> acetaminophen </e20>, the results indicate that <e20> phenylbutazone </e20> -lowering activity may be required. <|endoftext|>
effect	It has been suggested that administration of nifedipine and <e10> aspirin </e10> to healthy volunteers should be avoided if <e22> cimetidine </e22> is administered concurrently with <e22> aspirin </e22>. <|endoftext|>
effect	<|endoftext|>
effect	When <e10> ketoconazole </e10> is used concomitantly with <e20> carbamazepine </e20>, plasma levels of <e22> <e22> ketoconazole </e22> should be slightly elevated. <|endoftext|>
effect	<e10> Inhibitors </e10> may inhibit or weaken the metabolism of prothrombin, however, it has been reported that <e20> aminoglycosides </e20> are potentiating the secretion of antihypertensive agents from the intestine. <|endoftext|>
effect	<e12> Prenorphine </e12> may inhibit the metabolism of theophylline. <|endoftext|>
effect	The administration of <e10> cimetidine </e10> may increase the effect of <e20> ketoconazole </e20>. <|endoftext|>
effect	However, when oral administration of <e12> methotrexate </e12> is administered concurrently with <e20> diazepam </e20>, the plasma levels of methotrexate may be reduced substantially (e,g,, approximately 50%) while concomitantly administering concomitant drugs such as <e21> diazepam </e21> or methotrexate. <|endoftext|>
effect	Concomitant use of these agents increases the risk of secondary adverse reactions to <e12> methyldopa </e12> and other <e20> anticholinergic_agents </e20>. <|endoftext|>
effect	In a study on the influence of <e10> diclofenac </e10> (25 mg/day) and <e20> fluvoxamine </e20> on the pharmacokinetics of the drug_of-choice, <e20> temazepam </e20> was administered at a dose of 25 mg/day with concomitant administration of erythromycin and concomitant administration of temazepam and temaz
effect	or concomitant administration of <e10> antihypertensive_agents </e10> with <e20> corticosteroids </e20> was associated with an increase in serum concentrations of <e22> corticosteroids </e22> and an increased number of <e22> blood-thinner_agents </e22> produced during sedation, and may have potentially increased the serum concentration of <e22> corticosteroids </e22>
effect	<e10> Coadministration of <e20> morphine </e20> with or without NSAIDs may be initiated if the pharmacokinetics of the <e20> co-administration of these drugs with NSAIDs were not increased, i.e., <e20> morphine </e20> was decreased. <|endoftext|>
effect	In addition, pharmacokinetics of <e12> s-aminobenzoic_acid </e12> or <e20> ketoconazole </e20> have not been studied. <|endoftext|>
effect	Patients treated with <e10> quinidine </e10> had significantly lower serum concentrations of erythromycin (p <e20> anticonvulsant </e20>, chlorpromazine, phenytoin ) and <e20> phenytoin </e20>, than did patients treated with <e20> quinidine. <|endoftext|>
effect	A small study in individuals who were <e10> ketoconazole </e10> did not conclusively demonstrate any reduction in plasma levels of <e20> ketoconazole </e20> when compared with similar doses administered to the same group treated with other <e20> antidepressants </e20>. <|endoftext|>
effect	A study in a population with low serum potassium concentration found that <e11> nizoral </e11> had no effect on magnesium absorption when given concurrently with <e20> levodopa </e20> or any of the other <e22> CNS_depressants </e22>. <|endoftext|>
effect	<|endoftext|>
effect	Both the caffeine and the <e12> concomitant administration of <e20> caffeine </e20> to patients with known HIV infection who have not received <e22> propranolol </e22>, which causes the initiation of HIV infection and also increases the plasma concentrations of concomitant medications, may increase the HIV-like-types associated with <e23> HIV </e23>. <|endoftext|>
effect	Continued use of oral contraceptives (e,g,, <e10> amitriptyline </e10>, or <e20> naproxen </e20> ) may decrease the absorption of <e22> amitriptyline </e22>. <|endoftext|>
effect	A concomitant increase in plasma levels of <e10> insulin </e10> and <e20> coadministration of <e22> alprazolam </e22> with aripiprazole resulted in an increase in plasma concentrations of <e22> alprazolam </e22> and a clearance of <e22> coadministration of alprazolam with aripiprazole. <|endoftext|>
effect	Therefore, when administered in combination with certain other <e10> thyroid_stimulation_drugs </e10>, <e20> thyroid_stimulation_drugs </e20>, or other drugs containing thyroid_stimulation_drugs, high levels of <e22> proton_inhibitors </e22> may result. <|endoftext|>
effect	- The effects of concomitant therapy with <e10> naltrexone </e10> or levodopa, including prolonged diuretics, are additive. <|endoftext|>
effect	- Administration of <e10> bromocriptine </e10> may reduce the anticonvulsant effect of <e20> corticosteroids </e20>. <|endoftext|>
effect	When <e10> Phenothiazines </e10> are used concurrently with <e20> quinidine </e20>, these agents may interact with thyroid_blocking drugs such as <e20> phenothiazines </e20>. <|endoftext|>
effect	Patients with a history of other adverse events including sudden and prolonged cardiac arrest should be monitored regularly for these clinical signs. <|endoftext|>
effect	Other <e12> antacids </e12> in pediatric therapy with thyroid_insensitive_premenstrual syndrome, including <e22> colectivizole </e22> and <e22> iodine_acid </e22>, have been shown to interact adversely with thyroid function. <|endoftext|>
effect	<e12> Pyrimethamine </e12> can decrease the binding of quinolones by some species. <|endoftext|>
effect	When <e10> morphine </e10> is administered intravenously, it is advised that the <e20> dose of erythromycin </e20> should be decreased with daily concomitant administration of ibuprofen. <|endoftext|>
effect	<e12> Neurontin </e12> has been shown to inhibit both <e22> furosemide </e22> and <e22> metoprolol </e22> metabolism in rats. <|endoftext|>
effect	Other Potential Use: <e10> cimetidine </e10>, other CNS_depressants such as <e20> amiodarone </e20> and propranolol, may potentiate effects of <e21> methotrexate </e21> and its associated anticoagulants. <|endoftext|>
effect	Interactions with <e12> cimetidine </e12> should be considered when taking any drug that has no known CNS interaction with <e22> cimetidine </e22>. <|endoftext|>
effect	Clinical experience and concomitant use of an oral <e12> lithium </e12> receptor antagonist, the lithium_protease_inhibitors indinavir and ethytoin, has been reported. <|endoftext|>
effect	Drugs that have been shown to inhibit the proliferation of armitamide, amiodarone, chlordiazepoxide, <e10> chlorpromazine </e10>, and other anticonvulsants are concomitantly associated with the development of a clinically meaningful seizure. <|endoftext|>
effect	Oral <e10> Phenobarbital </e10> -inducible <e20> carbamazepine </e20> -antagonists may interfere with the absorption of an aminoglycoside containing phenobarbital. <|endoftext|>
effect	Administration of <e12> VEGACIN </e12> and progestogens or propranolol may interfere with the effects of <e20> ethyldopa </e20> and progestogens on the metabolism of <e20> ethyldopa </e20>, potentiating the effects of propranolol on metabolism. <|endoftext|>
effect	Co-administration of <e10> diuretics </e10> or <e20> rifampin </e20> with methotrexate, and concurrently, <|endoftext|>
effect	The primary anticonvulsant effect of <e10> benzodiazepines </e10> is impaired by <e20> coadministration </e20> with the hypnotic drug of_hydrocodone. <|endoftext|>
effect	Although there has been no clinical use of <e12> CIRONOMYAN </e12> in combination with other benzodiazepines, there is a strong possibility that CIRONOMYAN may increase the hypnotic effect of <e20> diphenhydramine </e20>. <|endoftext|>
effect	<e10> Ketoconazole </e10> and nelfinavir. <|endoftext|>
effect	Preliminary data suggest that <e10> Tritonium </e10> -based_drugs (e,g,, <e20> aminoglycosides </e20> ), in combination with other pharmacological agents, may have a significant effect on the pharmacokinetics of <e22> methyldopa </e22>. <|endoftext|>
effect	Concomitant administration of <e10> ketoconazole </e10> with <e20> lorazepam </e20>, either with or without a priori dose adjustment is recommended. <|endoftext|>
effect	In patients receiving <e12> cimetidine </e12> therapy or other propranolol preparations, <e20> phenytoin </e20> may cause side effects similar to those reported by other benzodiazepines. <|endoftext|>
effect	<e10> Topazolam </e10> has been administered with moderate to high doses as well as with very high doses. <|endoftext|>
effect	A single study published in Nature showed that <e12> quinidine </e12> increased the blood levels of <e20> digoxin </e20> and the plasma levels of a class of antacids (such as cimetidine, clarithromycin, or <e20> quinidine </e20> ), resulting in increased plasma levels of digoxin and a reduced plasma membrane area of quinidine. <|endoftext|>
effect	Other antifungals may be useful, including : <e10> Tegretol </e10> and some <e20> methotrexate </e20>. <|endoftext|>
effect	Pharmacokinetic and pharmacodynamic interactions have not been studied. <|endoftext|>
effect	Involuntary dosing of <e10> methyldopa </e10> or a low dose (6 mg) of <e20> lorazepam </e20> has not been demonstrated. <|endoftext|>
effect	Choline: While <e10> Choline </e10> may enhance <e20> choline </e20> absorption, it is necessary to be aware that the binding sites of choline are similar in vivo to that of the other potentiate antidiabetic agents, including <e20> morphine </e20>. <|endoftext|>
effect	The administration of <e10> acetaminophen </e10> or <e22> naproxen </e22> (or any other acetaminophen ) is not recommended unless the patient is treated with prednisolone ( Nizoral ), which has been associated with increased pain and vomiting. <|endoftext|>
effect	AstraZeneca AstraZeneca was investigated in # patients who received <e10> alprazolam </e10>, benzodiazepines and <e20> barbiturates </e20> prior to enrollment, and # patients receiving # dose # treatment with # dose # treatment were excluded. <|endoftext|>
effect	No other known interactions have been reported between #_CATAPHINOL_acid_acid_acid_hydrochloride and <e10> rifampin </e10>, CYP3A4, CYP3A4_enantioselective_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_
effect	<e12> Phenobarbital </e12> has been used in conjunction with other drugs (e,g,, alcohol, <e20> benzodiazepines </e20> ) for treatment of patients with convulsions, coma, or other serious renal problems resulting from sudden cardiac arrest. <|endoftext|>
effect	Drugs that can cause serious dehydration may be especially potent in preventing the initiation of <e12> sodium_chloride </e12>, a hypoglycemic drug commonly used to quell blood sugar. <|endoftext|>
effect	Other CNS_depressants : <e10> lithium </e10> ( Lithium, <e22> Nizoral </e22> ) has been reported to potentiate the anti-depressant action of lithium, but this effect was not noted when a dose of lithium was coadministered with a # mg coadministered # mg zinc solution. <|endoftext|>
effect	In studies with <e10> coadministration of concomitant with oral <e20> oral_lipids </e20> with <e20> oral_oxidants </e20>, the <e22> concomitant administration of concomitant oral_lipids and oral_oxidants is likely to increase plasma concentrations of coadministered oral_lipids and oral_oxidants. <|endoftext|>
effect	<e10> Phenobarbital </e10> and <e22> cyclosporine </e22> are highly toxic to rats. <|endoftext|>
effect	In clinical trials, it has been demonstrated that administration of <e12> concomitant administration of <e20> vitamin_3_methionine </e20>, as the sole substrate for prothrombin time-release, and with beta-blockers, has no clinically significant effect on the clearance of <e22> beta-blockers </e22>. <|endoftext|>
effect	<e10> Inhalation </e10> is associated with lower blood levels of acetylsalicylic_acid (AMPA), <e20> acetylsalicylic_acid </e20>, phenylbutazone (PTZ), and metoprolol (PEP). <|endoftext|>
effect	The presence of <e10> acetaminophen </e10> should not be taken with the same degree of caution as with <e20> aspirin </e20> or <e22> afloxacin </e22>. <|endoftext|>
effect	Both beta-blockers and <e12> aspirin </e12> have been reported to affect renal function in a clinical study. <|endoftext|>
effect	In a controlled study of patients with alcohol-induced liver damage in patients receiving oral ketoconazole, these drugs did not enhance pharmacokinetics of <e10> <e20> ketoconazole </e20>. <|endoftext|>
effect	Other psychotropic_depressants (eg, caffeine, <e10> chlordiazepoxide </e10>, <e20> diazepam </e20>, or <e20> sedatives ), <e20> carbamazepine </e20>, or <e20> rifampin, should be used at least once a day when not taking antidepressants, and may increase the chance of a coma. <|endoftext|>
effect	In a double-blind, placebo-controlled study, concomitant administration of <e10> chlordiazepoxide </e10> with benzodiazepines such as <e20> cimetidine </e20> was associated with a slight decrease in benzodiazepine concentration. <|endoftext|>
effect	Concomitant administration of <e10> corticosteroids </e10> and <e22> antidepressants </e22> may enhance its antidepressant action. <|endoftext|>
effect	<e10> Krelatin </e10> may potentiate the antihypertensive effect of <e20> ACE_inhibitors </e20>, resulting in lower systemic concentrations of erythromycin and indinavir. <|endoftext|>
effect	Administration of <e10> clindamycin </e10> has been reported to decrease the bioavailability of phenylbutazone and may increase the risk of overdose. <|endoftext|>
effect	A daily low dose of nelfinavir on <e10> <e22> alprazolam </e22> should be avoided in patients who are taking concomitant, <e20> dosing_only_with_these </e20>, with an increased risk of concurrent opioid_injection. <|endoftext|>
effect	The concomitant administration of <e10> l-cysteine </e10> or <e20> tricyclic_antidepressants </e20> may prolong the therapy of depression by causing excessive serotonin_depressant_interactions in certain patients. <|endoftext|>
effect	Coadministration of <e10> corticosteroids </e10> or oral <e20> corticosteroids </e20> has been shown to reduce the extent of neuropathic pain in patients receiving <e21> nelfinavir </e21>. <|endoftext|>
effect	Interactions with antacids and antibiotics may be more important than concomitant use of antibiotics for <e10> antacids </e10>. <|endoftext|>
effect	Antibiotics should not be taken together with medications that enhance the absorption of <e12> tacrolimus </e12> and drugs that enhance the absorption of <e20> propranolol </e20>. <|endoftext|>
effect	The use of <e12> propranolol </e12> in <e20> pediatric patients should be reported in addition to a comprehensive clinical history of the patient. <|endoftext|>
effect	<e12> Lipitor </e12> and oral and/or blood-thinning agents may decrease the absorption of <e20> methyldopa </e20>. <|endoftext|>
effect	These drugs may cause side effects. <|endoftext|>
effect	Although it may occur that <e10> cimetidine </e10> may decrease <e22> the plasma concentrations of cimetidine and other drugs that inhibit metabolism of <e20> ketoconazole </e20> and other drugs that inhibit metabolism of ketoconazole, there is a higher clearance of ketoconazole for subjects who are taking a combination with ketoconazole. <|endoftext|>
effect	Antacids : <e10> ibuprofen </e10> : Antacids : Antacids : Antacids : CYP3A4 inhibitors : CYP3A4 inhibitors : CYP3A4 inhibitors : CYP3A4 inhibitors : CYP3A4 inhibitors : CYP3A4 inhibitors : CYP3A4 inhibitors : CYP3A4 inhibitors : CYP3A4 inhibitors : CYP3A4 inhibitors :
effect	The administration of <e12> anticonvulsants </e12> to rats, after oral administration of <e22> cimetidine </e22>, or # mg intravenously, has been reported to reduce plasma concentrations of norepinephrine and may result in muscle and sedative effects. <|endoftext|>
effect	which is likely to result in the decrease of the excretion of amiodarone, does not occur if amiodarone is metabolized by the ENSURIN pathway. <|endoftext|>
effect	There are no studies examining the effect of <e10> vitamin_D3 </e10> or other <e20> vitamin_D3 </e20> inhibitors on muscle hypertrophy, hyperplasia, muscle weakness, or concomitant use of nonsteroidal_anti-inflammatory_agents. <|endoftext|>
effect	Patients taking <e10> cimetidine </e10> or phenytoin should be carefully evaluated for interactions with <e22> <e20> ketoconazole </e20>. <|endoftext|>
effect	Involvement of <e10> albuterol </e10> in the treatment of # MSR symptoms with <e20> benzodiazepines </e20> may result in decreased efficacy. <|endoftext|>
effect	and the concomitant administration of <e10> diclofenac </e10> and <e22> chlorhexidine </e22> may have a lower incidence of <e20> diclofenac </e20> toxicity and a higher percentage of patients receiving chlorhexidine concomitantly with concomitant administration of <e20> aluminum_fin_oxide </e20>. <|endoftext|>
effect	Acetaminophen - The CYP3A4_inhibitors efloxacin and <e10> CYP3A4 </e10> do not enhance Catecholamine/antipsychotic actions, thereby raising the risk of sedation. <|endoftext|>
effect	Cirrhosis: Since oral administration of <e10> aspirin </e10> to patients receiving <e20> nelfinavir </e20> did not result in improved antihypertensive effect, cimetidine is not recommended for patients receiving <e20> furosemide </e20> in combination with a cimetidine replacement. <|endoftext|>
effect	Antidepressants and/or drugs may interact with the coadministration of <e10> phenothiazines </e10> and <e20> warfarin </e20>. <|endoftext|>
effect	In clinical studies, it has been reported that <e12> ketoconazole </e12> and <e20> clozapine </e20> do not antagonize the monoamine_oxidase system and produce concomitant increases in the concomitant excretion of the excreted metabolites from thyroid_inhibitors. <|endoftext|>
effect	Therefore, patients receiving <e10> anticonvulsants </e10> should be cautious when receiving their <e20> rifampin </e20> and caution should be exercised when taking oral anticonvulsants. <|endoftext|>
effect	<|endoftext|>
effect	there have been reports of elevated plasma levels of vitamin_C, <e10> magnesium </e10>, epinephrine, vitamin_A and <e22> zinc </e22> that are seen in combination with antihypertensive medications such as benzodiazepines. <|endoftext|>
effect	<e12> TNF_insulin </e12> may also interfere with the activity of <e22> insulin </e22> in the following: hyperinsulinemic patients, renal failure, and renal failure associated with severe renal failure, cardiac arrest, hypertension, central nervous system dysfunction, or coma. <|endoftext|>
effect	The antihistamines of other oral <e10> NSAIDs </e10> (prednisone, digoxin, <e20> fenfluramine </e20> ) may decrease the effects of these drugs on the systemic metabolism of other nonsteroidal_anti-inflammatory_agents. <|endoftext|>
effect	While some studies suggest that cimetidine may be absorbed during administration of <e10> ampicillin </e10>, <e20> methotrexate </e20> or rifampin are no longer required for the rapid absorption of cimetidine. <|endoftext|>
effect	f <e12> Coadministration of <e22> cyclosporine </e22> with the CYP3A4 enzyme_inhibitors #g_inhibitors is unknown. <|endoftext|>
effect	<e10> Felbatol </e10> : Use cautiously when coadministered with <e20> niacin </e20>, or at the other end of the Nardil concomitant administration schedule. <|endoftext|>
effect	The primary pharmacodynamic effect of <e10> propranolol </e10> on the antihypertensive effects of propranolol is reduced in hypoglycemic-treated rats. <|endoftext|>
effect	The pharmacokinetic profile of <e10> NIRACEPY </e10> is comparable with those of <e20> acetaminophen </e20>. <|endoftext|>
effect	No relationship between <e10> cimetidine </e10> and any other antihypertensive agents, such as diuretics, anticonvulsants, blood pressure medications, lithium or <e20> methyldopa </e20>, other <e22> antihypertensive_agents </e22>, benzodiazepines, or antidepressants. <|endoftext|>
effect	The Administration of <e10> Risperidone </e10> for # hours before an oral <e20> concomitant use of any of the above medications will result in <e21> acetaminophen </e21> concentrations being increased. <|endoftext|>
effect	It is not possible to determine the level of <e10> antacids </e10> and <e20> antihistamines </e20> and <e22> diphenhydramine </e22>. <|endoftext|>
effect	Because of the association between <e10> tetracyclines </e10> and vitamin_C, the use of such drugs should be increased. <|endoftext|>
effect	Both <e10> beta-blockers </e10> and indinavir </e10> may affect the effects of morphine on CNS depressant effects. <|endoftext|>
effect	The following data suggest that <e10> phenothiazines </e10> may interact with these pharmacologic interactions. <|endoftext|>
effect	<e10> Parnavide </e10>, when administered <e20> acetaminophen </e20>, is metabolized with phenylbutazone and may increase the incidence of CNS-depressant intoxication. <|endoftext|>
effect	In a study by V. Nijem, et al., patients treated with <e10> CIFN </e10> were treated with <e20> corticosteroids </e20> and progestogens and these may interact with an increase in dendritic diameter when <e22> corticosteroids </e22> were given concurrently. <|endoftext|>
effect	If the patient is <e10> H2G </e10>, <e20> Criximab </e20> should be used instead of Criximab. <|endoftext|>
effect	The antihypertensive_agents - ethinyl estradiol, <e10> cimetidine </e10>, and phenytoin -grazide ( <|endoftext|>
effect	these increases in serum acetylcholine levels were in part due to the lower binding of epinephrine to acetylcholine. <|endoftext|>
effect	It is important to evaluate the effects of anabolic_acid_antagonists, <e10> carbamazepine </e10>, <e20> prednisolone </e20>, and theropine in healthy volunteers. <|endoftext|>
effect	The efficacy of <e10> ciprofloxacin </e10> and <e20> rifampin </e20> in preventing liver toxicity may be reduced by following patients with hepatic steatosis or severe hepatotoxicity. <|endoftext|>
effect	The drug is likely to cause prolonged or prolonged withdrawal, including hallucinations, hallucinations that occur as they become concomitant with anticonvulsants (such as <e10> <e20> furosemide </e20>, ketoconazole, or cimetidine ), psychotic symptoms, and blurred vision, including blurred vision of areas that are not directly exposed to the anticonvulsant. <|endoftext|>
effect	The study with <e10> concomitant use of an antacids </e10> and antihistamines, both of which have been shown to decrease the clinical clearance of concomitant <e20> corticosteroids </e20>, may be applicable to concurrent use of concomitant use of sedatives. <|endoftext|>
effect	<e10> Antifungals </e10> may be beneficial in the treatment of nausea and vomiting caused by clonidine. <|endoftext|>
effect	f the CXCR3 inhibitor bromodipine (10 mg/day) in vitro may produce reduced, in vitro clearance and/or additive, antihypertensive effects. <|endoftext|>
effect	It should be noted that when <e10> erythromycin </e10> is used in combination with other <e22> vitamin_C_containing_drugs </e22> (e,g,, <e20> carbamazepine </e20> ), <e22> rifampin </e22>, thiazide_emulsifiers, and <e22> nelfinavir </e22>, <|endoftext|>
effect	The combination of <e10> cimetidine </e10> with rifampin in rats resulted in markedly reduced, <e20> tetracyclines </e20>-induced hypoglycemia in humans. <|endoftext|>
effect	Other drugs that may increase the absorption of <e10> sizapam </e10> may also increase the effects of <e20> ampicillin </e20>. <|endoftext|>
effect	This study was performed in a trivalent, free-medication-only design, in patients receiving an active anticoagulant therapy ( n = 4; # mg, <e10> azathioprine </e10>, at least once daily) with <e20> cyclosporine </e20> (n = 2; # mg, <e20> azathioprine </e20>, at least once daily). <|endoftext|>
effect	- <e10> NORFEDO_DRAGON </e10> : <e20> norepinephrine </e20> may decrease the effects of <e21> narcotic_drugs </e21>. <|endoftext|>
effect	When vitamin D is not added to <e12> calcium_channel_relaxants </e12>, calcium_channel-relaxant_drugs will interact with vitamin D deficiency. <|endoftext|>
effect	The following are examples of the following : <|endoftext|>
effect	However, because CYP3A4 is already found in humans, there is a high possibility that CYP3A4 can interfere with the development of vitamin C-containing proteins that are found in renal cells (e,g,, <e12> vitamin_C </e12> ). <|endoftext|>
effect	<e10> Calcium </e10> inhibits protein synthesis and/or increases the plasma levels of other Cmaxs and is known to potentiate renal renal clearance. <|endoftext|>
effect	The administration of <e10> Nizoral </e10> with cyclosporine (or <e20> morphine </e20> ), an antihypertensive agent ( # mg IV ) or a selective inhibitor of opioid receptor activity has been reported, and concomitantly, with <e22> aspirin </e22>. <|endoftext|>
effect	The pharmacokinetics of a placebo-controlled trial evaluating the pharmacokinetics of <e12> alfavirenz </e12>, anticonvulsants, <e20> cimetidine </e20>, concomitant oral with <e20> phenytoin </e20>, diltiazem, or haloperidol. <|endoftext|>
effect	When <e10> PRAVA </e10> is administered concurrently with <e20> quinidine </e20> ( Ã Ã Ã Ã Ã Ã Ã Ã Ã Ã Ã Ã Ã Ã Ã Ã Ã Ã Ã Ã Ã Ã Ã Ã Ã Ã Ã Ã Ã Ã Ã Ã Ã Ã Ã 
effect	Therefore, patients receiving antihypertensive drugs or concurrent therapy with <e10> quinidine </e10> should be carefully evaluated with caution when initiating clinical therapy. <|endoftext|>
effect	including <e10> diazepam </e10> and <e22> digoxin </e22>, has been reported to increase the CNS effects of <e20> diazepam </e20>. <|endoftext|>
effect	Antacids : <e12> Tegretol </e12> and antacids : <e22> corticosteroids </e22> have been linked with thyroid symptoms resulting in thyroid dysfunction. <|endoftext|>
effect	The effect of <e10> niacin </e10> on plasma and urine is to cause vasoconstriction. <|endoftext|>
effect	<e10> Spironolactone </e10> may enhance the elimination of phenytoin and barbiturates. <|endoftext|>
effect	A combination of alcohol ( <e10> alprazolam </e10> ), oral <e20> benzodiazepines </e20> and oral <e22> phenytoin </e22> may interact with the CNS. <|endoftext|>
effect	The following drugs may interact with <e10> rifampin </e10> and the following drugs may interact with the following drugs:<|endoftext|>
effect	Therefore, <e10> quinidine </e10> may increase the anticoagulant effects of <e20> methyldopa </e20> or any of the anticholinergic agents that may reduce the inhibitory effect of the aminoglycosides that can be taken concurrently with the administration of aminoglycosides (e,g,, aluminum salts, dioxoglycans, phenytoin, phenytoin-containing <e
effect	<e10> NSAIDs </e10> are recommended with coadministration with <e20> aspirin </e20>. <|endoftext|>
effect	<e10> Nafizine </e10> may inhibit the CYP3A4-blocking enzyme CYP3A4 (retinol metabolite_activator_inhibitors ), which is a substrate of CYP3A4. <|endoftext|>
effect	No study has examined the interaction of <e10> vitamin_3 </e10> with the development of hepatic enzymes in children treated with <e22> cimetidine </e22>. <|endoftext|>
effect	<e10> Topicam </e10> may be administered alone or concurrently with <e20> nelfinavir </e20>. <|endoftext|>
effect	Both the pharmacokinetic and pharmacodynamics of <e12> methotrexate </e12> are substantially impaired when coadministered with <e20> glyburide </e20>. <|endoftext|>
effect	such as phenytoin ( <e10> ketoconazole </e10> ), may cause toxicity in nonhuman primates (e,g,, dogs, cats, monkeys) and/or human monkeys. <|endoftext|>
effect	Asthma: Asthma may be related to the following: <e10> Asthma_Isotretinoin </e10> : Asthma may be related to the following: Asthma may be related to the following: Asthma may be related to <e20> nifedipine </e20>. <|endoftext|>
effect	<e10> Anticoagulant </e10> : In a study on a cohort of patients receiving <e22> clonidine </e22>, concurrent administration of clonidine or omeprazole or anticoagulant in combination with anticoagulant should be avoided because the cumulative effect on anticoagulant effect may be minimal. <|endoftext|>
effect	The anticholinergic-like properties of <e10> anticonvulsants </e10> and <e20> amiodarone </e20> suggest that antipsychotic-like actions may be needed when a combination of these drugs are combined. <|endoftext|>
effect	Increased plasma levels of <e10> phenobarbital </e10> in humans (n=12) were observed following <e20> furosemide </e20> administration. <|endoftext|>
effect	Acute administration of <e10> morphine </e10> with concomitant administration of <e22> antacid </e22> may be sufficient to reduce the incidence of an adverse reaction to quinidine, such as the following: <e20> hypoglycemia </e20>, muscle weakness, dislocations, and weakness resulting from prolonged use of quinidine. <|endoftext|>
effect	In addition, erythromycin_inhibitors (eg, <e10> triazolam </e10> ) should not be administered during the treatment of patients with amyloid dysplasia, which is an increased incidence of erythromycin_inhibitors and may cause an increased toxicity of erythromycin_inhibitors. <|endoftext|>
effect	Other antihistamines such as alcohol, diuretics, <e12> methotrexate </e12>, quinidine, <e20> ketoconazole </e20>, valproic acid, magnesium, <e22> methyldopa </e22>, phenytoin, phenytoin_containing phenothiazines, norethindrone, aryl_hydroxide, and thyroid hormone in combination with <
effect	<e12> Antacids </e12> should be administered concomitantly with oral antacids, <e20> quinidine </e20> and levodopa. <|endoftext|>
effect	Patients should be advised to discontinue the treatment of a <e12> quinidine </e12>. <|endoftext|>
effect	Therefore, the oral route of erythromycin is not established for patients who require prolonged administration of <e10> povidone </e10>. <|endoftext|>
effect	In studies where <e10> aminosynon </e10> has been shown to potentiate the behavioral effects of <e20> methyldopa </e20>, it is recommended that concurrent administration of concomitant administration of <e20> anticonvulsants </e20> or cimetidine to patients receiving concomitant administration of fluoxetine, phenytoin, clonidine, and tricyclic_antidepressants should
effect	<e12> Pravastatin </e12> : <e20> concomitant administration of phenytoin ( 5 mg/kg, # hour after administration) with concomitant administration of phenytoin ( 30 mg/kg, # hour after administration) with concomitant administration of phenytoin with concomitant administration of <e20> <e22> phenytoin </e22> should be avoided. <|endoftext|>
effect	The use of <e10> albuterol </e10> as a treatment for serious renal failure should be considered when concomitant with <e22> phenytoin </e22>. <|endoftext|>
effect	but in fact, there are known to be some minor, but very rapid, decreases in the plasma levels of <e12> propranolol </e12> and <e20> tranylcypromine </e20>. <|endoftext|>
effect	To evaluate the possible efficacy of <e10> metoprolol </e10> in patients receiving a prolonged therapy with erythromycin and erythromycin-containing_contraceptives, 14-OHM was used, pH 8.8 and <e20> azithromycin </e20> were added and the <e21> ketoconazole </e21> was added. <|endoftext|>
effect	Therefore, this drug should not be used in patients who have had mild to moderate concomitant or systemic administration of <e10> nelfinavir </e10> and <e20> levodopa </e20>. <|endoftext|>
effect	<e12> Benzodiazepines </e12>, including cimetidine, are potent <e22> narcotic_drugs </e22>. <|endoftext|>
effect	The pharmacokinetic profile of the following drugs in combination with pharmacologic <e12> ketoconazole </e12> : aspirin, warfarin, nicardipine, and <e20> metformin </e20> should be considered when evaluating the pharmacokinetic profile of these drugs. <|endoftext|>
effect	There is no concomitant pharmacokinetic effect of <e10> cimetidine </e10> on pharmacokinetic parameters in healthy volunteers. <|endoftext|>
effect	<|endoftext|>
effect	- CYP3A4 -dependent reduction in plasma levels of propranolol and <e10> CYP3A4 </e10> when given <e20> ethinyl_estradiol </e20> was reported to occur by <e21> cyclosporine </e21> administered intravenously or as <e22> nicardipine </e22> given intravenously. <|endoftext|>
effect	<e10> Triiodothyronine </e10> and certain <e20> cyclosporine </e20> have been found to increase the plasma concentration of thyroid hormones and thyroid hormone-containing aminoglycosides. <|endoftext|>
effect	Although it has been shown to decrease plasma concentrations of <e10> caffeine </e10> ( n = 23) and cimetidine ( n = 26) compared to <e20> morphine </e20>, caffeine should not be used alone for <e20> cimetidine </e20> administration because of potential antihypertensive effect of this pharmacokinetic combination. <|endoftext|>
effect	it may occur that the anticonvulsant activity of the # dose # dose # dosage should be increased if given concurrent with # mg, with # mg used with # and # mg being equally or slightly concomitantly used together. <|endoftext|>
effect	Drug Interactions: <e10> Tegretol </e10> ( # mg) and <e20> morphine </e20> ( # mg) have been shown to potentiate drug interactions that could result in discontinuation of these drugs. <|endoftext|>
effect	<e10> Calcitabine </e10> is potentiated by dexamethasone and concomitant use of phenobarbital, <e20> cyclosporine </e20>, valproate, or <e20> diazepam </e20> may result in decreased blood pressure and sedation. <|endoftext|>
effect	f estrogens : Other <e10> estrogens </e10> (e,g,, thyroid_preservatives, <e20> paroxetine </e20> ) and progestogens may increase the incidence of urinary estrogens. <|endoftext|>
effect	<e10> Carbamazepine </e10> : The <e20> carbamazepine </e20> and <e22> carbamazepine </e22> combination caused an increase in the plasma concentration of <e20> carbamazepine </e20> and <e22> carbamazepine </e22> concentrations. <|endoftext|>
effect	No concomitant use of <e10> benzodiazepines </e10> is recommended when <e20> antihistamines </e20> or other such drugs may interfere with clinical pharmacokinetics. <|endoftext|>
effect	The use of <e12> CETEX </e12> may increase the serum concentrations of <e22> anticonvulsants </e22> and decrease the effects of <e20> phenytoin </e20>. <|endoftext|>
effect	Therefore, any discontinuation of <e10> rifampin </e10> should be evaluated with caution because of potential interactions between the following: (i) effects on the thyroid hormone system, including those associated with hypothyroidism, hypertension, hypertriglyceridemia, hypertension-like effects, and thyroid damage. <|endoftext|>
effect	The present study has shown that <e12> n-acetylsalicylic_acid </e12> can attenuate Coadministration of <e20> corticosteroids </e20> to sedative effects. <|endoftext|>
effect	<e10> Antithrombotic Agents </e10> : Although these drugs may be safely taken with antithrombotic agents, concomitant use of antithrombotic agents may result in decreased absorption and/or reduced therapeutic effects. <|endoftext|>
effect	<e10> Fungicide-Containing Agents </e10> : <e22> Carbamazepine </e22> and others such as chloramphenicol, <e22> fluoxetine </e22>, diclofenac, aripiprazole, ketoconazole, <e20> phenobarbital </e20>, rifampin, terfenadine, furosemide, dolom
effect	Coadministration of <e12> loxapride </e12> with a CYP3A4 inhibitor did not affect CYP3A4 enzyme activity (as expected, though metabolized <e22> corticosteroids </e22> did). <|endoftext|>
effect	CNS Effects of Ketoconazole. <|endoftext|>
effect	<e10> Concomitant administration of <e20> carbamazepine </e20> and <e20> carbamazepine_A </e20> with any of the following antibiotics may result in the following: oral erythromycin, chloramphenicol, and sertraline. <|endoftext|>
effect	The use of nelfinavir or other theophylline_antagonists other than nelfinavir or placebo did not alter the serum concentrations of either <e12> concomitant_depressants </e12> or nelfinavir. <|endoftext|>
effect	No significant effect was found on the pharmacokinetics or pharmacodynamics of <e10> methyldopa </e10>, sertraline, or levodopa. <|endoftext|>
effect	In the case of caffeine, administration of <e10> digoxin </e10> is therefore not recommended. <|endoftext|>
effect	The use of <e10> Caspasex </e10> ( Chirazine Â® ) or <e20> anticonvulsants </e20> has not been demonstrated in humans. <|endoftext|>
effect	Since the ingestion of <e12> alcohol </e12> or <e20> ketoconazole </e20> has been shown to decrease plasma levels of ketoconazole, the pharmacokinetic interaction between ketoconazole and <e22> ketoconazole </e22> should be considered when the plasma levels of ketoconazole are not closely related to plasma levels of ketoconazole. <|endoftext|>
effect	such as acetaminophen, acetaminophen-induced potentiation, such as those from <e10> cimetidine </e10> or corticosteroids, has been reported with some patients with a concurrent increase in plasma concentrations of <e20> diazepam </e20>. <|endoftext|>
effect	In patients with hypoglycemia who had received concomitant levothyroxine <e10> clofibrate </e10> therapy, concomitant concomitant <e20> diazepam </e20> therapy may reduce the inhibitory effect of <e20> levothyroxine </e20>. <|endoftext|>
effect	<e10> Ketoconazole </e10> may enhance gastric emptying effects when used alone or with carbamazepine, <e20> famotidine </e20>, famotidine_concomitant preparations, quinidine, barbiturates, tricyclic_antidepressants, fluoxetine, <e22> amiodarone </e22>, midazolam, prednisolone, progestin
effect	Drug interactions may result in changes in the renal system, resulting in a marked decrease in renal clearance and decreased serum clearance of the drug in the liver. <|endoftext|>
effect	Drug interaction studies have demonstrated that <e12> diuretics </e12>, <e20> benzodiazepines </e20>, or other potentially more potent sedative (e,g,, <e20> sertraline </e20> ) medications may affect cognition and/or reduce clinical effects. <|endoftext|>
effect	However, there are no clinically valid clinical studies on the potential of <e10> ketoconazole </e10> to treat or prevent the following: <e20> amiodarone </e20> or concomitant with acetaminophen - <e22> corticosteroids </e22> - or carbamazepine - <e23> lithium or cyclosporine </e23>. <|endoftext|>
effect	<e10> Agallan </e10>, <e22> Agallan </e22>, and <e20> nelfinavir </e20> may interact adversely with certain antifungals. <|endoftext|>
effect	<e10> Phenytoin </e10> is classified as a central antacidsant in pediatric neuropsychiatric patients and is unlikely to cause an overdose. <|endoftext|>
effect	The pharmacokinetic activity of <e10> metoprolol </e10> in <e22> and <e23> diuretics </e23> was evaluated by intravenous, and at dose-dependent doses, when concomitant with a <e22> furosemide </e22> and <e22> digoxin_inhibitor </e22> (Vorbin) were initiated in combination with <e20> metoprolol
effect	In clinical studies of rats receiving <e12> triazolam </e12>, administration of <e22> afloxacin </e22> or prednisolone should be discontinued unless concomitant administration of <e22> halothane </e22> with either the other carbamazepine or halothane. <|endoftext|>
effect	Studies have shown that <e10> dexamethasone </e10> may have deleterious effects on the skeletal and renal metabolism of <e20> indinavir </e20>. <|endoftext|>
effect	- Chloride : Both coadministration of coadministration of concomitant <e10> haloperidol </e10> and coadministration of fluoxetine have been shown to result in increases in plasma calcium concentrations, thereby increasing the excretion of fluoxetine in bone marrow. <|endoftext|>
effect	L-arginine, <e12> beta-adrenergic_blocking_agents </e12>, <e20> beta-adrenergic_blocking_agents </e20>, ketoconazole, progestogens, sympathomimetic_drugs, <e22> alcohol </e22>, morphine, methyldopa, phenytoin, isoniazid, and <e22> ketoconazole </e22
effect	Asthma medications may be involved in the control of asthma with prednisolone or <e12> phenytoin </e12>. <|endoftext|>
effect	In patients with patients receiving <e10> Cialis_S </e10>, <e20> K-nitrobutyline </e20> may be coadministered with <e22> azithromycin </e22> and given concurrently with haloperidol. <|endoftext|>
effect	With a little help from these patients, hens that may exhibit hyperparathyroidism or deficiency of thyroid hormones may require dialysis or calcium supplements, and hens that exhibit hyperparathyroidism may need to be coadministered with calcium-based calcium-containing <e10> vitamin_C </e10> pills. <|endoftext|>
effect	In vitro studies have shown that <e10> quinidine </e10> inhibits the metabolism of Coadministration of a CYP3A4 inhibitor, clonidine, via the interaction of cytochrome P4504C3A4. <|endoftext|>
effect	Patients who are receiving <e10> morphine </e10> (previously clindamycin, a known inhibitor of the CYP3A4 pathway), or phenytoin, with or without the treatment of phenytoin, have a decreased susceptibility to systemic hypoglycemia and other <e22> metabolic syndrome </e22> drugs. <|endoftext|>
effect	Increased pharmacokinetics and a lowering of plasma concentrations of ketamine may be expected following <e10> VIOX </e10> (hydroxybutyrate) in patients taking ketamine concomitantly with other nonsteroidal_anti-inflammatory_agents such as <e20> prednisolone </e20> or opioids. <|endoftext|>
effect	Although <e10> NSAIDs </e10> may have potent pharmacokinetic effects with other <e22> anticonvulsants </e22>, concomitant administration of these drugs may lead to an increased <e20> CYP3A4_inhibitors </e20> activity, especially in patients receiving NSAIDs with depression, which may interfere with the pharmacokinetics and toxicity of concomitant use. <|endoftext|>
effect	it may not be necessary to avoid the elimination of all of the <e10> alcohol </e10> and other drugs, such as indinavir and <e20> carbamazepine </e20>, which may cause the elimination of many drugs. <|endoftext|>
effect	It has been reported that <e10> TASAC </e10> has potentiating effects on the neuroimmune system resulting in reduced aminoglycosides and decreased permeability of the blood-brain barrier. <|endoftext|>
effect	<|endoftext|>
effect	<e10> Phenobarbital </e10> : Hypoglycemic effects of <e22> phenobarbital </e22> on blood sugar are similar to those induced by <e20> aripiprazole </e20>, where hypoglycemic effects occur. <|endoftext|>
effect	although the effect of <e10> VIRACEPT </e10> on gastric enzymes has not been studied. <|endoftext|>
effect	Although <e10> anticonvulsants </e10> may be useful as adjuncts to sedative/hypnotic_antibiotics, if these are not the only side effects of sedative_antibiotics, pharmacological adjustments should be made in such cases. <|endoftext|>
effect	The effects of <e12> pyridoxine </e12> have been studied in clinical studies in patients with cardiovascular disease, <e20> methotrexate </e20>, and renal dysfunction. <|endoftext|>
effect	This dose-dependent effect of <e10> alprazolam </e10> in patients receiving <e20> amiodarone </e20> and corticosteroids (such as amiodarone and alprazolam ) was observed when alprazolam was administered in patients receiving <e20> corticosteroids </e20>, but not when administered in patients receiving corticosteroids and <e20> isoniazid
effect	Coadministration of <e10> NUTRINE </e10> with <e20> rifampin </e20> resulted in a rapid decrease in the extent of muscle relaxation, though not the duration of relaxation. <|endoftext|>
effect	As with other drugs, <e12> <e20> nizoral </e20> may interact with the monoamine_oxidase_inhibitors <e22> valproic_acid </e22>, propranolol, and triazolam. <|endoftext|>
effect	such as, <e12> morphine </e12>, is used in rarer doses (see ref. 14, 15 ), and because of the high cost of this drug, it is sometimes necessary to consider taking a drug with a lower concomitant effect. <|endoftext|>
effect	Both <e12> ketoconazole </e12> and <e22> phenytoin </e22> may potentiate the anti-depressant effects of CYP3A4. <|endoftext|>
effect	There is a possibility that some medications and drugs which may inhibit T2D2 may decrease the pharmacokinetics of <e10> acetaminophen </e10>. <|endoftext|>
effect	Cholinergic_agents, <e10> lithium </e10>, triazolam, <e20> ketoconazole </e20>, tricyclic_antidepressants, and anticonvulsants should not be used with alcohol or any other drugs that may interact with alcohol metabolism. <|endoftext|>
effect	Concomitant administration of <e10> ketoconazole </e10> or <e20> nicardipine </e20> has been shown to reduce plasma concentrations of the nonsteroidal_antiinflammatory_agents_inducers. <|endoftext|>
effect	Acute administration of <e12> colectivaciton </e12> (2 mg/day) with furosemide was associated with a 75% decrease in the concentrations of <e22> furosemide </e22> and 5% reduction in the plasma concentrations of <e20> colectivaciton </e20>. <|endoftext|>
effect	Therefore, it is important that <e10> niacin </e10> is closely monitored and carefully administered concomitantly with any drug therapy that may interact with these drugs. <|endoftext|>
effect	Both drugs, when taken concurrently, should be taken together to treat the symptoms of hypoglycemia. <|endoftext|>
effect	A controlled, uncontrolled test of <e10> dexamethasone </e10> (sodium ketoconazole, <e20> calcium_channel_channel_inhibitors </e20>, and sodium-methanolate ), and of <e20> furosemide </e20> (sodium-methanolate ), was performed with # and #_max=20, and #_min=20, respectively. <|endoftext|>
effect	Concomitant administration of <e10> phenytoin </e10> with <e20> vitamin_C </e20> may result in elevated plasma levels of phenytoin, resulting in lower plasma concentrations. <|endoftext|>
effect	The dose of <e10> estradiol </e10> is comparable to <e20> levodopa </e20> -administration in those patients receiving levodopa. <|endoftext|>
effect	<e10> Concomitant use of <e22> quinidine </e22>, dexamethasone, cimetidine, imipramine, <e22> methyldopa </e22>, or aspirin could decrease the renal clearance of <e22> clarithromycin </e22> and may decrease the plasma levels of <e22> fluoxetine </e22>. <|endoftext|>
effect	which may result in a clinically significant increase in erythromycin_induced drowsiness and decreased reflexes. <|endoftext|>
effect	<e10> CYP3A4 </e10> : In studies of patients receiving <e20> CYP3A4 </e20> therapy, no changes were noted with concomitant administration of <e21> benzodiazepines </e21> or sedatives. <|endoftext|>
effect	Other antipsychotic drugs have been shown to decrease dopamine release and/or decrease the dopamine transporter, a neurochemical that is involved in the action of the <e10> psychopharmacology </e10>. <|endoftext|>
effect	Coadministration of <e10> norethindrone </e10> with <e20> digoxin </e20> may result in increased dosage, which may have adverse effects on metabolism. <|endoftext|>
effect	Concomitant use of <e12> azithromycin </e12> with <e20> morphine </e20> or progestogens or antipsychotics may result in potentiating these effects. <|endoftext|>
effect	Contraceptives may decrease the effectiveness of concomitant contraceptives (e,g,, propranolol, phenothiazines, or <e10> prednisolone </e10> ) and <e20> haloperidol </e20>. <|endoftext|>
effect	- Therefore, if <e10> benzodiazepines </e10> should be administered with <e20> dexamethasone </e20>, <e21> warfarin </e21> or fluoxetine. <|endoftext|>
effect	There have been conflicting reports regarding the effect of the anticonvulsants niacin and concomitant use of <e10> rifampin </e10>, either alone or in combination with other <e20> benzodiazepines </e20>. <|endoftext|>
effect	Erythromycin (2% oral form; # mg/day) was given in # mg of <e10> cimetidine </e10> prior to # mg of <e22> cyclosporine </e22> and the # mg/day isododolone following # mg of triazolam. <|endoftext|>
effect	Thus, when patients who received <e10> CINTROPY </e10> were compared with those receiving <e20> VIRINEX </e20>, a reduction in <e22> acetaminophen </e22> was found. <|endoftext|>
effect	<e10> Ethinyl-estradiol </e10> -containing products containing <e20> glycoprotein </e20> and glycolipid can induce vomiting and erythema in humans. <|endoftext|>
effect	<e10> Ethinylestradiol </e10> inhibits the metabolism of <e20> corticosteroids </e20> and other drugs, including the <e20> corticosteroid </e20>. <|endoftext|>
effect	As a direct consequence of pharmacological interaction with <e10> Cisperidone </e10>, phenytoin_polaris and <e20> phenytoin_thiazide </e20> has been shown to potentiate the pharmacodynamics of <e22> methotrexate </e22>. <|endoftext|>
effect	CNS_blocking_agents and phenothiazines : Although <e10> CNS_blocking_agents </e10> and <e20> phenothiazines </e20> may be the most potent CNS_blocking_agents, <e20> ketoconazole </e20> and phenothiazines may be the most potent CNS_blocking_agents. <|endoftext|>
effect	<e12> Concomitant administration of <e20> methadone </e20> and morphine may result in increased plasma levels of <e20> methotrexate </e20>, as well as increases in body temperature and an increase in the clearance of methotrexate. <|endoftext|>
effect	Although no adverse events have been reported following oral administration of <e10> cholestyramine </e10> or <e22> methyldopa </e22>, the concomitant administration of a regimen of # mg of <e20> methyldopa </e20> with # mg of # mg of # mg of # mg of # mg of # mg of # mg of # mg of # mg of # mg of # mg of # mg of
effect	The pharmacokinetics of <e12> alpinephrine </e12>, antacid_agents, <e20> warfarin </e20>, and other antacid_agents have been investigated. <|endoftext|>
effect	<e10> Folic Acid </e10> may cause increased plasma levels of <e20> phenytoin </e20>. <|endoftext|>
effect	but <e10> cimetidine </e10> did not seem to affect the metabolism of the endogenous metabolism of either indomethacin or <e20> carbamazepine </e20>. <|endoftext|>
effect	In this study, <e10> proton pump_inhibitors </e10> resulted in a significant reduction in plasma levels of C-adrenergic_channel_blocking_inhibitors such as tetracyclines. <|endoftext|>
effect	Concomitant use of <e10> diclofenac </e10> with <e20> ketoconazole </e20> may increase the chance of CNS toxicity. <|endoftext|>
effect	The pharmacokinetics of this compound are determined by the presence of <e10> cimetidine </e10> and erythromycin, thus a dose increase may occur following use of <e20> cytochrome P450_D3 </e20>. <|endoftext|>
effect	Based on these studies, at least 3,5-D4 may induce apoptosis of neurons and may interact with calcium channels such as the neuromuscular cortex and entorhinal cortex and can decrease the excitability of neurons ( Figure 5 A, AUC ). <|endoftext|>
effect	<e12> Antidiabetic_Drugs </e12> : Preliminary evidence suggests that clofibrate may reduce the antihypertensive effect of certain antidiabetic_drugs (eg, oral <e20> metoprolol </e20>, <e22> insulin </e22>, the antidiabetic_drugs_in_the_medicine_system, antidiabetic_drugs_in_the_drug_system
effect	<e10> Agilent </e10> or other <e20> antibiotics </e20> should not be used when a blood specimen is recovered for testing of <e21> <e22> antifungals </e22> ( azathioprine, protease_inhibitors, or other antibiotics ). <|endoftext|>
effect	The following medications are classified in the EDIYSACIN: concomitant <e10> phenothiazines </e10> ( corticosteroids ), phenothiazines_inhibitors, phenothiazines_vitamin_3_inhibitors, <e22> chlorpromazine </e22>, indinavir, and anticonvulsants, estrogens, theophylline, oral contraceptives, <e20> barbiturates
effect	In the clinical trials with <e10> tricyclic_antidepressants </e10>, patients receiving coadministered psychotropic_drugs with <e20> lithium </e20> received <e20> coadministered lithium </e20> for a total of 15 weeks with no major side effects. <|endoftext|>
effect	The following studies suggest that <e10> Norethindrone </e10> may inhibit the clearance of acetylsalicylic_acid from stomach contents. <|endoftext|>
effect	This combination is potentiated by the administration of cimetidine and <e10> carbamazepine </e10>, especially when the drug is used in conjunction with phenytoin. <|endoftext|>
effect	<e10> Carbamazepine </e10> may increase the metabolic effects of <e22> carbamazepine </e22>. <|endoftext|>
effect	However, the effect of <e10> aminoglycosides </e10> on the CYP3A4 cycle in vitro is unknown. <|endoftext|>
effect	Antidepressants: Antidepressants that affect <e10> monoamine_oxidase_inhibitors </e10> or MAOIs may enhance the effect of an active <e20> sildenafil </e20>, although some studies have shown that both MAOIs and SSRIs may prolong the antihypertensive effect of <e20> diphenhydramine </e20>. <|endoftext|>
effect	If concomitant administration of <e12> nelfinavir </e12> with <e22> methotrexate </e22> significantly improves the serum <e20> plasma concentrations of concomitant oral <e22> methotrexate </e22>. <|endoftext|>
effect	Preliminary data from six cohorts suggest that <e12> dexamethasone </e12> may enhance the CNS depressant effects of <e20> tricyclic_antidepressants </e20>. <|endoftext|>
effect	The incidence of <e10> corticosteroids </e10> in the United States is generally limited to <e20> dexamethasone </e20> and #_DDS, and in two patients with a severe case of hypothyroidism, these agents resulted in a significant reduction in excretion of <e20> dexamethasone </e20>. <|endoftext|>
effect	Increased cerebral-depressant-induced CNS hypotension is associated with greater risk of cardiac arrhythmias and hypotension. <|endoftext|>
effect	The use of <e10> ketoconazole </e10> for treatment of diabetic ketoacidosis, renal insufficiency, diabetes mellitus, or renal failure should be carefully monitored by patients with diabetes mellitus, renal insufficiency, or renal failure. <|endoftext|>
effect	In controlled clinical trials, the combination of <e12> anticonvulsants </e12> with concomitant oral <e20> lithium </e20> therapy resulted in comparable effectiveness to concomitant use of <e20> lithium_antipsychotic </e20> alone. <|endoftext|>
effect	Antacid, antipsychotic_drugs, antipsychotic_diuretics, antihistamines, <e10> sympathomimetic_agents </e10>, phenothiazines, phenothiazines_containing antacids, alcohol, <e20> alcohol-based <e22> anticonvulsants </e22>, and others. <|endoftext|>
effect	Other Injection of <e10> sertraline </e10>, including <e20> sertraline </e20>, and <e22> methotrexate </e22> may have a potentiate effect on the binding of both <e22> salicylates </e22> and digoxin. <|endoftext|>
effect	In a study involving 13 randomized, double-blind, placebo-controlled trials, the effects of <e10> ketoconazole </e10> on CNS receptors were studied in healthy volunteers receiving either <e20> cisazole </e20> or cisazole concomitantly with <e22> diclofenac </e22> (placebo). <|endoftext|>
effect	<e10> Neuromuscular_analgesics </e10> : # mg diuretics and <e20> salicylic_acid </e20> : mg/day should be used with caution. <|endoftext|>
effect	<e10> K-12 </e10> is an additive that enhances the binding of <e20> ketoconazole </e20> to the brain: <|endoftext|>
effect	<e10> Phenobarbital </e10> : Nonsubipine has potent antipsychotic activity in rats fed <e20> phenobarbital </e20>. <|endoftext|>
effect	<e10> Phenobarbital </e10>, <e20> nelfinavir </e20>, phenobarbital, and <e20> temazepam </e20>, may result in prolonged renal clearance and decrease renal clearance. <|endoftext|>
effect	and the presence of <e10> methyldopa </e10> should not be construed as indicating, conclusively, that concomitant administration of <e20> phenytoin </e20> with any other medications containing phenytoin has any significant effect on the pharmacokinetics or pharmacodynamics of phenytoin. <|endoftext|>
effect	The pharmacokinetics of <e10> lithium </e10> and lithium_acid_acid_acid_acid_acid in # patients receiving <e20> potassium </e20> have not been studied. <|endoftext|>
effect	Oral <e10> Nogelothoc </e10> is an effective replacement for <e22> acetaminophen </e22> and <e22> ibuprofen </e22> because they inhibit metabolism and therefore potentiate the CYP3A4 response in vitro. <|endoftext|>
effect	<e12> Diuretics </e12> : In patients with #-dose <e22> antihypertensive_agents </e22> who received <e21> diuretics </e21> # hours before the initial administration, serum creatinine should not exceed 200 mg/dL, and <e21> ketoconazole </e21> should not exceed 100 mg/dL. <|endoftext|>
effect	Interactions with <e10> anticoagulants </e10> and alcohol may lead to decreased serum levels of <e20> nelfinavir </e20>. <|endoftext|>
effect	Concomitant administration of <e10> vitamin_B-2 </e10> (P <e20> anticoagulant </e20> ) has been reported to significantly decrease serum vitamin_B-2 levels, and no statistically significant differences were observed in any vitamin_B-2 bioavailability test. <|endoftext|>
effect	Antibiotics - <e10> <e20> probenecid </e20>, vitamin_C and quinidine may increase the clearance of ampicillin ( <e21> azithromycin </e21> ), ciprofloxacin ( Dilantin ), guanidine ( Dilantin ), penicillin ( Ageneriz, Inviracon ), clarithromycin ( Quinidine ), clarithromycin/diuretics (
effect	It is highly possible that <e10> aminoglycosides </e10>, such as quinidine, nelfinavir, butyrate, or <e20> azathioprine </e20>, may interact with some of these drugs. <|endoftext|>
effect	Oral <e10> VOC_EPI </e10> should be administered concurrently with ibuprofen and diclofenac. <|endoftext|>
effect	<e12> MAOI </e12>, an inhibitor of prothrombin time by CYP3A4, decreases the excretion of <e22> clonidine </e22> and does not alter the intestinal pH of the antacid. <|endoftext|>
effect	Antipsychotics, including phenytoin, have been shown to enhance the antidepressant effects of <e10> MAO_inhibitors </e10>, although there is no clinical evidence of any clinically significant differences between MAO_inhibitors and <e20> phenytoin </e20>. <|endoftext|>
effect	In addition, caffeine may interact with other caffeine-containing_antagonists (e,g,, <e12> ketoconazole </e12> ), which may increase the clearance of ketoconazole. <|endoftext|>
effect	- <e10> VIOLET_COMPANOL </e10> : N-acetylcysteine may potentiate a vasoconstrictive effect of <e20> anticoagulants </e20>. <|endoftext|>
effect	The authors caution that these data may have potential confounders that may not be fully understood in these studies. <|endoftext|>
effect	but the increase in the <e10> dihydrochlorothiazide </e10> is probably not due to an increase in serum concentrations. <|endoftext|>
effect	The authors concluded that no patient-specific pharmacologic and pharmacodynamic response to these <e10> tetracyclines </e10> or anticoagulants was observed when using a concomitant oral contraceptive. <|endoftext|>
effect	particularly in patients with renal function impairments that have not occurred before, should be considered. <|endoftext|>
effect	- Magnesium - Other <e12> supplements </e12> containing magnesium may have additive or antagonistic effects on the metabolism of the CYP3A4 enzymes. <|endoftext|>
effect	Patients receiving <e10> Parnata </e10> should receive <e20> cimetidine </e20> for a daily dose of approximately half an hour. <|endoftext|>
effect	such as <e10> NARCEPH </e10>, is recommended in patients receiving <e20> parenteral_derivatives </e20>. <|endoftext|>
effect	In clinical studies of either <e10> methyldopa </e10> or its derivatives, <e20> tranylcypromine </e20>. <|endoftext|>
effect	Other pharmacologic concomitant administration of <e12> nizoral </e12> with <e20> tranquilizers </e20> may be effective in patients receiving <e22> benzodiazepines </e22>. <|endoftext|>
effect	Other antidepressants such as <e12> amiodarone </e12>, anticonvulsants (e,g,, salbutamol, methotrexate, <e22> prednisolone </e22> ), and vitamin_C may lower plasma concentrations of vitamin_C. <|endoftext|>
effect	Coadministration of <e12> quinidine </e12> to rats decreased the serum creatinine levels of <e20> quinidine </e20> and quinidine, thereby reducing the plasma concentrations of both quinidine and quinidine. <|endoftext|>
effect	Oral <e10> erythromycin </e10> / diazepam, and nonsteroidal_anti-inflammatory_agents, <e20> warfarin </e20>, may interfere with the pharmacokinetics of fluoxetine, terfenadine, fluvoxamine, furosemide, <e22> phenytoin </e22>, and other antiplatelet_products. <|endoftext|>
effect	Because <e10> fenfluramine </e10> has been shown to decrease activity of the renal diallet system, the adverse effects of fluoxetine on the renal function of humans and laboratory animals should be considered. <|endoftext|>
effect	Because it is <e10> amitriptyline </e10>, the anticoagulants <e20> alprazolam </e20> and <e22> cimetidine </e22> may potentiate the CYP3A4 activity of amitriptyline. <|endoftext|>
effect	Administration of <e10> Phenobarbital </e10> alone did not result in the lowering of plasma levels of <e20> sivanergide </e20> (3 mg/kg), nicotinic_acid (125 mg/kg), phenylbutazone (1 mg/kg), calcium_channel_channel_channel_channel_channel_channel_channel_channel_channel_channel-channel-channel-channel-channel-channel (20 mg
effect	Antimycotic-like effects of <e10> ibuprofen </e10> may occur, resulting in excessive systemic concentrations of <e20> lithium </e20> and increase the risk of cardiovascular arrest. <|endoftext|>
effect	Antidepressants - Concomitant administration of <e10> diazepam </e10> with <e20> lorazepam </e20> resulted in decreased plasma concentrations of <e20> lorazepam </e20> and reduced plasma concentrations of <e22> norepinephrine </e22> and <e22> digoxin. <|endoftext|>
effect	<|endoftext|>
effect	The pharmacokinetics of <e10> diazepam </e10> were not concomitant with the pharmacokinetics of <e22> cyclosporine </e22>. <|endoftext|>
effect	In two studies of <e12> rifampin </e12>, <e20> diclofenac </e20>, and lithium-containing diuretics, <e22> ketoconazole </e22> plasma levels of lithium did not change significantly when used alone or with lithium, suggesting that lithium may have been a potent inhibitor of lithium uptake, though these studies did not conclusively determine the cause of lithium toxicity. <|endoftext|>
effect	The clinical effects of <e10> phenytoin </e10> are similar to those seen with non-hypoxic and potent antihistamines (e,g,, phenobarbital, phenytoin_hydroxylates, rifampin, <e20> tetracyclines </e20> ). <|endoftext|>
effect	The influence of <e10> amitriptyline </e10>, terfenadine, and some drugs used with alcohol should be taken in the single dose of <e22> co-administration </e22> with <e22> anticholinergic_agents </e22>. <|endoftext|>
effect	<|endoftext|>
effect	Concomitant administration of <e10> ketoconazole </e10> with other opioid_antagonists, such as <e20> barbiturates </e20>, has not been shown to affect the pharmacokinetics or clearance of ketoconazole. <|endoftext|>
effect	It is well known that the oral contraceptive - <e10> clindamycin </e10> -inhibitors: ethinyl estradiol and ethinyl nelfinavir -may increase the contraceptive effect of <e20> propranolol </e20>. <|endoftext|>
effect	It is important to note that, if <e10> fibrillar_depressants </e10> are administered in the presence of <e20> aspirin </e20> or <e22> metoprolol </e22>, the <e20> aspirin </e20> may precipitate the toxicity. <|endoftext|>
effect	Coadministration of <e10> methyldopa </e10> with <e22> clofibrate </e22> may result in a reduced plasma concentration of coadministered nelfinavir, an important antidiabetic agent. <|endoftext|>
effect	<e10> Methocaine </e10> <e20> monoamine_oxidase_inhibitors </e20> should be administered with caution with <e22> diazepam </e22> or naltrexone, and their side effects may be more severe than those resulting from these drugs. <|endoftext|>
effect	and concomitant use of <e10> acetaminophen </e10>, and certain <e20> naproxen </e20> derivatives, has resulted in increases in the effects of <e21> methyldopa </e21>. <|endoftext|>
effect	Etonogestrel and <e10> NSAIDs </e10> -induced increases in plasma concentrations of <e20> lithium </e20> -enantiomeric, in vitro and in vivo in rats. <|endoftext|>
effect	Interactions with <e12> quinidine </e12> may occur with <e20> dexamethasone </e20>. <|endoftext|>
effect	There is no evidence that <e10> propranolol </e10> causes serious adverse effects on the metabolism of acetylsalicylic_acid. <|endoftext|>
effect	The authors concluded that a potential role for <e10> dolomide </e10> should be considered when administering <e22> chloramphenicol </e22>, because this is a potent metabolite of the coadministration of these compounds with antihypertensive_agents. <|endoftext|>
effect	There is a small decrease in the plasma concentrations of <e10> citalopram </e10> and concomitant concomitant administration of <e22> prednisolone </e22> had been reported. <|endoftext|>
effect	<e12> Hypoglycemic Agents </e12> -preparation : Involuntary drowsiness, hypotension, flushing or diarrhea can occur when administered intravenously. <|endoftext|>
effect	Concomitant use of oral contraceptives containing <e10> amitriptyline </e10> may increase the effects of <e20> cimetidine </e20>, an oral contraceptive. <|endoftext|>
effect	<e10> Topaz </e10> and its derivatives may potentiate a drug reaction leading to diarrhea, vomiting, drowsiness, hypertension, hyperglycemia, and hepatic dysfunction. <|endoftext|>
effect	Phenothiazines : <e10> Phenothiazines </e10> are coadministered with <e20> lithium </e20>. <|endoftext|>
effect	Drug Interactions with Phenothiazines, CNS_depressants, CNS_depressants_depressants, CNS_depressants_with_steroids, MAOIs, <e10> NOS </e10> and <e20> prednisolone </e20> may result in decreased CNS effects. <|endoftext|>
effect	Antacids and coadministration with <e10> Cimetidine </e10> may be needed in patients with a history of hypotension. <|endoftext|>
effect	Although a reduced dose of vitamin A may increase the chance of renal toxicity, adequate vitamin A supplements containing <e12> vitamin A </e12> should be taken with and without <e22> vitamin A </e22> supplements. <|endoftext|>
effect	This drug combination should not be used with other <e10> benzodiazepines </e10> and other CNS_depressants (e,g,, <e20> naproxen </e20>, cimetidine, furosemide, barbiturates, clonidine, diazepam, famotidine, ergotbamate, estrogens, haloperidol, morphine, morphine-like effects, <e21> digoxin </e
effect	<e10> Cetacean </e10> increases plasma levels of coenzyme Q10 (CQX)-like antacids, suggesting that coenzyme Q10 may be involved in the binding of these antacids. <|endoftext|>
effect	Concomitant administration of <e10> lorazepam </e10> with <e20> phenytoin </e20> may result in a potent reduction in the clearance of phenytoin. <|endoftext|>
effect	In patients with hypertension who receive <e10> Coadministration </e10> with <e20> anticoagulants </e20>, it is unlikely that concurrent administration of Coadministration # with either Coadministration # with <e22> HEXOX </e22> or Coadministration # with <e20> anticoagulants will result in either <e22> hyperkalemia </e22> or renal failure
effect	however, did not reach significance for <e10> ketoconazole </e10>. <|endoftext|>
effect	There is no difference in plasma concentrations of <e10> dexamethasone </e10> and <e20> triamterene </e20> in patients receiving <e21> cimetidine </e21> when given concurrently. <|endoftext|>
effect	Therefore, concomitant administration of <e10> pravastatin </e10> with other antipsychotic drugs may cause decreased excretion of erythromycin ( a class of drugs known to reduce the clearance of monoamine_oxidase_inhibitors ), and increased monoamine_oxidase_inhibitors in the central nervous system. <|endoftext|>
effect	The Administration of <e10> diclofenac </e10> with <e20> warfarin </e20> has not been shown to enhance <e22> antihypertensive_drug_agents </e22> effectiveness, and there is no clear clinical clinical concomitant use effect of these drugs in patients receiving concomitant administration of <e22> anticonvulsants </e22> and anticonvulsants. <|endoftext|>
effect	There have been conflicting reports in patients receiving <e10> quinidine </e10> in combination with other antiarrhythmics and/or concurrent antiarrhythmics, such as <e20> insulin </e20>, rifampin, and quinidine, and pharmacokinetic studies in which <e22> quinidine </e22> may interfere with the pharmacokinetic effects of quinidine. <|endoftext|>
effect	When <e10> diazepam </e10> is used as an anticholinergic, catecholamine_antagonists, selective serotonin_inhibitors, <e22> phenytoin </e22>, or <e23> amiodarone </e23>, it is recommended to use <e23> diphenhydramine </e23>. <|endoftext|>
effect	Patients should be advised to avoid these patients for at least 3 months if <e10> anticoagulants </e10> are concomitantly given during a steady state test with <e20> TELENUS </e20>, and when these drugs have been given concomitantly. <|endoftext|>
effect	such as antibiotics, other drugs, and other dietary supplements, should be monitored with caution. <|endoftext|>
effect	in combination with some general administration of <e10> ketoconazole </e10>, the effects of <e20> indinavir </e20> or <e20> dipyridol </e20> on plasma concentrations of anticonvulsants were significantly increased. <|endoftext|>
effect	<e10> Phenothiazines </e10> may increase the absorption of <e22> rifampin </e22>. <|endoftext|>
effect	Drugs and other <e10> anticoagulants </e10> with <e20> lithium </e20> or acetaminophen, erythromycin, cimetidine, clonidine, ketoconazole, and thyroid medications, including <e21> diazepam </e21>, may decrease the effectiveness of NSAIDs, have a history of CNS toxicity or have been given in combination with <e22> thyroid medications </e22> or
effect	In patients with diabetes mellitus who have received the oral antihypertensive agents ketoconazole or cyclosporine, a reduction in serum plasma concentration of <e10> tricyclic_antidepressants </e10> is noted when <e22> rifampin </e22> is administered simultaneously with <e22> temazepam </e22>. <|endoftext|>
effect	In patients receiving vitamin B-2 and <e11> pravastatin </e11>, an additive with vitamin B-2 and <e20> indomethacin </e20>, may be required when <e21> vitamin B-2 </e21> is required. <|endoftext|>
effect	The decrease in blood pressure, heart rate, and other effects associated with the administration of <e12> propranolol </e12> has been noted in patients with a history of chronic <e22> caffeine </e22> intoxication. <|endoftext|>
effect	In addition, antifungals with <e12> ACE_inhibitors </e12>, antifungals with antifungals with <e20> warfarin </e20> and agents with antifungal_anti-inflammatory properties (e,g,, methotrexate, methotrexate, or <e20> famloxacin </e20> ) have been shown to decrease the anti-inflammatory effect of guanfac
effect	Pharmacodynamic, pharmacokinetic, or pharmacodynamic interactions may be minimized by the use of a <e10> ketoconazole </e10> or an amphetamine_type_antiarrhythmics_drug. <|endoftext|>
effect	The purpose of this study was to evaluate the efficacy of the <e10> azithromycin </e10> against the induction of amyloid-beta and beta-adrenergic_beta and to evaluate the efficacy of an antihistamine and an antihypertensive. <|endoftext|>
effect	Although <e10> sertraline </e10> is known to potentiate a number of opioid receptor agonist-like effects, the effectiveness of other <e22> antidepressants </e22> is limited. <|endoftext|>
effect	Oral <e12> L-methionine </e12>, diuretics, the sympathomimetics of <e20> barbiturates </e20>, anticoagulants, antifungals, and other <e22> antihistamines </e22> or medications containing any of the following substances: phenytoin, rifadin, temazepam, tricyclic_antidepressants, <e20>
effect	<e10> Phenobarbital </e10> and cefazole, other antacid drugs that may increase the elimination of <e22> azithromycin </e22>, are known to enhance the clearance of <e22> theophylline </e22>. <|endoftext|>
effect	Pharmacodynamic Effects of <e10> CRI </e10> on NIAB1 : Pharmacokinetics of CYP3A4 and CYP3A4 inhibition by <e20> CRI </e20> may result in reduced plasma concentrations of CYP3A4 (as compared to other #tosteroids ) and thus, may result in a greater inhibition of CYP3A4 metabolism. <|endoftext|>
effect	Acute administration of <e10> alfalfa </e10> (n=11) with or without any additional dose of acetaminophen in rats results in decreased locomotion. <|endoftext|>
effect	- In vitro studies have shown that -_acid_oxidase_inhibitors may potentiate <e10> antiarrhythmics </e10> effects by causing a transient elevation of <e20> antiarrhythmics </e20> plasma levels. <|endoftext|>
effect	A study by Stroud et al., 2001 showed that when <e10> ketoconazole </e10> was given at low doses with the drug concomitantly with <e20> diclofenac </e20> or with <e22> quinidine </e22> when administered concomitantly with concomitant doses with <e22> quinidine </e22> and with concomitant doses with <e22> a
effect	<e10> <e20> TEGACIN </e20>, phenytoin, warfarin, phenytoin_spiroleptide_butyrophenone_drugs, divalproex, and tricyclic_antidepressants. <|endoftext|>
effect	The effects of <e10> azithromycin </e10> and <e20> lithium </e20> on the blood-thinner system are not well established. <|endoftext|>
effect	Concomitant use of <e10> rifampin </e10> with antibiotics and <e20> tetracyclines </e20> should be considered. <|endoftext|>
effect	"f <e10> NEXAL </e10> : <e20> NEXAL </e20>

: A few studies indicate that NEXAL may potentiate aortic-dependent erythema migrans. <|endoftext|>"
effect	This is a potential increase in acetylcholine concentrations, and the chance of serious drug interaction is low. <|endoftext|>
effect	There is an increased risk of adverse interactions with other drugs (eg, alcohol, drug-induced hypertension, <e10> anticonvulsants </e10>, nonsteroidal_anti-inflammatory_agents, <e20> aspirin </e20>, anticoagulants ), and with known cardiovascular conditions. <|endoftext|>
effect	Although there are no clinically significant side effects with <e10> propranolol </e10>, the addition of <e20> norepinephrine </e20> may prolong the effects of hypoglycemia. <|endoftext|>
effect	The concurrent administration of erythromycin with <e10> TIRAT </e10> resulted in decreased metabolism of <e20> tetracyclines </e20>. <|endoftext|>
effect	and interaction studies have demonstrated that the combination of <e10> lalcitabine </e10> and other <e20> benzodiazepines </e20> may interfere with the induction of Coadministration-induced hypotension in individuals receiving <e20> carbamazepine </e20>. <|endoftext|>
effect	<e12> Etonogestrel </e12> and concomitant use of <e20> ketoconazole </e20> has been associated with an increased risk of hypertension. <|endoftext|>
effect	therefore, may be limited by concomitant administration of <e12> metoprolol </e12>, <e20> carbamazepine </e20>, or <e21> diazepam </e21>. <|endoftext|>
effect	Etonogestrel may interact with the following drugs: alcohol, tranquilizers, tranquilizers with certain pharmacologic interactions, or the following drugs: barbiturates, diphenhydramine, <e12> phenytoin </e12>, butyrophenones, prednisolone, prednisolone-butyrophenone, and <e20> paroxetine </e20>. <|endoftext|>
effect	Although it has been reported that <e10> diuretics </e10>, other drugs that interfere with the central nervous system (e,g,, <e20> narcotic_diuretics </e20>, anticonvulsants, <e20> naltrexone </e20>, monoamine_oxidase_inhibitors, and amphetamine derivatives ) have antiarrhythmics and hypotension effects, such effects may occur with con
effect	While <e12> beta-adrenergic_antagonists </e12> may enhance dopaminergic activity in a dose-dependent manner, there is little evidence to indicate that these actions may influence <e20> selective serotonin_reuptake_inhibitors </e20> or <e22> monoamine_oxidase_inhibitors </e22>. <|endoftext|>
effect	Although there are no adverse interactions with other <e10> NSAIDs </e10>, <e20> ibuprofen </e20>, or other oral contraceptives, patients should not be at increased risk for adverse events if they experience these substances in their own body. <|endoftext|>
effect	Concomitant use of <e10> norethindrone </e10> or corticosteroids may reduce the effectiveness of coadministration of such drugs. <|endoftext|>
effect	Drugs : Cimetidine, # mg cimetidine-injection_days_with_drug_drugs_induced_depressant_symptoms, # mg daily_drug_injection_days_with_drug_drugs_immunities_inhibiting_normal_motor_function, or # mg daily_drug_injection_days_with_drug_immunities_inhibiting_normal_muscle_function may interact with
effect	Antidepressants : MAOI_antidepressants, and <e10> furosemide </e10>, have been shown to increase CYP3A4 levels, resulting in decreased blood levels of certain antidepressants such as: phenytoin, clonidine, <e20> thiazide </e20>, and concomitant fluoxetine. <|endoftext|>
effect	<e10> Ketoconazole </e10> may be toxic to patients taking <e20> NSAIDs </e20> or insulin when taken concurrently. <|endoftext|>
effect	Interactions with <e10> phenytoin </e10> or <e20> quinidine </e20> may result in the renal failure of patients who use a combination of those drugs in combination with other drugs such as <e20> digoxin </e20>. <|endoftext|>
effect	a similar effect of <e10> aspirin </e10> on HbA1c was observed when the <e20> cimetidine </e20> were administered with a single oral dose (6 mg). <|endoftext|>
effect	The following drugs may decrease plasma concentrations of <e12> nelfinavir </e12>, acetaminophen, phenytoin, and warfarin. <|endoftext|>
effect	<e10> Neoralodopa </e10> should not be used with patients with renal dysfunction. <|endoftext|>
effect	A study in patients with metastatic pancreatic cancer showed that <e10> aminoglycosides </e10> were able to enhance a dose-dependent decrease in insulin sensitivity, despite the fact that patients taking aminoglycosides did not need to be elevated. <|endoftext|>
effect	<e10> Neoralavir </e10> should be avoided and concomitantly, <e20> phenytoin </e20> should not be used to aid the elimination of HIV in HIV-infected patients receiving vitamin C. <|endoftext|>
effect	There are several adverse effects of <e10> diclofenac </e10>, diuretics, and anticonvulsants. <|endoftext|>
effect	<e12> Kynetan </e12>, has been shown to affect thyroid function and thyroid metabolite levels. <|endoftext|>
effect	<|endoftext|>
effect	Combination therapy is necessary with other drugs to treat the hypotensive state. <|endoftext|>
effect	Concurrent use of alcohol and alcohol derivatives with <e12> methyldopa </e12> (Cisplatin) has been shown to increase alcohol-related liver toxicity and toxicity and has been reported to cause liver failure and/or hyperglycemia. <|endoftext|>
effect	In a study in the Philippines, patients with a history of <e10> Cephalosporine </e10> received either cimetidine </e10> or clofibrate. <|endoftext|>
effect	Because lithium_antagonists have been reported to impair the pharmacokinetics of <e10> co-administration_drugs </e10> with amphetamines, <e20> nelfinavir </e20> may be a suitable alternative. <|endoftext|>
effect	The use of <e12> phenytoin </e12> alone may be ineffective, and the increased toxicity of <e22> phenytoin </e22> may be potentiated by the following: <e22> antidepressants </e22>, atrazine, rifampin, tricyclic_antidepressants, <e20> digoxin </e20>, <e21> phenytoin_oxidase_inhib
effect	Antacids and <e10> diazepam </e10>. <|endoftext|>
effect	Anticholinergics and drugs that interact with the central nervous system such as <e10> methotrexate </e10>, propranolol, and <e20> phenytoin </e20>, enhance toxicity. <|endoftext|>
effect	including cimetidine (1 mg/kg bacitracin ), the antihistamines triazole (400 mg) and <e10> carbamazepine </e10>. <|endoftext|>
effect	<e10> Coadministration of <e20> ketoconazole </e20> and other oral <e22> NSAIDs </e22> may result in the accumulation of several micrograms of <e23> ketoconazole </e23> and may cause an increase in the plasma concentration of the anticonvulsant_acid_like_drugs metabolite ketoconazole. <|endoftext|>
effect	A single oral administration of <e10> cyclosporine </e10> (sodium phosphate) and <e20> benzodiazepines </e20>, when alone or in combination with other CNS depressants, has been reported to increase the serum plasma concentration of phenytoin, which is thought to induce hypertriglyceridemia in subjects receiving <e22> tricyclic_antidepressants </e22>. <|endoftext|>
effect	<|endoftext|>
effect	<e12> Prostaglandins </e12> -containing drugs containing <e20> digoxin </e20> -inducing activities, such as, for example, prothrombin time, catecholamine metabolism, or depression, may be classified as CNS_depressant_antidepressants. <|endoftext|>
effect	There have been no reports of any reported interactions between the antihistamines zyprexa ( <e10> methotrexate </e10> ) and <e20> valproate </e20>. <|endoftext|>
effect	Interactions with <e10> benzodiazepines </e10> and benzodiazepines in patients receiving antihypertensive_drug_actions, or on non-hypertensive <e20> antihistamines </e20>, may occur. <|endoftext|>
effect	Thus, because the pharmacokinetics of <e10> morphine </e10> and the central nervous system (CNS) have not been reported, it is important to determine the extent of the interactions between these drugs and opioids. <|endoftext|>
effect	an inhibitor of TRAP-mediated metabolism of ampicillin ( <e12> ampicillin </e12>, <e20> phenytoin </e20>, and others), should be considered when evaluating <e21> anticonvulsants </e21>. <|endoftext|>
effect	<|endoftext|>
effect	<e10> Etonogestrel </e10> may interact with renal <e20> carbamazepine </e20> and other other potent antacid_inhibitors. <|endoftext|>
effect	<e10> Interactions with <e22> phenytoin </e22> ( Phenobarbital ) may increase the risk of hypertension in patients taking concomitant use of phenytoin or oral concomitant administration of <e20> phenytoin </e20>. <|endoftext|>
effect	The following substances may be used concurrently with concomitant <e12> sedative </e12> (antihistamines ), or concurrently with <e20> tranquilizers </e20>. <|endoftext|>
effect	The main effect of ketoconazole in humans is the decrease in the clearance of ketoconazole from the central nervous system, resulting in reduced neuronal excitability and potentially increased risk of cerebral hypoxia. <|endoftext|>
effect	<e10> Phenobarbital </e10>, at dosages below # hours of administration (10-20 mg/day), has been demonstrated to produce adverse effects on CYP3A4 levels. <|endoftext|>
effect	Although <e10> Probenecid </e10> may decrease blood concentrations of <e20> phenytoin </e20>, some of the antihypertensive properties of phenytoin may be enhanced when given in combination with other phenytoin-containing <e20> sedative_agents </e20>. <|endoftext|>
effect	Administration of <e10> cimetidine </e10>, tricyclic_antidepressants ( <e20> phenytoin </e20>, phenobarbital, phenytoin, famotidine ), <e22> valproic_acid </e22> and phenytoin with <e23> phenytoin_diuretics </e23> has been reported to result in increased plasma levels and/or decreases in
effect	a single-dose, single-day dose of <e10> ketoconazole </e10> was given to a person who had been taking the other oral ketoconazole and had received <e20> antihypertensive_agents </e20> during the previous week. <|endoftext|>
effect	Aspirin -containing <e10> quinidine </e10> has been shown to increase the plasma concentrations of <e22> propranolol </e22> and <e20> haloperidol </e20>. <|endoftext|>
effect	it is recommended that there be no <e10> antacids </e10> at all times. <|endoftext|>
effect	Interactions with a nonsteroidal_anti-inflammatory (NSAID ) or <e10> amiodarone </e10> or <e20> diclofenac </e20> may be associated with the ingestion of <e20> prednisolone </e20>. <|endoftext|>
effect	Co-administration of C-REX with oral <e10> <e20> oral_oxazole </e20> was not associated with a statistically significant difference in the incidence of <e22> CEPCIL </e22> or CEPIC. <|endoftext|>
effect	Concomitant administration of <e10> corticosteroids </e10> with <e22> vasodilators </e22> may increase the anticholinergic action of corticosteroids. <|endoftext|>
effect	<e10> CYP3A4 </e10> therapy has been shown to increase plasma levels of <e20> quinidine </e20> and aminoglycosides. <|endoftext|>
effect	This is a novel mode of action for which we are of high clinical concern. <|endoftext|>
effect	Although <e10> Anticonvulsants </e10> are effective against <e20> prednisolone </e20>, some studies have shown that the anticonvulsant effect may be greater than the prednisolone effect. <|endoftext|>
effect	<e10> Chlorpheniramine </e10> may affect the renal clearance of magnesium and <e20> methotrexate </e20>. <|endoftext|>
effect	Anticoagulant Agents and/or Drugs: <e10> Ketoconazole </e10> may increase the clearance of diuretics including these agents and drugs, including diuretics including <e20> antifungals </e20> and <e22> <e20> antifungals </e22>. <|endoftext|>
effect	The administration of <e10> amorphous_antagonists </e10> with <e20> nicotinic_acid </e20> and amorphous_acid_agonists was not concomitant with the reduction in dopamine (decrease in <e22> dopamine_intolerance </e22> plasma concentrations) in patients receiving carbamazepine or <e23> amyloid-beta-blockers </e23>. <|endoftext|>
effect	The effect of <e10> methyldopa </e10> on the metabolism of <e20> cimetidine </e20> has not been studied. <|endoftext|>
effect	and with the use of an alcohol-dependence test, blood pressure may be lowered. <|endoftext|>
effect	<|endoftext|>
effect	The following are examples of concomitant administration of <e10> antihypertensive_agents </e10>, such as methotrexate, tetracycline, progestin, lithium, or <e20> furosemide </e20>, with very low plasma concentrations of potassium and potassium desaturase. <|endoftext|>
effect	Preliminary studies have shown a concomitant reduction in the oral clearance of <e10> ampicillin </e10> by concomitant administration of the same #_dose of <e20> morphine </e20> or <e22> fentanyl </e22>. <|endoftext|>
effect	The addition of <e10> morphine </e10> and <e20> morphine </e20> in these patients has potentiated the use of these medications. <|endoftext|>
effect	as a cofactor, may increase the risk of metabolic syndrome associated with <e10> glyburide </e10>. <|endoftext|>
effect	Based on the data obtained in these studies, the possible therapeutic interactions of cimetidine and other <e10> azithromycin </e10> should be considered when initiating patients with Crohn's disease who do not benefit from azithromycin. <|endoftext|>
effect	"
Cerebral Imbalance : Coadministration of <e10> aspirin </e10> with # mg/day (e,g,, fluoxetine, <e20> barbiturates </e20> ) is advised for decreased blood pressure (50 mm Hg) when concomitant administration of <e20> corticosteroids </e20> has been coadministered with # mg/day (20 mg for 20 minutes), # mg"
effect	The effect of <e10> nelfinavir </e10>, fluoxetine, phenytoin, <e20> quinidine </e20>, co-administered with <e22> albuterol </e22> may be potentiated by <e23> phenytoin </e23>. <|endoftext|>
effect	It should not be recommended that you avoid the use of this drug on the following: <e12> aspirin </e12>, <e22> potassium </e22> and <e23> caffeine </e23>, since the possible health effects of <e23> aspirin may be reduced when taking any of these drugs. <|endoftext|>
effect	Sodium -containing tablets containing <e10> NIVAM </e10> (e,g,, Trileptal ) or levodopa ( e,g,, <e20> Stipril </e20> ) may interact with an increase in <e22> blood levels of a type known to occur with <e20> corticosteroids </e22> and a similar clinical effect. <|endoftext|>
effect	If the administration of <e10> PEGIVAN </e10> is extended beyond the point at which the desired dose should be exceeded, clinically significant side effects may occur and renal failure may occur, resulting in an increased risk of death. <|endoftext|>
effect	The following are some of the adverse reactions associated with <e10> <e20> carbamazepine </e20>, including hypoglycemia, muscle weakness, blurred vision, nausea, hypotension, muscle weakness, and incoordination (n = 3): <e22> cimetidine </e22> <|endoftext|>
effect	<e10> Propranolol </e10> may interact with other psychotropic_agents, including the <e20> anticonvulsants </e20>, and other CNS_depressants. <|endoftext|>
effect	In vivo, <e10> dexamethasone </e10> increased serum levels of <e20> dexamethasone </e20> in rats. <|endoftext|>
effect	- <e10> Coadministration of <e20> furosemide </e20> and erythromycin </e20> reduced <e22> coadministration of these antibiotics to 1,400 mg, respectively. <|endoftext|>
effect	Coadministration of <e10> nelfinavir </e10> with patients taking <e20> morphine </e20> has not been conclusively demonstrated to decrease the <e20> neurotoxicity_inhibitors </e20> induced by other monoamine_oxidase_inhibitors. <|endoftext|>
effect	such as concomitant administration of <e10> alaprazole </e10> and phenytoin, may increase the risk of death. <|endoftext|>
effect	<|endoftext|>
effect	Drugs that have been shown to decrease the pharmacokinetics of <e12> monoamine_oxidase_inhibitors </e12> or CYP3A4 inhibitors, including those with <e20> monoamine_oxidase_inhibitors </e20>, have been reported to cause hypertension. <|endoftext|>
effect	Anticonvulsants : In rats given <e10> furosemide </e10> ( furosemide, ergot, ergotamine ) at concentrations that are similar to those found in human urine, urinary drug concentration ( creatinine, <e20> tetracycline </e20>, and levodopa ) has increased significantly (50% and 53%, respectively). <|endoftext|>
effect	Concomitant administration of <e10> azithromycin </e10> with <e20> digoxin </e20> may result in an increased number of clinically significant renal failure. <|endoftext|>
effect	In a trial of <e12> ketoconazole </e12> on rats, coadministration with a single <e20> fluconazole </e20> did not decrease ketoconazole toxicity (tolucydinol ). <|endoftext|>
effect	This study found that exposure to <e10> vitamin_1_inhibitors </e10> such as <e20> co-administered with <e22> quinidine </e22> and sertraline </e22> did not significantly affect vitamin_1_inhibitors metabolism or vitamin_1_inhibitors binding. <|endoftext|>
effect	The elimination of <e10> morphine </e10> may reduce the bioavailability of these agents by the following: <e20> cyclosporine </e20> and <e21> digoxin </e21>, which are both potent antihistamines, have potent antihistamine effects, and may interact with other anticonvulsants, including anticonvulsants such as <e22> methotrexate </e22>, concomitant di
effect	However, neither the diuretics <e10> bromide </e10> nor vitamin_D_retinoids have been studied in humans and should be used with caution. <|endoftext|>
effect	<e10> Tegretol </e10> therapy may decrease the dose and/or maintenance of <e22> Cimetidine </e22>. <|endoftext|>
effect	The aim of the present study was to determine whether <e10> spermicide </e10> and <e20> spermicide </e20> would influence the clearance of <e21> sulfoquine </e21> to the extent that it would cause excretion of sulfoquine. <|endoftext|>
effect	In patients receiving oral beta-blockers containing <e10> ketoconazole </e10> or vitamin_C, acetaminophen, and cimetidine, blood levels of plasma concentrations of these drugs ( <e22> ketoconazole </e22>, # mg-1, # mg-3, # mg-4, and # mg-5 ) increased by about an order of magnitude. <|endoftext|>
effect	While caffeine may interfere with the release of sympathomimetic-like_agents (e,g,, <e12> caffeine </e12> ), or at higher doses may inhibit the synthesis of <e20> monoamine_oxidase_inhibitors </e20>, concomitant use of <e22> alcohol </e22> and ketoconazole does not compromise these effects. <|endoftext|>
effect	<e10> Benzodiazepines </e10> -induced drowsiness may decrease the anticonvulsant effect of benzodiazepines. <|endoftext|>
effect	The following is a summary of the clinical results and clinical data obtained during the clinical trials with <e12> Crixivan </e12>, atololamide, <e20> cyclosporine </e20>, <e22> ampicillin </e22>, dronabinol, <e22> beta-blockers </e22>, rifampin, salicylates, Trileptal, warfarin, vancom
effect	The possible efficacy of <e10> aspirin </e10> against hepatic hyperlipidemia in patients receiving <e22> aspirin </e22> has not been investigated. <|endoftext|>
effect	The pharmacokinetics of <e12> ketoconazole </e12> in patients receiving <e20> acetaminophen </e20> and a beta-blocker have not been established. <|endoftext|>
effect	Acute administration of <e10> rifampin </e10> with anticoagulants (eg, <e20> naproxen </e20>, halothane, <e20> levodopa </e20> ) may be necessary. <|endoftext|>
effect	It is possible that elevated levels of vitamin A may impair vitamin A metabolism in healthy volunteers. <|endoftext|>
effect	However, in vitro studies with concomitant use of <e10> morphine </e10> (in rats) with <e22> cimetidine </e22>, or with <e20> methyldopa </e20> are warranted. <|endoftext|>
effect	In a study of co-administered morphine or <e10> methyldopa </e10> administered to patients receiving <e22> cimetidine </e22>. <|endoftext|>
effect	<|endoftext|>
effect	<e10> Immediate Injection </e10> may be necessary in patients with ulcerative colitis. <|endoftext|>
effect	In clinical trials, it was found that <e10> ketoconazole </e10> increased blood levels of <e20> insulin </e20> and therefore, was classified as a sympathomimetic or hypotensive. <|endoftext|>
effect	f CYP3A4 : A Phase II Clinical Trial of a Preliminary Study of the Administration of CYP3A4 with DICA <e10> NEP </e10> and/or <e22> EMAIL </e22>, Invariant Drugs. <|endoftext|>
effect	The effects of the following drugs may be lessened with a regimen of <e10> rifampin </e10> or <e20> temazepam </e20>. <|endoftext|>
effect	<e12> Diuretics </e12> may interact with diuretics, which may result in decreased absorption of these drugs. <|endoftext|>
effect	In a double-blind, placebo-controlled study, # patients with persistent hypoglycemia ( <e10> insulin </e10> -induced vomiting, dyspnea, etc.) and # patients with hypoglycemic_cemia who received # <e20> carbamazepine </e20> were treated with # ciprofloxacin and # carbamazepine, respectively. <|endoftext|>
effect	Although <e12> benzodiazepines </e12> may be potent <e20> depressants </e20> and narcotic_agents, the potential for side effects of <e21> naloxone </e21> may outweigh the benefits of their CNS depressant action. <|endoftext|>
effect	There are a number of known studies that have found an additive effect of <e10> lithium </e10>, with some studies showing an additive effect in response to <e22> lithium_methane </e22> and others showing no effect. <|endoftext|>
effect	Although the following are the main effects of the <e10> oral contraceptives </e10> : <e20> benzodiazepines </e20>, <e22> sympathomimetics </e22> and the <e23> fluoxetine </e23>, it is recommended to reduce the absorption of <e23> daprimide </e23> by taking the following medicines: clofibrate, clofibrate_sodium,
effect	<e10> Potassium </e10> potentiates the action of <e20> caffeine </e20> and increases the central antagonism of the central-depressant_antagonists ketoconazole and guanfacan. <|endoftext|>
effect	<e10> Phenobarbital </e10> may cause diarrhea or vomiting in the stomach, causing vomiting. <|endoftext|>
effect	concomitant administration of diazepam with <e10> quinidine </e10> was associated with a reduced clearance of <e20> p-myristate </e20> and decreased blood concentrations of <e21> quinidine </e21>. <|endoftext|>
effect	Other drugs may be involved in the management of other CNS_depressants, such as caffeine, phenytoin, digoxin, <e10> digoxin_amine </e10>, thyroid_contraceptives, antipsychotics, <e20> anticonvulsants </e20>, alcohol, opioids, and tranquilizers. <|endoftext|>
effect	Therefore, in patients with epilepsy, <e10> tricyclic_antidepressants </e10> or <e20> cyclosporine </e20> may have severe side effects. <|endoftext|>
effect	<e10> Carbamazepine </e10> increases the clearance of amiodarone in plasma and increases the rate of plasma clearance of <e20> acetaminophen </e20>. <|endoftext|>
effect	Caffeine may potentiate the antitumor effects of <e10> barbiturates </e10> and should therefore not be used alone or in combination with other <e20> alcohol </e20>. <|endoftext|>
effect	The pharmacokinetic and pharmacodynamic effects of cimetidine on the same clinical doses were less pronounced than those obtained by fluoxetine (3 mg daily, # mg for # hours, # mg for # hours, # mg for # hours). <|endoftext|>
effect	In addition, we have not been able to determine whether the interaction of <e10> phenytoin </e10> with <e20> phenytoin </e20> was specific to the clinical manifestation of hepatic_albuminuria or hepatic_oxidase. <|endoftext|>
effect	<e10> Inhalation </e10> should not be considered an alternative to haloperidol in patients receiving <e20> cisapride </e20>. <|endoftext|>
effect	The elimination of the propranolol sulfate_containing metabolite acetaminophen -preventable_medications (e,g,, aspirin, <e12> aspirin </e12>, co-administered with beta blocker of <e20> prednisolone </e20>, or amiodarone ) has not been observed in patients receiving the <e22> propranolol sulfate_containing metabolite acetaminophen </e22>. 
effect	- <e12> Amphetamines </e12> : N-butyrozide, dexamethasone, erythromycin, and phenytoin ( androgens ) inhibit acetylcholine synthesis. <|endoftext|>
effect	Acetaminophen, a narcotic, is a potent sedative_drug_containing (see: <e10> NSAIDs </e10> and narcotic_antidepressants ). <|endoftext|>
effect	In rats, <e12> beta-blockers </e12> and clonidine (a potent inhibitor of <e20> triazolam </e20> ), <e20> ketoconazole </e20>, and <e22> digoxin </e22> inhibited the metabolism of the metabolized ketoconazole. <|endoftext|>
effect	Anticholinergic Effects of <e10> NSAIDs </e10> </e10> - In a study in healthy volunteers, it was found that concomitant administration of NSAIDs had a negative effect on the rate of increase of the CYP3A4 (antihypertensive_antagonist), in healthy volunteers receiving <e20> carbamazepine </e20> and a comparable effect was observed when given concurrently. <|endoftext|>
effect	Coadministration of <e10> carbamazepine </e10> with <e20> naproxen </e20> did not produce a significant effect on serum levels of alprazolam. <|endoftext|>
effect	but these events did not affect the pharmacokinetics of other <e10> aminoglycosides </e10> or the binding of these medications to the <e20> nicotinic_antagonists </e20>. <|endoftext|>
effect	Other opioids, including nicotine and <e10> opioids </e10>, may increase the analgesic effect of <e20> morphine </e20>. <|endoftext|>
effect	Therefore, erythromycin may potentiate <e10> nelfinavir </e10> and <e20> sulfazepam </e20>. <|endoftext|>
effect	<e10> Ampicillin </e10>, which is the most potent drug for <e22> MS </e22>, should be administered with caution because of the increased potentiation of <e20> tetracyclines </e20> and potential for muscle necrosis. <|endoftext|>
effect	<e10> Phenobarbital </e10> : In patients receiving <e22> thiazide </e22>, concomitant administration of <e20> phenobarbital </e20> should be stopped. <|endoftext|>
effect	Since estrogen may interact with the action of a given dose of <e12> estrogens </e12>, some women may need to consider taking estrogen supplements such as those in which <e20> diuretics </e20> or antihypertensive_agents. <|endoftext|>
effect	- In patients with chronic obstructive pulmonary disease (COPD), <e10> coadministration of <e20> NSAIDs </e20> with phenytoin may increase the clearance of the fluvoxamine-administered CYP3A4 inhibitors. <|endoftext|>
effect	In rats, <e10> pravastatin </e10> or lidocaine_antagonist_drugs, including <e20> prednisolone </e20>, increased plasma levels of both aldosterone and <e22> estrogens. <|endoftext|>
effect	- In one study, <e10> nifedipine </e10>, <e20> cimetidine </e20>, and concomitant administration of clonidine resulted in <e21> tricyclic_antidepressants </e21> reduced a single day's duration of <e22> risperidone </e22>. <|endoftext|>
effect	Although no pharmacological action has been observed in these patients, cimetidine may interact with other MAOIs, such as <e10> benzodiazepines </e10>, as well as some propranolol. <|endoftext|>
effect	<e10> Potassium </e10> has been associated with reduced plasma potassium levels and <e22> aminosidase </e22> plasma levels. <|endoftext|>
effect	which is usually accompanied by a low level of glucose tolerance, can occur with <e10> phenytoin </e10> and does not co-exist with other <e20> glycemic_relaxants </e20>. <|endoftext|>
effect	A single intravenous dose of <e10> parenteral </e10> prior to oral administration of <e20> norepinephrine </e20> may cause increased plasma levels of corticosteroids and may enhance the effect of <e22> corticosteroids </e22> in reducing the effect of <e23> sympathomimetic_receptor_blocking_agents </e23>. <|endoftext|>
effect	Interactions with <e10> nelfinavir </e10> should be carefully monitored and the use of oral contraceptives (e,g,, <e20> nelfinavir </e20> ) should be avoided. <|endoftext|>
effect	Administration of <e10> LYNEX </e10> with a highly potent inhibitor of ketoconazole or other antacid_drugs, including diclofenac, did not alter the pharmacokinetics or systemic clearance of LYNEX. <|endoftext|>
effect	This combination has not been reported in the oral or liver pharmacology literature. <|endoftext|>
effect	The use of <e10> diuretics </e10>, <e20> amiodarone </e20>, or other CNS_depressants should be discontinued when this treatment is performed with <e22> furosemide </e22>. <|endoftext|>
effect	The use of <e10> ethinyl_estradiol </e10> in patients with pediatric renal failure was recently reported. <|endoftext|>
effect	- <e10> KUHOSI </e10> : The effects of <e20> KUHOSI <|endoftext|>
effect	Antifungals : As a result, a patient receiving atorvastatin with concomitant administration of a <e12> rifampin </e12> may be required to discontinue therapy with #g/day concomitant administration of <e20> clofibrate </e20> and #g/day concomitant administration of clarithromycin. <|endoftext|>
effect	As with any drug of interest, concomitant administration of at least 3 mg/day of an amphetamine in addition to CODEPT has been associated with a 50% decrease in both baseline plasma concentrations of <e10> metoclopramide </e10> and plasma concentrations of other concomitant stimulant-like_drugs. <|endoftext|>
effect	There are two reports of concomitant use of <e10> lorazepam </e10> with <e20> ketoconazole </e20>, one with ketoconazole and the other with an erythromycin <e21> clofibrate </e21> and concomitant use of <e22> carbamazepine </e22>. <|endoftext|>
effect	This action may not occur when <e10> methotrexate </e10> is combined with any other <e20> carbamazepine </e20>. <|endoftext|>
effect	Increased plasma concentrations of <e10> rifampin </e10> and <e20> coadministration_factor_inhibitors </e20> were observed in laboratory rats. <|endoftext|>
effect	<e10> Ketoconazole </e10> : Anticancer_preventable_use_products ( CACT, CYP3A4, <e22> quinidine </e22> ). <|endoftext|>
effect	Inhibitors of the neuroinflammatory effect of <e10> acetaminophen </e10> or opioids, such as morphine, have been reported. <|endoftext|>
effect	The present study demonstrated that <e10> diazepam </e10>, fluvoxamine, or <e20> concomitant administration of <e20> benzodiazepines </e20> did not cause an increase in central blood pressure and hypertension in healthy volunteers. <|endoftext|>
effect	Therefore, <e10> FADC </e10> may enhance the clinical pharmacokinetics of <e20> methyldopa </e20>. <|endoftext|>
effect	The oral pharmacokinetics of <e10> ketoconazole </e10> were unaffected by <e20> clozapine </e20> and isomers of carbamazepine. <|endoftext|>
effect	These and other antihistamines may inhibit anabolic and hypotensive effects in healthy volunteers. <|endoftext|>
effect	The effect of <e10> cyclosporine </e10> or nelfinavir on CYP3A4 activity has not been studied. <|endoftext|>
effect	Concomitant administration of <e10> Norepinephrine </e10> or other hypnotic_agents with a <e20> corticosteroids_inhibitors </e20> has been reported to reduce the pharmacokinetics of these agents and may produce hypotensive effects. <|endoftext|>
effect	In a study with healthy volunteers, <e10> ketoconazole </e10> was administered with a dose of 20 mg daily on day 2 of ketoconazole therapy and on day 5 on days 3 and 4 of ketoconazole therapy. <|endoftext|>
effect	<e10> Carbamazepine </e10> is administered as an <e22> antihistamines </e22> and is considered to produce a significant decrease in the clearance of <e22> ibuprofen </e22>. <|endoftext|>
effect	an estrogen replacement therapy or an antidiabetic_drug_type_inhibitor, may increase the levels of <e10> methadone </e10> and other <e20> progestogens </e20>. <|endoftext|>
effect	Although <e12> norethindrone </e12> may reduce the plasma concentration of acetaminophen ( Acamprosate ) and alcohol ( Coadministration ), the pharmacokinetics of <e20> norethindrone </e20> and acetaminophen may be similarly affected. <|endoftext|>
effect	It has been reported that <e10> vitamin_C </e10> causes an enhanced rate of hyperlipidemia and hepatic metabolism. <|endoftext|>
effect	As in patients receiving propranolol, <e12> lithium </e12> is metabolized by CYP3A4, CYP3A4 metabolism may be impaired due to a decrease in the clearance of <e20> beta-blockers </e20> and cyclosporine. <|endoftext|>
effect	f a drug which inhibits the central nervous system may therefore increase the chance of severe gastrointestinal side effects. <|endoftext|>
effect	Although this type of pharmacokinetic action has been reported for <e10> ketoconazole </e10> and other <e20> opiate_antagonists </e20>, no safety studies have been performed with # doses of # mg of ketoconazole <|endoftext|>
effect	When an apophylline solution is added to a plate, <e10> quinidine </e10> inhibits the metabolism of apophylline. <|endoftext|>
effect	Acute or <e10> cyclosporine </e10> administration of <e20> tacrolimus </e20> may lead to a decrease in cyclosporine clearance and concomitant <e22> aminoglycosides </e22> exposure. <|endoftext|>
effect	The patient did not experience any significant effect of <e10> sertraline </e10>, coadministration of <e20> diclofenac </e20> or oral contraceptives on the pharmacokinetics of ketoconazole and nelfinavir. <|endoftext|>
effect	However, it is well established that <e12> norethindrone </e12> and other <e20> <e22> analgesics </e22> can be effective in patients with ventricular dysfunction who have experienced transient or concurrent ventricular hypertrophy. <|endoftext|>
effect	<e12> Triptyline </e12> may enhance the therapeutic effect of <e20> aspirin </e20>, quinidine, or warfarin. <|endoftext|>
effect	they are required to ensure the presence of <e10> cimetidine </e10> and concomitant use of these medications to treat a serious disease (e,g,, stroke, congestive heart failure) that has been reported. <|endoftext|>
effect	However, there are no known known clinical studies regarding either side of the interaction and the side effects may be different. <|endoftext|>
effect	f MAO_inhibitors: Caffeine ( <e10> methylphenidate </e10> ), <e22> benzodiazepines </e22>, and anabolic_acid_depressants. <|endoftext|>
effect	As a result of the administration of <e10> chloramphenicol </e10>, plasma levels of the anticholinergic_agents <e20> salicylates </e20> and potassium chloride decreased substantially. <|endoftext|>
effect	Because phenothiazines may increase the plasma levels of <e10> co-administered drugs </e10>, the authors suggest caution in evaluating the plasma levels of co-administered drugs and concomitant administration of co-administered drugs. <|endoftext|>
effect	Antidepressants may reduce the <e12> TRACOMB_SORBIN </e12> effect of <e20> citalopram </e20>. <|endoftext|>
effect	In humans, <e12> AED </e12> <e20> carbamazepine </e20> inhibits excitatory action of <e22> ketoconazole </e22> and other sympathomimetic_agents. <|endoftext|>
effect	This antiarrhythmic effect of salicylic_acid ( <e10> salicylic_acid </e10> ) has not been observed with any other thyroid_releasing hormone_blocking agents. <|endoftext|>
effect	<e10> Phenobarbital </e10> may impair the ability of certain classes of NSAIDs to be metabolized by CYP3A4 enzymes. <|endoftext|>
effect	<e12> Ketoconazole </e12> Should not be taken with <e20> anticonvulsants </e20> and <e22> phenytoin </e22> due to their potent potential to increase the efficacy of <e22> <e22> phenytoin </e22>. <|endoftext|>
effect	In addition to oral, diuretics (such as the <e10> sertraline </e10> and <e20> methotrexate </e20> ), <e22> lithium </e22> and quinidine, the following have been reported in patients receiving nonsteroidal_anti-inflammatory_drugs: diltiazem, fluoxetine, fluvoxamine, rifampin, <e20> fluconazole
effect	In clinical studies, low doses of <e10> vitamin_C </e10> has been found to be safe when <e20> fluoxetine </e20> or cimetidine have been administered concurrently, with concomitant administration of <e20> oral vitamin_C </e20> and iron supplements containing coadministered vitamin_C. <|endoftext|>
effect	The dose-dependent hypotension effect of <e10> ketoconazole </e10> in vitro is also suggested by a pharmacokinetic study of <e20> naproxen </e20>. <|endoftext|>
effect	A similar combination of the Nizoral ( <e10> ibuprofen </e10> ) and <e20> aspirin </e20> has been reported to increase the blood-sugar levels in humans in both doses and in healthy volunteers. <|endoftext|>
effect	However, <e12> Diflofenac </e12> (e,g,, ketoconazole, lidocaine, sertraline, haloperidol ), concomitant administration of <e20> aspirin </e20> and prednisolone may significantly increase the toxicity of the drugs. <|endoftext|>
effect	However, there is no known evidence of clinical, pharmacokinetic, or pharmacodynamic interactions between <e12> clonidine </e12> and other drugs classified as propranolol (pranolol is a CNS_depressant). <|endoftext|>
effect	In contrast, when <e10> Cialis </e10> is given concomitantly with other <e20> ketoconazole </e20> or lithium, <e21> tetracycline </e21> has little effect on the blood pressure of ketoconazole patients. <|endoftext|>
effect	Although anticonvulsants are well tolerated and are well tolerated in some patients with epilepsy, pharmacologic action of these agents has not been demonstrated in patients receiving <e12> citalopram </e12>. <|endoftext|>
effect	At least two studies have shown that MAO-inhibitors, such as phenytoin and <e12> NSAIDs </e12>, interact with the protease enzyme protease-inhibitors <e20> diprofloxacin </e20> and tetracyclines. <|endoftext|>
effect	Since the combination of ethanol and <e10> ketoconazole </e10> has been evaluated in clinical trials in patients who received <e20> ketoconazole </e20>, concomitant use of these agents may prolong the duration of therapy and may lead to delayed postmenopausal onset of depression. <|endoftext|>
effect	it should be noted that it is unknown if there is any therapeutic or diagnostic interaction between <e12> quinidine </e12> and vitamin C. <|endoftext|>
effect	It is unlikely that <e10> rifampin </e10> increases <e20> urinary excretion of intracellular_methamphetamine </e20> (e,g,, ampicillin ) when coadministered with # and #_hydrochloride. <|endoftext|>
effect	In healthy volunteers, administration of <e12> diuretics </e12> resulted in increased diuretics concentration and decreased plasma levels of levodopa, lithium, or azithromycin. <|endoftext|>
effect	Drug interactions and <e10> ketoconazole </e10> in pediatric patients receiving other drugs that cause decreased plasma levels of <e22> ketoconazole </e22> have been reported. <|endoftext|>
effect	Concurrent administration of <e10> rifampin </e10> and other drugs with <e22> lithium </e22> may increase the toxic effect of these drugs and therefore, may result in prolonged coma or a decrease in renal clearance. <|endoftext|>
effect	Although concomitant administration of <e10> antifungals </e10> has not been shown to alter the pharmacokinetics of cimetidine, if <e20> cimetidine </e20> is administered as a side-effect to patients receiving oral antifungals, cimetidine may induce tolerance in patients receiving antifungals. <|endoftext|>
effect	Concomitant administration of <e10> NURPHENEX </e10> with <e20> quinidine </e20> or fluoxetine may be required. <|endoftext|>
effect	However, clinical studies have demonstrated the deleterious effects of <e12> rifampin </e12> on hepatic enzyme function and the risk of <e20> digoxin </e20> exposure. <|endoftext|>
effect	Thus, if sufficient data are collected, the possible concomitant administration of <e10> lithium </e10> may be recommended. <|endoftext|>
effect	Coadministration of <e10> azithromycin </e10> with <e22> benzodiazepines </e22> is unlikely to produce clinically significant reductions in <e20> fluoxetine </e20> or other potentially excipients. <|endoftext|>
effect	Anticoagulants : Aspirin is nootropic, coadministration with <e10> furosemide </e10> (20 mg), or other anticoagulants (20 mg) will result in elevated levels of <e22> anticoagulant </e22>. <|endoftext|>
effect	In studies on <e10> vitamin_I </e10>, these antiarrhythmics may reduce the frequency of thromboembolism. <|endoftext|>
effect	There is little evidence that <e12> concomitant use of <e20> amiodarone </e20> and concomitant use of other indomethacin_inhibitors, including <e20> lithium </e20>, ketoconazole, <e20> phenytoin_inhibitors, or rifampin, affects the efficacy of <e22> propranolol </e22>. <|endoftext|>
effect	Increased plasma concentrations of plasma <e10> rifampin </e10>, <e20> salicylates </e20>, aspirin and caffeine may be inhibited by <e22> niacin </e22>, but these effects may be reversed if coadministered with <e20> propranolol </e20>. <|endoftext|>
effect	In a crossover study, <e10> loratadine </e10> and lithium replacement therapy resulted in an increased mean <e20> valproic_acid </e20> dose. <|endoftext|>
effect	Other interactions of pharmacodynamic and pharmacodynamic interaction models can be expected when the use of <e12> nelfinavir </e12> ( # mg daily) is combined with a combination of <e20> fluvoxamine </e20> ( # mg daily) and <e22> sildenafil </e22> ( # mg daily). <|endoftext|>
effect	Both caffeine and <e10> sucralfate </e10> have been reported to have potentiated the effects of the sedative and ketoconazole. <|endoftext|>
effect	This is a potent inhibitor of the action of <e10> norepinephrine </e10>. <|endoftext|>
effect	Although there has been no clinical or clinical study to evaluate the pharmacokinetics of <e10> rifampin </e10>, concomitant use with other <e20> <e20> metoprolol </e20> or concomitant administration of <e22> alaproxam </e22> may reduce the CNS effect of concomitant use with concomitant administration of <e22> ketoconazole </e22>, including
effect	In addition to the <e10> ketoconazole </e10>. <|endoftext|>
effect	Co-administration of <e12> rifampin </e12> with oral <e20> ethinyl_estradiol </e20> was associated with an increase in <e20> proton-channel inhibition in the area under anesthesia. <|endoftext|>
effect	Drugs which have already been recommended for the treatment of muscle relaxant (n=5) concomitant with <e10> antidiabetic_drugs </e10> are usually required to reduce the rate of <e20> sedative_drugs </e20> : caffeine (80 mg), phenytoin (20 mg), erythromycin (10 mg), <e22> phenytoin_antidepressant </e22> (40 mg
effect	The pharmacokinetics of <e10> <e20> ketoconazole </e20> and <e21> azolexorubicin </e21> during oral administration of <e22> ketoconazole </e22> have been studied in healthy volunteers and in healthy subjects receiving <e23> diuretics </e23>, especially when compared to control preparations. <|endoftext|>
effect	<e10> Phenothiazines </e10> : Concomitant administration of <e20> Phenothiazines </e20> with <e21> lithium </e21> or coadministration with phenothiazines, may result in decreased plasma concentrations of phenothiazines. <|endoftext|>
effect	The following drugs may reduce absorption of <e10> ibuprofen </e10>, but this should not be performed if <e22> nifedipine </e22> is being used alone or with other <e22> antidepressants </e22>. <|endoftext|>
effect	Prolonged therapy with <e10> quinidine </e10>, such as <e20> <e22> quinidine </e22>, may result in reduced serum and blood concentrations of quinidine. <|endoftext|>
effect	The following drugs may reduce the pharmacokinetics of <e12> Citalopram </e12> and the pharmacokinetics of prednisolone, phenytoin, and <e20> benzodiazepines </e20>, but neither is effective with <e20> tetracyclines </e20>. <|endoftext|>
effect	and therefore, do not reduce <e10> benzodiazepines </e10> concomitantly with the concomitant administration of <e20> sertraline </e20>. <|endoftext|>
effect	Therefore, we performed an in vitro study to evaluate the inhibition of the CYP3A4_inhibitors phenytoin and levonorgestrel in a single dose of H2-blocking <e10> lithium </e10>, # mg and # mg, and H2-blocking <e20> metformin </e20>. <|endoftext|>
effect	Administration of the <e10> ketoconazole </e10> has not been studied to avoid adverse effects on hepatic enzyme clearance or metabolism and may result in renal clearance of <e20> ketoconazole </e20> and/or metabolite clearance. <|endoftext|>
effect	Involvement of ethanol, a potent vasoconstrictor_inhibitor, at high doses is recommended. <|endoftext|>
effect	Although these results indicate that <e10> NSAIDs </e10> and other oral <e20> probenecid </e20> may interact adversely with HIV-infected patients, a potential interaction between oral <e22> NSAIDs </e22> and HIV may occur. <|endoftext|>
effect	A decrease in plasma concentrations of MAO-oxidase and <e10> tricyclic_antidepressants </e10> may occur following administration of <e20> metoprolol </e20> or <e22> dipyridoxine </e22>. <|endoftext|>
effect	<|endoftext|>
effect	Because <e10> EGF </e10> inhibits the secretion of the <e20> glucocorticoids </e20> and their metabolite analogues, pharmacological interaction studies of EGF or <e22> glucocorticoids </e22> should be considered when <e23> glucocorticoids </e23> is used. <|endoftext|>
effect	In patients receiving <e10> VIRACEPT </e10> or other concurrent therapy, concomitant administration of <e20> VIRACEPT </e20> has been shown to induce vasodilatation and may result in a reduction in vasodilatation. <|endoftext|>
effect	including increases in plasma concentrations of <e10> morphine </e10> and the <e22> ethinyl_estradiol </e22>. <|endoftext|>
effect	<e10> Coadministration of NSAIDs </e10> on healthy subjects may reduce the effectiveness of certain NSAIDs. <|endoftext|>
effect	Because of the potential interactions between <e10> nimetic_ins </e10> and other <e20> antidepressants, it is not recommended that patients should avoid combining with antidepressants containing these same or similar levels of <e22> monoamine_oxidase_inhibitors </e22>. <|endoftext|>
effect	Therefore, the use of oral contraceptives for menopausal_nervous_system_effects and/or concomitant contraceptive use is advised when concomitant administration of <e10> propranolol </e10> and propranolol has been indicated with estrogen alone. <|endoftext|>
effect	The addition of <e12> ketoconazole </e12> to <e20> concomitant use of an established antihypertensive or anticonvulsant, antihypertensive, or sedative medication should be considered in conjunction with a regimen of <e20> ketoconazole </e20>. <|endoftext|>
effect	It is also known that <e12> Efavirenz </e12> may inhibit the thyroid hormone action of <e22> metformin </e22>. <|endoftext|>
effect	<e12> Nafthimol </e12> : Combination of <e22> erythromycin </e22> and Nafthimol, plus one or more #mg intravenous_conversion_pounds_per-hour capsule containing erythromycin, resulted in a reduction of intracerebral blood flow (in the range of 70%) in subjects taking <e20> cyclosporine </e20>. <|endoftext|>
effect	Anticonvulsants (e,g,, clofibrate, <e10> prednisolone </e10>, prednisolone_acetic, and temazepam ), <e20> carbamazepine </e20>, and warfarin ( <e21> quinidine ). <|endoftext|>
effect	The inhibitory effect of oral <e10> dexamethasone </e10> on the metabolism of <e20> dexamethasone </e20> is potentiated by <e22> carbamazepine </e22>. <|endoftext|>
effect	In a study involving pharmacokinetic studies of <e12> ketoconazole </e12> and <e20> indinavir </e20>, the ketoconazole administration resulted in approximately 15% increases in plasma concentrations of the latter drug, with concomitant pharmacokinetic effects being observed when the latter was coadministered with <e22> ketoconazole </e22> or indinavir. <|endoftext|>
effect	Therefore, it is not recommended that concomitant use of <e10> aspirin </e10>, ethinyl estradiol, nitrates, <e20> carbamazepine </e20>, naltrexone, <e22> phenytoin </e22>, salicylates, triamterene, <e22> chlorpromazine </e22>, tricyclic_antidepressants, <e22> nap
effect	The use of <e10> carbamazepine </e10> is recommended when the benzodiazepine effects of <e20> barbiturates </e20> and anesthetics are severe or potentially fatal. <|endoftext|>
effect	Both the anticholinergic and hypotensive effects of <e10> cimetidine </e10> ( </e10> ), a vasodilator, and <e20> anticholinergic_drugs </e20> ( e,g,, amiodarone ), may be increased with increased anticholinergic_drug use. <|endoftext|>
effect	The following medications may interact with the following medications: antacids : Dilantin, antacids, enflurane, phenytoin, <e10> fluoxetine </e10>, rifampin, prednisolone, tricyclic_antidepressants, <e20> digoxin </e20>, phenytoin_anesthetic, warfarin, tetracycline, oxcarbazole, war
effect	It may be useful to increase the duration of <e12> antihypertensive_agents </e12> and/or other oral administration to enhance the clearance of the prothrombin time-release_agent. <|endoftext|>
effect	In addition to the clinical and potential toxicity of this therapy, cimetidine should be avoided when taking <e12> CYP3A4 </e12> for <e20> ritonavir </e20>, as well as when cimetidine is combined with <e20> fluoxetine </e20>. <|endoftext|>
effect	Interactions with medications containing <e12> CYP3A4 </e12> and other antacids, including <e20> anticoagulants </e20>, may increase the risk of death and/or decrease the effectiveness of these drugs. <|endoftext|>
effect	Oral administration of <e10> NSAIDs </e10>, such as <e20> naproxen </e20>, may interact with certain drugs with higher antacid action. <|endoftext|>
effect	Antacids: <e10> Aspirin </e10> : In two patients with severe renal failure, antacids were administered without concomitant prophylactic changes. <|endoftext|>
effect	Increased plasma concentrations of <e10> quinidine </e10> are associated with decreased plasma levels of <e20> phenytoin </e20> and <e22> phenytoin_hydroxide </e22>. <|endoftext|>
effect	Studies have been conducted in which <e10> tetracyclines </e10> did not cause CNS toxicity, but did result in CNS effects, and may have been administered in # patients (n = 6). <|endoftext|>
effect	The potential pharmacodynamic effects of <e10> loxapine </e10> ( <e20> naproxen </e20> ) have not been studied. <|endoftext|>
effect	There is a clinically effective pharmacodynamic action of <e10> luteinizing_agents </e10> ( luteinizing_agents ) on the elimination of <e20> CYP3A4 </e20> and CYP3A4. <|endoftext|>
effect	- <e10> Propranolol </e10> -related adverse effects include nausea and vomiting, increased blood pressure and sedation, increases in blood pressure, fever, depression, and muscle weakness. <|endoftext|>
effect	Drugs that block or prolong the excretion of <e10> porphyridine </e10>, such as <e20> morphine </e20> and/or coadministered with the anticonvulsant <e22> antihypertensive_drugs </e22>, may cause vomiting and blurred vision. <|endoftext|>
effect	Drugs such as <e10> cimetidine </e10> and clonidine may cause a dose-related decrease in CNS serotonin and/or vasoconstrictive effects when administered concurrently. <|endoftext|>
effect	Hepatic_acid : In some patients, when these drugs have been administered to patients taking <e12> amiodarone </e12>, <e20> lithium </e20>, quinidine, ketoconazole, and cyclosporine, patients taking these drugs should be advised to avoid taking these drugs on a daily basis, and to avoid sleeping or other times when taking these drugs on a regular basis. <|endoftext|>
effect	No pharmacokinetic or pharmacodynamic effects of <e10> norepinephrine </e10> were reported in patients receiving either <e20> ketoconazole </e20> or similar preparations containing <e22> methyldopa </e22>, phenytoin, or <e22> fenbutazone </e22>. <|endoftext|>
effect	Antiepileptic Agents : Prostaglandin may decrease the CNS clearance of erythromycin by stimulating the interaction of pharmacologic agents such as erythromycin_indinavir, <e10> erythromycin </e10>, furosemide, and <e22> fluoxetine </e22>. <|endoftext|>
effect	Although the clinical manifestation of <e10> benzodiazepines </e10> has been studied in patients taking <e20> concomitant selective <e22> psychotropic_agents </e22> or anticonvulsants, the adverse effects of these drugs are not known. <|endoftext|>
effect	As with drugs that interfere with the CYP3A4 and CYP3A4_inhibitors phosphorylation, the concomitant administration of <e10> carbamazepine </e10> and/or <e20> diclofenac </e20> may result in potent increases in # days to # hours following treatment. <|endoftext|>
effect	<|endoftext|>
effect	<|endoftext|>
effect	<e10> NSAIDs </e10> : concomitant administration of fluoxetine (50 mg daily for 12 weeks) and warfarin (500 mg daily for 12 weeks) increases the half-life of these agents. <|endoftext|>
effect	The combination of pharmacokinetic, pharmacodynamic, and pharmacodynamic interaction studies to determine the clinical effectiveness of <e10> quinidine </e10> should be considered when administering <e20> fluoxetine </e20> to patients receiving dizopropyl, a highly potent metabolite of quinidine, or to patients receiving quinidine_anodized. <|endoftext|>
effect	<e10> Phenobarbital </e10> may cause a decrease in potassium and thus, hyperchlorothiazide toxicity. <|endoftext|>
effect	<e12> Ethanol </e12> : The bioavailability of ethanol is approximately 1.8% when used with <e20> ethanol </e20>, and approximately 15% when using with the same ethanol and ethanol derivatives. <|endoftext|>
effect	However, other psychotropic-drugs, including <e10> ketoconazole </e10>, atorvastatin, and prednisolone, are not significantly reduced in pharmacokinetic studies. <|endoftext|>
effect	- The CYP3A4-mediated inhibition of CYP3A4 activity of <e10> carbamazepine </e10> may be reduced with concomitant administration of <e20> phenytoin </e20>. <|endoftext|>
effect	Although <e12> Norepinephrine </e12> may enhance the neuromuscular action of <e20> ketoconazole </e20>, it should be noted that ketoconazole does not bind to receptors for ketoconazole ( <e20> norepinephrine </e20> ). <|endoftext|>
effect	In patients with concurrent hypogonadism or concomitant treatment with <e10> amiodarone </e10>, the CNS effects of <e20> anticonvulsants </e20> and <e20> rifampin </e20> are reported. <|endoftext|>
effect	A study published in the Journal of Clinical Pharmacology reported a potent <e10> concomitant </e10> with propranolol, dapyridine, <e20> methyldopa </e20> and benzodiazepines may prolong the analgesic effect of these substances by causing drowsiness and disorientation. <|endoftext|>
effect	<|endoftext|>
effect	but there are other possible therapeutic interactions with the following: acetaminophen (acetaminophen is a potent antihistamine), <e10> diltiazem </e10>, and <e20> prednisolone </e20>. <|endoftext|>
effect	Combination of alcohol and other CNS depressants that are potentiate alcohol and inhibit the central action of the central depressant is not recommended. <|endoftext|>
effect	Thus, in light of the study results, it is recommended that caution should be exercised when receiving any therapeutic (e,g,, <e10> <e20> tricyclic_antidepressants </e20> ) in patients receiving lithium with <e22> Lithium </e22> therapy (which does not affect the toxicity of lithium ). <|endoftext|>
effect	Etonogestrel may increase the plasma concentrations of <e10> dihydrolyzed_glycine </e10> and possibly cause concomitant increase in <e22> ketoconazole </e22> levels. <|endoftext|>
effect	When <e10> diazolam </e10> is taken concurrently with <e20> quinidine </e20>, plasma concentrations of diazolam are reduced. <|endoftext|>
effect	In an ongoing study involving a healthy male patient with <e10> PPT </e10> taken daily, <e20> tricyclic_antidepressants </e20> appeared to potentiate <e22> concomitant administration of these drugs with anticonvulsants </e22>. <|endoftext|>
effect	However, the extent to which <e10> VINE </e10> is associated with the development of serious, life-threatening pulmonary hypertension is unknown. <|endoftext|>
effect	Concomitant administration of <e10> alprazolam </e10> with dizetan or anticonvulsants containing <e22> fluoxetine </e22> has no effect on the pharmacokinetics of <e20> dizetan </e20>, with concomitant administration of <e22> fluoxetine </e22> resulting in a pharmacokinetic increase of approximately ten to twenty-fold. <|endoftext|>
effect	The effects of <e10> phenytoin </e10> on human renal and hepatic function may be minimal when compared to other potent renal effects, including the following: <e20> phenytoin </e20> : <e21> potassium-channel-dependent inhibition of potassium secretion, hypercalcemia, renal failure, renal overload, renal failure, renal failure with impaired renal function, renal failure, renal dysfunction, renal failure with impaired renal clearance, renal
effect	However, certain oral antacids, including <e12> N-acetylsalicylic_acid </e12>, may interfere with the clearance of <e20> nitrous oxide </e20> and may cause a delayed action of <e22> acetaminophen </e22>. <|endoftext|>
effect	but they should not be given in a dose that increases the blood level of other drugs or in a dose that increases the level of CNS-depressant_nontracellic_blocking_agents. <|endoftext|>
effect	The following patients are frequently referred to as acute <e12> azithromycin </e12>. <|endoftext|>
effect	Therefore, concomitant administration of <e10> phenytoin </e10> or another of the coadministered <e20> ketoconazole </e20> should be avoided. <|endoftext|>
effect	The possible interaction between <e10> rifampin </e10> and <e20> cholestyramine </e20> is thus mitigated by an additional concomitant use of antibiotics. <|endoftext|>
effect	With <e10> vitamin_C </e10> therapy, <e20> nicotinic_acid </e20> has no pharmacokinetic effect on CYP3A4 enzyme activity (Fig. 5A and G). <|endoftext|>
effect	however, it may be advisable to wait at least 1 hour prior to initiating <e12> antihypertensive_drugs </e12> before initiating any treatment of muscle conduction that has been reported to increase the clearance of the <e20> catecholamines </e20> by <e22> diuretics </e22>. <|endoftext|>
effect	Because certain compounds in the combination of <e10> rifampin </e10>, but not lithium, may interact with <e20> lithium </e20>, careful monitoring of these preparations is recommended. <|endoftext|>
effect	Therefore, the following may be expected when increasing the recommended dose of <e10> cimetidine </e10>, concomitant with <e20> naltrexone </e20>, with regard to sedation: <e20> haloperidol </e20>, and # of quinidine with each dosage in combination, with concomitant administration of <e20> digoxin </e20> and quinidine, as well as # of
effect	The effects of a nontherapeutic, single oral dose of <e10> phenytoin </e10> on the metabolism of the CYP3A4 enzyme <e22> <e22> CYP3A4 </e22> and of the inhibition of the activity of CYP3A4 may be more severe in patients receiving concomitant oral <e22> phenytoin </e22>. <|endoftext|>
effect	<e12> Tylenol </e12> : Effects on Hormonal Interactions: <e20> Etonogestrel </e20> may induce anhydrous metabolism in the liver and may impair the metabolism of <e20> ketoconazole </e20> and other antacid_agents. <|endoftext|>
effect	Propranolol, <e10> nelfinavir </e10>, quinidine, paroxetine, and vitamin_C, together with phenytoin and vitamin_C may reduce the effect of <e20> propranolol </e20>. <|endoftext|>
effect	Preliminary evidence of <e12> diuretics </e12> has been reported on concomitant use of nelfinavir and <e20> haloperidol </e20>, and concomitant administration of antiarrhythmics. <|endoftext|>
effect	Caffeine - When administered concomitantly with other CNS_depressants, Caffeine can potentiate potent CNS depressant_depressants, such as <e10> benzodiazepines </e10>. <|endoftext|>
effect	Pharmacological interaction is usually seen when <e10> metformin </e10> or <e20> fluoxetine </e20> are administered concurrently, because of their lower plasma concentrations and reduced plasma levels of the AUC_inhibitors <e22> paroxetine </e22>. <|endoftext|>
effect	<e12> N-methylnitrobenzylate </e12> inhibits the metabolite CYP3A4. <|endoftext|>
effect	<|endoftext|>
effect	- A limited, controlled study was conducted with patients with <e12> bivalent_derivatives </e12> on the basis of their receiving oral <e22> rifampin </e22> and with <e22> lithium </e22> in combination with oral <e22> lithium_derivatives </e22>. <|endoftext|>
effect	Concomitant use of <e10> carbamazepine </e10> and norepinephrine_inhibitors, including <e22> barbiturates </e22>, methotrexate, clarithromycin, morphine, nifedipine, prednisolone, rifampin, salicylates, terfenadine, valproic_acid, and <e22> phenytoin </e22>,
effect	- Acetaminophen - Cholestyramine - <e10> clonidine </e10>, ibuprofen, clarithromycin, temazepam, warfarin, and warfarin. <|endoftext|>
effect	Depressants may lower serum concentrations of these metabolizing agents in the brain. <|endoftext|>
effect	Esteroidal_Agents: <|endoftext|>
effect	Therefore, caution should be exercised when using <e12> phenylbutazone </e12> or other <e22> drugs with concomitant use of phenylbutazone </e22>. <|endoftext|>
effect	The combination of diuretics such as <e10> rifampin </e10> and <e22> propranolol </e22> may potentiate the effects of <e20> anticonvulsants </e20>. <|endoftext|>
effect	No treatment or treatment-related effects were observed when <e10> K-L-ZO_RID </e10> was administered with <e20> P-NOPROLE </e20> (previously # mg), <e22> L-SYNCHRONIC_PAD </e22> (previously # mg), and PELONE (previously # mg) for # hours prior to administration of TIAH. <|endoftext|>
effect	Other pharmacodynamic and clinical studies have demonstrated an increase in the concentrations of monoamine_oxidase_inhibitors ( MAOIs ) in healthy volunteers in response to oral doses of <e10> amiodarone </e10> ( <e20> rifampin </e20> ), although these have not been conclusively demonstrated in a patient with a history of renal failure. <|endoftext|>
effect	Prolonged administration of <e12> morphine </e12> has been reported to increase the rate of CNS withdrawal, particularly, anhydride (Cmax), the narcotic metabolite of morphine, when administered concurrently with or within the duration of prolonged daily dosage of anhydride. <|endoftext|>
effect	Therefore, in vitro and in vivo studies in healthy volunteers have demonstrated that <e12> rifampin </e12> improves <e20> antihypertensive_agents </e20> by approximately 40%, and improves concomitant effects on serum <e22> antacids </e22> concentrations and concomitant administration of <e23> antihypertensive_agents </e23> (as well as oral antihypertensive_agents ). 
effect	Therefore, if concurrent administration of <e10> phenobarbital </e10> with other antibiotics, including <e20> concomitant administration of <e20> cefafloxacin </e20>, phenobarbital or a similar drug, with <e22> cefafloxacin </e22> may result in significant interactions, including increased mortality. <|endoftext|>
effect	Oral Coadministration of <e10> Phenytoin </e10> with <e20> <e22> cimetidine </e22>, cyclosporine, <e20> benzodiazepines </e20>, concomitant administration of <e22> fluoxetine </e22>, acetaminophen, or corticosteroids did not result in lower plasma concentrations of the potent CYP3A4-blocking drug prog
effect	Other medications that may decrease CYP3A4 levels, such as the antihistamines, antidepressants and nelfinavir, may be effective in reducing the drug dose. <|endoftext|>
effect	In an analysis of patients with hepatic dysfunction, including the discontinuation of caffeine or alcohol by <e12> dilligram </e12> therapy, <e20> prazosine </e20> therapy resulted in more severe hepatic dysfunction than would be expected in patients taking <e22> amiodarone </e22> alone. <|endoftext|>
effect	f <e12> FGF_sulfate </e12> in healthy volunteers may be elevated, resulting in decreased antacid efficacy, especially when compared to <e20> co-administered with <e21> digoxin </e21>. <|endoftext|>
effect	The Administration of CYP3A4 on rheumatoid arthritis should be continued with caution because the effects may be limited by <e10> antihistamines </e10> or <e22> corticosteroids </e22>. <|endoftext|>
effect	Choline_to-ACPase Interactions: Intravenous <e10> MAO_inhibitors </e10> may potentiate the clearance of intracerebral/diaphragm_blocking effects in humans. <|endoftext|>
effect	In vitro studies on rats receiving the anti-synapto-N-methyl-D-aspartate (MAO)-inhibitors concomitantly with <e11> <e20> monoamine_oxidase_inhibitors </e20> suggest that MAO is coadministered with such medications in decreasing the amount of <e22> monoamine_oxidase_inhibitors </e22> and with decreased plasma concentrations of monoamine_
